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“Talking nonsense is the sole privilege mankind possesses over the other 
organisms. It’s by talking nonsense that one gets to the truth! I talk nonsense, 
therefore I’m human” 
Fyodor Dostoievsky: Notes from Underground, White Nights, The Dream of a 
Ridiculous Man, and Selections from The House of the Dead. 
“The darker the night, the brighter the stars, 
The deeper the grief, the closer is God!” 
 Fyodor Dostoievsky: Crime and Punishment. 
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1. INTRODUCTION 
Chirality has profound implications in the biological activity of organic molecules. 
Agrochemicals and drugs interact with biological matrices or drug targets such as 
proteins, nucleic acids or biomembranes that display complex three-dimensional 
structures capables of recognizing specifically a molecule in only one of the many 
possible arrangements in the three dimensional space, determining the binding mode 
and affinity of a drug molecule.1 As the drug target is made of small fragments with 
chirality, biological systems in most cases, recognize a pair of enantiomers as different 
substances, and the two enantiomers will elicit different responses. Thus, one 
enantiomer may act as a very effective therapeutic drug whereas the other enantiomer is 
totally inactive or even highly toxic. Thalidomide is a classical example with this 
regards. This drug was synthesized as a racemate and widely prescribed for morning 
sickness from 1957 to 1962 in the European countries and Canada. This led to an 
estimated over 10.000 babies born with defects due to the teratogenic properties of the S 
enantiomer. Although further studies demonstrated that the stereogenic center of 
thalidomide is easily racemized in vivo and that the teratogenic effects would not have 
been avoided by using enatiomerically pure R-thalidomide, the chirality story about this 
drug had a great impact on modern chiral drug discovery and development. Drug 
agencies are imposing more regulation constrains for the approval of new racemic 
drugs. Similarly, chirality may determine the mechanical, optical or electromagnetic 
properties of materials by imposing determined molecular arrangements.2  
Although the majority of natural products are in single enantiomeric form, for 
example, amino acids and carbohydrates, there are still great demands for chiral 
artificial products in high enantiomeric purity to be used in different ways, especially in 
the pharmaceutical industry. Accordingly, chemists have developed different methods 
to obtain enantiomerically enriched compounds which involve the conversion or 
derivatization of readily available natural chiral compounds (chiral pool), the resolution 
of racemates or asymmetric synthesis.3  
Asymmetric synthesis refers to the conversion of an achiral starting material to a 
single enantiomeric form of a chiral product by using a properly dessigned reaction. It is 
currently the most powerful and most commonly used method for chiral molecule 
preparation. In asymmetric synthesis a certain amount of a chiral substance is required 
to induce enantioselectivity to the reaction. Among the types of asymmetric reactions, 
the most desirable and the most challenging is catalytic asymmetric synthesis, in which 
a molecule of a chiral catalyst can create millions of chiral product molecules, just as 
enzymes do in biological systems. Catalytic asymmetric synthesis often has significant 
economic advantages over stoichiometric asymmetric synthesis of enantiomerically 
pure compounds, since it requires less chiral material and minimizes the production of 
chemical waste. 4  
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2 
On the other hand, C-C bond formation is a proccess of most importance in organic 
synthesis for the construction of the carbon skeleton in organic molecules. Among 
them, the conjugate addition of carbon nucleophiles to electrophilic double bonds, 
usually referred as Michael addition, is one of the most attractive and frequently used 
methods for this purpose (Scheme 1). The research on this transformation has been 
boosted by the wide diversity of compounds that can serve as nucleophiles and 
electrophiles to generate a varied array of products.5 Such reactions often result in the 
generation of a new stereocenter, and consequently a considerable effort has been 
devoted to the development of asymmetric catalytic versions of 1,4-addition reactions.6 
Unsaturated carbonyl compounds, nitroalkenes and less frequently unsaturated sulfones 
have been used as electrophilic partners in asymmetric conjugate additions of easily 
enolizable nucleophiles such as 1,3-dicarbonyl and related compounds. 
 
Scheme 1.  Nucleophilic conjugate addition to electrophilic alkenes 
 In this context, α,β-unsaturated imines (1-azabutenes), readily prepared via 
condensation of N-substituted amines with the parent unsaturated ketones, have 
emerged as an interesting family of compounds with important applications in the 
synthesis of nitrogen-containing molecules. However, in contrast to carbonyl substrates 
and nitroalkenes, the asymmetric conjugate addition to α,β-unsaturated imines has been 
scarcely explored probably due to the lower electrophilicity of these substrates. 7 This 
thesis is aimed to developing new catalytic asymmetric reactions using α,β-unsaturated 
imines as electrophiles. In particular the addition of malonate ester derivatives will be 
explored (Scheme 2). 
 
Scheme 2. Conjugate addition of malonate ester derivatives to α,β-unsaturated imines 
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2. LITERATURE REVIEW 
In this chapter the most relevant literature involving conjugate imines as reaction 
substrates will be reviewed. Only reactions involving the participation of the whole 
moiety will be considered, therefore simple 1,2-nucleophilic additions to the imine 
group will not be reviewed. Because of length reasons, reactions involving conjugate 
oximes or hydrazones will be only exceptionally mentioned. Similarly, examples in 
which the double C=N bond is a part of an aromatic heterocycle, such as 2-
vinylpyridines, or where the electrophilicity of the C=C double bond arises primarily 
from conjugation with a carbonyl group as in vinyl pyrrolidinones will neither be 
considered. 
2.1. 1-Aza-1,3-butadienes as simple Michael acceptors 
2.1.1. Reactions involving carbon nucleophiles 
2.1.1.1. Conjugate addition of carbonyl and related compounds 
Owing to their ambident electrophilic character, α,β-unsaturated imines can 
undergo either 1,2- or 1,4- (conjugate) nucleophilic addition processes. However control 
of the regioselectivity is generally difficult, and very often double nucleophilic addition 
products are obtained. One of the first conjugate additions of carbon nucleophiles to 
unsaturated C=N double bonds was described by Mahgoub who reported in 1990 the 
addition of 1,3-pentanedione and methyl acetoacetate to 2-styryl-2(1H)quinoxalinones 
in the presence of triethylamine.8 
In 2013, as a part of their research addressed to the synthesis of pyridines, the group 
of Palacios reported the related addition of malononitrile and phenylacetonitrile to 
fluorinated imines to give the corresponding enamines, which can be further 
transformed into amino pyridines after treatment with NaH and dehydrogenation 
(Scheme 3).9 
 
Scheme 3. Conjugate addition of nitriles to fluorinated α,β-unsaturated imines 
In 2014, the group of Hu developed a formal 1,4-conjugate addition of α-alcoxy 
esters to β,γ-unsaturated N-sulfonylimino esters (Scheme 4). 
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Scheme 4. Formal 1,4-conjugate addition of α-alcoxy esters to β,γ-unsaturated N-
sulfonylimino esters 
This three-component process catalyzed by Rh(II) allowed the synthesis of a wide 
variety of conjugate addition products from imines and diazo esters having aromatic 
groups and alkyl or benzyl alcohols, with yields ranging from 5% to 95% and 
diastereomeric ratios higher than 95:5 in all cases. 
The authors propose a mechanism where the alcohol and the diazo ester react in the 
presence of Rh to give an oxonium ylide in equilibrium with an enolate, which is 
trapped by the unsaturated imine in a transition state where an intramolecular hydrogen 
bond interaction is the key factor for the control of the diastereoselectivity of the 
reaction (Scheme 5). 
 
Scheme 5. Proposed mechanism for the diastereoselective three component reaction 
The resulting products could be subjected to different transformations. For instance, 
the enamine could be hydrogenated on Pd/C to give the corresponding amine with only 
a slight loss of diastereisomeric ratio. Depending on the R group, the hydroxyl group 
can be deprotected under different conditions. Finally, the products with the free 
hydroxyl group, can lead to the corresponding 2,3-dihydrofurans via cyclization with p-
toluenesulfonic acid under reflux in toluene.10 
Silyl enol ethers as nucleophiles in the Mukaiyama-Michael addition with 
unsaturated aldimines have been extensively used by Shimizu. This group has carried 
out several examples of double nucleophilic addition in which a silyl enol ether first 
attacks the β-carbon followed by the 1,2-addition of a second silyl enol ether or another 
carbon nucleophile. The reaction is performed in the presence of a Lewis acid such as a 
Ti(IV) halides or AlCl3 in the presence of a controlled amount of water, and permitted a 
variety of nucleophiles (Scheme 6). 
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Scheme 6. Double nucleophilic addition of silyl enol ether and other nucleophiles 
The double addition products can be transformed into dihydropyrroles and pyrroles 
with good to excellent yields (Scheme 7).11-14 
 
Scheme 7. Synthesis of dihydropyrroles and pyrroles by Shimizu 
The same group has also reported the double addition reaction of different silyl enol 
ethers and trimethylsilyl cyanide to N-allylidene amines prepared from acrolein and 
diphenylethyl- or tritylamine. Work-up with TFA allowed obtaining homoglutamic acid 
derivatives or, in the case of the product obtained from the ketene silyl thiocetal derived 
from S-cyclohexyl propanothioate, a valerolactam derivative (Scheme 8).15 
 
Scheme 8. Synthesis of homoglutamic acid derivatives and valerolactams from acrolein 
imines 
2.1.1.2. Conjugate addition of cyanide 
Shimizu has also applied the double nucleophilic addition methodology in the 
enantioselective synthesis of chiral 2-aminopentadinitriles. The bis-cyanation of 
unsaturated aldimines derived from (R)-phenylglycinol with TMSCN catalyzed by 
AlCl3 provided the expected products with high diastereoselectivities in almost all the 
cases (Scheme 9, Table 1).16 
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Scheme 9. Diastereoselective bis-cyanation of (R)-phenylglycinol-derived imines 
Table 1. Asymmetric bis-cyanation of chiral α,β-unsaturated aldimines. 
Entry R1 R2 R3  Yield (%) (R,S):(R,R) 
1 Me Me -  76 93:3 
2 CH2CH=CH2 Me -  71 96:4 
3 (E)-CH2CH=CHMe Me -  68 86:14 
4 (E)-CH2CH=CHPh Me -  50 90:10 
5 CH2(Me)C=CH2 Me -  73 92:8 
6 CH2CH=CH2 H TMS  54 91:9 
7 (E)-CH2CH=CHMe H TMS  64 81:19 
8 CH2C≡CH H TMS  47 79:21 
 
2.1.1.3. Conjugate addition of organometallic reagents. 
The first example involving the conjugate addition of an organometallic reagent to 
α,β-unsaturated aldimines was reported in 1997 by the group of Ricci. These researchers 
studied the nucleophilic addition of different organocuprates to 1-aza-1,3-butadienes 
derived from bis- and mono(trimethylsilyl)methylamine in the presence of a 
stoichiometric amount of BF3·Et2O (Scheme 10). 
 
Scheme 10. Nonenantioselective addition of organocuprates to unsaturated silylmethyl 
aldimines 
The reaction performed in a 1,4- regioselective manner in the majority of the 
examples studied, except with cuprates having heteroaromatic ligands (thiophene or 
furan) that favored the 1,2-addition product.17 
In 2001, Tomioka et al. reported the regioselective addition of organolithium 
reagents to α,β-unsaturated aldimines. The regioselectivity of the reaction was 
determined by the electronic and steric properties of the N protecting group. Imines 
having electron-withdrawing aryl groups on the nitrogen favor the 1,2-addition product 
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while alkyl or bulky aryl groups (2,6-diisopropylphenyl) favored the 1,4-addition 
process. The reaction allowed the preparation of alcohols after hydrolysis of the imine 
and reduction. The enantioselective 1,4-addition of phenyllithium was achieved in 93% 
ee by performing the reaction in the presence of an excess of a C2 symmetric ether as 
chiral inducer (Scheme 11). This example constitutes the first enantioselective 
conjugate addition of an organometallic reagent to an α,β-unsaturated imine.18 
 
Scheme 11. Regio- and enantioselective 1,4-addition of PhLi to α,β-unsaturated 
aldimines and subsequent derivatization to the corresponding alcohol 
The asymmetric conjugate addition of organocopper reagents to chiral N-tert-
butanesulfinyl α,β-unsaturated imines was described by Ellman in 2005. Two different 
reaction conditions involving the use of Bu2CuCN·BF3·Et2O or Me2CuLi were tested 
with a few ketimines and one aldimine, the reaction products being obtained with 
moderate yields and diastereoselectivities (Scheme 12).  
 
Scheme 12. Diastereoselective conjugate addition of organocuprates to chiral N-sulfinyl 
α,β-unsaturated imines 
The authors rationalized the facial selectivity of the reaction following a model in 
which, the cuprate coordinates to the sulfinyl oxygen on the opposite face from the tert-
butyl group. Coordination activates the molecule for the conjugate addition and at the 
same time aligns the cuprate for the addition reaction. Delivery of the cuprate is only 
possible through one of the imine isomers accessible via equilibration of the imine 
isomers (Scheme 13).19 
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Scheme 13. Proposed model of diastereofacial selectivity for the conjugate addition to 
chiral N-sulfinyl imines 
The first asymmetric catalytic conjugate addition of an organometallic reagent to a 
unsaturated imine was developed by Tomioka in 2005. This group reported the 
conjugate addition of dialkylzinc reagents to N-2,4,6-triisopropylphenylsulfonyl 
aldimines using a complex of Cu(MeCN)4BF4 with a chiral amidophosphine ligand as 
catalyst. The resulting enamines were hydrolyzed and reduced to give the corresponding 
β-alkylated alkanols with moderate to high enantiomeric excesses. The use of the bulky 
2,4,6-triisopropylphenyl group attached to the imine nitrogen was essential to favor the 
conjugate addition by hampering the approach of the reagent to the azomethinic carbon 
due to steric hindrance (Scheme 14).20 
 
Scheme 14. Conjugate addition of dialkylzinc reagents to N-arylsulfonyl aldimines 
One of the authors of this work (Soeta) and others reported in 2016 the 1,2-addition 
of dialkylzinc reagents to related N-tosyl aldimines using a Cu-NHC catalyst. Although 
the regioselectivity could be shifted to the 1,4- pathway by changing the copper source 
and the NHC catalyst, the enantioselectivities obtained were low in all the cases.21  
Also in 2005, the group of Carretero described the first catalytic enantioselective 
1,4-addition of dialkylzinc reagent to α,β-unsaturated ketimines. A copper(I)-
phosphorimidite complex catalyzed the conjugate addition of dimethylzinc to a variety 
of substituted N-(2-pyridylsulfonyl) α,β-unsaturated imines derived from chalcones to 
give the corresponding enamines with excellent yields and diastereisomeric ratios, and 
moderate enantiomeric excess for the majority of products (Scheme 15). The enamines 
could be hydrolyzed or subjected to ozonolysis without loss of the optical purity. 
Addition of bulkier dialkylzinc reagents such as diethyl- or dibutylzinc, at low 
temperatures, took place with similar yields but with lower enantiomeric excesses than 
in the case of Me2Zn. The presence of the coordinating 2-pyridylsulfonyl group proved 
to be essential for the reaction to proceed.22 
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Scheme 15. Copper-phosphorimidite-catalyzed enantioselective conjugate addition of 
dimethylzinc to N-(2-pyridyl)sulfonyl imines derived from chalcones 
Palacios and Vicario have developed a copper(I)-catalyzed enantioselective 
conjugate addition of diethylzinc to N-aryl α,β-unsaturated imines derived from α-keto 
esters. The best results in this case were obtained with a phosphoramidite ligand derived 
from TADDOL, which lead regioselectively to the 1,4-adduct, obtaining exclusively the 
Z-α-dehydroaminoesters bearing a stereogenic center in the γ-position, with high yields 
and fair to good enantiomeric excesses (Scheme 16). 
 
Scheme 16. Enantioselective synthesis of α-dehydroaminoesters 
The reaction worked with substrates having electron poor or electron rich aromatic 
rings attached at either the double bond or the nitrogen atom. The authors demonstrated 
the possibility of transforming the resulting α-dehydroaminoesters into chiral carboxylic 
acids by ozonolysis, or into α-aminoesters via hydrogenation.23,24 
The alkylation of imines derived from cyclic enones has been studied by the group 
of Zezschwitz and Westmeier. In 2014, they described the first enantioselective 
conjugate addition of dialkylzinc reagents to cyclic N-tosyl imines employing the same 
copper(I)-phosphorimidite catalyst previously used by Carretero. In this way, different 
five or six member cyclic enamines were prepared with moderate to good yields, 
diastereoselectivities and with excellent enantiomeric excesses. The enamines could be 
transformed into chiral cyclopentyl- and cyclohexylamines using different reductive 
methods (Scheme 17). The reaction was also tested with the N-tosyl imine derived from 
chalcone although with a moderate yield and ee. The tosyl amines can be detosylated by 
treatment with Boc2O and Mg.25 
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Scheme 17. Enantioselective synthesis chiral cyclic enanimes 
The same group developed a procedure for the enantioselective 1,4-conjugate 
addition of aryl groups to cyclic α,β-unsaturated N-tosyl imines using in this case 
arylzinc halides as reagents and a Rh-BINAP complex as catalyst. After stereodivergent 
reduction of the intermediate enamines with a Ru complex and formic acid, the 
corresponding 3-arylcycloakylamines were obtained with high yields, high 
diastereoselectivity (dr > 97:3) and excellent enantioselectivities (Scheme 18).26 
 
Scheme 18. Enantioselective synthesis of 3-arylcycloalkylamines by rhodium-catalyzed 
1,4-addition and subsequent stereodivergent reduction 
The same Rh-BINAP catalyst has been applied in the enantioselective 1,2-addition 
of Me3Al to cyclic N-tosyl imines. The authors noticed that a change of solvent to 
toluene inverted the regioselectivity favoring the 1,4-addition product (6:1) with the 
tosyl imine derived from 2-cyclohexenone. The 1,4-addition pathway was also favored 
with imines derived from substituted cyclohexanones having a stereogenic center 
(mismatched catalyst) or with the imine derived from 4,4-dimethyl-2-cyclopentenone.27 
Recently, Ansoo and Hyunwoo reported the conjugate addition of arylboronic acids 
to imines from β,γ-unsaturated α-keto esters using a rhodium(I) complex with the chiral 
bicyclic bridgehead phosporamidite ligand (R)-briphos (Scheme 19). 
 
Scheme 19. Rh-catalyzed asymmetric 1,4-addition of arylboronic acids to α,β-
unsaturated N,N-dimethylsulfamoyl imino esters 
The reaction has a wide scope, permitting variation at both the γ-aryl substituent on 
the substrate and the aryl group on the boronic acid. The resulting enamines were 
obtained with good yields, good diastereoselectivities favoring the Z-isomer, and 
excellent enantioselectivities regardless of the substitution on the aromatic groups. The 
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authors showed the synthetic utility of the resulting products with several 
transformations. 
Based on DFT calculations and X-ray analysis of the Rh-briphos complex, the 
authors proposed a transition state to explain the observed stereochemistry (Figure 1).28 
 
Figure 1. Stereochemical model for the Rh-briphos catalyzed reaction 
The same catalyst proved to be useful for the conjugate addition of arylboronic 
acids to enones and α,β-unsaturated imines derived from chalcones, as well as in the 
1,2-addition to imines.29 
2.1.1.4. Friedel-Crafts alkylation 
The only example of Friedel-Crafts alkylation involving 1,4-addition to unsaturated 
imines reported to date was described by Hu and Zhao in 2015. These authors carried 
out the alkylation at the C2 position of C3-substituted indoles using β,γ-unsaturated α-
ketimino esters catalyzed by a chiral phosphoric acid. Substitution on the C3 position of 
the indole, which is the most reactive position, shifted the reaction to the C2 position. 
Both the indole and the imine were amenable to substitution, providing products with 
good enantiomeric excesses in most of the examples. The reaction could be scaled up to 
one gram without erosion of optical purity (Scheme 20).30 
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Scheme 20. Enantioselective Friedel-Crafts alkylation of indoles and β,γ-unsaturated α-
ketimino esters 
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2.1.1.5. Nitro-Michael reaction 
In 2011, the group of Liu reported the aza-Henry reaction of nitromethane with 
chiral N-tert-butanesulfinylimines derived from 1,1,1-trifluoromethyl enones. The 
authors discovered that conjugated imines having a perfluoropropyl group attached to 
the azomethinic carbon reacted in a 1,4-regioselective manner to give two 1,4-adducts 
with excellent diastereoselectivities (Scheme 21).31 
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Scheme 21. Diastereoselective conjugate addition of nitromethane to perfluoro-α,β-
unsaturated N-tert-butanesulfinyl ketimines 
On the other hand, Jiang and Wang have reported the organocatalytic conjugate 
addition of nitroalkanes to 2-iminochromenes yielding 2-amino-4H-chromenes which 
have a wide application in medicinal chemistry. The desired products were obtained 
with excellent yields and enantioselectivities when nitromethane was used as 
nucleophile. Bulkier nitroalkenes provided the expected products with good yields and 
high enantioselectivities but with poor diastereoselectivities (Scheme 22).32 
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Scheme 22. Enantioselective synthesis of 2-amino-4H-chromenes 
2.1.1.6. Radicalary conjugate addition reactions  
The group of Tomioka reported in 2008 the reaction of the tetrahydrofuran-2-yl 
radical, generated directly by addition of dimethylzinc to THF in air, with α,β-
unsaturated N-tosyl aldimines to give the 1,4-adducts as major products. The slow 
addition of the imine and the use of dimethylzinc instead of diethylzinc were proved 
essential to favor the 1,4-addition (Scheme 23).33 
 
Scheme 23. Addition of the tetrahydrofuran-2-yl radical to α,β-unsaturated N-tosyl 
aldimines 
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2.1.2. Reactions involving nitrogen and phosphorous nucleophiles 
In 2004 the group of Shimizu described the double nucleophilic addition of azides 
and tetraallyl tin reagents to α,β-unsaturated aldimines promoted by SnCl4·5H2O to 
obtain good yields of 1,3-hydroxy azides in a reaction where the unsaturated aldimine 
played as a latent unsaturated aldehyde (Scheme 24).34 
 
Scheme 24. Double nucleophilic addition of azide and tetraallyl tin reagents to 
unsaturated aldimines 
The reaction most probably proceeds via reaction of TMSN3 with acetic acid to 
give HN3 which adds to the unsaturated imine in a 1,4-fashion, followed by hydrolysis 
of the imine effected by the liberated HCl from SnCl4·5H2O, and addition of the tin 
reagent to the resulting aldehyde. 
In 2009, the group of Palacios reported the conjugate addition of amines to an α,β-
unsaturated imine derived from an α-aminophosphonate to afford α-
dehydroaminophosphonates with a γ-stereogenic center bearing an amino group with 
excellent yields. Depending on the amine, different double bond isomers were obtained, 
which could be isomerized to the E isomer by treatment with triethylamine in 
dichloromethane. The reaction could also be performed in a multicomponent fashion 
generating the imine in situ and subsequently adding the amine (Scheme 25).35 
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Scheme 25. Synthesis of γ-amino-α-dehydroaminophosphonates 
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Later, in 2015, Maruoka developed a highly enantioselective aza-Michael reaction 
of hydroxamic acid to quinone imine ketals catalyzed by chiral boronic acids, allowing 
the synthesis of densely functionalized cyclohexenes (Scheme 26).36 
 
Scheme 26. Enantioselective aza-Michael addition of hydroxamic acid to quinone imine 
ketals 
Even though different conjugate additions of phosphites to α,β-unsaturated imines 
have been reported during the last twenty years,37-39 the first enantioselective example 
involving a phosphorous nucleophile was not described until 2012. That year, the group 
of Leung reported the enantioselective hydrophosphination of α,β-unsaturated ketimines 
with diphenylphosphine catalyzed by a chiral palladacycle yielding the desired enamino 
phosphines with high yields and high enantiomeric excesses (Scheme 27).40 
 
Scheme 27. Enantioselective conjugate addition of diphenylphosphine to unsaturated 
imines 
2.1.3. Reactions involving sulfur nucleophiles 
The first example found in the literature regarding the conjugate addition of sulfur 
nucleophiles to α,β-unsaturated imines was reported by Shimizu in 2002. This group 
performed the double addition of thiols and tetraallyl tin to α,β-unsaturated aldimines to 
give 1,3-amino sulfurs with variable yields and poor diastereoselectivity (Scheme 28).41 
 
Scheme 28. Double addition of thiols and tetraallyl tin to α,β-unsaturated aldimines 
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The reaction most probably proceeds via a mechanism involving the initial 
conjugate addition of the thiol promoted by TiCl4. Subsequent protonation is carried out 
by the HCl liberated from TiCl4 and the thiol to generate an imino species, which in turn 
is attacked by the allyltin to give the double nucleophilic addition product (Scheme 29). 
 
Scheme 29. Mechanism for the double nucleophilic addition 
In 2008, Naito reported the regioselective hydroxysulfenylation of α,β-unsaturated 
oxime ethers via a radical mechanism using triethylborane, thiophenol and oxygen 
(Scheme 30). 
 
Scheme 30. Hydroxysulfenylation of α,β-unsaturated oxime ethers 
The authors proposed a radical mechanism in which PhSBEt2 acts as an initiator for 
the reaction with triplet oxygen leading to the formation of the final products (Scheme 
31).42 
 
Scheme 31. Proposed mechanism for the hydroxysulfenylation reaction 
2.1.4. Reactions involving boron nucleophiles 
In 2009, the group of Fernandez published the conjugate addition of 
bis(pinacolato)diboron to different α,β-unsaturated imines. The reaction was carried out 
in the presence of MeOH as additive, an alcoxide or hydroxide as base, and a 
combination of copper chloride and a phosphine ligand as catalyst, to obtain the 
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corresponding β-boryl imines with good conversions except in the case of unsaturated 
oximes (Scheme 32). 
 
Scheme 32. Cu-mediated conjugate addition of B2pin2 to α,β-unsaturated imines 
The corresponding imino boronates (except when R = OH) could be oxidized with 
sodium borate affording different β-imino alcohols with excellent yields (Scheme 
33).43,44 
 
Scheme 33. Oxidation of imino boronates with sodium perborate 
In a later research, the same group studied the effect of iron salts in the reaction. 
They showed that the iron salt coordinates with the nitrogen of the imine, increasing the 
electrophilicity on the β-position. In this reaction, the boron nucleophile is generated 
upon interaction of bis(pinacolate)diboron and a PPh3/Cs2CO3 organocatalyst. Both, the 
iron salt and the organocatalyst play in a synergetic way and none of them alone can 
activate the substrates (Scheme 34).45 
 
Scheme 34. Iron-activated conjugate addition of boron nucleophiles 
In 2011, the group of Fernandez developed a highly enantio- and diastereoselective 
synthesis of γ-amino alcohols from α,β-unsaturated imines. The reaction was carried out 
in a one-pot fashion involving a copper-catalyzed enantioselective conjugate addition of 
B2(pin)2 to the imine, followed by reduction of the imine moiety with BH3 or DIBAL-H 
and oxidation of the borane with H2O2 in basic medium. The chiral γ-amino alcohols 
were obtained with excellent yields, good syn (reduction with BH3) or anti (reduction 
with DIBAL-H) diastereoselectivity and high enantiomeric excesses (Scheme 35).46,47 
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Scheme 35. Enantioselective one pot synthesis of chiral γ-amino alcohols 
Finally, in 2014, Kobayashi et al. reported another example of enantioselective 
conjugate addition of bis(pinacolato)diboron to α,β-unsaturated N-benzyl imines 
catalyzed by a chiral copper-bipyridine complex in water. After oxidation of the 
resulting imino boronates with sodium perborate, β-imino alcohols were obtained with 
excellent enantiomeric excesses (Scheme 36).48 
 
Scheme 36. Copper-bipyridine-catalyzed enantioselective synthesis of chiral β-imino 
alcohols in water 
2.2. 1-Aza-1,3-butadienes as substrates in cycloaddition reactions  
2.2.1. Diels-Alder and formal [4+2] cycloaddition reactions 
2.2.1.1. Diels-Alder reaction 
With minor exceptions, in this section we will only consider reactions involving 
conjugate imines and alkenes as substrates to give 6-membered aza-cycles. 
a) Nonenantioselective reactions 
The participation of simple α,β-unsaturated imines as heterodienes in Diels-Alder 
reactions typically suffers from low conversions, competitive imine additions or imine 
tautomerization hampering or precluding [4+2] cycloadditions.49-56 In 1989, the group of 
Boger introduced the use of α,β-unsaturated N-benzenesulfonyl imines with the 
expectation that the presence of an electron-withdrawing substituent would accentuate 
the electron-deficient nature of the 1-aza-1,3-butadiene and accelerate the [4+2] reaction 
with electron-rich dienophiles. This group reported the reaction of these substrates with 
different alkenes to give the corresponding N-benzenesulfonyl-1,2,3,4-
tetrahydropyridines with moderate yields and excellent diastereoselectivities (Scheme 
37).57 
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Scheme 37. Diels-Alder reaction of α,β-unsaturated N-benzenesulfonyl imines with 
vinyl ethers 
The scope of the Diels-Alder reaction with α,β-unsaturated N-benzenesulfonyl 
imines has been expanded with different dienophiles obtaining a wide range of 
tetrahydropyridines with a high control of diastereoselectivity (Scheme 38),58-61 and the 
reaction has been applied in the synthesis of many biologically active natural 
products.62-65 
 
Scheme 38. Synthesis of tetrahydropyridines from α,β-unsaturated N-benzenesulfonyl 
imines 
On the other hand, Fowler introduced in 1990 the use of N-acyl-α-cyano-1-
azadienes, which have been applied as dienophiles in aza-Diels-Alder reactions with 
different kinds of dienes obtaining the cyclic adducts with variable yields (Scheme 
39).66 
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Scheme 39. Examples of aza-Diels-Alder reactions with N-acyl-α-cyano-1-azadienes 
Recently, the reaction between α,β-unsaturated N-sulfonyl imines and 2-
trimethylsilyloxyfuran catalyzed by nickel(II) has been described by the group of Wang. 
For this reaction, the authors propose a cascade mechanism involving a vinylogous 
Mukaiyama 1,6-Michael/Michael addition sequence, in which 2-silyloxyfuran performs 
as nucleophile and electrophile sequentially. This methodology combined with 
subsequent reduction provides a facile access to biologically important fused 
piperidine/butyrolactone skeletons in good yield with exclusive diastereoselectivity 
under mild reaction conditions (Scheme 40).67 
 
Scheme 40. Diastereoselective synthesis of fused piperidine/butyrolactone compounds 
Highly reactive benzines have also been used as dienophiles in the [4+2] 
cycloaddition of benzyne and different 1-azadienes to obtain 1,4-dihydroquinolines with 
moderate to good yields (Scheme 41).68 The resulting dihydroquinolines were converted 
into 2,4-diarylquinolones.69 
 
Scheme 41. Synthesis of 1,4-dihydroquinolines 
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b) Asymmetric diastereoselective reactions 
In 1998, Tietze reported the synthesis of tetrahydro- and dihydropyridines by the 
hetero Diels-Alder reaction of enantiopure α,β-unsaturated N-sulfinyl imines and enol 
ethers (Scheme 42). The reaction was performed at 11 Kbar of pressure and led to 
tetrahydropyridines in high yield, good endo/exo selectivities, but with low induced 
diastereoselectivities (up to 2.1:1). The reaction did not work with tetrasubstituted 
alkenes. The sulfinyl group could be removed with MeLi followed by treatment with 
acetyl chloride or dimethyl sulfate. An example of intramolecular reaction was also 
reported.70 
 
Scheme 42. Diastereoselective Diels-Alder reaction with α,β-unsaturated N-sulfinyl 
imines 
In 2005, Barluenga described a single example of diastereoselective Diels-Alder 
reaction between an unsaturated aldimine and an alkynyl(carboxy)carbene complex 
derived from (-)-8-phenylmenthol. The resulting dihydropyridine was obtained with 
98:2 diastereomeric ratio and the chiral auxiliary could be removed by treatment with 
[Cu(MeCN)4]BF4 in wet CH2Cl2 to give an aldehyde group with 99.5% ee.71 
Boger has developed a procedure for the diastereoselective Diels-Alder reaction of 
N-sulfonyl-1-aza-1,3-butadienes with optically active enol ethers derived from chiral 
benzyl alcohols or α-hydroxy lactams as dienophiles (Scheme 43). The reaction was 
highly endo selective and the highest facial selectivity was obtained with the enol ether 
derived from 3-hydroxypyrrolidin-2-one (48:1). The protecting group on the nitrogen 
can also be amenable to variation although the best results were obtained with 
arylsulfonyl groups. The high diastereoselectivity was attributed to a highly organized 
[4+2] cycloaddition transition state.72 
 
Scheme 43. Diastereoselective Diels-Alder reaction with chiral enol ethers 
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A similar strategy has been reported by Palacios but using enamines derived from 
α-amino acids as dienophiles obtaining modest diastereoselectivities.73 
c) Asymmetric catalytic reactions 
A first attempt of enantioselective Lewis acid-catalyzed Diels-Alder reaction with 
1-azadienes was carried out by Motorina in 1999. The intramolecular reaction of a 1-
cyano-1-aza-1,3-butadiene was achieved in the presence of Cu(II)-BOX complexes. 
Although the reaction proceeded under smoother conditions than the thermal process, 
very low enantiomeric induction was observed (ee = 8%).74,75 
In 2007, Carretero et al. developed the first highly enantioselective aza-Diels-Alder 
reaction of vinyl ethers with N-sulfonyl α,β-unsaturated imines derived from chalcone 
using a DBFOX-Ni complex as catalyst. The choice of the N-(8-quinolinesulfonyl) 
group attached to the imine nitrogen was crucial to obtain the cycloadduct with high 
stereocontrol (Scheme 44). 
 
Scheme 44. Enantioselective synthesis of chiral lactams 
In most cases, the products were obtained with moderate yields (61-73%) and good 
to excellent enantiomeric excesses (77-92%). Different vinyl ethers including 
dihydrofuran were good substrates for the reaction. Aryl substituents of different 
electronic and steric nature at the β-position (R2) were tolerated. In contrast, substitution 
compatibility at the imine carbon was more limited with a dramatic drop of yield and 
enantioselectivity being observed with bulky groups (R1 = naphthyl).76,77 
Recently, Rovis has developed an enantio- and diastereoselective formal [4+2] 
cycloaddition involving nitroalkenes and 1-azadienes as two electron-deficient partners 
(Scheme 45). 
 
Scheme 45. Formal [4+2] addition of 1-azadienes and nitroalkenes 
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The resulting nitropiperidines were obtained with good yields, diastereoselectivity 
and variable enantioselectivity (46-92% ee). The electronic properties of the aryl rings 
at the 4-position of the azadiene have no apparent effect on the yield and enantiomeric 
excesses remained high in all the cases. However, ortho substitution, although tolerated, 
produced lower yields and enantioselectivities. Aliphatic enal-derived azadienes were 
not competent substrates and chalcone derived imines required higher catalyst load and 
gave the cycloadducts with lower yield and enantioselectivity. Only nitroalkenes 
bearing aliphatic substituents at the β-position of the double bond were reactive, and 
sterically more-demanding nitroalkenes required longer reaction times. The reaction 
uses zinc as catalyst and a novel BOPA ligand. The presence of two fluorine atoms in 
the ligand was essential, by limiting the undesired coordination of the azadiene to the 
Lewis acid, thus allowing the reaction to be carried out at lower temperature. The 
reaction seems to proceed in a stepwise mechanism involving initial conjugate addition 
of the imine nitrogen to the nitroalkene followed by conjugate addition of the resulting 
nitronate to the unsaturated iminium.78 
A bifunctional organocatalytic strategy for the enantioselective construction of aza-
spirocyclic skeletons has been developed by Wang through the Diels-Alder reaction 
between cyclic keto/enolate salts and 1-aza-1,3-butadienes. The desired products were 
obtained with good yields, diastereo- and enantioselectivities (Scheme 46). The use of a 
bifunctional organocatalyst bearing a primary amine and a thiourea moiety was essential 
for the success of the reaction, which is believed to take place through a double 
activation mechanism in which the primary amine activates the enolate via iminium 
formation while the thiourea moiety activates de N-sulfonyl azadiene through hydrogen 
bond formation.79 
 
Scheme 46. Organocatalytic Diels-Alder reaction between cyclic keto/enolate salts and 
1-aza-1,3-butadienes 
On the other hand, Masson has reported the enantioselective Diels-Alder reaction of 
1-aza-dienes with enecarbamates catalyzed by chiral phosphoric acids to give 4,5,6-
trisubstituted 1,4,5,6-tetrahydropyridines. The resulting products were obtained with 
high diastereoselectivity favoring the all-trans isomer and with excellent 
enantioselectivities in most of the examples (Scheme 47). The authors proposed a 
highly asynchronous concerted mechanism with the chiral phosphoric acid serving as a 
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bifunctional catalyst with the OH group activating the 1-azadiene as Brønsted acid and 
the phosphoryl oxygen atom activating the enecarbamate as a Lewis base.80 
 
Scheme 47. Enantioselective Diels-Alder reaction of 1-aza-dienes with enecarbamates 
catalyzed by chiral phosphoric acids 
2.2.1.2. Base-promoted formal [4+2] cycloadditions with carbonyl compounds 
The sequential Michael addition of carbonyl enolates to 1-aza-1,3-butadienes 
followed by a intramolecular nitrogen nucleophilic attack to the carbonyl group allows 
the synthesis of 6-membered aza-cyclic compounds. A first example reported by Jones 
in 1988 involved the Michael addition of diethyl malonate to 2-(1-alkenyl)-2-
imidazolines to give the 1,4-adduct which cyclized during chromatography on silica gel 
to a hexahydroimidazol[1,2-a]pyridine.81 
This strategy has been employed by Palacios in the synthesis of fluorinated 3,4-
dihydropyridin-2-ones from azadienes and esters via a Michael addition/lactamization 
reaction. The reaction with dimethyl malonate had to be carried out at rt to avoid 1,2-
addition to the imine. The required fluorinated unsaturated imines were prepared via a 
Wittig-Horner reaction. Both, the Wittig-Horner and the cyclization reactions could be 
achieved in a one pot manner (Scheme 48).82 
 
Scheme 48. Synthesis of dihydropyridin-2-ones and pyridines via Michael/cyclization 
strategy 
The same authors extended this methodology to the synthesis of pyridines by using 
nitriles instead of esters and performing the reaction at rt (Scheme 49).83 
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Scheme 49. Synthesis of fluorinated pyridines 
However, when malononitrile was reacted with α,β-unsaturated N-tosyl imines 
derived from chalcone under dual hydrogen-bonding/basic catalysis, Lu and Xie 
obtained chiral cyclohexa-1,3-dienes instead of the expected dihydropyridines. By using 
cinchonine as catalyst moderate yields (31-53%) and good enantioselectivities (81-91%) 
were obtained (Scheme 50). 
 
Scheme 50. Reaction between N-tosyl β,γ-unsaturated imines and malononitrile to 
obtain the corresponding cyclohexa-1,3-dienes 
The authors propose a stepwise mechanism involving a Michael addition of 
malononitrile to give an intermediate that undergoes a Knoevenagel condensation, 
followed by an intramolecular cyclization and a proton transfer resulting in the 
corresponding cyclohexa-1,3-dienes (Scheme 51).84  
 
Scheme 51. Proposed mechanism for the formation of cyclohexa-1,3-dienes 
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2.2.1.3. Acid-promoted formal [4+2] cycloadditions with carbonyl compounds 
Under acidic conditions 1-aza-1,3-butadienes have been shown to undergo 
cyclocondensation with β-keto esters and 1,3-diketones to give acyl substituted 
dihydropyridines.85-86 
The first enantioselective version of this reaction was reported by Gong in 2008 in a 
three-component manner using α,β-unsaturated aldehydes, primary amines and 1,3-
dicarbonyl compounds (Scheme 52). The proposed mechanism for this reaction 
involves the in situ formation of the unsaturated imine by condensation between a 
primary amine and the unsaturated aldehyde, which undergo a 1,4- conjugate addition 
with a 1,3-dicarbonyl compound followed by condensation and dehydration. The use of 
a chiral phosphoric acid that activates the imine led to the formation of enantioenriched 
products. The reaction allowed variation in all the reactants and the dihydropyridines 
were obtained with excellent enantiomeric excesses. The procedure is also applicable to 
2,4-pentanedione as nucleophile, although in this case lower enantioselectivities were 
obtained.87 
 
Scheme 52. Three component asymmetric synthesis of dihydropyridines 
Later, Zheng and Zhang reported a similar reaction with β,γ-unsaturated α-keto 
esters instead of enals and pentanedione instead of keto esters, using in this case a chiral 
imidodiphosphoric acid as catalyst (Scheme 53). The reaction performed with high 
enantioselectivities but low yields in most of the cases. 
 
Scheme 53. Reaction between β,γ-unsaturated α-keto esters, aryl amines and 
pentanedione 
A mechanistic proposal by the authors involved the condensation between the β,γ-
unsaturated α-keto ester and the aryl amine to give a β,γ-unsaturated α-imino ester 
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which is activated by hydrogen bonding with the imidophosphoric acid at the same time 
as the pentanedione. Michael addition followed by attack of the amino group to the 
carbonyl group and dehydration would deliver the chiral 1,4-dihydropyridines (Scheme 
54).88 
 
Scheme 54. Mechanistic proposal for the cyclization reaction 
A formal [4+2] cycloaddition reaction between α,β-unsaturated N-tosyl imines and 
aldehydes to give dihydropyridines catalyzed by a ruthenium porphyrin complex as 
Lewis acid has been developed by the group of Matsubara. The reaction provided the 
cycloaddition products with unprecedented substitution patterns. Reduction with SmI2 
yielded the detosylated dihydropyridines (Scheme 55). 
 
Scheme 55. Ruthenium catalyzed synthesis of unsymmetrical dihydropyridines 
The authors proposed a mechanism in which the catalyst both activates the imine 
and forms the enolate. After the 1,4-addition step, the corresponding dihydropyridines 
would be obtained upon attack of the nitrogen atom to the carbonyl group and water 
elimination (Scheme 56).89 
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Scheme 56. Reaction mechanism for the ruthenium catalyzed synthesis of 
dihydropyridines 
2.2.1.4. Formal [4+2] cycloadditions with carbonyl compounds via enamine activation 
Nucleophilic activation of carbonyl compounds can be achieved by conversion into 
enamines upon treatment with catalytic secondary or primary amines. The group of 
Chen reported in 2008 the aza-Diels-Alder reaction between α,β-unsaturated N-tosyl 
imines and aliphatic aldehydes in the presence of the Hayashi-Jørgensen catalyst, a 
prolinol derivative (Scheme 57).90 
 
Scheme 57. Enantioselective Diels-Alder reaction between N-tosyl α,β-unsaturated 
imines and aliphatic aldehydes 
The obtained hemiaminals were subjected to different transformations such as 
oxidation of the hydroxyl group to give pyrimidones, dehydrogenation to pyridines, 
hydrogenation to dihydro- or tetrahydropyridines, or hydrolysis to dicarbonyl 
compounds keeping intact the integrity of the chiral center (Scheme 58). 
Literature Review 
28 
 
Scheme 58. Synthetic transformations of a chiral hemiaminal 
Over the following years, these authors have expanded the applicability of this 
methodology with different aldehydes, obtaining a wide range of chiral aza-cyclic 
compounds with high enantiomeric excesses (Scheme 59).91-94 
 
Scheme 59. Organocatalytic enantioselective Diels-Alder reactions with aldehydes 
The same authors have also studied the enamine activation strategy in the reaction 
of 1-azadienes derived from saccharin and interrupted cyclic 2,5-dienones. The reaction 
catalyzed by 9-amino-9-deoxyepiquinidine and benzoic acid yields the cycloadducts 
with exclusive δ,ε-regioselectivity, and excellent diastereo- and enantioselectivity. 
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Remarkably, the reaction does not work with fully conjugate 2,4-dienones. The 
substrate scope is wide and besides saccharin derivatives, 1-azadienes with the 1,2,3-
benzoxathiazine-2,2-dioxide motif and acyclic unsaturated N-tosyl imines are 
appropriate substrates in this reaction (Scheme 60).95 
 
Scheme 60. Cycloaddition of 1-azadienes and interrupted cyclic 2,5-dienones 
Moreover, the group of Chen reported the enantioselective synthesis of 
hydropyrano[2,3]pyridines via a sequential aza-Diels-Alder/oxa-Michael reaction 
between enone enals and unsaturated N-tosyl imines with variable yields but excellent 
enantiomeric excesses (Scheme 61). The reaction also allowed the synthesis of 
hexahydrofuro[2,3-b]pyridines enantioselectively. However, attempts to construct a 
fused oxepane ring were not successful.96 
 
Scheme 61. Asymmetric sequential aza-Diels-Alder/oxa-Michael reaction 
Very recently, Liu et al. accomplished the asymmetric synthesis of ring-fused 
piperidines in a one-pot operation from cyclic hemiaminals and α,β-unsaturated N-tosyl 
imines using the Hayashi-Jørgensen catalyst (Scheme 62). The piperidine fused 
products containing N,O- or N,N- acetal moieties were obtained with variable yields, but 
with full diastereoselectivity and enantiomeric excesses above 99%.97 
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Scheme 62. Synthesis of piperidine fused products 
Finally, the group of Chen has reported the cycloaddition between 1-aza-1,3-
butadienes containing a 1,2-benzoisothiazole-1,1-dioxide or 1,2,3-benzoxathiazine-2,2-
dioxide motif and conjugate linear dienals in the presence of the Hayashi-Jørgensen 
catalyst to give chiral cyclohexene derivatives. Remarkably, in this case the 1-azadienes 
react as regio- and chemoselective dienophiles in normal-electron-demand Diels-Alder 
reactions with HOMO-raised trienamines (Scheme 63).98 
 
Scheme 63. 1-Azadienes as dienophiles in Diels-Alder reactions 
2.2.1.5. Formal [4+2] cycloadditions with carbonyl compounds via acyl activation 
Nucleophilic addition of tertiary nitrogen atoms to acid derivatives yields N-acyl 
ammonium derivatives, increasing the acidity of the α-hydrogens and therefore 
activating the nucleophilicity of the carbonyl compound. Chiral guanidines and 
isothioureas have been frequently used as acyl activation catalysts in asymmetric 
synthesis. In 2012, the Smith group reported the enantioselective conjugate addition of 
carboxylic acids to N-tosyl α,β-unsaturated imines catalyzed by a chiral isothiourea to 
yield dihydropyridones (Scheme 64).99 In a later work, the same authors extended this 
methodology to imines derived from γ-oxo-α,β-unsaturated esters with excellent results 
using (-)-tetramisole hydrochloride as the catalyst.100 
 
Scheme 64. [4+2] Cycloaddition of carboxylic acids and unsaturated imines catalyzed 
by isothioureas 
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The authors postulate a mechanism in which nucleophilic addition of the catalyst to 
a mixed anhydride formed in situ is followed by deprotonation by a base to give an 
ammonium enolate which undergoes a Michael addition with the unsaturated imine, to 
give an acyl ammonium cation which is intramolecularly attacked by the imine nitrogen 
to give the final dihydropyridone (Scheme 65).99 
 
Scheme 65. Mechanism of dihydropyridone formation 
The group of Smith has also described the enantioselective formal cycloaddition of 
bench-stable N-acyl imidazoles with β-trifluoromethyl α,β-unsaturated ketimines and 
α,β-unsaturated saccharin derivatives catalyzed by isothiourea hydrochloride salts in the 
absence of base with moderate to excellent enantioselectivities (Scheme 66). Detailed 
mechanistic studies revealed the importance of the “imidazolium effect” in promoting 
reactivity and highlighted key differences with traditional base-promoted processes.101 
 
Scheme 66. Enantioselective cycloaddition between acyl imidazoles and different 
Michael acceptors 
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Pericàs and Izquierdo have developed a PS-supported isothiourea catalyst that has 
been used in batch and flow processes for the cycloaddition of carboxylic acid esters 
and α,β-unsaturated N-tosyl imines derived from chalcones or conjugate imines derived 
from saccharin with excellent enantiomeric excesses (Scheme 67).102 
 
Scheme 67. Enantioselective synthesis of chiral lactams with a PS-supported 
isothiourea catalyst 
N-acyl activation has also been employed for the synthesis of pyridines when the 
acid derivative bears a leaving group on the α-carbon. According to this strategy, the 
group of Smith reported the synthesis of functionalized pyridines by reacting 
(phenylthio)acetic acid and N-tosyl α,β-unsaturated ketimines or β-trifluoromethyl α,β-
unsaturated N-tosyl imines in the presence of an achiral isothiourea catalyst (Scheme 
68).103  
 
Scheme 68. Synthesis of pyridines from α,β-unsaturated N-tosyl imines and 
(phenylthio)acetic acid 
The reaction takes place through acyl activation as in the synthesis of 
dihydropyridones, but after the cyclization step, the resulting lactam undergoes 
elimination of thiophenol followed by a thermal N- to O- sulfonyl migration affording 
the corresponding pyridines (Scheme 69). 
 
Scheme 69. Elimination and sulfonyl migration affording pyridines 
A similar strategy for the synthesis of trisubstituted pyridines starting from p-
chlorophenyl chloroacetate and α,β-unsaturated N-tosyl imines has been employed by 
Chi using 4-dimethylaminopyridine (DMAP) instead of an isothiourea as the catalyst 
(Scheme 70).104 
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Scheme 70. DMAP catalyzed synthesis of trisubstituted pyridines 
The mechanism of this reaction is similar to that of the reaction catalyzed by 
isothiurea, with the DMAP activating the acid through the formation of an N-acyl 
pyridinium cation (Scheme 71). 
 
Scheme 71. Mechanism for the formation of pyridines catalyzed by DMAP 
Recently, Du and Lu reported a similar reaction catalyzed by DMAP using α-bromo 
acetic acid instead of the α-chloro acetic ester justified by the lower price of the 
nucleophile. This new methodology was also extended to the synthesis of fused pyridin-
2-ones using cyclic 1-azadienes derived from saccharin as electrophiles (Scheme 72).105 
 
Scheme 72. Synthesis of pyridines and pyridin-2-ones from α-bromoacetic acid 
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2.2.1.6. NHC-catalyzed formal [4+2] cycloadditions with carbonyl compounds 
In 2006, in the context of N-heterocyclic carbene (NHC) catalysis studies, the 
group of Bode recognized that protonation or trapping of Breslow-type intermediates 
should lead to catalyst-bound enols or enolates poised for C-C bond formation (Scheme 
73). 
 
Scheme 73. NHC activation of enals 
By implementing this strategy, this group used the generated enolates as 
dienophiles and developed the first NHC catalyzed Diels-Alder reaction with α,β-
unsaturated N-sulfonyl aldimines. To increase the electrophilicity of the enal, trans-4-
oxo-2-butenoates were used as substrates. Hindered triazolium catalysts were required 
to avoid formation of γ-lactams resulting from 1,2-addition to the imine. Under the 
optimized conditions, dihydropyridones were obtained with fair yields and excellent 
enantioselectivities (Scheme 74). 
 
 
Scheme 74. NHC catalyzed Diels-Alder reaction of enals and unsaturated imines 
The authors postulated a mechanism in which the formed Z-enolate reacts as the 
dienophile with the α,β-unsaturated imine through an endo transition state (Scheme 
75).106 
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Scheme 75. Mechanism for the NHC catalyzed cycloaddition of enals and unsaturated 
imines 
In 2011, the group of Ye described the Diels-Alder addition of ketenes to 1-aza-1,3-
butadienes via NHC catalysis obtaining chiral dihydropyridones. This procedure 
represents the first example of enantioselective cycloaddition reaction with α,β-
unsaturated N-tosyl imines in which a quaternary chiral center is generated (Scheme 
76).107 
 
Scheme 76. NHC catalyzed synthesis of chiral dihydropiridones from ketenes and 
unsaturated imines 
Later, they applied this methodology for the asymmetric conjugate addition of α-
chloro aldehydes to β-trifluoromethyl β,γ-unsaturated imines via NHC catalysis 
obtaining the corresponding N-tosyl or N-boc protected lactames with excellent 
diastereomeric ratios (dr > 20:1) and enantiomeric excesses (96-99%). According to the 
exclusive cis-stereoselectivity observed in the obtained lactams, the authors suggested 
that the reaction takes place through a concerted [4+2] cycloaddition reaction pathway 
instead of a stepwise mechanism involving a Michael type reaction followed by 
intramolecular cyclization (Scheme 77).108,109 
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Scheme 77. Enantioselective synthesis of trisubstituted chiral lactams from α-
chloroaldehydes via NHC-catalysis 
In 2012, the group of Rovis developed a procedure for the NHC asymmetric 
cycloaddition of simple aliphatic aldehydes with α,β-unsaturated N-tosyl imines derived 
from chalcones, obtaining dihydropyridones with excellent yields, diastereo- and 
enantioselectivity (Scheme 78).110 The use of an oxidant allowed the generation of the 
enolate intermediates from simple aldehydes instead of enals or α-chloroaldehydes. 
 
Scheme 78. NHC catalyzed asymmetric oxidative cycloaddition of aliphatic aldehydes 
with N-tosyl α,β-unsaturated imines 
Almost simultaneously, the group of Chi developed NHC catalyzed cycloadditions 
of unsaturated imines with esters instead of aldehydes. In these cases the NHC catalyst 
activates the ester favoring formation of the enolate by a base in a similar manner as in 
the acyl activation catalysis with isothioureas or DMAP (Scheme 79). 
 
 
Scheme 79. NHC activation of esters 
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This group first reported the cycloaddition of p-nitrophenyl arylacetic esters with 
N-tosyl imines derived from chalcones (Scheme 80). Both, the arylacetic ester and the 
imine were amenable to different substitution, and the resulting chiral dihydropyridones 
were obtained with fair to good yields, good diastereoselectivity and moderate to good 
enantiomeric excesses (60-98%).111 
 
Scheme 80. NHC catalyzed reaction of arylacetic esters and α,β-unsaturated imines 
Later, the group extended the scope of the reaction with alkylacetic or acetic esters 
and chalcones or α,β-unsaturated N-tosyl imines derived from chalcones, obtaining in 
all the cases the corresponding lactones or lactams with excellent enantiomeric excesses 
(Scheme 81).112,113 
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Scheme 81. NHC catalyzed reaction of alkylylacetic and acetic acid esters with α,β-
unsaturated imines 
A variation of this reaction was reported in 2016 by the group of She. These authors 
proposed the use of 1,3-dioxoisoindolin-2-yl acetic esters as nucleophiles because the 
required catalyst loading is lower than the required with 4-nitrophenol esters and 
because the N-hydroxy-phthalimide from the ester can catalyze a subsequent N- to C-
sulfonyl migration reaction.114 
2.2.1.7. Formal [4+2] cycloadditions via Rauhut-Currier reaction catalyzed by 
phosphines or amines 
In 2012, the group of Chi employed a chiral aminophosphine catalyst to achieve the 
first enantioselective intramolecular [4+2] annulation of electron-deficient alkenes and 
N-sulfonyl α,β-unsaturated imines (Scheme 82).115 
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Scheme 82. Intramolecular phosphine catalyzed enantioselective [4+2] annulation of 
acrylates and N-sulfonyl α,β-unsaturated imines 
Furthermore, the reaction can be carried out with azatrienes having a second vinyl 
substituent instead of the B aromatic ring. These substrates can undergo a second [4+2] 
to provide polycyclic chiral sulfonyl enamines. 
The authors postulated the reaction mechanism as a tandem Rauhut-Currier/SN2-
substitution sequence in which the high diastereoselectivity likely results from a 
favorable SN2 reaction of intermediate A and reversible interconversion between 
intermediates A and B (Scheme 83). 
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Scheme 83. Tandem Rauhut-Currier/SN2 mechanism 
The same year, the group of Zhong reported an intermolecular version for this 
reaction with vinyl ketones in both nonenantioselective and enantioselective fashion 
affording a wide range of substituted tetrahydropyridines (Scheme 84).116,117 
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Scheme 84. Intermolecular phosphine catalyzed [4+2] annulation of vinyl ketones and 
α,β-unsaturated imines 
Later, Wei and Shi applied a thiourea-phosphine catalyst derived from a natural 
amino acid in the reaction between vinyl ketone and oxindole derived α,β-unsaturated 
imines in the enantioselective synthesis of 2’,3’-dihydro-1’H-spiro[indoline-3,4’-
pyridin]2-ones.118 
Other chiral aminophospine catalysts have been reported by Wu to perform the 
enantioselective cycloaddition of methyl vinyl ketone to α,β-unsaturated N-tosyl imines 
with variable yields, moderate to good diastereoselectivities and moderated 
enantiomeric excesses.119 
Finally, the triphenylphosphine catalyzed reaction of enones and α,β-unsaturated 
imines has been applied by Fan and Bakulev in the synthesis of tetrahydropyridines 
containing a thiazole moiety. These compounds were studied for their fungicidal and 
insecticidal properties.120 
On the other hand, the group of Loh reported in 2013 the synthesis of highly 
functionalized pyridines from allenoate esters and unsaturated imines via an aza-
Rauhut-Currier/cyclization/desulfonylation sequence using a tertiary amine (TMEDA) 
instead of a phosphine as catalyst (Scheme 85).121 
  
Scheme 85. Synthesis of pentasubstituted pyridines catalyzed by TMEDA 
In the proposed mechanism, TMEDA reacts with the allenoate ester to give an 
ammonium ylide which undergoes 1,4-addition to the unsaturated imine. After 
intramolecular proton transfer, intramolecular aza-1,4-addition yields the cyclized 
product which expulses the TMEDA catalyst and suffers desulfonylation to afford the 
pyridine (Scheme 86). 
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Scheme 86. Proposed mechanism for the synthesis of pyridines catalyzed by TMEDA 
2.2.1.8. Other formal [4+2] cycloadditions  
Saito and coworkers developed cross-conjugated azatrienes as substrates in diene-
transmissive Diels-Alder reactions, i.e., two sequential (tandem) cycloadditions that 
involve and initial Diels-Alder reaction of a cross-conjugated triene (or equivalent) with 
a dienophile, followed by a second Diels-Alder reaction of the mono-adduct on the 
newly formed diene unit to give a bis-adduct. In their first example, these authors 
performed the hetero Diels-Alder cycloaddition reaction using tosyl isocyanate and the 
cross-conjugated azatrienes, obtaining the corresponding dihydropyrimidones with a 
diene system that allowed a second cycloaddition with different dienophiles to give 
bicyclic products (Scheme 87).122 
Scheme 87. Diene-transmissive Diels-Alder reactions using tosyl isocyanate and cross-
conjugated azatrienes 
Over the next years, this group enlarged the scope of this reaction using ketenes and 
alkenes as dienophiles to obtain lactams and tetrahydropyridines which can undergo a 
second cyclization reaction with a wide range of dienophiles. In the first case, the first 
[4+2] cycloaddition is believed to take place through a [2+2] cycloaddition followed by 
[1,3]-sigmatropic rearrangement of the resulting lactam (Scheme 88).123-125 
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Scheme 88. Examples of diene-transmissive hetero Diels-Alder reactions of cross-
conjugated azatrienes with ketenes or alkenes 
In 2006 the group of Orru reported a multicomponent approach for the synthesis of 
dihydropyrimidones. The reaction involves the in situ generation of 1-azadienes via a 
Horner-Wadsworth-Emmons reaction from phosphonates, aldehydes and isocyanides, 
and their ulterior cycloaddition with isocyanates (Scheme 89).126 
 
Scheme 89. Horner-Wadsworth-Emmons/aza-Diels-Alder synthesis of 
dihydropyrimidones 
On the other hand, the group of Palacios has reported a related cycloaddition 
between N-tosyl isocyanate and fluoroalkylated α,β-unsaturated imines yielding 3,4-
dihydropyridin-2(1H)-ones with good yields under mild conditions (Scheme 90). The 
use of N-tosyl isocyanate was essential in this reaction, since phenylisocyanate 
promoted 1,2-addition to give triazinane-2,4-diones. 
 
Scheme 90. Synthesis of fluorinated 3,4-dihydropyridin-2(1H)-ones 
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Supported by computational studies, the authors propose a mechanism involving a 
first nucleophilic attack of the unsaturated imine nitrogen to the electron-deficient 
carbon of the isocyanate followed by an intramolecular aza-Michael addition leading to 
the formation of the 3,4-dihydropyridin-2(1H)-one.127  
2.2.2. Formal [4+1] cycloaddition reactions 
The use of azadienes in [4+1] annulation reactions to give pyrrole derivatives has 
been barely explored compared with the [3+2] approach. The first [4+1] annulation 
using unsaturated imines was reported in 1999 by Murai and coworkers. The reaction of 
α,β-unsaturated imines with carbon monoxide catalyzed with Ru3(CO)12 provided β,γ- 
or α,β-unsaturated γ-lactams.128 
In 2009, Masson and Zhu reported the synthesis of 2-amino-5-cyanopyrroles via a 
[4+1] cycloaddition between 2-cyano-1-azadienes and isocyanides in the presence of a 
catalytic amount of AlCl3 with good to excellent yields. The required azadienes were 
prepared in a multicomponent fashion from enals, amines and TMSCN involving an 
IBX/TBAB-mediated oxidative Strecker reaction (Scheme 91). 
 
Scheme 91. [4+1] Cycloaddition of isocyanides and 2-cyano-1-azadienes 
The authors proposed a mechanism for this reaction involving 1,4-addition of the 
isocyanide to the imine coordinated to AlCl3, followed by attack of the nitrogen atom to 
the nitrilium and a subsequent [1,3]-H shift in the resulting cycloadduct to produce the 
pyrrole (Scheme 92).129 
 
Scheme 92. Proposed mechanism for the [4+1] cycloaddition reaction 
A similar strategy for the synthesis of pyrroles from alkyl or acyl isocyanides and 
unsaturated imines has been reported by Liu using Cp2ZrCl2. The reaction is thought to 
proceed through the formation of circonocene 1-aza-1,3-butadiene complexes.130,131 
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Simultaneously, Iwasawa et al. developed a [4+1] cycloaddition of terminal alkynes 
with N-benzyl or N-methyl α,β-unsaturated imines catalyzed by rhodium(I) giving rise 
to pyrroles with moderate to good yields (Scheme 93).132 
 
Scheme 93. Synthesis of pyrroles from alkynes and α,β-unsaturated imines catalyzed by 
Rh(I) 
In 2014, Wang and Xu reported a novel methodology for the synthesis of 
trifluoromethylated pyrroles from unsaturated imines and trifluoroacetic anhydride. 
Excellent yields were obtained for a number of 2-trifluoromethyl pyrroles having 
differently substituted aromatic rings at the 5 position (Scheme 94). 
 
Scheme 94. Synthesis of trifluoromethylated pyrroles 
The authors proposed a reaction mechanism involving the initial 1,4-addition of 
triphenylphosphine to the imine, subsequent attack of the negatively charged nitrogen to 
a TFA molecule to form an amide and intramolecular substitution to give the pyrrole 
(Scheme 95).133 
 
Scheme 95. Proposed mechanism for the synthesis of trifluoromethylated pyrroles 
In 2010, Xiao and Chen reported the diastereoselective [4+1] annulation of sulfur 
ylides with α,β-unsaturated N-sulfonyl imines derived from keto esters. The use of 
chiral sulfur ylides prepared from an atropoisomeric binapthyl-derived sulfide allowed 
the preparation of chiral pyrrolines with high to excellent yields, diastereoselectivities 
and enantiomeric excesses (Scheme 96). The use of N-sulfonyl imines was crucial as 
PMP-protected imines did not react with the sulfur ylide.134 
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Scheme 96. Synthesis of chiral pyrrolines from chiral sulfur ylides 
A study rationalized the stereoinduction of the reaction on the basis of two effects: 
a) the preferential approach of the imine from the Si face of the ylide to avoid the steric 
repulsion between the TIPBS group of the imine and the naphthalenyl ring of the 
atropoisomeric sulfide, and b) the favorable Coulombic interactions between the 
negative charged N of the imine and the positive charged S of the ylide, leading to a 
cisoid/quasi [4+2]-addition conformation (Scheme 97). 
 
Scheme 97. Rationalization of the origin of stereoselectivity 
Another diastereoselective synthesis of dihydropyrroles via a [4+1] annulation 
reaction was described by Tang in 2011. N-Tosyl imines derived from chalcone reacted 
with tert-butyl diazoacetate in the presence of catalytic amounts of Fe(Tcpp)Cl and 4-
methylpyridine to produce 2-alcoxycarbonyl dihydropyrroles with good yields and 
excellent diastereoselectivities (>50:1). Aliphatic imines were not suitable substrates for 
this reaction (Scheme 98). The reaction with unsaturated diesters also allowed the 
synthesis of dihydrofurans.135 
 
Scheme 98. [4+1] cycloaddition of unsaturated imines and tert-butyl diazoacetate 
Simultaneously, the group of He reported the diastereoselective [4+1] annulation of 
allylic carbonates and α,β-unsaturated N-tosyl imines derived from chalcone catalyzed 
by triphenylphosphine. The reaction with cyclic α,β-unsaturated imines gave the 
corresponding cyclic fused pyrrolines (Scheme 99).136 
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Scheme 99. Cycloaddition of allylic carbonates and N-tosyl α,β-unsaturated imines 
The authors proposed two plausible mechanisms for the formation of the pyrrolines 
involving α- or γ-addition of the initially formed allylic phosphorous ylide to the imine 
(Scheme 100). 
 
Scheme 100. Possible mechanisms for the Ph3P catalyzed cycloaddition 
Finally in 2015, the group of Chen developed the first catalytic enantioselective 
[4+1] annulation reaction between ammonium ylides derived from 3-bromooxindoles 
and α,β-unsaturated imines catalyzed by cinchona alkaloid derivatives. Moreover, the 
reaction could be extended to acyclic α-bromo esters with slight modification of the 
reaction conditions (Scheme 101).137 
 
Scheme 101. Catalytic enantioselective [4+1] annulation of 3-bromooxindoles and α,β-
unsaturated imines 
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2.2.3. Formal [3+2] and [2+3] cycloaddition reactions 
One of the first examples of [3+2] cycloaddition reactions involving α,β-
unsaturated imines was reported by the group of Bergman. This group utilized cobalt 
dinitrosyl/alkene adducts as the two atom components that underwent [3+2] annulation 
reaction with either α,β-unsaturated aldehydes or imines catalyzed by Sc(OTf)3 to give 
tri- or tetracycles, which after retrocycloaddition with bicyclo[2.2.1]hepta-2,5-diene led 
to the formation of bicyclic olefins (Scheme 102).138 
 
Scheme 102. [3+2] Cycloaddition involving cobalt dinitrosyl/alkene adduct and α,β-
unsaturated imines 
In 2008, the group of Bode reported the enantioselective synthesis of cyclopentane 
fused β-lactams using NHC catalysis. By changing from β-acyl substituted enals to β-
alkyl or β-aryl substituted enals, from unsaturated aldimines to unsaturated ketimines, 
and the base, a shift of reactivity from the previously described [4+2] reaction106 to a 
formal [3+2] reaction was observed (Scheme 103).139 The resulting products were 
obtained with moderate to excellent yields, good diastereomeric ratios and excellent 
enantiomeric excesses. 
 
Scheme 103. NHC catalyzed enantioselective synthesis of bicyclo[3.2.0]lactams 
Supported by the all cis substitution observed in the bicyclo-β-lactams, the authors 
proposed a mechanism involving a crossed-benzoin/oxy-Cope rearrangement as the key 
bond-forming step. The preference for this reaction mechanism instead of a Diels-Alder 
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reaction is probably due to the use of nonactivated enals in which the protonation on the 
β-carbon is too slow (Scheme 104).140 
 
Scheme 104. Proposed mechanism for the formation of bicyclo[3.2.0]lactams 
Later in 2013, Chi discovered that by using cis-enals and phenol-derived additives, 
the NHC catalyzed reaction with α,β-unsaturated N-sulfonyl imines delivered 
cyclopentanones instead of lactams as reported by Bode, with excellent diastereo- and 
enantioselectivity (Scheme 105).141 The use of additives was essential to avoid 
isomerization of the cis- to the trans-enal that led to the fused lactam products observed 
by Bode.139 
 
Scheme 105. Enantioselective synthesis of chiral cyclopentanones via NHC catalysis 
The authors attributed the change of reactivity to the formation of different 
diastereomeric intermediates, which would prefer to undergo a final Mannich-type 
reaction in the case of trans enals or a Claisen-type reaction in the case of cis enals 
(Scheme 106). 
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Scheme 106. Compared mechanistic pathways for the reaction of cis- and trans-enals 
Previous to the work of Chi, He and Tian described the [3+2] annulation reaction of 
α-benzyl allenoates with α,β-unsaturated N-tosyl imino esters catalyzed by phosphines 
to yield cyclopentenes with a trans exocyclic enamine moiety with moderate to high 
diastereoselectivities and moderate yields (Scheme 107). 
 
Scheme 107. Phosphine catalyzed [3+2] annulation between allenoates and α,β-
unsaturated N-tosyl imino esters 
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Based on a deuterium-labelled experiment the authors proposed the mechanism 
outlined in Scheme 108 for the formation of the cyclopentenes.142 
 
Scheme 108. Mechanism for the synthesis of cyclopentenes 
Later, the group of Huang reported the sequential [2+3] and [3+2] annulation 
domino reaction of allenoates and α,β-unsaturated N-tosyl imines derived from 
chalcones, using triphenylphosphine as a catalyst to give cyclopentane fused 
dihydropyrroles with moderate to high yields and excellent diastereoselectivities. The 
presence of the phenyl group attached to the γ-carbon of the allenoate was required for 
the reaction to proceed, probably due to activation of the methylene by π-conjugative 
effect (Scheme 109).143 
 
Scheme 109. Sequential [2+3] and [3+2] annulation domino reaction between methyl 6-
phenylhexa-2,3-dienoate and α,β-unsaturated N-tosyl imines 
Finally, Shi reported recently the enantioselective [3+2] or [3+2]/ [4+2] cascade 
reaction between α,β-unsaturated imines and 3-isothiocyanato oxindoles to give 
spirocyclic oxindoles using a bifunctional thiourea derived from cinchona alkaloid as 
the catalyst. Furthermore, when N-((1E,4E)-1,5-diphenylpenta-1,4-dien-3-
ylidene)methane-sulfonamide was used as electrophile, the first [3+2] cycloaddition 
reaction was followed by a subsequent [4+2] cycloaddition reaction to give tricyclic 
compounds (Scheme 110).144 
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Scheme 110. Enantioselective synthesis of spirocyclic oxindoles 
2.2.4. Formal [3+3] cycloaddition reactions 
In 2015, the group of Zhou and Wang reported the spiroannulation [3+3] between 
1-azadienes derived from saccharin and indoline-2-thiones using a thiourea bifunctional 
catalyst. A wide range of different products could be obtained with this methodology in 
82-99% yield and 76-99% ee (Scheme 111). 
 
Scheme 111. Synthesis of chiral spiro[thiopyranoindole-benzoisothiazole] heterocycles 
Furthermore, α,β-unsaturated N-tosyl imines derived from chalcone could also be 
used as substrate to give the corresponding product with 90% yield, >20:1 dr and 94% 
ee.145 
Simultaneously, the group of Chen developed a [3+3] cycloaddition using the same 
kind of imines derived from saccharin with different ketones via enamine-enamine 
catalysis. After optimization of reaction conditions they obtained the desired 
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cycloadducts with excellent yields and enantiomeric excesses in most of the cases, using 
9-amino-9-deoxyepiquinine as the catalyst and salicylic acid as an additive (Scheme 
112). 
 
Scheme 112. Enamine-enamine catalysis in the [3+3] cycloaddition of ketones to 
unsaturated imines 
The analogous cyclic (E)-4-styryl-benzo[e][1,2,3]oxathiazine-2,2-dioxide also gave 
the [3+3] adduct with good yield and ee. However, when an acyclic β,γ-unsaturated N-
tosyl imino ester was used, hydrolysis to the corresponding keto ester was observed.146 
2.2.5. Cyclopropanation and other cyclization reactions 
In 2005, the group of Tang, described the cyclopropanation of α,β-unsaturated 
imines via a Michael addition-elimination reaction of tellurium ylides to give vinyl 
cyclopropanecarbaldehydes with high diastereoselectivities and good yields in the 
majority of examples. Enantiomerically enriched products (95-99% ee) could be 
obtained by using enantiomerically enriched chiral tellurium ylides (Scheme 113). 
 
Scheme 113. Diastero- and enantioselective cyclopropanation of α,β-unsaturated N-
phenyl imines with tellurium ylides 
Furthermore, the major vinyl cyclopropanecarbaldehyde could be transformed into 
a cycloheptadiene via a Wittig reaction followed by a [3,3] sigmatropic rearrangement 
(Scheme 114).147 
 
Scheme 114. Synthesis of a cycloheptadiene 
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As a part of a study addressed to the synthesis of dihydrofurans, Zhue and Xie 
described two examples of cyclopropanation of unsaturated imines with diethyl 
bromomalonate in basic medium (Scheme 115). The reaction proceeded through a 
Michael addition/intramolecular substitution domino process.148  
 
Scheme 115. Cyclopropanation of N-tosyl imines with diethyl 2-bromomalonate 
When 2-halo-1,3-diketones were used as substrates under the same reaction 
conditions functionalized 2,3-dihydrofurans instead of cyclopropanes were obtained. 
(Scheme 116).148 
 
Scheme 116. Base-promoted synthesis of dihydrofurans from 2-halo-1,3-diketones and 
N-tosyl imines 
The authors proposed a domino sequence involving deprotonation of the dione 
followed by a Michael addition to the unsaturated imine and intramolecular alkylation 
to give a cyclopropane. Base-promoted fragmentation of the cyclopropane ring and oxa-
Michael addition to the resulting unsaturated imine to gave corresponding 2,3-
dihydrofurans (Scheme 117). 
 
Scheme 117. Proposed domino mechanism for the formation of 2,3-dihydrofurans 
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The group of Cheng has developed several cascade reactions via NHC catalysis 
involving α,β-unsaturated N-sulfonyl ketimines and 2-acylvinyl cinnamaldehydes for 
the stereoselective synthesis of highly functionalized indane derivatives. Depending on 
the structure of the catalyst, indeno[2,1-c]pyran-1-one derivatives or indenocyclopenta-
1-ones were obtained selectively and with excellent enantioselectivity (Scheme 
118).149,150 
 
Scheme 118. Diastereo- and enantioselective synthesis of indane derivatives 
2.3. Reactions involving C-H activation or metalation of 1,3-butadienes  
Bergman and Ellman have described the alkylation and alkenylation at the β 
position of conjugated imines by using alkenes or alkynes, respectively, catalyzed by 
rhodium salts. After alkylation, the resulting products were hydrolyzed to unsaturated 
aldehydes. Hydrolysis with aqueous acid favored the formation of the E isomer, while 
the Z isomer could be obtained by hydrolysis under milder conditions with AcOH in 
THF. The procedure allows the synthesis of β,β-substituted enals, which are difficult to 
obtain by other methods (Scheme 119).151 
 
Scheme 119. Formation of unsaturated aldehydes from unsaturated imines and alkenes 
The reaction is believed to proceed via coordination of the imine to the Rh catalyst 
followed by oxidative addition to the C-H bond. Association of the alkene followed by 
migratory insertion of the Rh-H bond and subsequent reductive elimination gives the 
alkylated aza-diene or the aza-triene in the reaction with alkynes (Scheme 120). 
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Scheme 120. Rh-catalyzed alkylation of unsaturated imines 
On the other hand, when terminal alkynes were used, instead of the expected 
azatrienes the reaction delivered dihydropyridines, which could be converted into 
pyridines by oxidation and deprotection of the nitrogen.152 Formation of the 
dihydropyridine most likely happens through the in situ electrocyclization of the aza-
triene (Scheme 121). 
 
Scheme 121. One-pot synthesis of dihydropyridines and pyridines 
A similar cycloaddition of alkynes and α,β-unsaturated imines via C-H activation 
catalyzed by cobalt has been reported by Yoshiaki (Scheme 122).153 
 
 
Scheme 122. Synthesis of unsymmetrical dihydropyridines catalyzed by cobalt 
Recently, the group of Walsh also reported the cross-coupling reaction of arylbromides 
and unsaturated N-(biphenylmethyl) imines catalyzed by palladium complexes, 
obtaining the corresponding 1,2- or 1,4-addition products with excellent 
regioselectivities and high yields by properly choosing the reaction conditions (Scheme 
123).38 The use of acidic (biphenylmethyl)amines was a requirement to generate the π-
allyl intermediate. 
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Scheme 123. Pd-catalyzed cross coupling of aryl bromides and unsaturated aldimines 
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3. OBJETIVES 
α,β-Unsaturated imines (1-azabutenes) have been used  as starting materials  in the 
synthesis of nitrogen-containing molecules since long time ago. The conjugate addition 
of carbon nucleophiles to this kind of compounds is an efficient way to form a new C-C 
bond giving rise to enamines with the concomitant formation of a new stereogenic 
center. However, in contrast to unsaturated carbonyl compounds and nitroalkenes, the 
asymmetric conjugate addition of carbon nucleophiles to α,β-unsaturated imines has 
been more scarcely explored and, in particular, no asymmetric examples with 1,3-
dicarbonyl compounds as nucleophiles appeared in the literature prior to the start of our 
research.   
The development of asymmetric conjugate additions to α,β-unsaturated imines 
poses several challenges: 
a. Low electrophilicity of the substrate due to the low electronegativity of the N 
atom. 
b. Control of regioselectivity: 1-azabutenes often prefer to undergo 1,2-addition or 
give double nucleophilic addition. 
c. Control of diastereoselectivity: the enamine double bond can be obtained with 
either E or Z geometry. 
d. Control of enantioselectivity: the newly formed stereogenic center should be 
formed in only one configuration. 
Considering these challenges, this thesis has been focused in the development of 
new diastereo- and enantioselective conjugate addition reactions of carbon nucleophiles 
to α,β-unsaturated imines employing metal catalysis for this purpose. The following 
reactions have been studied: 
1. Asymmetric conjugate addition of malonate esters to α,β-unsaturated N-tosyl 
imines catalyzed by La(III) complexes. 
 
2. Asymmetric conjugate addition of malonate esters to β-trifluoromethyl α,β-
unsaturated N-tosyl imines catalyzed by Cu(II) and Mg(II) complexes. 
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3. Diastereoselective Mukaiyama-Michael reaction of silylketene acetals with N-
tosyl imines derived from β,γ-unsaturated α-keto esters. 
 
4. Asymmetric conjugate addition of malonate esters to N-tosyl imines derived from 
β,γ-unsaturated α-keto esters catalyzed by La(III) complexes. 
 
5. Diastereodivergent enantioselective conjugate addition of 2-chloromalonate esters 
to N-tosyl imines derived from β,γ-unsaturated α-keto esters catalyzed by La(III) 
or Ca(II) complexes. 
 
6. Catalytic asymmetric [3+2] cycloaddition of 2-isocyanatomalonate esters and α,β-
unsaturated imines through a tandem Michael addition/intramolecular addition to 
isocyanate process. 
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4. RESULTS AND DISCUSSION 
4.1. Asymmetric conjugate addition of malonate esters to α,β-
unsaturated N-tosyl ketimines catalyzed by pyBOX-La(OTf)3  
At the onset of our research there where only a limited number of methods for the 
enantioselective conjugate addition of carbon nucleophiles to α,β-unsaturated imines 
reported in the literature, most of them involving the reaction of organometallic 
reagents. These include the asymmetric conjugate addition of organocuprates to chiral 
N-tert-butylsulfinyl imines reported by Ellman19 and the copper(I)-catalyzed additions 
of dialkylzinc reagents to different unsaturated imines reported by Tomioka,20 
Carretero22 and Palacios,23,24 respectively. Besides these examples, a conjugate addition 
of malonate esters or related 1,3-dicarbonyl compounds to unsaturated imines in an 
enantioselective fashion had not been reported, to the best of our knowledge, although 
Palacios had described the nonenantioselective conjugate addition of malonate esters to 
fluorinated unsaturated imines followed by lactamization to give pyridones.82 In this 
chapter, we will describe our efforts to develop the first example of asymmetric 
conjugate addition of malonate esters to unsaturated imines as an efficient procedure to 
access chiral δ-amino acid derivatives (Scheme 124). 
 
Scheme 124. Conjugate addition of malonate esters to α,β-unsaturated N-tosyl imines 
4.1.1. Synthesis of α,β-unsaturated N-tosyl imines 2  
In this investigation we have used N-tosyl imines 2 as electrophiles since the 
reactivity of imines toward nucleophilic attack is significatively increased by the 
presence of strong electron-withdrawing groups on the azomethinic nitrogen. 
Compounds 2 were prepared from the corresponding enones and TsNH2 upon treatment 
with TiCl4 and Et3N following the procedure described by Carretero (Scheme 125).22 A 
number of tosyl imines 2 derived from chalcones (R1 and R2 = Ar) or β-alkyl substituted 
aryl imines (R1 = Ar, R2 = alkyl) were prepared following this procedure in 75-85% 
yield. However, the synthesis of the unsaturated imine where R2 is aliphatic (Me) was 
not possible because of enolization of the N-sulfonyl imine during the preparation of the 
starting material. 
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Scheme 125. Synthesis of α,β-unsaturated N-tosyl imines 2 
4.1.2 Optimization of the reaction conditions 
For the optimization of the reaction conditions, we studied the addition of dimethyl 
malonate (1a, R = OMe) to N-tosyl imine 2a (R1 = R2 = Ph). Following previous 
experience of the group on the conjugate addition of nitromethane155 to unsaturated 
imines we decided to test complexes of trivalent metals and pyBOX ligands as potential 
catalysts in our reaction (Table 2). 
When the reaction was carried out in the presence of the pyBOX1-La(OTf)3 in 
dichloromethane we did not observe any advance of the reaction after 24 h (Table 2, 
entry 1). However, after addition of 4Å molecular sieves (MS) the reaction proceeded 
smoothly to give compound 3aa (R = MeO, R1 = R2 = Ph) in 81% yield (Table 2, entry 
2). The combined use of Lewis acid and MS has been documented in a number of 
reactions involving metal enolates as intermediates. 4Å MS most likely works as an 
effective proton scavenger favoring the generation of metal enolates in high 
concentration.156 Compound 3aa was obtained as a ca. 9:1 mixture of diastereomers 
with 86% enantiomeric excess for the major diastereomer (Table 2, entry 2). The 
geometry of the double bond was assigned as E for the major diastereomer and Z for the 
minor one by NOESY experiments (Figure 2). Particularly relevant for the assignment 
of this stereochemistry was the interaction between the NH of the sulfonamide group at 
δ 7.81 ppm and the triplet benzylic proton at δ 3.89 ppm observed in the minor Z-
diastereomer. These results contrast with those reported for the Cu(I)-catalyzed addition 
of diethylzinc to related unsaturated imines, which give the Z-isomers as the major 
products.22 On the other hand, no cyclization to the corresponding lactam was observed 
under the reaction conditions. Yb(III), Sc(III) and In(III) triflates in combination with 
pyBOX1 were also tested (Table 2, entries 3-5) although we did not observe any 
advance of the reaction. 
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Table 2. Enantioselective addition of 1,3-dicarbonyl compounds 1 to unsaturated imine 
2a (R1 = R2 = Ph).a 
 
entry M ligand 1 R T (°C) t (h) 3 yield (%)b ee (%)c 
1d La pyBOX1 1a MeO rt 48 3aa -e - 
2 La pyBOX1 1a MeO rt 24 3aa 81 86 
3 Yb pyBOX1 1a MeO rt 48 3aa -e - 
4 Sc  pyBOX1 1a MeO rt 48 3aa -e - 
5 In pyBOX1 1a MeO rt 48 3aa -e - 
6 La pyBOX2 1a MeO rt 24 3aa 65 -8 
7 La pyBOX5 1a MeO rt 16 3aa 60 -6 
8 La pyBOX6 1a MeO rt 42 3aa 59 12 
9 La pyBOX7 1a MeO rt 24 3aa 86 56 
10 La pyBOX8 1a MeO rt 106 3aa 25 12 
11 La pyBOX1 1a MeO 0  64 3aa 63 92 
12 La pyBOX1 1b EtO rt 48 3ba 73 83 
13 La pyBOX1 1c iPrO rt 120 3ca 16 - 
14 La pyBOX1 1d Me rt 170 3da 69 36 
15 La pyBOX1  -f rt 48  -e - 
a
 Reaction conditions: 1 (0.3 mmol), 2a (0.125 mmol), ligand (0.0125 mmol), M(OTf)3 (0.0125 
mmol), 4Å MS (20 mg), CH2Cl2 (0.8 mL). b Yield of isolated product. c Only for the major (E)-
diastereomer. Determined by HPLC with chiral stationary phases; opposite sign indicates 
different enantiomers. d Reaction carried out without MS. e No reaction observed after 48 h. f 
Malononitrile was used as nucleophile. 
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Figure 2. NOESY experiments carried out with the minor (above) and major 
(below) diastereomers of compound 3aa 
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We also tested different pyBOX ligands with La(OTf)3 (Table 2, entries 6-10), 
although none of them provided better results than pyBOX1. The use of toluene, hexane 
or THF was prevented due to the low solubility of the imine in these solvents. Finally, 
the enantioselectivity of the reaction could be increased up to 92% ee by carrying out 
the reaction at 0 °C, although with a loss of yield (Table 2, entry 11). The effect of the 
substituent R attached to the carbonyl group of the nucleophile was also tested. First, we 
tested the use of other malonate esters. Diethyl malonate (1b, R = EtO) performed 
similarly to dimethyl malonate providing the expected addition product (3ba, R = EtO, 
R1 = R2 = Ph) with 73% yield and 83% ee (Table 2, entry 12). However, increasing the 
bulk of the alkoxy group as in diisopropyl malonate (1c, R = iPrO) produced a serious 
decrease on the reaction rate and the conjugate addition product was obtained in only 
16% yield after 120 h (Table 2, entry 13). Moreover, 2,4-pentanedione (1d, R = Me) 
reacted slowly with imine 2a to give the corresponding product (3da, R = Me, R1 = R2 
= Ph) with 59% yield but with low diastereo- and enantioselectivity (Table 2, entry 14). 
Finally, malononitrile did not react under the optimized conditions. 
4.1.3 Scope of the reaction 
Next, we studied the scope of the addition of dimethyl malonate (1a, R = MeO) to 
different imines 2a-p under the optimized conditions. The results are gathered in Table 
3. The reaction could be carried out with imines bearing an aromatic ring attached to the 
β carbon, substituted with either electron-donating or electron-withdrawing substituents 
(Table 3, entries 1-8) to give the expected products with good diastereoselectivities 
(from 71:29 to 97:3) favoring the E-diastereomer and high enantiomeric excesses (70-
92%). The group R1 can be also a heterocyclic furanyl ring (Table 3, entries 9 and 10). 
When R1 was a phenyl group substituted with electron-withdrawing groups, good yields 
of the addition products could be obtained after 24 h. However, when R1 was an 
aromatic ring substituted with an electron-donating group, or an electron-rich 
heterocycle (Table 3, entries 8-10), the reaction required longer times and the 
corresponding products were obtained with slightly lower yields. Finally, the reaction 
allowed imines with R1 being an aliphatic group. Imine 2i (R1 = Me) reacted with 
dimethyl malonate to give the expected product 3ai in almost quantitative yield, with 
good diastereoselectivity and 75% ee for the major diastereomer (Table 3, entry 11). 
However, imine 2j bearing a bulky tert-butyl group did not react under similar 
conditions (Table 3, entry 12). The R2 group attached to the imine was also amenable to 
variation (Table 3, entries 13-18). Aromatic rings bearing either electron-donating or 
electron-withdrawing groups were permitted without much influence on the 
enantioselectivity of the reaction. 
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Table 3. Enantioselective addition of dimethyl malonate to unsaturated imines 
catalyzed by pyBOX1-La(OTf)3.a 
 
 
 
entry 2 R1 R2 t (h) 3 yield(%)b dr (E/Z) ee (E/Z)c 
1 2a Ph Ph 24 3aa 81 89:11 86/- 
2d 2a Ph Ph 64 3aa 63 95:5 92/- 
3 2b 4-FC6H4 Ph 24 3ab 88 90:10 86/- 
4d 2b 4-FC6H4 Ph 64 3ab 66 97:3 90/- 
5 2c 4-ClC6H4 Ph 24 3ac 93 88:12 86/- 
6 2d 4-BrC6H4 Ph 24 3ad 99 77:23 85/- 
7 2e 4-NO2C6H4 Ph 24 3ae 97 87:13 90/- 
8 2f 4-MeOC6H4 Ph 72 3af 80 71:29 69/- 
9 2g 2-furanyl Ph 45 3ag 78 79:21 94/52 
10 2h 3-furanyl Ph 45 3ah 66 84:16 85/60 
11 2i Me Ph 24 3ai 98 88:12 75/54 
12 2j t-Bu Ph 64 3aj -e - - 
13 2k Ph 4-FC6H4 24 3ak 67 88:12 86/55 
14 2l Ph 4-ClC6H4 24 3al 80 84:16 80/46 
15 2m Ph 4-NO2C6H4 24 3am 84 80:20 82/49 
16 2n Ph 4-MeOC6H4 24 3an 86 71:29 80/42 
17 2o Ph 2-FC6H4 24 3ao 84 76:24 82/28 
18 2p Ph 3-NO2C6H4 24 3ap 99 82:18 84/48 
a
 Reaction conditions: 1a (0.3 mmol), 2 (0.125 mmol), pyBOX1 (0.0125 mmol), La(OTf)3 (0.0125 
mmol), 4Å MS (20 mg), CH2Cl2 (0.8 mL), rt. b Yield of isolated product. c Determined by HPLC 
with chiral stationary phases. d Reaction carried out at 0 °C. e No reaction was observed after 64 h. 
4.1.4 Determination of the absolute stereochemistry of compound 3aa 
The absolute stereochemistry of compound 3aa was established by chemical 
correlation with compound 4 of known stereochemistry. A sample of compound (E)-3a 
(ee = 82% ee) was hydrolyzed upon treatment with HCl in THF at 40 °C to give ketone 
4 in quantitative yield without loss of optical purity (Scheme 126). By comparison of 
the optical rotation sign and chiral HPLC retention times of compound 4 obtained in 
this way with those described in the literature for (S)-4,157 we established the 
configuration of the stereogenic center of (E)-3aa (Table 3, entry 1) to be S. Hydrolysis 
of the minor (Z)-3aa diastereomer provided again (S)-4 but with only 20% ee. For the 
other compounds 3ab-ap, the stereochemistry was assigned upon the assumption of a 
common stereochemical mechanism. 
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Scheme 126. Hydrolysis and determination of the absolute stereochemistry of 
compound (E)-3aa 
These results indicate the preference of methyl malonate to attack from the Re face 
of the double bond of the unsaturated imine 2. Taking into account previous studies on 
La(III)-pyBOX catalyzed reactions,155,158 we propose a plausible catalytic cycle with the 
participation of an octa-coordinated La(III) species III with both the 1,3-dicarbonyl 
compound and the imine coordinated to the metal center (Figure 3).159 In this complex, 
the unsaturated imine 2, in its s-trans conformation would be oriented to avoid the steric 
interaction with the phenyl group of the ligand, thus leading to the conjugate addition 
product 3 having the S-configuration at the stereogenic center and the E-geometry at the 
double bond. 
 
Figure 3. Plausible mechanism and stereochemical model 
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4.1.5 Synthetic transformations 
Enamines 3 can be used as starting materials for the synthesis of optically active 
nitrogenated compounds such as δ-amino esters and piperidones. Thus, hydrogenation 
of (S,E)-3aa over Pd/C gave a 75:25 mixture of two diastereomeric δ-amino diesters 5 
and 6 in 95% yield, favoring the (S,R)-diastereomer 5. Both diastereomers 5 and 6 could 
be separated after column chromatography and subjected to chemical transformations 
separately. Decarboxylation of either 5 or 6 upon treatment with tetraethylammonium 
hydroxide160 in DMSO gave the monoesters 7 and 8 in 70% and 60% yield, respectively 
(Scheme 127).  
 
Scheme 127. Hydrogenation and decarboxylation of compound 3aa 
On the other hand, lactamization of compounds 5 and 7 by basic treatment with 
LiHMDS in toluene161 gave the chiral piperidones 9 and 10, respectively (Scheme 128).  
 
Scheme 128. Synthesis of chiral piperidones 9 and 10 
The relative stereochemistry of compound 9, was established considering the 
coupling constants of the ring-attached protons (Figure 4). The signal corresponding to 
H3 appeared at 3.72 ppm as a doublet with a J = 12.0 Hz (ax-ax), indicating its axial 
disposition as well as that of H4. Moreover H6 appeared as a dd at 5.90 ppm showing 
coupling constant values of 5.1 Hz (ax-ax) and 2.4 Hz (eq-eq) which indicated the 
equatorial disposition of this proton. Accordingly, the stereochemistry of compound 9 
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was assigned to be 3R,4S,6R. Hence, the stereochemistry of compounds 5-10 was 
assigned as indicated in Schemes 126 and 127. 
 
Figure 4. NMR coupling constants in compound 9 
In summary, in this chapter we have developed the first enantioselective conjugate 
addition of dimethyl malonate to α,β-unsaturated N-tosyl imines, catalyzed by La(III)-
pyBOX complexes, to give the corresponding γ-dehydro-δ-amino diesters bearing a 
stereogenic center at the allylic position. The reaction provided the (E)-enamine as the 
major diastereomer with good yields and enantioselectivities. The enamino esters were 
shown to be effective synthons for the preparation of optically active δ-amino esters 
bearing two stereogenic centers at the β and δ positions, and for the preparation of 
optically active lactams. 
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4.2. Enantioselective Michael addition of malonate esters to β-
trifluoromethyl-α,β-unsaturated imines 
The interest in the chemistry of chiral organofluorine compounds has experienced a 
tremendous growth in the last years due to their wide range of applications in medicinal 
and agricultural chemistry, as well as in material science.162 Among organofluorinated 
compounds, those having a trifluoromethyl group attached to a stereogenic center 
deserve special attention due to the occurrence of this structural motif in bioactive 
compounds163 and chiral reagents (Figure 5).164 
 
Figure 5. Examples of drugs and chiral auxiliaries bearing a trifluoromethyl group 
These stereocenters are most frequently prepared by nucleophilic addition reactions 
to trifluoromethylated prostereogenic groups such as trifluoromethyl ketones and 
trifluoromethyl imines.165 In this context, several carbon nucleophiles have been also 
reported to undergo enantioselective Michael-type reactions with β-trifluoromethyl α,β-
unsaturated carbonyl compounds166 or with nitroalkenes167 to obtain compounds with a 
trifluoromethylated sterogenic center not connected to a heteroatom. However, no 
examples of enantioselective conjugate addition of carbon nucleophiles to β-
trifluoromethyl α,β-unsaturated imines have been reported previously, to the best of our 
knowledge. Considering this, and keeping in mind the importance of fluorine-
containing amino acids in medicinal chemistry,168 we decided to study the 
enantioselective conjugate addition of malonate esters to β-trifluoromethyl α,β-
unsaturated N-tosyl imines as an efficient procedure to access to chiral β-
trifluoromethyl-δ-amino acid derivatives, a reaction that has no precedents in the 
literature (Scheme 129). 
 
Scheme 129. Conjugate addition of malonate esters to β-trifluoromethyl α,β-unsaturated 
N-tosyl imines 
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4.2.1. Synthesis of β-trifluoromethyl α,β-unsaturated N-tosyl imines 11 
The imines to be used in this study 11a-l were synthesized by condensation of the 
corresponding (Z)-β-trifluoromethyl enones and p-toluenesulfonamide in the presence 
of TiCl4 and Et3N, following the procedure described by A. D. Smith.103 Imines 11, 
specially those containing nitro groups, were sensitive to hydrolysis by silica gel and 
their purification was difficult. In most of the cases, after a fast column 
chromatography, further purification by crystallization from hexane-EtOAc or Et2O-
EtOAc was required giving rise to moderate or low yields. Following this procedure we 
were able to prepare a set of twelve imines having an aromatic ring with different 
substitution and electronic character attached to the azomethinic carbon, with yields 
ranging from 24-74% (Scheme 130). Again, the preparation of unsaturated imines 11 
having an aliphatic (Me) group attached to the imine carbon was not possible due to 
enolization of the N-sulfonyl imine. 
F3C Ar
O
+ S
O
O
H2N
Et3N, TiCl4
CH2Cl2
0 oC to reflux
F3C Ar
N
11
11a, Ar = Ph
11b, Ar = 4-MeC6H4
11c, Ar = 4-ClC6H4
11d, Ar = 4-BrC6H4
11e, Ar = 4-NO2C6H4
11f, Ar = 4-MeOC6H4
11g, Ar = 3-MeC6H4
11h, Ar = 3-ClC6H4
11i, Ar = 3-NO2C6H4
11j, Ar = 3-MeOC6H4
11k, Ar = 2-MeOC6H4
11l, Ar = 2-naphthyl
Ts
 
Scheme 130. Synthesis and structure of β-trifluoromethyl α,β-unsaturated N-sulfonyl 
imines 11 
Imines 11 were obtained as only one C=N geometric isomer. It was possible to 
obtain a monocrystal of imine 11a suitable for X-ray analysis (CCDC 1535016) that 
showed the E,E geometry for the C-C and C-N double bonds in this compound (Figure 
6). 
 
Figure 6. Ortep plot for the X-ray structure of compound 11a. The thermal ellipsoids 
are drawn at the 50% probability level 
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4.2.2. Optimization of the reaction conditions with copper(II) triflate 
The reaction between dimethyl malonate 1a and the imine 11a was firstly attempted 
by using pyBOX-La(OTf)3 complexes as in our previous reaction with tosyl imines 
derived from chalcone (Section 4.1). However, when this catalytic system was applied, 
the expected Michael addition product 12aa was obtained with good yields but low 
enantioselectivities (Table 4). Other pyBOX complexes with trivalent metal triflates 
such as Yb(OTf)3, Sc(OTf)3 or In(OTf)3 performed similarly or even worse than 
La(OTf)3.  
Table 4. Enantioselective conjugate addition of dimethyl malonate 1a to imine 11a 
catalyzed by pyBOX-M(III) complexes.a 
 
 
entry M(OTf)3 pyBOX t (h) yield (%)b dr (E/Z) ee (%) (E/Z)c 
1 La(OTf)3 pyBOX1 16 99 72:28 75/34 
2 La(OTf)3 pyBOX2 43 99 78:23 -15/-2 
4 La(OTf)3 pyBOX4 40 99 82;18 -18/-9 
5 La(OTf)3 pyBOX5 40 99 82:18 -28/-11 
6 La(OTf)3 pyBOX6 37 79 89:11 -16/5 
7 La(OTf)3 pyBOX7 44 86 73:27 -76/-39 
3 La(OTf)3 pyBOX8 48 99 77:23 45/-3 
8 Sc(OTf)3 pyBOX1 96 -d -- -- 
9 Yb(OTf)3 pyBOX1 96 19 43:57 69/42 
10 In(OTf)3 pyBOX1 96 -d -- -- 
a
 Reaction conditions: 1a (0.3 mmol), 11a (0.125 mmol), ligand (0.0125 mmol), M(OTf)3 
(0.0125 mmol), 4Å MS (110 mg), CH2Cl2 (1.1 mL), rt. b Yield of isolated product. c Determined 
by HPLC with chiral stationary phases. d Little advance of the reaction was observed after the 
indicated time. 
The low stereocontrol obtained with pyBOX-trivalent metal complexes led us to 
test the reaction in the presence of other potential catalysts. First, we tested the reaction 
in the presence of BOX-Cu(OTf)2 complexes, which are very commonly used chiral 
Lewis acids (Table 5).169 
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Table 5. Enantioselective conjugate addition of dimethyl malonate 1a to imine 11a 
catalyzed by BOX-M(II) complexes.a 
 
entry M BOX t (h) yield (%)b dr (E/Z)c ee (%) (E/Z)d 
1e Cu BOX1 24 -f - - 
2 Cu BOX1 96 60 80:20 -33/35 
3 Cu BOX2 96 85 66:34 -85/71 
4 Cu BOX3 96 -f - - 
5 Cu BOX4 96 31 70:30 -55/54 
6 Cu BOX5 72 77 80:20 67/-41 
7 Cu BOX6 96 -f - - 
8 Cu BOX7 72 93 90:10 95/-75 
9 Cu BOX8 96 58 36:64 30/-70 
10 Cu BOX9 96 92 72:28 -2/-7 
11 Cu BOX10 96 47 80:20 -32/25 
12e,g Cu BOX7 96 -h - - 
13g Cu BOX7 72 36 47:53 76/-65 
14i Cu BOX7 24 23 38:62 4/7 
15 Zn BOX7 96 36 92:8 57/-43 
16e Mg BOX7 20 99 92:8 86/-52 
17 Ca BOX7 96 81 84:16 69/-49 
a
 Reaction conditions: 1a (0.3 mmol), 11a (0.125 mmol), BOX (0.0125 
mmol), M(OTf)2 (0.0125 mmol), 4Å MS (110 mg), CH2Cl2 (1.1 mL). b Yield 
of isolated product. c Determined by 1H NMR. d Determined by HPLC with 
chiral stationary phases; opposite sign within a same diastereomer indicates 
opposite enantiomers. e MS was not used. f Little advance of the reaction was 
observed after the indicated time. g Et3N (0.016 mmol). h Hydrolysis of the 
imine was observed. iEt3N (0.3 mmol).  
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All the BOX ligands with the exception of BOX8 favored the formation of the E-
enamine.  Indene-derived bis-oxazoline (BOX7) lead to the best results in terms of yield 
and stereoselectivity providing enamine 12aa in 93% yield, as a ca. 90:10 mixture of 
E/Z-diastereomers and 95% ee for the major E-diastereomer, after 96 hours (Table 5, 
entry 8). Addition of a catalytic amount of triethylamine in an attempt to speed up the 
reaction brought about a decrease in the yield due to hydrolysis of the imine, as well as 
an erosion in the stereoselectivity, which could not be avoided even in the presence of 
MS (Table 5, entries 12 and 13). Addition of one equivalent of triethylamine produced 
an inversion in diastereoselectivity, the Z-isomer being obtained as the major one in 
almost racemic form (Table 5, entry 14). 
We also tested the reaction in the presence of the BOX7 complexes with Zn(II), 
Mg(II) and Ca(II) triflates. The reaction with the Zn(II) complex proceeded sluggishly 
and gave compound 12aa in only 36% yield after 96 hour (Table 5, entry 15). On the 
other hand, in the presence of the Ca(II) complex compound 12aa was obtained with 
good yield (81%),  fair diastereo- and poor enantioselectivity after 96 h (Table 5, entry 
17). Remarkably, the reaction in the presence of BOX7-Mg(OTf)2 proceeded fast in 
absence of MS and was completed after only 20 hours producing compound 12aa in 
quantitative yield with good diastereoselectivity (E:Z = 92:8) although with a slighly 
lower enantiomeric excess (Table 5, entry 16) than the obtained with the BOX7-Cu(II) 
catalyst. 
4.2.3. Scope of the reaction catalyzed by the BOX7-Cu(OTf)2 catalyst 
The conditions established in Table 5, entry 8, were applied to the β-
trifluoromethyl-α,β-unsaturated N-tosyl imines 11a-l previously synthesized, all of them 
having an aromatic ring attached to the imine carbon. The results are gathered in Table 
6. The reaction could be carried out with imines bearing an aromatic ring attached to the 
imine carbon substituted with either electron-donating or electron-withdrawing groups. 
Good to excellent yields of compounds 12 were obtained in almost all the cases except 
when the phenyl group is substituted with a strong electron donating group (MeO) at the 
ortho or para positions (Table 6, entries 6 and 11). However, this drawback is not found 
when this group is in meta position (Table 6, entry 10). A bulky 2-naphthyl group 
attached to the azomethinic carbon was also tolerated (Table 6, entry 12). Compounds 
12a-l were obtained with fair to good diastereoselectivities (from 60:40 to 90:10) 
favoring the E-diastereomer and with high enantiomeric excesses (from 83% to 97% ee 
for the major E-diastereomer) regardless of the electronic character of the substituent on 
the aromatic ring, although para-substituted rings gave slightly higher 
enantioselectivities (Table 6, entries 2-6). 
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Table 6. Enantioselective conjugate addition of dimethyl malonate (1a) to β-
trifluoromethyl-α,β-unsaturated N-tosyl imines 11 catalyzed by BOX7-Cu(OTf)2.a 
F3C
NTs
Ar
CO2Me
CO2Me 4Å MS, CH2Cl2
111a
F3C Ar
NHTs+
Cu(OTf)2
(S,E )-12aa
MeO
O
MeO O
O
N N
O
BOX7 F3C NHTs
ArMeO
O
MeO O
(S,Z)-12aa
+
 
entry 11 Ar t (h) 12 yield (%)b dr (E/Z)c ee (%) (E/Z)d 
1 11a Ph 68 12aa 93 90:10 95/75 
2 11b 4-MeC6H4 89 12ab 86 89:11 94/40 
3 11c 4-ClC6H4 112 12ac 82 87:13 97/32 
4 11d 4-BrC6H4 89 12ad 75 89:11 95/43 
5 11e 4-NO2C6H4 89 12ae 86 74:26 90/54 
6 11f 4-MeOC6H4 112 12af 34 84:16 94/56 
7 11g 3-MeC6H4 136 12ag 97 87:13 94/41 
8 11h 3-ClC6H4 89 12ah 86 82:18 91/49 
9 11i 3-NO2C6H4 64 12ai 94 60:40 83/58 
10 11j 3-MeOC6H4 89 12aj 87 83:17 87/82 
11 11k 2-MeOC6H4 112 12ak 23 72:28 89/17 
12 11l 2-naphthyl 112 12al 60 87:13 93/27 
a
 1a (0.3 mmol), 11 (0.125 mmol), BOX7 (0.0125 mmol), Cu(OTf)2 (0.0125 mmol), 4Å MS (110 
mg), CH2Cl2 (1.1 mL), rt. b Yield of isolated product. c Determined by 1H NMR. d Determined by 
HPLC with chiral stationary phases.  
4.2.4. Determination of the absolute stereochemistry of compound 12aa 
Compound 12aa obtained in the presence of the BOX7-Cu(OTf)2 ligand could be 
crystallized (CCDC 1535017) and subjected to X-ray analysis (Figure 7). 
 
Figure 7. Ortep plot for the X-ray structure of compound 12aa. The thermal ellipsoids 
are drawn at the 50% probability level. Flack parameter-0.01(3) 
 
Results and Discussion 
74 
From this analysis it could be established the configuration of the stereogenic center 
as S, and also confirmed the E-geometry of the enamine double bond in the major 
diastereomer, similarly as in the major product obtained in the addition of malonate 
esters to imines derived from chalcone under La(III) catalysis. The stereochemistry of 
all compounds 12 was assigned by analogy. 
4.2.5. Optimization of the reaction conditions with magnesium(II) triflate 
As indicated previously in section 4.2.2., the BOX7-Mg(OTf)2 complex showed 
high catalytic activity in the reaction between dimethyl malonate (1a) and imine 11aa 
(Table 5, entry16). Accordingly, we decided to study the application of magnesium(II)-
BOX complexes in the conjugate addition of dialkyl malonates to β-trifluoromethyl α,β-
unsaturated N-tosyl imines. Further optimization of the reaction conditions was 
achieved by testing Mg(OTf)2 in combination with several BOX complexes (Table 7). 
Table 7. Enantioselective conjugate addition of dimethyl malonate 1a to imine 11a 
catalyzed by BOX-Mg(OTf)2 complexes.a 
 
entry BOX T (°C) t (h) yield (%)b dr (E/Z)c ee (%) (E/Z)d 
1 BOX1 rt 20 82 92:8 51/44 
2 BOX2 rt 15 99 88:12 -74/66 
3 BOX3 rt 46 40 65:35 0/0 
4 BOX4 rt 20 99 92:8 -29/18 
5 BOX5 rt 15 92 90:10 55/-39 
6 BOX6 rt 16 96 95:5 85/-44 
7 BOX7 rt 20 99 92:8 86/-52 
8 BOX8 rt 5 99 91:9 68/-57 
9 BOX9  rt 50 63 91:9 59/-38 
10e BOX7 0 40 99 96:4 89/-75 
11f BOX7 0 16 98 96:4 89/-55 
12g BOX7 0 4d 56 89:11 91/-83 
13e BOX7 -10 41 93 96:4 91/-49 
a
 Reaction conditions: 1a (0.3 mmol), 11a (0.125 mmol), BOX (0.0125 mmol), Mg(OTf)2 
(0.0125 mmol), CH2Cl2 (1.1 mL). b Yield of isolated product. c Determined by 1H NMR. d 
Determined by HPLC with chiral stationary phases; opposite sign within a same 
diastereomer indicates opposite enantiomers. e 4 Å MS was used. f 3 Å MS was used . g 5 
Å MS was used.  
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Unfortunately, none of the BOX ligands tested improved the enantioselectivity of 
the reaction (Table 7, entries 1-9). Only ligand BOX6 provided compound 12aa with 
similar diastereo- and enantioselectivity as BOX7. A decrease of temperature to 0 °C 
almost completely stopped the reaction, which required the addition of 4 Å MS to 
proceed. In this way (Table 7, entry 10), compound 12aa was obtained with slightly 
improved enantiomeric excess (89%) and diastereomeric ratio (96:4). 3 Å MS led to 
similar results (Table 7, entry11). On the other hand, the reaction in the presence of 5 Å 
MS was notably slower and, although a slight increase of ee (91%), was observed, 
product 12aa was obtained with low yield and poorer dr (Table 7, entry 12). We tried 
further optimization in the presence of 4 Å MS. Thus, performing the reaction at -10 °C 
gave compound 12aa in 96:4 dr and 91% ee for the major diastereomer (Table 7, entry 
13). Other solvents (CHCl3, DCE, THF, acetonitrile, toluene or iPrOH) were tested but 
none of them improved the results obtained in dichloromethane. 
4.2.6. Scope of the reaction catalyzed by the BOX7-Mg(OTf)2 catalyst 
Although performing the reaction at -10 °C allowed to increase the ee in the case of 
compound 12aa, reactions carried out with other imines proved this was not a general 
trend, no improvement being observed in many cases after decreasing the temperature 
from 0 °C to -10 °C. Therefore, Table 8 shows the results obtained at 0 °C. 
Table 8. Enantioselective conjugate addition of dimethyl malonate (1a) to β-
trifluoromethyl-α,β-unsaturated N-tosyl imines 11 catalyzed by BOX7-Mg(OTf)2.a 
 
entry 11 Ar t (h) 12 yield (%)b dr (E/Z)c ee (%) (E/Z)d 
1 11a Ph 68 12aa 99 96:4 89/75 
2 11b 4-MeC6H4 16 12ab 99 95:5 89/61 
3 11c 4-ClC6H4 18 12ac 93 95:5 97/63 
4 11d 4-BrC6H4 72 12ad 85 95:5 91/43 
5 11e 4-NO2C6H4 17 12ae 97 84:16 89/78 
6 11f 4-MeOC6H4 40 12af 92 93:7 93/69 
7 11g 3-MeC6H4 16 12ag 91 95:5 86/58 
8 11h 3-ClC6H4 19 12ah 99 93:7 83/96 
9 11i 3-NO2C6H4 16 12ai 97 78:22 79/62 
10 11j 3-MeOC6H4 16 12aj 99 93:7 86/62 
11 11k 2-MeOC6H4 72 12ak 91 94:6 92/11 
12 11l 2-naphthyl 20 12al 99 94:6 88/49 
13e 11a Ph 100 12ba 94 88:12 85/35 
a
 1a (0.3 mmol), 11 (0.125 mmol), BOX7 (0.0125 mmol), Mg(OTf)2 (0.0125 mmol), 4Å MS (110 
mg), CH2Cl2 (1.1 mL), 0 ºC. b Yield of isolated product. c Determined by 1H NMR. d Determined by 
HPLC with chiral stationary phases. e reaction carried out with diethyl malonate (1b). 
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In general, the reaction with BOX7-Mg(OTf)2 gave compounds 12 with better 
diastereomeric ratios but slightly lower enantiomeric excesses than the reaction with 
BOX7-Cu(OTf)2. The best enantioselectivities were observed with imines having para 
substitution in the aromatic ring attached to the imine (Table 8, entries 2-6), especially 
in the cases of a 4-Cl or a 4-MeO substituent. Good diastereomeric E/Z ratios above 
90:10 were obtained in all the cases except with imines having nitrophenyl substituents 
(Table 8, entries 5 and 9). The reaction of diethyl malonate and imine 11a was also 
carried out to give compound 12ba with good dr and ee (Table 8, entry 13), although 
these results were inferior to those obtained with dimethyl malonate. Finally, 
diisopropyl malonate did not react with 11a under the optimized conditions. 
4.2.7. Synthetic transformations 
Some transformations on compound 12aa that show the potential application of 
enamines 12 in the synthesis of optically active trifluoromethyl-containing nitrogenated 
compounds are displayed in Scheme 131. For instance, reduction of compound 12aa 
could be efficiently achieved by treatment with triethylsilane in the presence of boron 
trifluoride to give δ-amino esters 13 and 14 in 92% yield with good diastereoselectivity 
(dr 88:12) and without noticeable erosion in the ee. On the other hand, treatment of 
compound 13 with triethylammonium hydroxide in DMSO brought about cyclization 
instead of decarboxylation giving the trifluoromethylated piperidone 5a with good 
yield. 
 
Scheme 131. Synthetic transformations of compound 12aa 
As in the case of compound 9 (section 4.1.5), the relative stereochemistry of 
compound 15, and hence, of its precursor 13, was established considering the coupling 
constants of the ring-attached protons (Figure 8). In particular the proton in α to the 
carbonyl group appeared as a doublet with J = 11.4 Hz (ax-ax) indicating its axial 
disposition, while the proton in α to the phenyl group appeared as a triplet with J = 3.8 
Hz characteristic of a proton in equatorial disposition. 
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Figure 8. Significative coupling constants in compound 15 
In summary, in this chapter we have developed the first enantioselective conjugate 
addition of malonates to β-trifluoromethyl α,β-unsaturated N-tosyl imines to give the 
corresponding γ-dehydro-δ-amino esters bearing a trifluoromethylated stereogenic 
center at the allylic position. The reaction can be catalyzed either by BOX-Cu(II) and 
BOX-Mg(II) complexes. Both catalysts provided the E-enamine as the major 
diastereomer with good yields, fair to good diastereoselectivities and good to excellent 
enantioselectivities. In general, best enantioselectivities were obtained with the copper 
catalyst while the magnesium complex favored higher diastereoselectivities. The 
enamino esters have been proved to be effective synthons for the preparation of 
optically active β-trifluoromethyl δ-amino esters and optically active trifluoromethyl 
piperidones. 
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4.3. Mukaiyama-Michael addition to N-tosyl imines derived from β,γ-
unsaturated α-keto esters: E,Z-stereodivergent synthesis of α,β-
dehydroamino esters 
α,β-Dehydroamino acid derivatives are non-proteinogenic amino acids that are 
often found as structural subunits in natural products produced by bacteria, fungi, 
marine organisms and plants, and play an important role in the biosynthesis of other 
non-proteinogenic amino acids and D-amino acids (Figure 9).170 
 
Figure 9. Examples of natural and bioactive α,β-dehydroamino acid derivatives 
Some of these compounds have shown antibiotic and other intriguing biological 
activities.171 The presence of the double bond in the dehydroamino acid residue reduces 
the conformational flexibility of peptides, a property that is useful for structure-activity 
studies and for the design of secondary structure in peptides,172 and it also confers 
resistance to enzymatic degradation and alters their bioactivity.173 These properties are 
affected by the E/Z configuration of the double bond of the dehydroamino acid 
moiety.174 Furthermore, α,β-dehydroamino acid derivatives are widely used as starting 
materials in the synthesis of natural and unnatural α-amino acids as well as in the 
synthesis of heterocyclic compounds.175 According to these pharmacological and 
synthetic potential, much synthetic effort has been devoted to the preparation of 
dehydroamino acids and their derivatives.170 In most of the reported procedures the 
thermodynamically stable Z-isomer is predominantly formed  while  the synthesis of the 
E-isomer normally takes place with lower selectivity or requires the use of 
stereoisomerically pure starting materials that are usually prepared in multistep 
sequences or involves difficult isomer separation. 
On the other hand, the conjugate addition of different nucleophiles to β,γ-
unsaturated α-keto esters has been applied as a new strategy in the synthesis of α,β-
dehydroamino esters by the groups of Palacios,23,24 Liu10 and Kim.28 In all these cases 
the reaction takes place stereoselectively to give the corresponding dehydroamino esters 
with the Z-configuration at the double bond. Therefore, the development of synthetic 
procedures based on this approach that could lead stereoselectively to the either E or Z 
dehydroamino esters starting from a same set of reactants would represent an important 
advance in the synthesis of this kind of compounds. 
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In this chapter we report the development of new procedures for the E/Z 
stereodivergent synthesis of α,β-dehydroamino esters via a Mukaiyama-Michael 
addition of silylketene acetals to N-tosyl imines of β,γ-unsaturated α-keto esters 
(Scheme 132). 
 
Scheme 132. Mukaiyama-Michael reaction with N-tosyl imines of β,γ-unsaturated α-
keto esters 
4.3.1. Synthesis of N-tosyl imines 17 derived from β,γ-unsaturated α-keto esters   
The imines to be used in this section and in sections 4.4 and 4.5 were synthesized 
by condensation of the corresponding (E)-β,γ-unsaturated α-keto esters and p-
toluenesulfonamide in the presence of TiCl4 and Et3N, following the same procedure 
used in the synthesis of imines 2 as described by Carretero.22 Following this procedure a 
number of differently substituted imines 17a-o were prepared in 36-76% yield from the 
corresponding unsaturated keto esters (Scheme 133). 
 
Scheme 133. Synthesis and structure of N-tosyl imines 17 derived from β,γ-unsaturated 
α-keto esters 
Imines 17 were obtained as only one diastereomer. X-ray analysis of imine 17b 
(CCDC 1442206) indicated the Z-geometry of the C=N in these imines, unlike in imines 
11 where the C=N bond geometry was E. The X-ray analysis also showed the 
preference for the s-trans conformation in the crystal structure (Figure 10). 
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Figure 10. Ortep plot for the X-ray structure of compound 17b. The thermal ellipsoids 
are drawn at the 50% probability level 
4.3.2. E/Z-stereodivergent Mukaiyama-Michael reaction with imines 17 
Our initial goal was to develop an enantioselective Mukaiyama-Michael reaction of 
silylketene acetals with N-tosyl imines derived from β,γ-unsaturated α-keto esters.  We 
expected that the 1,2-imino carbonyl moiety would act as a chelating scaffold or as a 
double hydrogen-bond acceptor, improving the binding of the substrate to the catalyst 
and expediting the catalytic action by Lewis acid or hydrogen-bonding catalysts.  
Accordingly, we tested the reaction between trimethylsilyl ketene acetal 16 and 
unsaturated imine 17a (R1 = Ph, R2 = Et, Scheme 132) catalyzed by different chiral 
BOX-Cu(OTf)2 and pyBOX-La(OTf)3 complexes. In all the cases the reaction was 
completed in 2 h to give compound 18a with good diastereoselectivity although with 
low enantiomeric excess (best 31% ee obtained with the BOX1-Cu(OTf)2 catalyst). 
This low enantioselectivity was attributed to a fast nonenantioselective background 
reaction. In fact, Cu(OTf)2 alone was able to catalyze the reaction to give compound 
18a in 95% yield as a 97:3 E/Z mixture of diastereomers after 45 minutes. 
In the view of these results we attempted the reaction in the presence of several 
hydrogen-bonding catalysts (Figure 11). 
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Figure 11. Hydrogen-bonding catalysts tested in the reaction of compounds 16 and 17a 
In these cases, the reaction required longer times to be completed and, remarkably, 
delivered compound 18a favoring the formation of the Z-isomer, although in racemic 
form. In fact, similar results were obtained when the reaction was carried out in the 
absence of any catalyst, compound 18a being obtained as a 9:91 E/Z mixture of 
diastereomers in 84% yield after 20 hours. 
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Thus, although we were not able to develop an enantioselective method for this 
Mukaiyama-Michael reaction, the fact that both E/Z diastereomers of compound 18 
could be selectively prepared from the same set of reagents encouraged us to study the 
scope of this diastereodivergent reaction. 
a) Non-catalyzed Z-selective Mukaiyama-Michael reaction 
The reaction between 2-methyl-1-methoxy-1-trimethylsilyoxyprop-1-ene (16) and 
imines 17 was carried out at room temperature in dichloromethane as the solvent (Table 
9). 
Table 9. Non-catalyzed Mukaiyama Michael addition of trimethylsilyl ketene acetal 16 
to N-tosyl imines of α-keto esters 17.a 
 
entry 17 Ar R 18 yield (%)b dr (E/Z)c 
1 17a Ph Et 18a 84 9:91 
2 17b 4-MeC6H4 Et 18b 77 9:91 
6 17c 4-ClC6H4 Et 18c 80 9:91 
9 17d 4-NO2C6H4 Et 18d 98 8:92 
3 17e 4-MeOC6H4 Et 18e 56 14:86 
7 17f 3-ClC6H4 Et 18f 87 11:89 
10 17g 3-NO2C6H4 Et 18g 99 10:90 
4 17h 3-MeOC6H4 Et 18h 82 11:89 
8 17i 2-ClC6H4 Et 18i 95 13:87 
11 17j 2-NO2C6H4 Et 18j 58 1:99 
5 17k 2-MeOC6H4 Et 18k 72 15:85 
12 17l 2-furyl Et 18l 69 14:86 
13 17n Ph Me 18n 82 11:89 
14 17o Ph iPr 18o 75 11:89 
a
 16 (0.6 mmol), 17 (0.25 mmol), CH2Cl2 (1.2 mL), rt, 20-24 h. b Yield of the 
diastereomer mixture after chromatography. c Determined by 1H NMR. 
 The reaction conditions were applied to a number of N-tosyl imines derived from 
ethyl γ-aryl-β,γ-unsaturated α-keto esters 17a-k, bearing either electron-donating or 
electron-withdrawing groups at the ortho, metha or para positions of the phenyl ring, 
and to an heteroaryl-substituted ester 17l. The reaction provided the expected α,β-
dehydroamino esters favoring the formation of the Z-isomers (Z)-18a-l in all the 
examples studied, with diastereomeric ratios ranging from 85:15 to 99:1 (Table 9, 
entries 1-12). The methyl and isopropyl esters 17n and 17o gave similar results to ethyl 
ester 17a (Table 9, entries 12-13). 
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b) Copper(II)-catalyzed E-selective Mukaiyama-Michael reaction 
The E-selective reaction was carried out using a 10 mol % load of copper(II) triflate 
as catalyst in dichloromethane at room temperature. The results are summarized in 
Table 10. 
Table 10. Mukaiyama Michael addition of trimethylsilyl ketene acetal 16 to N-tosyl 
imines of α-keto esters 17 catalyzed by Cu(OTf)2.a 
R1 CO2R
2
NTs
+
OTMS
OMe R1 NHTs
CO2R
2
CO2Me
1716 (E)-18
R1 CO2R
2
NHTs
CO2Me
(Z)-18
CH2Cl2, rt
+
major minor
Cu(OTf)2
 
entry 17 Ar R 18 yield (%)b dr (E/Z)c 
1 17a Ph Et 18a 95 97:3 
2 17b 4-MeC6H4 Et 18b 99 93:7 
6 17c 4-ClC6H4 Et 18c 99 94:6 
9 17d 4-NO2C6H4 Et 18d 99 92:8 
3 17e 4-MeOC6H4 Et 18e 95 88:12 
7 17f 3-ClC6H4 Et 18f 99 97:3 
10 17g 3-NO2C6H4 Et 18g 99 94:6 
4 17h 3-MeOC6H4 Et 18h 99 96:4 
8 17i 2-ClC6H4 Et 18i 99 99:1 
11 17j 2-NO2C6H4 Et 18j 99 86:14 
5 17k 2-MeOC6H4 Et 18k 91 97:3 
12 17l 2-furyl Et 18l 80 91:9 
13 17n Ph Me 18n 99 97:3 
14 17o Ph iPr 18o 87 96:4 
a
 16 (0.6 mmol), 17 (0.25 mmol), Cu(OTf)2 (0.025 mmol), CH2Cl2 (1.9 mL), rt, 
20-90 min. b Yield of the diastereomer mixture after chromatography. c 
Determined by 1H NMR. 
 When the reaction between silyl ketene acetal 16 and imines 17a-o was carried out 
in the presence of 10 mol % copper(II) triflate in dichloromethane at room temperature, 
a faster reaction took place to give the expected α,β-dehydroamino esters in high yield, 
favoring in these cases the formation of the E-isomers (E)-18a-o in all the examples 
studied (Table 10). In general, better yields and diastereoselectivities were observed for 
the copper-catalyzed reaction compared with the non-catalyzed reaction, with 
diastereomeric ratios E/Z above 90:10 in most of the cases. 
 
 
 
Results and Discussion 
83 
4.3.3. Assignment of the stereochemistry of compounds 18 
Initial attempts to assign the E/Z configuration of the double bond in compounds 18 
by 1H NMR following four different spectroscopic criteria established by Mazurkiewicz 
et al.176 for related N-acyl-α,β-dehydro-α-amino acid esters led to contradictory results 
(Table 11). 
Table 11. Application of 1H NMR spectroscopic criteria by Mazurkiewicz et al. to 
determine the geometry of the double bond in compounds 18.176 
 criterion 
 δ for Z-18a δ for E-18a concordance 
1 δCH=Z<δCH=E 7.31 6.91 - 
2 δNHZ<δNHE 6.16 6.65 + 
  δCH= (CDCl3) for Z-18a δCH= (TFA) for Z-18a  
3 δCH=Z(CDCl3)<δCH=Z (TFA) 7.31 7.64 + 
  δCH= (CDCl3) for E-18a δCH= (TFA) for E-18a  
4 δCH=E (CDCl3)>δCH=E (TFA) 6.91 7.04 - 
 
Thus, we performed NOESY experiments with samples of products 18 obtained 
under non-catalytic conditions and under copper catalysis. 4-Nitrophenyl derivatives 
18d were used in these experiments in order to avoid overlapping of 1H NMR signals in 
the aromatic region. NOESY experiments with compound 18d (major compound in 
non-catalytic conditions) showed a small interaction between the NH proton (δ 6.16 
ppm) and the benzylic proton (δ 4.69 ppm), which indicated the possible Z-geometry for 
the double bond in this compound. No significative interactions were found however in 
NOESY experiments with the Cu-catalyzed reaction product (Figure 12). 
Furthermore, suitable crystals for X-ray analysis (CCDC 1442362) of compound 
18n (copper-catalyzed reaction) could be obtained which allowed us to unambiguously 
establish the (E)-configuration for the double bond in this compound (Figure 13). 
 
Figure 13. Ortep plot for the X-ray structure of compound 18n (copper catalyzed 
reaction). The thermal ellipsoids are drawn at the 50% probability level 
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Figure 12. NOESY experiments carried out with compound 18d obtained under non-
catalytic conditions (above) and under Cu(OTf)2 catalysis (below) 
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On the basis of these results and 1H NMR characteristic chemical shifts (Table 12) 
we established that all compounds 18 resulting from the non-catalyzed reaction have the 
Z-configuration at the double bond while those obtained through the copper-catalyzed 
reaction have the E-configuration. Thus, in all the cases the olefinic hydrogens appear at 
higher field for the E-isomer (δCH=Z  > δCH=E) while the N-H proton appears at higher 
field for the Z-isomer (δNHE > δNHZ). Similarly, the benzylic proton in the β-substituent 
also appears at higher field for the Z-isomer (δArCHE  > δArCHZ). 
Table 12. Comparation of significative 1H NMR chemical shifts for compounds (Z)-18 
and (E)-18.a 
entry 18 Ar R δNH  (Z)-18 
δNH  
(E)-18 
δCH=C 
(Z)-18 
δCH=C 
(E)-18 
δArCH 
(Z)-18 
δArCH 
(E)-18 
1 a Ph Et 6.20 6.61 7.31 7.01 4.41 4.81 
2 b 4-MeC6H4 Et 6.14 6.58 7.29 6.97 4.35 4.77 
3 c 4-MeOC6H4 Et 6.18 6.58 7.27 6.96 4.35 4.76 
4 d 3-MeOC6H4 Et 6.18 6.59 7.27 6.97 4.37 4.79 
5 e 2-MeOC6H4 Et 6.19 6.57 7.34 7.06 4.69 5.18 
6 f 4-ClC6H4 Et 6.28 6.62 7.26 6.91 4.46 4.77 
7 g 3-Cl-C6H4 Et 6.30 6.67 7.23 6.89 4.41 4.75 
8 h 2-Cl -C6H4 Et 6.11 6.65 7.35 6.93 5.03 5.35 
9 i 4-NO2C6H4 Et 6.16 6.71 7.31 6.90 4.69 4.88 
10 j 3-NO2C6H4 Et 6.21 6.74 7.29 6.89 4.65 4.88 
11 k 2-NO2C6H4 Et 6.65 6.69 7.03 6.88 4.93 5.42 
12 l 2-furyl Et 6.40 6.71 7.04 6.69 4.56 5.04 
13 m Ph Me 6.23 6.57 7.30 7.00 4.35 4.72 
14 n Ph iPr 6.24 6.60 7.29 6.98 4.45 4.86 
a
 
1H NMR carried out in CDCl3 at 300 MHz. δ values referenced to residual CHCl3 (δ = 7.26 ppm). 
The results indicate that the unsaturated imine 17 adopts the s-cis conformation in 
the non-catalytic reaction while it prefers the s-trans conformation during the copper-
catalyzed reaction. Although a full explanation for this preference is not possible at this 
moment, our hypothesis is that the non-catalyzed reaction takes place through a cyclic 
Diels-Alder-like transition state (Figure 14, TS-1) with the incipient negative charge on 
the nitrogen atom stabilizing the incipient positive charge at the acetal carbon, which is 
only possible in the s-cis conformation.59,73  On the other hand, in the presence of 
copper triflate, coordination of the copper ion to the imine renders the substrate more 
electrophilic and the reaction takes place through an acyclic transition state (Figure 14, 
TS-2) with the unsaturated imine having the s-trans conformation. 
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Figure 14. Proposed transition states for the Mukaiyama-Michael reaction. Non-
catalyzed (TS-1) and copper-catalyzed (TS-2) 
In summary, we have developed new protocols for the stereodivergent synthesis of 
N-tosyl α,β-dehydroamino esters via a Mukaiyama-Michael addition. The reaction of 
silylketene acetals with N-tosyl imines derived from β,γ-unsaturated α-keto esters 
provided the corresponding (Z)-α,β-dehydroamino esters. Morover, the E-isomers were 
obtained when the reaction was performed in the presence of a catalytic amount of 
copper triflate. This strategy allowed the stereoselective synthesis of (E)- or (Z)-α,β-
dehydroamino esters from a same set of reactants, which has no precedents in the 
literature. We have also established a correlation between the 1H NMR chemical shifts 
and the stereochemistry of the double bond in these compounds. 
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4.4. Enantioselective conjugate addition of malonate esters to N-tosyl 
imines derived from β,γ-unsaturated α-keto esters  
In the previous chapter we disclosed the synthesis of α,β-dehydroamino acid 
derivatives via nucleophilic conjugate addition to imines derived from β,γ-unsaturated 
α-keto esters. By a judicious election of the reaction conditions we were able to carry 
out the Mukaiyama-Michael reaction of silylketene acetals and N-tosyl imines derived 
from β,γ-unsaturated α-keto esters to selectively give E- or Z- α,β-dehydroamino esters 
from the same set of reactants. Unfortunately, high levels of enantiocontrol in these 
reactions could not be obtained under the action of any of the chiral catalysts that were 
tested.  
On the other hand, we have shown in sections 4.1 and 4.2 that 1,3-dicarbonyl 
compounds are prone to catalysis by chiral Lewis acid such as pyBOX-M(III) and 
BOX-M(II) complexes, which efficiently promoted the enantioselective conjugate 
addition of malonate esters to unsaturated ketimines to give chiral enamines.  By 
considering both strategies together, we envisioned  that chiral α,β-dehydroamino esters 
may be obtained in an enantioselective fashion by achieving the conjugate addition of 
malonate esters 1 to imines 17 derived from β,γ-unsaturated α-keto esters under the 
proper enantioselective catalytic conditions (Scheme 134). 
 
Scheme 134. Conjugate addition of malonate esters to N-tosyl imines derived from β,γ-
unsaturated α-keto esters 
4.4.1. Optimization of the reaction conditions 
A preliminary screening of catalytic complexes based on trivalent metal salts and 
pyBOX ligands was undertaken using the reaction between dimethyl malonate (1a, R = 
Me) and the α,β-unsaturated N-tosyl imine 17a (R1 = Ph, R2 = Et) in the presence of 4 Å 
MS and dichloromethane as the solvent, according to the conditions developed in 
section 4.1 (Table 13). 
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Table 13. Enantioselective addition of malonate esters 1 to unsaturated imine 17a (R1 = 
Ph, R2 = Et) catalyzed by pyBOX-M(III) complexes.a 
 
entry M pyBOX 1 R solvent t (h) 19 yield (%)b dr (E/Z)c ee (%)d 
1 La pyBOX1 1a Me CH2Cl2 16 19aa 94 2:98 -86 
2 Yb pyBOX1 1a Me CH2Cl2 44 19aa 23 27:73 30 
3 Sc pyBOX1 1a Me CH2Cl2 46 19aa - - - 
4 In pyBOX1 1a Me CH2Cl2 46 19aa - - - 
5 La pyBOX2 1a Me CH2Cl2 19 19aa 90 1:99 -52 
6 La pyBOX5 1a Me CH2Cl2 26 19aa 91 4:96 -35 
7 La pyBOX7 1a Me CH2Cl2 19 19aa 96 13:87 26 
8 La pyBOX8 1a Me CH2Cl2 26 19aa 94 13:87 16 
9e La pyBOX1 1a Me CH2Cl2 16 19aa 98 7:93 -74 
10f La pyBOX1 1a Me CH2Cl2 15 19aa 92 8:92 -73 
11 La pyBOX1 1a Me CHCl3 17 19aa 99 5:95 -78 
12 La pyBOX1 1a Me DCE 17 19aa 89 4:96 -86 
13 La pyBOX1 1a Me toluene 16 19aa 93 4:96 -61 
14 La pyBOX1 1a Me THF 16 19aa 99 2:98 -83 
15 La pyBOX1 1a Me dioxane 35 19aa 96 11:89 -55 
16 La pyBOX1 1a Me Et2O 18 19aa 95 2:98 -86 
17 La pyBOX1 1b Et CH2Cl2 18 19ba 94 1:99 -91 
18 La pyBOX1 1b Et Et2O 20 19ba 87 3:97 -76 
19 La pyBOX1 1c iPr CH2Cl2 16 19ca 94 2:98 -73 
20 La pyBOX1 1c iPr Et2O 15 19ca 99 3:97 -25 
21g La pyBOX1 1a Me CH2Cl2 41 19aa 94 5:95 -87 
22g La pyBOX1 1b Et CH2Cl2 64 19ba 93 1:99 -86 
 
a
 Reaction conditions: 1 (0.6 mmol), 17a (0.25 mmol), pyBOX (0.025 mmol), M(OTf)3 (0.025 mmol), 4Å 
MS (110 mg), solvent (2.2 mL). b Yield of isolated product. c Determined by 1H NMR. d Only for the major 
(Z)-diastereomer. Determined by HPLC with chiral stationary phases; opposite sign indicates opposite 
enantiomers. e 3 Å MS was used. f 5 Å MS was used. g Reaction carried out at 0 °C. 
The complexes of Sc(OTf)3 or In(OTf)3 with pyBOX1 were completely inactive 
and no significative progress of the reaction was observed after 46 hours (Table 13, 
entries 3 and 4) while the complex with Yb(OTf)3 promoted a sluggish reaction and 
provided the expected product 19aa with low yield, fair diastereomeric ratio and low 
30% ee (Table 13, entry 2). Pleasantly, the pyBOX1-La(OTf)3 complex was more 
active and, after 16 h, allowed obtaining compound 19aa in excellent yield, with 
outstanding diastereoselectivity and high 86% ee (Table 13, entry 1). Other pyBOX 
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ligands were tested in combination with La(OTf)3 but none of them improved the results 
obtained with pyBOX1 (Table 13, entries 5-8). The pore size in the molecular sieves 
seemed not to have any effect on the performance of the reaction and either 3 Å or 5 Å 
MS afforded similar results as 4 Å MS (Table 13, entries 9 and 10). Next we studied 
different solvents. Unfortunately, none of them produced any upturn in the results; only 
diethyl ether performed similarly to dichloromethane (Table 13, entries 11-16). The 
influence of the alcoxy group in the malonate ester was also assessed. Slightly enhanced 
stereoselectivity was obtained with diethyl malonate (1b, R = Et, Table 13, entry 17), 
while diisopropyl malonate (1c, R = iPr) gave the reaction product with only 73% ee 
(Table 13, entry 18). Surprisingly, the use of diethyl ether with these two esters was 
deleterious unlike with dimethyl malonate (Table 13, entries 19 and 20). Finally, a 
decrease of temperature to 0 °C resulted in a decrease in the reaction rate and a slight 
loss of the optical purity in the resulting enamine (Table 13, entry 22)  
Finally, it is worth remarking that compound 12aa was obtained as a single 
diastereomer with excellent diastereoselectivity (dr = 99:1) favoring the Z configuration 
in the double bond (see below). 
4.4.2. Scope of the reaction 
With the optimized conditions in hand, we studied the scope of the reaction with 
different imines 17. Since diethyl malonate was proved to give better results than 
dimethyl or diisopropyl malonate, most of the research was restricted to this 
nucleophile. The results are gathered in Table 14. 
Different imines 17 having aromatic substitution at the double bond (γ-carbon) of 
the unsaturated ketimino ester were suitable substrates for the reaction (Table 14, entries 
1-10). In general the reaction took place with excellent diastereoselectivity favoring the 
formation of the isomer having the Z configuration at the enamine double bond, with 
E/Z ratios higher than 10:90, except in the case of compound 19bj that was obtained as 
an E/Z 29:71 mixture (Table 14, entry 10).  High enantiomeric excesses above 86% 
were obtained when R1 was a phenyl group substituted with either neutral (Me) or 
electron donating (MeO) substituents at any of the positions (Table 14, entries 2, 5 and 
8). The best enantioselectivity was obtained when R1 was a 2- or 3-clorophenyl ring 
(Table 14, entries 6 and 9). Nevertheless, when a nitro group is attached to the aromatic 
ring, a dramatic drop in the enantiomeric excess (Table 14, entries 4, 7 and 10) was 
observed. The substituent R1 can also be a heteroaromatic ring (Table 14, entry 11) the 
corresponding enamine being obtained with excellent diastereoselectivity and still 84% 
ee. Finally, the alkoxy group in compound 17 was also amenable to variation. Imines 
17n and 17o derived from methyl or isopropyl keto esters gave the corresponding 
products with excellent diastereo- and enantioselectivity (Table 14, entries 12 and 13). 
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Table 14. Enantioselective addition of dialkyl malonates to unsaturated imines 17 
catalyzed by pyBOX1-La(OTf)3.a 
 
entry 1 R 17 R1 R2 t (h) 19 yield (%)b dr (E/Z)c   ee (E/Z)d 
1 1b Et 17a Ph Et 18 19ba 94 1:99 7/91 
2 1b Et 17b 4-MeC6H4 Et 39 19bb 99 1:99 -/88 
3 1b Et 17c 4-ClC6H4 Et 30 19bc 97 6:94 21/88 
4 1b Et 17d 4-NO2C6H4 Et 72 19bd 99 5:95 24/69 
5 1b Et 17e 4-MeOC6H4 Et 39 19be 99 1:99 22/86 
6 1b Et 17f 3-ClC6H4 Et 39 19bf 97 1:99 44/90 
7 1b Et 17g 3-NO2C6H4 Et 72 19bg 99 7:93 38/52 
8 1b Et 17h 3-MeOC6H4 Et 43 19bh 91 7:93 37/88 
9 1b Et 17i 2-ClC6H4 Et 72 19bi 99 2:98 23/95 
10 1b Et 17j 2-NO2C6H4 Et 120 19bj 95 29:71 60/20 
11 1b Et 17l 2-furanyl Et 63 19bl 93 2:98 7/84 
12 1b Et 17n Ph Me 21 19bn 99 1:99 14/87 
13 1b Et 17o Ph iPr 20 19bo 98 1:99 44/89 
14 1a Me 17a Ph Et 16 19aa 94 2:98 2/86 
15 1c iPr 17a Ph Et 16 19ca 94 3:97 83/73 
 
a
 Reaction conditions: 1 (0.6 mmol), 17 (0.25 mmol), pyBOX1 (0.025 mmol), La(OTf)3 (0.025 mmol), 4 
Å MS (110 mg), solvent (2.2 mL), rt. b Yield of isolated product. c Determined by 1H NMR. d Determined 
by HPLC with chiral stationary phases. 
To complete the study, we assessed the performance of dimethyl 2-methylmalonate 
(1d) in the reaction with four different unsaturated imines 17 (Table15).  
The reaction of dimethyl 2-methylmalonate with these imines took place with 
excellent yields in all the cases but variable results in terms of stereoselectivity. Quite 
surprisingly, dimethyl 2-methymalonate (1d) showed different behavior to that of 
dimethyl malonate (1a). Thus, the best result was obtained with the 4-methoxyphenyl 
derivative 17e that provided the conjugate addition product 20de with excellent 
diastereoselectivty and 97% ee (Table 15, entry 4). However, the reaction with the p-
clorophenyl derivative 17c provided in this case the lower dr (32:68) and ee (Table 15, 
entry 2), while the nitro derivative 17d gave the imine with good dr and 81% ee (Table 
15, entry 3). 
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Table 15. Enantioselective addition of dimethyl 2-methylmalonate (1d) to unsaturated 
imines 17 catalyzed pyBOX1-La(OTf)3.a 
R1
NTs
CO2Et
CO2Me
CO2Me
17
+
1d
pyBOX1
4Å MS
CH2Cl2, rt
La(OTf)3 +
R1 CO2Et
NHTs
(S,E)-20
R1 NHTs
CO2Et
MeO2C
(S,Z)-20
N
N
OO
N
PhPh
minor major
MeO2C
MeO2C MeO2C
 
entry 17 R1 t (h) 20 yield (%)b dr (E/Z)c   ee (E/Z)d 
1 17a Ph 92 20da 88 5:95 20/83 
2 17c 4-ClC6H4 67 20dc 99 32:68 14/40 
3 17d 4-NO2C6H4 44 20dd 99 7:93 34/81 
4 17e 4-MeOC6H4 67 20de 92 3:97 97/97 
 
a
 Reaction conditions: 1d (0.6 mmol), 17 (0.25 mmol), pyBOX1 (0.025 mmol), La(OTf)3 (0.025 
mmol), 4 Å MS (110 mg), solvent (2.2 mL), rt. b Yield of isolated product. c Determined by 1H 
NMR. d Determined by HPLC with chiral stationary phases. 
4.4.3. Determination of the stereochemistry of compounds 19 
The stereochemistry of the double bond in compounds 19 was initially assigned as 
Z on the basis NOESY experiments carried out with compound 19be. The spectrum 
showed an interaction between the NH enamine proton at δ 6.73 and the benzylic proton 
at δ 4.62, which is only possible if the double bond has the Z configuration (Figure 15). 
 
Figure 15. NOESY experiments carried out with compound 19be 
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Furthermore, compound 19bn could be crystallized and subjected to X-ray analysis, 
which allowed us to confirm the geometry of the double bond as Z and also to establish 
the configuration of the stereogenic center as S (Figure 16). The absolute 
stereochemistry for the other obtained enamines 19 was assigned by analogy upon the 
assumption of a uniform stereochemical pathway. 
 
Figure 16. Ortep plot for the X-ray structure of compound 19bn. The thermal ellipsoids 
are drawn at the 50% probability level 
Furthermore, compound 19bn was hydrolyzed to the known ketone 21177 upon 
treatment with 2 equivalents of benzylamine and a catalytic amount of La(OTf)3 and 4 
Å MS in dichloromethane (Scheme 135). 
4Å MS,
CH2Cl2, r.t
Ph NHTs
CO2Me
La(OTf)3
(S,Z)-19bn
ee = 86%
EtO
O
EtO O
+
NH2 Ph CO2Me
EtO
O
EtO O
O
(S)-21bn
[α]D25 = +14 (CHCl3, ee= 86%)
Lit. [α]D25 = - 9 (CHCl3, ee = 98%)
(undetermined stereochemistry)
 
Scheme 135. Hydrolysis of compound 19bn 
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4.5. Diastereodivergent enantioselective conjugate addition of 2-
chloromalonate esters to N-tosyl imines derived from β,γ-unsaturated 
α-keto esters 
The introduction of highly functionalized fragments into an organic molecule is of 
paramount importance in organic synthesis since this allows increasing the possibilities 
of further functional or structural modifications in later stages of the synthetic sequence. 
Following the research on nucleophilic enantioselective addition of malonic acid 
derivatives to unsaturated imines disclosed in the previous chapter, we decided to study 
the reaction between dialkyl 2-chloromalonates and N-tosyl imines derived from β,γ-
unsaturated α-keto esters to give the corresponding highly functionalized chloro-
enamino esters (Scheme 136). 
 
Scheme 136. Conjugate addition of 2-chloromalonate esters to N-tosyl imines derived 
from β,γ-unsaturated α-keto esters 
4.5.1. Optimization of the reaction conditions with lanthanum(III) triflate 
The conditions previously developed for the addition of diethyl malonate with the 
pyBOX1-La(OTf)3 catalyst were initially applied to the reaction between diethyl 2-
chloromalonate (1e) and imine 17a, giving the Z-enamine 22ea with high dr (3:97) and 
82% ee (Table 16, entry 1). It was also found that the amount of diethyl 2-
chloromalonate could be reduced to 1.5 equivalents without any noticeable effect (Table 
16, entry 2). Different pyBOX ligands were then tested. All of them led to poorer results 
than pyBOX1 (Table 16, entries 3-9) except pyBOX9, which performed similarly 
(Table 16, entry 10). A decrease in the reaction temperature in the presence of pyBOX1 
or pyBOX9 had little impact on the enantioselectivity, although the pyBOX9 complex 
seemed to be slightly more active (Table 16, entries 11 and 12). Decreasing the 
temperature to -10 °C improved the ee up to 86%, however, further decrease of 
temperature to -20 °C slowed down the reaction leading to long times without a 
noticeable effect on the enantioselectivity (Table 16, entry 14). Other pyBOX 
complexes with trivalent metal triflates such as Yb(OTf)3, Sc(OTf)3 or In(OTf)3 were 
assessed but proved to be inactive and did not yield enamine 22ea. 
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Table 16. Enantioselective addition of diethyl 2-chloromalonate to imine 17a catalyzed 
by trivalent metal salts.a 
 
 
entry ligand t (h) T (ºC) yield (%)b dr (E:Z)c ee (%)d 
1e pyBOX1 16 rt 97 3:97 -82 
2 pyBOX1 14 rt 92 3:97 -82 
3 pyBOX2 19 rt 89 4:96 -22 
4 pyBOX3 16 rt 88 9:91 -16 
5 pyBOX4 39 rt 90 7:93 -3 
6 pyBOX5 40 rt 87 7:93 -44 
7 pyBOX6 40 rt 91 8:92 -41 
8 pyBOX7 16 rt 92 7:93 -46 
9 pyBOX8 43 rt 92 10:90 13 
10 pyBOX9 16 rt 93 2:98 82 
11 pyBOX1 40 0 89 5:95 -82 
12 pyBOX9 22 0 93 3:97 83 
13 pyBOX9 40 -10 83 8:92 86 
14 pyBOX9 92 -20 62 1:99 87 
15e,f BOX1 16  rt 86 90:10 -73 
a
 Reaction conditions: 1e (0.187 mmol), 17a (0.125 mmol), pyBOX (0.0125 mmol), 
La(OTf)3 (0.0125 mmol), 4 Å MS (110 mg), CH2Cl2 (1.1 mL). b Yield of isolated product. c 
Determined by 1H NMR. d Only for the major diastereomer. Determined by HPLC analysis 
with chiral stationary phases; opposite sign indicates opposite enantiomers. e Reaction 
carried out with 0.3 mmol of 1e/0.125 mmol of 17a.f  Reaction carried out with Cu(OTf)2 
instead of La(OTf)3. 
Furthermore, while performing this study, we also tested the BOX1-Cu(OTf)2 
complex as catalyst, which allowed obtaining compound 22ea in 86% yield after 16 h. 
Quite surprisingly, the E- instead of the Z-enamine was obtained as the major 
diastereomer with this catalyst, although with moderate 73% ee (Table 16, entry 15). 
We will come back to this E-selective reaction in a next section of this chapter. 
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4.5.2. Scope of the reaction catalyzed by the pyBOX9-La(OTf)3 catalyst 
With the optimized conditions in hand (Table 16, entry 13), we proceeded to study 
the scope of this reaction with a number of unsaturated imines 17 (Table 17). 
Table 17. Enantioselective addition of dialkyl 2-chloromalonates to unsaturated imines 
17 catalyzed by pyBOX9-La(OTf)3.a 
 
 
entry 1 R 17 R1 R1 t (h) 22 yield (%)b dr (E:Z)c ee (%) (E/Z)d 
1 1e Et 17a Ph Et 40 22ea 83 8:92 83/86 
2 1e Et 17b 4-MeC6H4 Et 94 22eb 89 5:95 94/86 
3 1e Et 17c 4-ClC6H4 Et 91 22ec 89 6:94 52/86 
4 1e Et 17d 4-NO2C6H4 Et 42 22ed 93 2:98 69/87 
5 1e Et 17e 4-MeOC6H4 Et 90 22ee 99 4:96 76/86 
6 1e Et 17f 3-ClC6H4 Et 91 22ef 91 11:89 94/82 
7 1e Et 17g 3-NO2C6H4 Et 40 22eg 99 4:96 67/87 
8 1e Et 17h 3-MeOC6H4 Et 67 22eh 99 24:76 85/85 
9 1e Et 17i 2-ClC6H4 Et 45 22ei 91 3:97 77/88 
10 1e Et 17j 2-NO2C6H4 Et 69 22ej 99 6:94 95/88 
11 1e Et 17k 2-MeOC6H4 Et 63 22ek 99 1:99 50/87 
12 1e Et 17m 2-thiophenyl Et 40 22em 94 1:99 61/84 
13 1e Et 17n Ph Me 43 22en 91 8:92 84/83 
14 1e Et 17o Ph iPr 43 22eo 84 2:98 80/92 
15 1f Me 17a Ph Et 15 22fa 82 5:95 64/84 
a
 Reaction conditions: 1 (0.187 mmol), 17 (0.125 mmol), pyBOX9 (0.0125 mmol), La(OTf)3 (0.0125 
mmol), 4 Å MS (110 mg), CH2Cl2 (1.1 mL), -10 °C. b Yield of isolated product. c Determined by 1H 
NMR. d Determined by HPLC with chiral stationary phases. 
The addition of diethyl 2-chloromalonate (1e, R = Et) could be successfully 
achieved with a number of unsaturated imines having a substituted aromatic ring 
attached to the double bond (γ-position). Excellent yields were obtained in all the cases 
regardless the position and electronic nature of the substituent on the aromatic ring 
(Table 17, entries 1-11). The Z-isomer was obtained as the major diastereomer in all the 
cases with very high diastereoselectivity (dr > 2: 98) except in the cases of the imines 
substituted with a 3-chloro- or 3-methoxyphenyl group (Table 17, entries 6 and 8). 
Enantiomeric excesses above 80% were obtained for the major diastereomer in all the 
cases. It is worth remarking that, unlike in the addition of diethyl malonate, the presence 
of nitro groups did not lessen the stereoselectivity. The imine also allowed a 2-
thiophenyl group attached to the double bond (Table 17, entry 12). A bulkier iPr group 
at the ester moiety produced a rise in the enantiomeric excess up to 92% ee, while the 
methyl ester performed similarly to the ethyl derivative (Table 17, entries 13-14). 
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Finally, dimethyl 2-chloromalonate (1f, R = Me) was also tested giving similar results 
as diethyl 2-chloromalonate (Table 17, entry 15). 
4.5.3. Optimization of the reaction conditions with calcium triflate 
As it has been advanced in section 4.5.1, the use of the BOX1-Cu(OTf)2 instead of 
pyBOX9-La(OTf)3 in the reaction of 1e and 17a produced a shift of diastereoselectivity 
towards the E-enamine. Although (E)-22ea was obtained only with fair 
enantioselectivity, this change of selectivity prompted us to check other catalysts based 
on divalent metals (Table 18). 
Table 18. Enantioselective addition of diethyl 2-chloromalonate to imine 17a catalyzed 
by divalent metal salts.a 
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entry M ligand t (h) T (ºC) yield (%)b dr (E/Z)c ee (E)d 
1e Cu BOX1 16h rt 86 90:10 -77 
2 Mg BOX1 14h rt 91 90:10 -91 
3 Zn BOX1 88h rt 69 56:44 -72 
4 Ca pyBOX1 14h rt 89 93:7 -96 
5 Ca pyBOX1 40h 0 95 96:4 -98 
6 Ca pyBOX8 16h 0 88 93:7 94 
7 Ca pyBOX9 39h 0 97 95:5 95 
8f Ca pyBOX1 25h 0 85 96:4 -97 
a
 Reaction conditions: 1e (0.187 mmol), 17a (0.125 mmol), ligand (0.0125 mmol), M(OTf)2 
(0.0125 mmol), 4 Å MS (110 mg), CH2Cl2 (1.1 mL). b Yield of isolated product. c Determined by 
1H NMR. d Only for the major diastereomer. Determined by HPLC analysis with chiral stationary 
phases; opposite sign indicates opposite enantiomers. e Reaction carried out with 0.3 mmol of 
1e/0.125 mmol of 17a.f  Reaction carried out with 0.00625 mmol of pyBOX1-Ca(OTf)2 /0.125 
mmol of 17a. 
The BOX1 complexes of Cu(II), Mg(II) and Zn(II) triflates, and pyBOX1-
Ca(OTf)2 were tested in the reaction of 1e and 17a. In all the cases the reaction showed 
E-selectivity, the pyBOX1-Ca(OTf)2 catalyst giving the best result (Table 18, entry 4).  
Decreasing the temperature to 0 °C allowed further improvement of the stereoselectivity 
(Table 18, entry 5). pyBOX8 and pyBOX9 gave similar results to pyBOX1. Finally, it 
should be remarked that the catalyst load could be reduced to 5 mol % without a 
noticeable impact on the result (Table 18, entry 8). On the view of these results, further 
optimization was not considered necessary. 
Results and Discussion 
97 
 4.5.4. Scope of the reaction catalyzed by the pyBOX1-Ca(OTf)2 catalyst 
The optimal conditions established for the Ca(OTf)2 catalyzed reaction (Table 18, 
entry 8) were applied to the same set of N-tosyl imines previously studied with 
La(OTf)3. The results are shown in Table 19. 
Table 19. Enantioselective addition of dialkyl 2-chloromalonates to unsaturated imines 
17 catalyzed by pyBOX1-Ca(OTf)2.a 
 
 
 
entry 1 R 17 R1 R1 t (h) 22 yield (%)b dr (E/Z)c ee (%) (E/Z)d 
1 1e Et 17a Ph Et 25 22ea 85 96:4 97/70 
2 1e Et 17b 4-MeC6H4 Et 38 22eb 94 96:4 98/61 
3 1e Et 17c 4-ClC6H4 Et 39 22ec 95 95:5 98/85 
4 1e Et 17d 4-NO2C6H4 Et 23 22ed 99 92:8 98/78 
5 1e Et 17e 4-MeOC6H4 Et 38 22ee 99 95:5 98/71 
6 1e Et 17f 3-ClC6H4 Et 39 22ef 91 95:5 98/70 
7 1e Et 17g 3-NO2C6H4 Et 40 22eg 99 93:7 93/58 
8 1e Et 17h 3-MeOC6H4 Et 44 22eh 98 96:4 96/77 
9 1e Et 17i 2-ClC6H4 Et 93 22ei 95 95:5 98/92 
10 1e Et 17j 2-NO2C6H4 Et 44 22ej 98 97:3 99/22 
11 1e Et 17k 2-MeOC6H4 Et 63 22ek 99 95:5 95/8 
12 1e Et 17m 2-thiophenyl Et 23 22em 99 97:3 97/47 
13 1e Et 17n Ph Me 42 22en 91 96:4 98/90 
14 1e Et 17o Ph iPr 66 22eo 84 94:6 98/79 
15 1f Me 17a Ph Et 15 22fa 92 92:8 98/80 
a
 Reaction conditions: 1 (0.187 mmol), 17 (0.125 mmol), pyBOX1 (0.00625 mmol), Ca(OTf)2 (0.0125 
mmol), 4 Å MS (110 mg), CH2Cl2 (1.1 mL), 0 °C. b Yield of isolated product. c Determined by 1H NMR. 
d
 Determined by HPLC with chiral stationary phases. 
In all the cases, products 22 were obtained as the E-enamines preferientally with 
excellent yields, diastereomeric ratios and enantiomeric excesses, regardless of the 
electronic nature and substitution pattern of the group attached to the double bond and 
the alkoxy group of the ester moiety. Also, the diastereomeric ratios and enantiomeric 
excesses were higher than those obtained in the reaction catalyzed by La(OTf)3 as a 
general trend. 
After obtaining these results, we checked the pyBOX1-Ca(OTf)2 catalyst in the 
reaction of diethyl malonate (1b) and α,β-unsaturated N-tosyl iminoester 17a. 
Unfortunately, no advance of the reaction was observed after 5 days at room 
temperature (Scheme 137). 
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Scheme 137. Attempted reaction of diethyl malonate (1b) and imine 17a under 
pyBOX1-Ca(OTf)2 catalysis 
4.5.5. Determination of the absolute stereochemistry of compounds 22 
The absolute stereochemistry of the stereogenic center in the Z- or E-enamines 22ea 
obtained upon catalysis by pyBOX9-La(OTf)3 or pyBOX1-Ca(OTf)2, respectively, was 
determined by chemical correlation with compounds of known stereochemistry. For this 
purpose, enamines 22ea obtained by any of these two procedures were subjected to a 
two step sequence involving hydrogenolysis of the C-Cl bond to give enamines 29ba, 
followed by hydrolysis to give ketone 21ba (Scheme 138). 
 
 
Scheme 138. Determination of the absolute stereochemistry of compound 22ea 
Different attempts to carry out the hydrogenolysis of (Z)- or (E)-22ea such as  
hydrogenation on Pd/C or treatment with PhSH led to compound 19ba with 
considerable isomerization of the double bond. Eventually, transformation of compound 
22ea without isomerization of the double bond nor erosion of the optical purity could be 
achieved by homogeneous hydrogenation with the [Rh(COD)]BF4-dppp complex. Upon 
this treatment, compound (Z)-22ea, resulting from the pyBOX9-La(III) catalyzed 
reaction, was converted into a new enamine that was identified as (R,Z)-19ba after 
comparison with the features of the same compound obtained by addition of diethyl 
malonate to imine 17a catalyzed by pyBOX1-La(OTf)3 (Section 4.4.2). Hydrolysis of 
(R,Z)-19ba by treatment with benzylamine gave ketone (R)-21ba in 92% ee. According 
to this synthetic correlation we assigned the (S,Z) stereochemistry to 22ea. 
A similar sequence carried out with (E)-22ea, resulting from the pyBOX1-Ca(II) 
catalyzed reaction, gave again ketone (R)-21ba at the end of the sequence indicating 
that the stereochemistry of the stereogenic center in the starting compound was S. 
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The Z-configuration of the double bond of products (Z)-22 in the La-catalyzed 
reaction indicates the preference of the unsaturated imines 17 to adopt an s-cis 
conformation in the transition state, while in the Ca-catalyzed reaction imines 17 should 
adopt the s-trans conformation to give the E-enamine. The configuration of the 
stereogenic center in compounds 22 would be the resultant of both: a topological 
approach of the nucleophile dictated by the stereogenic center of the chiral ligand, and 
the conformation of the unsaturated imine dictated by the accommodation of the 
reacting species in the TS (note that the reactions under La or Ca catalysis with the same 
ligand pyBOX1 lead to opposite configurations R and S, respectively, in the final 
products). At the current stage of the research, it has not been possible to give a reliable 
explanation of the stereochemical course of the reaction. Further research, including 
computational calculations, may be required. 
4.5.6. Synthetic transformations 
Besides the above transformation, we have achieved the reaction between (E)-
enamine (S,E)-22ea and hydroxylamine to give a chiral cyclopropane oxime 23ea in 
90% yield (Scheme 139). The reaction provided a single diastereomer without any loss 
of enantiomeric excess with respect to the starting material. The 1H NMR of compound 
23ea showed two doublets at  δ 3.67 and 3.27 ppm with a J value of 9.0 Hz 
corresponding to the two cyclopropanic protons. Based on similar J values reported in 
the literature for related cyclopropanes,178-182 the cis geometry was assigned to 
compound 23ea. 
 
Scheme 139. Synthesis of a chiral cyclopropane oxime 
In summary, in sections 4.4 and 4.5 we have developed procedures for the 
conjugate addition of different malonate ester derivatives to N-tosyl imines derived 
from β,γ-unsaturated α-keto esters to give chiral α,β-dehydroamino esters. The addition 
of diethyl malonate and diethyl 2-chloromalonate catalyzed by pyBOX-La(OTf)3 
complexes led to the corresponding dehydroamino esters with the Z-configuration at the 
double bond with high enantiomeric excesses. On the other hand, pyBOX-Ca(OTf)2 
complexes catalyzed the addition of diethyl 2-chloromalonate favoring the formation of 
the dehydroamino esters with the E-configuration with excellent enantioselectivity. 
Some synthetic transformation of the resulting products showed their potential 
applicability in organic synthesis. 
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4.6. Catalytic asymmetric formal [3+2] cycloaddition of 2-
isocyanatomalonate esters and unsaturated imines: synthesis of highly 
substituted chiral γ-lactams 
Pyrrolidinones (γ-lactams) and, in particular, 2-alkoxycarbonylpyrrolidinones 
(pyroglutamic acid derivatives) have been extensively used as building blocks in 
synthetic chemistry183 and as chiral ligands in asymmetric catalysis.184 They are also 
structural units frequently encountered in numerous biologically active natural products 
and pharmaceuticals (Figure 17).185 
 
Figure 17. Examples of bioactive natural compounds incorporating a pyrrolidinone 
unit 
Given the widespread chemical significance of these scaffolds, the development of 
new efficient and atom economy processes for the construction of these heterocyclic 
systems, especially in an enantioselective manner, constitutes an important challenge in 
current organic synthesis. Besides procedures based on the structural modification of 
nitrogen-containing heterocycles such as pyrrolidinones, pyroglutamic acid or 
succinimides,186 cyclization procedures in which the pyrrolidinone heterocycle is 
formed from acyclic precursors in an asymmetric fashion result especially appealing. 
Examples include the enantioselective Michael addition/lactamization reaction of 2-
amino acids and unsaturated acid derivatives,187 the NHC catalyzed coupling of imines 
with unsaturated aldehydes188 or the reaction between 2-aminomalonates and Morita-
Baylis-Hillman carbonates catalyzed by chiral Lewis.189 
On the other hand, the application of isocyano-190 and isothiocyanato191 esters in 
asymmetric synthesis has experienced a growing interest in the last years. These 
compounds can react with different unsaturated groups to give a variety of five-
membered nitrogen containing heterocycles. In particular, several examples involving 
their participation in asymmetric catalytic [3+2] cycloaddition reactions with conjugate 
carbonyl compounds to give enantiomerically enriched pyrrolidines192 or 
thiopyrrolidinones,193 respectively, have been reported in the literature. 
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In contrast, the use of isocyanato esters in asymmetric catalysis is almost unknown. 
The isocyanate group is more reactive than the isothiocyanate and the application of 2-
isocyanato esters in reactions that combine both nucleophilic and electrophilic behavior 
(1,3-dipole-like behavior) is challenging. In fact, 2-isocyanato esters have been mainly 
used as electrophiles for the preparation of ureas and carbamates,194 while reactions 
making use of their 1,3-dipole-like character are very scarce. To the best of our 
knowledge, the organocatalytic reaction of 2-isocyanatomalonate esters and aldehydes 
to give oxazolidinones developed by Takemoto195 is the only example reported in the 
literature, so far. In this chapter we will disclose the development of the first 
enantioselective formal [3+2] cycloaddition of 2-isocyanatomalonates with alkenes to 
give highly substituted α,β-unsaturated γ-lactams (Scheme 140). 
 
Scheme 140. Formal [3+2] cycloaddition between 2-isocyanatomalonate esters and 
unsaturated imines 
4.6.1. Synthesis of α,β-unsaturated N-(o-methoxyphenyl)imines 25 
Preliminary experiments on the reaction of diethyl 2-isocyanatomalonate with 
chalcone or its N-tosyl imine 2a showed that these were not reactive substrates in the 
presence of different metal complexes. The reaction was then tested with α,β-
unsaturated N-(o-methoxyphenyl)imines 25 that yielded the expected product. A 
number of imines 25a-n having different substitution were then prepared in 32-74% 
yield from the corresponding enones and o-anisidine by treatment with TiCl4 and Et3N 
following a similar procedure as described for the previous imines (Scheme 141).22 
Imines 25 have the E-geometry at the C=C bond, but were obtained as 2:1 to 7:3 
mixtures of C=N geometric isomers and used without separation. 
 
Scheme 141. Synthesis of α,β-unsaturated N-(o-methoxyphenyl)imines 25 
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4.6.2. Optimization of the reaction conditions  
We initially investigated the activity of the pyBOX1-La(OTf)3, pyBOX1-Ca(OTf)2 
and BOX1-Mg(OTf)2 complexes in the reaction between diethyl 2-isocyanatomalonate 
(24b) and imine 25a derived from o-anisidine and chalcone (Table 20, entries 1-3).  
Table 20. Enantioselective [3+2] cycloaddition of 2-isocyanatomalonate esters 24 with 
unsaturated imine 25a. Optimization of reaction conditions.a 
 
entry M ligand 24 R solvent T (°C) t (h) 26 yield (%)b ee (%)c 
1 La pyBOX1 24b Et CH2Cl2 rt 3 26ba 81 3 
2 Ca pyBOX1 24b Et CH2Cl2 rt 3.5 26ba 89 -67 
3 Mg BOX1 24b Et CH2Cl2 rt 2 26ba 97 -67 
4 Mg BOX2 24b Et CH2Cl2 rt 2.5 26ba 83 -5 
5 Mg BOX5 24b Et CH2Cl2 rt 2.5 26ba 89 5 
6 Mg BOX7 24b Et CH2Cl2 rt 3 26ba 94 63 
7 Mg BOX8 24b Et CH2Cl2 rt 3 26ba 97 29 
8 Mg BOX9 24b Et CH2Cl2 rt 2.5 26ba 97 71 
9 Mg BOX9 24b Et CH2Cl2 0  3 26ba 96 80 
10 Mg BOX9 24b Et CH2Cl2 -20  45 26ba 68 43 
11 Mg BOX9 24a Me CH2Cl2 0 2 26aa 98 49 
12 Mg BOX9 24c iPr CH2Cl2 0 2 26ca 98 89 
13 Mg BOX9 24c iPr DCE 0 2.5 26ca 98 76 
14 Mg BOX9 24c iPr CHCl3 0 2.5 26ca 89 91 
15 Mg BOX9 24c iPr Et2O 0 2.5 26ca 96 91 
16 Mg BOX10 24c iPr Et2O 0 1.5 26ca 97 97 
a
 Reaction conditions: 1 (0.19 mmol), 25a (0.125 mmol), ligand (0.0125 mmol), M(OTf)n (0.0125 mmol), 
4 Å MS (110 mg), solvent (1.1 mL). b Yield of isolated product. c Determined by HPLC with chiral 
stationary phases; opposite sign indicates opposite enantiomers. 
In all the cases, the reaction proceeded smoothly to give pyrrolidinone 26ba, which 
features a conjugated exocyclic double bond, a structural moiety that is present in a 
large number of antitumor compounds. Compound 26ba was obtained as a single 
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geometric isomer having the Z configuration at the double bond. Regarding 
enantioselectivity, the pyBOX1-La(OTf)3 complex gave compound 26ba in almost 
racemic form, while the pyBOX1-Ca(OTf)2 and BOX1-Mg(OTf)2 complexes showed 
similar enantioselectivities (ee = 67%), although the magnesium complex seemed 
slightly more active. Further research was, therefore, continued by testing several BOX-
Mg complexes. The best result was obtained with BOX9 that provided compound 26ba 
in 98% yield with 71% ee (Table 20, entry 8). A decrease of temperature to 0 °C 
increased the ee up to 80%, however further decrease of temperature to -20 °C produced 
a dramatic drop in the enantioselectivity (Table 20, entries 9 and 10). With the optimal 
temperature (0 °C), the effect of the alkoxy group in the 2-isocyanatomalonate ester was 
tested (Table 20, entries 9, 11 and 12). It was found that diisopropyl 2-
isocyanatomalonate (24c) underwent a more enantioselective reaction than dimethyl 
(24a) or diethyl 2-isocyanatomalonates (24b), giving lactam 26ca with 89% ee. Next, 
the solvent effect was checked. The use of diethyl ether as the solvent in the addition of 
isocyanate 24c to imines 25a allowed increasing the ee of compound 26ca up to 91% 
(Table 20, entry 15). Finally, in view of the important effect of the substitution at the 
central carbon of the BOX ligand on the enantioselectivity of the reaction, compare 
BOX8 and BOX9 (Table 20, entry 7 vs entry 8), the cyclopropanic BOX10 ligand was 
prepared and tested providing compound 26ca in excellent 97% yield and 97% ee 
(Table 20, entry 16). 
4.6.3. Scope of the reaction 
With the best available conditions, the scope of reaction of diisopropyl 2-
isocyanatomalonate (24c) and α,β-unsaturated N-(o-methoxyphenyl)imines 25 using the 
BOX10-Mg(OTf)2 complex as catalyst was studied. The results are gathered in Table 
20. The reaction could be carried out with imines bearing at the β-carbon an aromatic 
ring substituted with either electron-withdrawing (Table 21, entries 2 and 3) or electron-
donating groups (Table 21, entry 4), to give the expected products 26cb-cd with 
excellent yields and enantioselectivities. R1 can also be a heterocyclic furanyl ring 
(Table 21, entry 5). In this case, compound 26ce was obtained in almost quantitative 
yield and slightly lower ee (88%). The introduction of a bulky tert-butyl group on the β-
carbon brought about a decrease on the reaction rate and the expected lactam 26cf was 
obtained with low yield and enantioselectivity (Table 21, entry 6). The R2 group 
attached to the azomethinic carbon was also amenable to variation (Table 21, entries 7-
14). Aromatic rings bearing either electron-withdrawing or electron-donating groups 
were permitted without showing much influence on the enantioselectivity of the 
reaction. Again, when R2 was a 2-furanyl group, compound 26cm was obtained with 
lower ee, although with high yield (Table 21, entry 13). A naphthyl group attached to 
the imine was also tolerated, compound 26cn being obtained in 98% yield and 98% ee 
(Table 21, entry 14). As anticipated, dimethyl and diethyl 2-isocyanatomalonates 
reacted with imine 25a to give the expected lactams 26aa and 26ba with lower 
enantioselectivity than diisopropyl 2-isocyanatomalonate (Table 21, entries 15 and 16). 
In all the examples studied compounds 26 were obtained as single diastereomers with 
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the Z-configuration at the exocyclic double bond, except in the cases of imines 25k and 
25l, bearing an o-substituted phenyl ring attached to the azomethinic carbon, which 
provided ca. 1:1 mixtures of diastereomers (Table 21, entries 11 and 12).  
Table 21. Enantioselective [3+2] cycloaddition of 2-isocyanatomalonate esters 24 with 
unsaturated imines 25.a 
 
entry 24 R 25 R1 R2 t (h) 26 yield (%)b ee (%)c 
1 24c iPr 25a Ph Ph 1.5 26ca 97 97 
2 24c iPr 25b 4-ClC6H4 Ph 1.5 26cb 93 96 
3 24c iPr 25c 4-NO2C6H4 Ph 1.5 26cc 98 98 
4 24c iPr 25d 4-MeOC6H4 Ph 1.5 26cd 98 96 
5 24c iPr 25e 2-furanyl Ph 1 26ce 98 88 
6 24c iPr 25f tBu Ph 20 26cf 26 23 
7 24c iPr 25g Ph 4-ClC6H4 1.5 26cg 94 99 
8 24c iPr 25h Ph 4-NO2C6H4 1 26ch 98 95 
9 24c iPr 25i Ph 4-MeOC6H4 1 26ci 97 98 
10 24c iPr 25j Ph 3-NO2C6H4 3 26cj 87 97 
11 24c iPr 25k Ph 2-ClC6H4 1.5 26ck 98d 98e 
12 24c iPr 25l Ph 2-NO2C6H4 27 26cl 98d 99 
13 24c iPr 25m Ph 2-furanyl 1 26cm 98 83 
14 24c iPr 25n Ph 2-naphthyl 1 26cn 98 98 
16 24a Me 25a Ph Ph 1 26aa 97 76 
15 24b Et 25a Ph Ph 1 26ba 96 77 
17f 24c iPr 25a Ph Ph 1.5 26ca 96 94 
a
 Reaction conditions: 24 (0.19 mmol), 25 (0.125 mmol), BOX10 (0.0125 mmol), Mg(OTf)2 (0.0125 
mmol), 4 Å MS (110 mg), Et2O (1.1 mL), 0 °C. b Yield of isolated product. c Determined by HPLC with 
chiral stationary phases. d Obtained as a ca. 1:1 mixture of E/Z isomers. e Determined after enamine 
hydrolysis. f Reaction carried out with 1.6 mmol of 25a. 
Remarkably, the reaction of 24c and 25a could be carried out on a 1.6 mmol scale 
(500 mg) to give the expected product 26ca in 96% yield with minimal erosion in the 
enantioselectivity (94% ee, Table 21, entry 17), demonstrating the practicality of this 
newly developed procedure. 
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 4.6.4. Determination of the absolute stereochemistry of compound 26cb 
Compound 26cb could be crystallized and subjected to X-ray analysis (CCDC 
1544707), what allowed to stablish the geometry of the enamine double bond as Z, and 
the configuration of the stereogenic center as R (Figure 18). The absolute 
stereochemistry of all compounds 26 was assigned by analogy upon the assumption of a 
uniform stereochemical pathway, as usually. 
 
Figure 18. Ortep plot for the X-ray structure of compound 26cb. The thermal ellipsoids 
are drawn at the 50% probability level. Flack parameter -0.16(8) 
4.6.5. Synthetic transformations 
To illustrate the potential application of the γ-lactams resulting from this [3+2] 
cycloaddition, we carried out some synthetic modifications of compound 26cb. First, 
the hydrolysis of the enamine moiety was carried out by treatment with concentrated 
aqueous HCl in THF to give ketone 27ca in 90% yield (Scheme 142). 
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Scheme 142. Hydrolysis of compound 26ca 
The relative stereochemistry of compound 27ca was determined by NOESY 
experiments that showed the interaction between proton H4 and one of the protons of 
the phenyl ring attached to C3 (ring A), indicating that both H4 and this phenyl group 
are on the same side of the pyrrolidinone ring (Figure 19) 
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Figure 19. NOESY experiments carried out with compound 27ca 
On the other hand, reduction of the enamine double bond was performed by 
treatment with NaBH3CN-AcOH in EtOH, which provided two amines 28ca and 29ca 
in 75% and 11% yield, respectively (Scheme 143). The stereochemistry of the major 
amine could be assigned after crystallization and X-ray analysis (CCDC 1544708). The 
stereochemistry of the minor amine remains unassigned. 
Ph
H
N
iPrO2C
iPrO2C HN O
Ph
26ca
NaBH3CN, AcOHOMe
EtOH, 0 °C, Ph NH
iPrO2C
iPrO2C HN O
Ph
H
H
MeO
Ph NH
iPrO2C
iPrO2C HN O
Ph
MeO
+
28ca 29ca
75% 11%
 
Scheme 143. Reduction of the enamine moiety in compound 26ca and X-ray structure 
of compound 28ca. The thermal ellipsoids drawn at the 50% probability level 
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Also, the chemoselective transesterification of the diisopropyl ester 26ca to give the 
mixed diester 30ca was efficiently achieved in 89% yield by treatment with 
NaOMe/MeOH. In the 1H NMR spectra of compounds 30ca there is a singlet signal at 
3.81 ppm corresponding to the new methyl ester group, while both methyls of the 
remaining isopropyl ester show well separated doublet signals at 0.92 and 0.57 ppm due 
to the anisotropic effect of the phenyl group attached to C3, which is oriendted to the 
same side of the molecule (Scheme 144). 
 
Scheme 144. Chemoselective transesterification and decarboxylation of compound 
26ca 
Finally, the pyroglutamic acid derivative 31ca was obtained in 87% yield after 
hydrolysis/decarboxylation upon treatment of 26ca with an excess of 
tetraethylammonium hydroxyde in DMSO at 80 °C (Scheme 144). The relative 
stereochemistry (trans) was assigned according to the coupling constant values (2.0 Hz) 
between H2 and H3 by comparison with J values reported in the literature for similar 
compounds.196 
All the above reactions took place without noticeable loss of enantiomeric excess 
with respect to starting 26ca. 
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4.6.6. Mechanistic proposal 
A simplified mechanistic proposal for the formal [3+2] cycloaddition is outlined in 
Scheme 145. Thus, initial coordination of both reaction partners to the BOX-Mg(OTf)2 
complex would result in nucleophilic activation of the malonate ester via enolization 
together with electrophilic activation of the imine (intermediate I). Conjugate addition 
would then lead to enamine intermediate II which would undergo nucleophilic addition 
to the isocyanate group giving lactam III. Finally, imine/enamine tautomerization and 
decoordination would give the final products and release the catalyst. 
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Scheme 145. Simplified mechanistic proposal. Mg* = Mg-BOX 
In summary, we have developed the first enantioselective formal [3+2] 
cycloaddition of 2-isocyanatomalonate esters with electrophilic alkenes. Using a BOX-
Mg(OTf)2 complex as catalyst, diisopropyl 2-isocyanatomalonate reacted with α,β-
unsaturated N-(o-anisidyl) imines to give highly substituted chiral pyrrolidinones 
featuring a conjugate exocyclic double bond. The reaction products, which are 
derivatives of pyroglutamic acid, were obtained with excellent yields and high to 
excellent enantioselectivities for a significative number of unsaturated imines. The use 
of the N-(o-anisidyl) group was essential for the success of the reaction as neither the 
unsaturated ketone nor the unsaturated N-tosyl imine were reactive with this catalyst. 
Furthermore, the reaction does not require the use of diastereomerically pure imines.  
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5. EXPERIMENTAL SECTION 
General procedures 
All catalytic reactions were carried out in glassware oven-dried overnight at 120 ºC. 
Reactions were monitored by TLC analysis using Merck Silica Gel 60 F-254 thin layer 
plates. After elution, TLC plates were observed under UV light and chemically revealed 
using a solution prepared from Ce(SO4)2 (10 g), phosphomolibdic acid (25 g) and 
concentrated H2SO4 (80 mL) in water (1L).  
Flash column chromatography was performed on Merck silica gel 60, 0.040-0.063 mm. 
Solvents and reagents 
Analytical quality solvents were used for general purposes. The following solvents were 
dried and purified when needed: CH2Cl2, 1,2-dichloroethane and toluene were freshly 
distilled from CaH2 under nitrogen. THF and diethyl ether were freshly distilled from 
Na/benzophenone under nitrogen. EtOAc, EtOH, iPrOH, CHCl3, acetonitrile and 1,4-
dioxane were dried and stored on 4 Å molecular sieves, triethylamine and tertiary 
amines were dried and stored on CaH2. Most reagents were commercially available and 
used as purchased without further purification.  
4 Å molecular sieves for the enantioselective reactions (8-12 mesh, beads Aldrich 
208604) were dried at the flame under vacuum (oil pump) and stored in a closed flask 
and used before a week. 
Melting points 
Melting points were measured in capillary tubes in a “Büchi M-560” instrument and are 
uncorrected. 
Nuclear magnetic resonance (NMR) 
NMR spectra were run in a Bruker Avance 300 DPX spectrometer (300 MHz for 1H, 75 
MHz for 13C and 282 MHz for 19F NMR). In some cases a Bruker Avance 400 
spectrometer (400 MHz for 1H) was used, especially for NOE and NOESY experiments. 
Samples were dissolved in deuterated solvents as stated, using the residual non-
deuterated solvent as internal standard (δ 7.26 for 1H NMR and δ 77.00 for 13C NMR in 
the case of CDCl3, δ 2.50 for 1H NMR and δ 39.52 for 13C NMR in the case of DMSO-
d6). For 19F NMR experiments, CFCl3 was used as internal standard. Chemical shifts (δ 
values) are given in ppm. Coupling constants (J) are given in Hz. The carbon 
multiplicity was determined by DEPT experiments. 
Polarimetry 
Specific optical rotations were measured in a Perkin-Elmer polarimeter using sodium 
light (D line 589 nm) in a 1 dm cell. Concentrations (c) are given in g/100 mL. 
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Mass spectrometry 
Electrospray ionization mass spectra (ESI) were recorded on a Waters Q-TOF premier 
mass spectrometer equipped with an electrospray source with a capillary voltage of 3.3 
kV.  
HPLC analyses 
Chiral HPLC analyses were performed in an Agilent 1100 series instrument equipped 
with a refraction index detector or in a Hitachi Elite Lachrom instrument equipped with 
a Hitachi UV diode-array L-4500 detector using chiral stationary columns from Daicel 
or Phenomenex. Variable mixtures of hexane and isopropanol were used as eluents. 
Retention times (tr) are expressed in minutes. 
Chiral ligands 
BOX and pyBOX ligands were commercially available or synthesized following 
procedures described in the literature. Some typical procedures follow: 
Synthesis of ligands BOX9 and BOX11197 
N1,N3-bis((1R,2S)-2-hydroxy-1,2-diphenylethyl)-2,2-dimethylmalonamide 
 
(1S,2R)-2-Amino-1,2-diphenylethanol (3.0 g, 14.0 mmol) was suspended in 
dichloromethane (36 mL), triethylamine (3.56 g, 35.0 mmol) was added and the 
reaction flask was introduced in a bath at 0 °C. After 10 minutes, malonyl dichloride 
(0.684 mL, 7.03 mmol) was added dropwise, and the mixture was stirred at room 
temperature overnight. Then, the reaction mixture was diluted with dichloromethane 
(200 mL), quenched with 2M HCl (2×40 mL) and brine (40 mL). The organic layer was 
dried over MgSO4, filtered and concentrated under reduced pressure. The crude product 
was used in the next step without further purification. 
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(4R,4'R,5S,5'S)-2,2'-(Propane-2,2-diyl)bis(4,5-diphenyl-4,5-dihydrooxazole) BOX9 
 
A solution of the previous bis-hydroxyamide (3.74g, 7.16 mmol) and 
(NH4)6Mo7O24·4H2O (1.13 g, 1.07 mmol) in p-xylene (215 mL) was heated at reflux in 
a Dean-Stark system for 20 h. After cooling to room temperature, the mixture was 
concentrated under reduced pressure and the chromatographed on silica gel eluting with 
hexane/EtOAc mixtures to give BOX9 (3.0g, 87%). 1H NMR (300 MHz, CDCl3) δ 
7.01-6.96 (m, 20H), 5.97 (d, J = 10.2 Hz, 2H), 5.60 (d, J = 10.2 Hz, 2H), 1.93 (s, 6H). 
Bis((4R,5S)-4,5-diphenyl-4,5-dihydrooxazol-2-yl)methane (BOX8) 
 
A solution of commercially available diethyl malonimidate dihydrochloride (0.61g, 2.66 
mmol) and (1S,2R)-2-amino-1,2-diphenylethanol (1.15 g, 5.31 mmol) in dry DCE (10.6 
mL) was refluxed under N2 atmosphere for 1 hour. Afterwards, a solution of Et3N (0.74 
mL, 5.31 mmol) dry DCE (2.8 mL) was added to the reaction mixture over 30 minutes, 
and the mixture was refluxed for additional 3.5 hours. The mixture was cooled down to 
room temperature until precipitation of a white solid. After filtration, the residue was 
purified by column chromatography eluting with DCM/MeOH mixtures (98:2 to 95:5) 
to give BOX8 (975 mg, 80%). 1H NMR (300 MHz, CDCl3) δ 7.02 (s, 10H), 6.99 (s, 
10H), 5.99 (d, J = 10.2 Hz, 2H), 5.65 (dt, J = 10.2, 0.9 Hz, 2H), 3.90 (t, J = 1.2 Hz, 2H).  
(4R,4'R,5S,5'S)-2,2'-(cyclopropane-1,1-diyl)bis(4,5-diphenyl-4,5-dihydrooxazole) 
BOX10198  
 
TMEDA (0.73 mL, 4.83 mmol) and diisopropyl amine (0.28 mL, 2.1 mmol) were added 
to a solution of previously prepared BOX8 (963 mg, 2.1 mmol) in dry THF (30 mL), 
under N2 atmosphere, and the solution was introduced in a bath at -65ºC. After 10 
minutes, BuLi 1.6 M in hexanes (2.62 mL, 4.2 mmol) was added to the reaction via 
syringe and the solution was warmed to -20ºC. After 50 minutes, the solution was 
cooled again to -65 ºC, 1,2-dibromoethane (0.19 mL, 2.2 mmol) was added and the 
reaction mixture was stirred for 16 h at room temperature. Then, the reaction was 
quenched with saturated aqueous NH4Cl (20 mL) and extracted with methyl tert-butyl 
ether (15 mL). The extract was dried over MgSO4, filtered and concentrated under 
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reduced pressure and purified by column chromatography eluting with  hexane/EtOAc 
mixtures (50:50 to 40:60) to give BOX10 (366 mg, 36%). 1H NMR (300 MHz, CDCl3) 
δ 7.02-6.96 (m, 20H), 5.96 (d, J = 10.2 Hz, 2H), 5.60 (d, J = 10.2 Hz, 2H), 1.83-1.76 
(m, 4H). 
Synthesis of ligands pyBOX9 and pyBOX4 
Dimethyl pyridine-2,6-bis(carbimidate) 
 
Sodium hydride (60% dispersion in mineral oil, 20.5 mg, 0.51 mmol) was added to a 
solution of pyridine-2,6-dicarbonitrile (0.6 g, 4.6 mmol) in anhydrous MeOH (5 mL) 
and the mixture was stirred at rt overnight. Acetic acid (34.6 µL, 0.61 mmol) was added 
and after 90 minutes, the solvent was removed under reduced pressure to give the title 
compound which was dried overnight in a desiccator containing P2O5 before use. 
2,6-Bis((4R,5S)-4,5-diphenyl-4,5-dihydrooxazol-2-yl)pyridine (pyBOX9) 
 
A solution of dimethyl pyridine-2,6-bis(carbimidate) (361 mg, 1.87 mmol) and (1S,2R)-
2-amino-1,2-diphenylethanol (812 mg, 3.75 mmol) in dichloromethane (20 mL) was 
heated under reflux for 5 days. The reaction mixture was then cooled to r.t., 
dichloromethane was evaporated under reduced pressure and the product was filtered 
and washed with water and methanol. The residue was purified by silica gel column 
chromatography to give pyBOX9 (663 mg, 68%). 1H NMR (300 MHz, CDCl3) δ 8.45 
(d, J = 8.1 Hz, 2 H), 8.04 (t, J = 7.8 Hz, 1 H), 7.06-6.96 (m, 20 H), 6.15 (d, J = 10.2 Hz, 
2 H), 5.83 (d, J = 10.2 Hz, 2 H). 
2,6-Bis((S)-4-isobutyl-4,5-dihydrooxazol-2-yl)pyridine (pyBOX4) 
Was prepared in 70% yield following the same procedure. 1H NMR 
(300 MHz, CDCl3) δ 8.16 (d, J = 7.8 Hz, 2H), 7.84 (t, J =7.5 Hz, 
1H), 4.60 (dd, J = 9.3, 8.1Hz, 2H), 4.43-4.33 (m, 2H), 4.08 (t, J = 
8.4 Hz, 2H), 1.89-1.68 (m, 4H), 1.89-1.80 (m, 2H), 1.77-1.68 (m, 
2H), 1.43-1.34 (m, 2H), 0.97 (d, J = 5.7 Hz, 6H), 0.96 (d, J = 5.7 
Hz, 6H). 
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5.1. Asymmetric conjugate addition of malonate esters to α,β-
unsaturated N-tosyl ketimines catalyzed by pyBOX-La(OTf)3 
5.1.1. Synthesis and characterization of α,β-usaturated N-tosyl imines 2  
The procedure reported by Carretero was followed:22 to a solution of enone (4.8 mmol) 
and p-toluenesulfonamide (820 mg, 4.8 mmol) in dry dichloromethane (60 mL) at 0 ºC 
under nitrogen atmosphere, was added via syringe Et3N (1.5 mL, 1.07 g, 10.6 mmol) 
followed by TiCl4 (0.58 mL, 1.0 g, 5.3 mmol). The reaction was heated at reflux 
temperature for 20 h. Then it was cooled to room temperature and quenched with water 
(50 mL). The two layers were separated and the aqueous layer was extracted with 
dichloromethane (3×50 mL). The combined organic layers were dried over MgSO4, 
filtered and concentrated under reduced pressure. Purification by flash column 
chromatography on silica gel eluting with hexane/EtOAc mixtures afforded the 
corresponding imines 2 (70-85% yield). The imines were recrystallized from ca. 1:1 
hexane/EtOAc mixtures and stored in the freezer. 
(E)-1,3-Diphenyl-N-tosylprop-2-en-1-imine (2a)22 
Mp 153-154 °C (hexane-EtOAc); 1H NMR (300 MHz,CDCl3) δ 
7.94 (d, J = 7.8 Hz, 2H), 7.66 (d, J = 7.2 Hz, 2H), 7.59-7.39 (m, 
8H), 7.32 (d, J = 8.1 Hz , 2H), 7.07 (d. J = 15.9 Hz, 1H), 2.43 (s, 
3H); 13C NMR (75 MHz, CDCl3) δ 177.7 (C), 148.9 (CH), 143.6 
(C), 138.8 (C), 134.6 (C), 132.1 (CH), 131.2 (CH), 130.4 (CH), 129.5 (CH), 129.1, 
(CH) 128.8 (CH), 128.5 (CH), 127.3 (CH), 21.7 (CH3). 
(E)-3-(4-Fluorophenyl)-1-phenyl-N-tosylprop-2-en-1-imine (2b)40 
Mp 138-139 °C (hexane-EtOAc); 1H NMR (300 MHz, CDCl3) 
δ 7.92 (d, J = 7.8 Hz, 2H), 7.64 (d, J = 6.9 Hz, 2H), 7.59-7.52 
(m, 3H), 7.46-7.41 (m, 2H), 7.32 (d, J = 8.1 Hz, 2H), 7.10 (t, J 
= 8.4 Hz, 2H), 7.03 (d, J = 16.2 Hz, 1H), 2.43 (s, 3H); 13C 
NMR (75 MHz, CDCl3) δ 177.5 (C), 164.5 (d, JC-F = 251.3 Hz, 
C), 147.5 (CH), 143.6 (C), 138.8 (C), 132.1 (C), 130.96 (d, JC-F = 3.0 Hz, CH), 130.90 
(d, JC-F = 8.3 Hz, CH), 129.6 (CH), 128.5 (CH), 127.3 (CH), 116.4 (d, JC-F = 22.5 Hz, 
CH), 21.7 (CH3); 19F NMR (282 MHz, CDCl3) δ -108.5 (s, 1F); 
(E)-3-(4-Chlorophenyl)-1-phenyl-N-tosylprop-2-en-1-imine (2c)40 
Mp 141-142 °C (hexane-EtOAc); 1H NMR (300 MHz, 
CDCl3) δ 7.92 (d, J = 7.5 Hz, 2H), 7.64 (d, J = 7.5, 2H), 7.58-
7.37 (m, 7H), 7.32 (d, J = 8.1 Hz, 2H), 7.01 (d, J = 15 Hz, 
1H), 2.43 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 147.2 (C), 
143.7 (C), 143.4 (C), 138.7 (C), 137.2 (C), 133.1 (CH), 132.2 (CH), 130.2 (CH), 130.0 
(CH), 129.7 (CH), 129.6 (CH), 129.5 (CH), 128.8 (CH), 128.5 (CH), 127.3 (CH), 21.7 
(CH3). 
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(E)-3-(4-Bromophenyl)-1-phenyl-N-tosylprop-2-en-1-imine (2d)40 
Mp 133-134 °C (hexane-EtOAc); 1H NMR (300 MHz, 
CDCl3) δ 7.92 (d, J = 7.8 Hz, 2H), 7.64 (d, J = 7.8 Hz, 2H), 
7.58-7.53 (m, 3H), 7.44 (dt, J = 7.5, 1.2 Hz, 4H), 7.32 (d, J = 
8.1 Hz, 2H), 6.99 (d, J = 16.2 Hz, 1H), 2.43 (s, 3H); 13C 
NMR (75 MHz, CDCl3) δ 177.3 (C), 147.2 (C), 143.7(C), 
138.7 (C), 133.6 (C), 132.4 (CH), 132.2 (CH), 130.3 (CH), 130.1 (CH), 129.6 (CH), 
128.6 (CH), 127.3 (CH), 125.7 (CH), 123.3 (CH), 21.7 (CH3). 
(E)-3-(4-Nitrophenyl)-1-phenyl-N-tosylprop-2-en-1-imine (2e) 
Mp 150-151 °C (hexane-EtOAc); 1H NMR (300 MHz, 
CDCl3) δ 8.27 (d, J = 8.7 Hz, 2H), 7.92 (d, J = 7.8 Hz, 2H), 
7.74-7.67 (m, 4H), 7.58 (tt, J = 7.5 Hz, 1.2, 1H), 7.46 (m, 
2H), 7.34 (d, J = 7.8 Hz, 2H), 7.07 (d, J = 16.2 Hz, 1H), 2.44 
(s, 3H); 13C NMR (75 MHz, CDCl3) δ 176.5 (C), 148.8 (CH), 144.3 (C), 144.0 (C), 
140.7 (C), 138.3 (C), 132.7 (C) 130.3 (CH), 129.7 (CH), 129.2 (CH), 128.7 (CH), 127.4 
(CH), 126.5 (CH), 124.4 (CH), 21.7 (CH3); HRMS (ESI) m/z 407.1076 [M]+, 
C22H19N2O4S required 407.1060. 
(E)-3-(4-Methoxyphenyl)-1-phenyl-N-tosylprop-2-en-1-imine (2f)99 
Mp 96-98 °C (hexane-EtOAc); 1H NMR (300 MHz, CDCl3) 
δ 7.92 (d, J = 7.8 Hz, 2H), 7.61 (d, J = 7.2 Hz, 2H), 7.56-7.50 
(m, 3H), 7.45-7.40 (m, 2H), 7.31 (d, J = 8.1 Hz, 2H), 7.04 (d, 
J = 10.5 Hz, 1H), 6.92 (dt, J = 8.7, 3 Hz, 2H), 3.86 (s, 3H), 
2.42 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 178.1 (C), 162.4 (C), 149.5 (CH), 143.42 
(C), 139.0 (C), 131.7 (CH), 130.9 (CH), 130.2 (CH), 129.5 (CH), 128.4 (CH), 127.4 
(CH), 127.3 (CH), 114.7 (CH), 55.6 (CH3), 21.7 (CH3). 
(E)-3-(Furan-2-yl)-1-phenyl-N-tosylprop-2-en-1-imine (2g)136 
Mp 125-126 °C (hexane-EtOAc); 1H NMR (300 MHz, CDCl3) δ 
7.92 (d, J = 7.8 Hz, 3H), 7.60-7.58 (m, 3 H), 7.52 (tt, J = 7.2, 1.5 
Hz, 1H), 7.42 (tt, J = 7.5, 1.8 Hz, 2H), 7.30 (d, J = 7.8 Hz, 2H), 
6.83 (d, J = 15.7 Hz, 1H), 6.67 (d, J = 3.6 Hz, 1H), 6.51 (q, J = 1.8 
Hz, 1H), 2.42 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 177.4 (C), 166.9 (C), 151.1 (CH), 
146.4 (C), 143.5 (C), 138.9 (C), 135.0 (CH), 131.8 (CH), 131.7 (CH), 130.0 (CH), 
129.5 (CH), 128.5 (CH) , 127.3 (CH), 117.2 (CH), 113.1 (CH), 21.7 (CH3). 
(E)-3-(Furan-3-yl)-1-phenyl-N-tosylprop-2-en-1-imine (2h) 
Mp 120-121 °C (hexane-EtOAc); 1H NMR (300 MHz, CDCl3) δ 
7.91 (d, J = 7.5 Hz, 3H), 7.62-7.58 (m, 3H), 7.53 (tt, J = 7.5, 2.4 
Hz, 1H), 7.48 (unresolved t, 1H), 7.42 (tt, J = 6.9, 1.5 Hz, 2H), 
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7.31 (d, J = 8.1 Hz, 2H), 6.99 (d, J = 15.6 Hz, 1H), 6.78 (br, 1H), 2.42 (s, 3H); 13C 
NMR (75 MHz, CDCl3) δ 177.8 (C), 145.9 (CH), 145.0 (CH), 143.6 (C), 139.5 (CH), 
138.8 (C), 131.9 (CH), 130.1 (CH), 129.5 (CH), 128.5 (CH), 127.3 (CH), 123.6 (C), 
122.6 (C), 107.7 (CH), 21.7 (CH3); HRMS (ESI) m/z 352.1.013 [M]+, C20H18NO3S 
required 352.1002. 
(E)-1-phenyl-N-tosylbut-2-en-1-imine (2i)92 
Mp 102-103 °C (hexane-EtOAc); 1H NMR (300 MHz, CDCl3) δ 7.90 
(d, J = 7.8 Hz, 2H), 7.56 (br d, J = 7.2 Hz, 2H), 7.49 (tt, J = 7.2, 2.4 
Hz, 1H), 7.41-7.35 (m, 2H), 7.31 (d, J = 8.1 Hz, 2H), 6.43 (dq, J = 
15.9, 6.6 Hz, 1H), 2.42 (s, 3H), 2.04 (d, J = 6.6 Hz, 3H); 13C NMR (75 
MHz, CDCl3) δ 177.9 (C), 150.3 (CH), 143.5 (C), 138.9 (C), 137.5 (C), 132.0 (CH), 
130.2 (CH), 129.5 (CH), 128.3 (CH), 127.6 (CH), 127.3 (CH), 21.7 (CH3), 19.6 (CH3). 
(E)-4,4-Dimethyl-1-phenyl-N-tosylpent-2-en-1-imine (2j)157 
Mp 158-163 °C (hexane-EtOAc); 1H NMR (300 MHz, CDCl3) δ 7.90 
(d, J = 7.8 Hz, 2H), 7.57 (d, J = 6.6 Hz, 2H) 7.51 (tt, J = 7.2, 2.1 Hz, 
1H), 7.39 (tt, J = 6.3, 1.2 Hz, 2H), 7.31 (d, J = 17.7 Hz, 3H), 6.35 (d, 
J = 15.9 Hz, 1H), 2.42 (s, 3H), 1.13 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 178.8 (C), 
163.9 (CH), 143.5 (C), 138.9 (C), 132.1 (CH), 130.4 (CH), 129.5 (CH), 128.3 (CH), 
127.3 (CH), 35.2 (C), 28.7 (CH3), 21.7 (CH3). HRMS (ESI) m/z 342.1534 [M]+, 
C20H24NO2S required 342.1522. 
(E)-1-(4-Fluorophenyl)-3-phenyl-N-tosylprop-2-en-1-imine (2k) 
Mp 173-174 °C (hexane-EtOAc); 1H NMR (300 MHz, CDCl3) 
δ 7.92 (d, J = 8.1 Hz, 2H), 7.71-7.67 (m, 2H), 7.59-7.56 (m, 
2H), 7.46-7.38 (m, 3H), 7.32 (d, J = 8.1 Hz, 2H), 7.13 (tt, J = 
8.7, 2.1 Hz, 2H), 7.04 (d, J = 15.9 Hz, 1H), 2.43 (s, 3H); 13C 
NMR (75 MHz, CDCl3) δ 176.4 (C), 165.2 (d, JC-F = 250.0 Hz, C), 148.7 (CH), 143.7 
(C), 138.7 (C), 134.5 (C), 133.4 (C), 132.7 (br, CH), 131.3 (CH), 129.6 (CH), 129.2 
(CH), 128.9 (CH), 127.3 (CH), 122.6 (br, C), 115.8 (d, JC-F = 21.8 Hz, CH), 21.7 (CH3); 
19F NMR (282 MHz, CDCl3) δ -107.2 (s, 1F); HRMS (ESI) m/z 380.1132 [M]+, 
C22H19FNO2S required 380.1121. 
(E)-1-(4-Chlorophenyl)-3-phenyl-N-tosylprop-2-en-1-imine (2l)99 
Mp 139-140 °C (hexane-EtOAc); 1H NMR (300 MHz, CDCl3) 
δ 7.92 (d, J = 8.1 Hz, 2H), 7.61-7.56 (m, 4H), 7.43-7.38 (m, 5 
H), 7.32 (d, J = 7.8 Hz, 2H), 7.04 (d, J = 15.9 Hz, 1H), 2.43 (s, 
3H); 13C NMR (75 MHz, CDCl3) δ 176.4 (C), 148.9 (CH), 
143.8 (C), 138.6 (C), 138.4 (C), 134.5 (C), 131.6 (CH), 131.4 (CH), 129.6 (CH), 129.2 
(CH), 128.9 (CH), 128.8 (CH), 127.3 (CH), 21.7 (CH3). 
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(E)-1-(4-Nitrophenyl)-3-phenyl-N-tosylprop-2-en-1-imine (2m) 
Mp 121-123 °C (hexane-EtOAc); 1H NMR (300 MHz, 
CDCl3) δ 8.29 (d, J = 8.4 Hz, 2H), 8.15 (br d, J = 15.3 Hz, 
1H), 7.92 (br d, J = 6 Hz, 2H), 7.79 (br d, J = 6.6 Hz, 2H), 
7.57 (br s, 2H), 7.44-7.42 (m, 3H), 7.34 (d, J = 8.1 Hz, 2H), 
7.01 (br d, J = 15.6 Hz, 1H), 2.44 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 175.1 (C), 
150.0 (CH), 149.6 (C), 144.2 (C), 143.2 (C), 138.1 (C), 134.1 (C), 131.9 (CH), 131.1 
(CH), 129.7 (CH), 129.3 (CH), 129.1 (CH), 127.4 (CH), 123.6 (CH), 121.9 (CH), 21.7 
(CH3); HRMS (ESI) m/z 406.0994 [M]+, C22H18N2O4S required 406.0987. 
(E)-1-(4-Methoxyphenyl)-3-phenyl-N-tosylprop-2-en-1-imine (2n)99 
Mp 128-129 °C (hexane-EtOAc); 1H NMR (300 MHz, 
CDCl3) δ 7.93 (d, J = 8.4 Hz, 2H), 7.70 (d, J = 8.7 Hz, 2H), 
7.59-7.56 (m, 2H), 7.43-7.40 (m, 3H), 7.30 (d, J = 8.1 Hz, 
2H), 7.05 (d, J = 15.9 Hz, 1H), 6.93 (dt, J = 9, 2.1 Hz, 2H), 
3.87 (s, 3H), 2.41 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 167.9 (C), 163.4 (C), 147.5 
(CH), 143.4 (C), 139.0 (C), 134.8 (C), 132.7 (CH), 130.9 (CH), 129.5 (CH), 129.1 
(CH), 128.7 (CH), 127.2 (CH), 113.9 (CH), 55.6 (CH3), 21.7 (CH3). 
(E)-1-(2-Fluorophenyl)-3-phenyl-N-tosylprop-2-en-1-imine (2o) 
An oil; 1H NMR (300 MHz, CDCl3) δ 7.95 (br s, 1H), 7.80 (br s, 
1H), 7.58-7.23 (m, 10H), 7.19-7.13 (m, 1H), 7.10-6.91 (m, 2H), 
2.44 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 173.7 (C), 149.7 (CH), 
148.9 (CH), 143.8 (C), 134.5 (C), 132.6 (CH), 131.4 (CH, d, JC-F = 
18.0 Hz), 129.6 (CH), 129.1 (CH), 128.8 (CH, d, JC-F = 7.5 Hz), 127.4 (CH, d, JC-F = 
11.3 Hz), 124.4 (CH), 122.7 (CH), 116.5 (CH), 115.8 (CH), 21.7 (CH3); 19F NMR (282 
MHz, CDCl3) δ -112.5 (s, 1F); HRMS (ESI) m/z 380.1132 [M]+, C22H19FNO2S required 
380.1121. 
(E)-1-(3-Nitrophenyl)-3-phenyl-N-tosylprop-2-en-1-imine (2p) 
Mp 134-135 °C (hexane-EtOAc); 1H NMR (300 MHz, 
CDCl3) δ 8.38 (dq, J = 8.4, 1.2 Hz, 1H), 8.15 (d, J = 16.5 Hz, 
1H), 7.94-7.92 (m, 3H), 7.66 (t, J = 7.8 Hz, 1H), 7.63 (br s, 
2H), 7.45-7.42 (m, 3H), 7.34 (d, J = 8.1 Hz, 2H), 7.03 (d, J = 
15.6 Hz, 1H), 2.44 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 174.8 (C), 149.7 (CH), 148.2 
(C), 144.2 (C), 140.0 (C), 138.1 (C), 135.8 (CH), 134.2 (C), 131.8 (CH), 129.8 (CH), 
129.7 (CH), 129.3 (CH), 129.1 (CH), 127.4 (CH), 126.3 (CH), 124.9 (CH), 121.9 (CH), 
21.7 (CH3); HRMS (ESI) m/z 406.0992 [M]+, C22H18N2O4S required 406.0987. 
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5.1.2. Enantioselective conjugate addition of methyl malonate to α,β-usaturated N-
tosyl imines 2 
5.1.2.1. General procedure for the enantioselective conjugate addition 
Anhydrous La(OTf)3 (7.3 mg, 0.0125 mmol) and pyBOX1 (4.6 mg, 0.012 mmol) were 
introduced in a Schlenk tube and it was filled with nitrogen. CH2Cl2 (0.4 mL) was 
added via syringe and the mixture was stirred for 30 min. Powdered 4Å MS (20 mg) 
was then added followed by a solution of imine 2 (0.12 mmol) dissolved in dry CH2Cl2 
(0.4 mL), and dimethyl malonate (1a, 35 µL, 0.3 mmol). The mixture was stirred at 
room temperature for the indicated time and chromatographed on silica gel eluting with 
hexane/EtOAc mixtures to give compounds 3. In general the minor Z-diastereomer 
eluted first from the column followed by the major E-diastereomer. 
5.1.2.2. General procedure for the synthesis of the racemic products 
Racemic compounds for comparative purpose were prepared by following the same 
procedure, using picolylamine instead of pyBOX1. 
5.1.2.3. Characterization of products 3 
See Table 3 (Page 64) for yield, dr and ee. 
Dimethyl 2-[(S,E)-1,3-diphenyl-3-(tosylamino)allyl]malonate (3aa). 
Chiral HPLC analysis: Chiralpak AD-H, hexane-iPrOH 80:20, 1 
mL/min, E-diastereomer: major enantiomer tr = 13.9 min, minor 
enantiomer tr = 18.3 min; Z-diastereomer unresolved tr = 65.3 
min. 
Major E-diastereomer: an oil; [α]D20 -76.0 (c 1.0, CHCl3, ee = 86%); 1H NMR (300 
MHz, CDCl3) δ 7.57 (d, J = 8.4 Hz, 2H), 7.35-7.18 (m, 6H), 7.16 (d, J = 8.4 Hz, 2H), 
6.96 (dd, J = 8.1, 2.4 Hz, 2H), 6.90 (dd, J = 8.1, 1.5 Hz, 2H), 6.05 (s, 1H), 5.95 (d, J = 
10.8 Hz, 2H), 4.00 (t, J = 10.5 Hz, 1H), 3.77 (d, J = 10.5 Hz, 1H), 3.67 (s, 3H), 3.40 (s, 
3H), 2.41 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 168.0 (C), 167.7 (C), 143.7 (C), 141.2 
(C), 136.4 (C), 135.8 (C), 135.3 (CH), 129.6 (CH), 129.1 (CH), 128.70 (CH), 128.69 
(CH), 128.6 (CH), 127.7 (CH), 127.0 (CH), 117.2 (CH), 58.1 (CH), 52.6 (CH3), 52.4 
(CH3), 44.1 (CH), 21.7 (CH3). Minor Z-diastereomer: an oil; [α]D20 -23.4 (c 0.95, 
CHCl3, ee = n.d.); 1H NMR (300 MHz, CDCl3) δ 7.81 (s, 1H), 7.50 (d, J = 8.1 Hz, 2H), 
7.36-7.32 (m, 2H), 7.22-7.05 (m, 8H), 6.70-6.69 (m, 2H), 5.45 (dd, J =10.8, 0.3 Hz, 
2H), 3.89 (t, J = 10.5 Hz, 1H), 3.74 (d, J = 10.2 Hz, 1H), 3.63 (s, 3H), 3.37 (s, 3H), 2.30 
(s, 3H); 13C NMR (75 MHz, CDCl3) δ 169.7 (C), 167.7 (C), 143.4 (C), 138.8 (C) , 137.8 
(C), 137.3 (C), 136.5 (C), 129.7 (CH), 128.8 (CH), 128.6 (CH), 128.1 (CH), 127.8 
(CH), 127.6 (CH), 127.4 (CH), 123.0 (CH), 57.8 (CH), 53.3 (CH3), 52.8 (CH3), 43.3 
(CH), 21.6 (CH3); HRMS (ESI) m/z 516.1453 [M+Na]+, C27H27NNaO6S required 
516.1451. 
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Dimethyl 2-[(S,E)-1-(4-fluorophenyl)-3-phenyl-3-(tosylamino)allyl]malonate (3ab) 
Chiral HPLC analysis: Chiralpak AD-H, hexane-iPrOH 80:20, 
1 mL/min, E-diastereomer: major enantiomer tr = 14.7 min, 
minor enantiomer tr = 18.0 min.; Z-diastereomer: unresolved tr 
= 68.3 min.  
Major E-diastereomer: an oil; [α]D20 -30.6 (c 1.0, CHCl3, ee 
= 86%); 1H NMR (300 MHz, CDCl3) δ 7.58 (d, J = 8.1 Hz, 2H), 7.33-7.24 (m, 4H), 
7.19 (d, J = 8.1 Hz, 2H), 6.94-6.87 (m, 6H), 6.04 (br s, 1H), 5.90 (d, 10.8 Hz, 1H), 3.98 
(t, J =10.5 Hz, 1H), 3.72 (d, J = 10.5 Hz, 1H), 3.66 (s, 3H), 3.42 (s, 3H), 2.42 (s, 3H); 
13C NMR (75 MHz, CDCl3) δ 167.9 (C), 167.7 (C), 161.7 (d, JC-F = 250.0 Hz, C), 143.9 
(C), 137.1 (C), 136.4 (C), 136.0 (C), 135.2 (C), 129.7 (CH), 129.3 (d, JC-F = 4.8 Hz, 
CH), 129.2 (d, JC-F = 7.9 Hz, CH), 128.7 (CH), 128.6 (CH), 127.7 (CH), 116.4 (CH), 
115.5 (d, JC-F = 26.2 Hz, CH), 58.1 (CH), 52.7 (CH3), 52.5 (CH3), 43.3 (CH), 21.7 
(CH3); 19F NMR (282 MHz, CDCl3) δ -115.7 (s, 1F). Minor Z-diastereomer: an oil; 
[α]D20 -39.8 (c 0.44, CHCl3, ee = n.d.); 1H NMR (300 MHz, CDCl3) δ 7.88 (s, 1H), 7.57 
(d, J = 8.1 Hz, 2H), 7.39 (d, J = 8.0 Hz, 2H), 7.29-7.23 (m, 3H), 7.14 (d, J = 8.4 Hz, 
2H), 6.95-6.83 (m, 2H), 6.77-6.73 (m, 2H), 5.47 (d, J = 10.8 Hz, 1H), 4.00 (t, J = 10.8 
Hz, 1H), 3.72 (s, 3H), 3.70 (d, J = 10.8 Hz, 1H), 3.47 (s, 3H), 2.38 (s, 3H); 13C NMR 
(75 MHz, CDCl3) δ 169.5 (C), 167.6 (C), 143.5 (C), 137.6 (C), 137.4 (C), 136.7 (C), 
134.7 (d, JC-F = 3.0 Hz, CH), 129.7 (CH), 129.3 (d, JC-F = 8.3 Hz, CH), 128.9 (CH), 
128.1 (CH), 127.8 (CH), 127.4 (CH), 122.9 (CH), 115.6 (d, JC-F = 21.0 Hz, CH), 57.7 
(CH), 53.4 (CH3), 52.9 (CH3), 42.8 (CH), 21.6 (CH3); 19F NMR (282 MHz, CDCl3) δ -
115.3 (s, 1F); HRMS (ESI) m/z 534.1373 [M+Na]+, C27H26FNNaO6S required 
534.1357. 
Dimethyl 2-[(S,E)-1-(4-chlorophenyl)-3-phenyl-3-(tosylamino)allyl]malonate (3ac) 
Chiral HPLC analysis: Chiralpak AD-H, hexane-iPrOH 80:20, 1 
mL/min, E-diastereomer: major enantiomer tr = 14.9 min, minor 
enantiomer tr = 18.0 min.; Z-diastereomer: unresolved tr = 63.5 
min.  
Major E-diastereomer: an oil; [α]D20 -17.6 (c 1.0, CHCl3, ee = 
86%); 1H NMR (300 MHz, CDCl3) δ 7.57 (d, J = 8.4 Hz, 2H), 7.35-7.16 (m, 7H), 6.91-
6.84 (m, 4H), 6.15 (s, 1H), 5.88 (d, J = 10.8 Hz, 1H), 3.97 (t, J = 10.5 Hz, 1H), 3.74 (d, 
J = 10.5 Hz, 1H), 3.67 (s, 3H), 3.43 (s, 3H), 2.43 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 
167.8 (C), 167.6 (C), 144.0 (C), 139.9 (C), 136.3 (C), 136.2 (C), 135.1 (C), 132.7 (C), 
129.6 (CH), 129.2 (CH), 129.0 (CH), 128.8 (CH), 128.7 (CH), 128.6 (CH), 127.7 (CH), 
116.0 (CH), 57.7 (CH), 52.7 (CH3), 52.5 (CH3), 43.4 (CH), 21.7 (CH3). Minor Z-
diastereomer: an oil; [α]D20 -4.1 (c 0.56, CHCl3, ee = n.d.); 1H NMR (300 MHz, 
CDCl3) δ 7.85 (s, 1H), 7.56 (d, J = 8.1 Hz, 2H), 7.39 (dd, J = 7.2, 1.5 Hz, 2H), 7.29-
7.12 (m, 8H), 6.72 (d, J = 8.4 Hz, 2H), 5.45 (d, J = 10.8 Hz, 1H), 3.99 (t, J = 10.8 Hz, 
1H), 3.71 (s, 3H), 3.70 (d, J = 10.8 Hz, 1H), 3.49 (s, 3H), 2.38 (s, 3H); 13C NMR (75 
NHTs
MeO2C
MeO2C
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MHz, CDCl3) δ 169.4 (C), 167.6 (C), 143.5 (C), 137.6 (C), 137.4 (C), 137.3 (C), 136.9 
(C), 133.2 (C), 129.7 (CH), 129.0 (CH), 128.8 (CH), 128.1 (CH), 127.8 (CH), 127.3 
(CH), 122.5 (CH), 57.5 (CH), 53.4 (CH3), 53.0 (CH3), 42.8 (CH), 21.7 (CH3); HRMS 
(ESI) m/z 550.1065 [M+Na]+, C27H26ClNNaO6S required 550.1062. 
Dimethyl 2-[(S,E)-1-(4-bromophenyl)-3-phenyl-3-(tosylamino)allyl]malonate (3ad) 
Chiral HPLC analysis: Chiralpak AD-H, hexane-iPrOH 80:20, 1 
mL/min, E-diastereomer: major enantiomer tr = 15.8 min, minor 
enantiomer tr = 19.3 min.; Z-diastereomer: unresolved tr = 64.0 
min. 
 Major E-diastereomer: an oil; [α]D20 -70.5 (c 0.9, CHCl3, ee = 
85%) for the mixture of diastereomers; 1H NMR (300 MHz, CDCl3) δ 7.56 (d, J = 8.1 
Hz, 2H), 7.38-7.25 (m, 6H), 7.18 (d, J = 8.7 Hz, 2H), 6.87 (dd, J = 6.3, 1.2 Hz, 2H), 
6.80 (d, J = 8.4, Hz, 2H), 6.07 (s, 1H), 5.88 (d, J = 10.5 Hz, 1H), 3.95 (t, J = 10.5 Hz, 
1H), 3.74 (d, J = 10.5 Hz, 1H), 3.68 (s, 3H), 3.44 (s, 3H), 2.43 (s, 3H); 13C NMR (75 
MHz, CDCl3) δ 167.8 (C), 167.6 (C), 144.0 (C), 140.5 (C), 136.24 (C), 136.17 (C), 
135.1 (C), 131.8 (C), 129.7 (CH), 129.3 (CH), 129.2 (CH), 128.8 (CH), 128.6 (CH), 
127.7 (CH), 120.9 (CH), 115.9 (CH), 57.6 (CH), 52.8 (CH3), 52.6 (CH3), 43.5 (CH), 
21.7 (CH3). Minor Z-diastereomer: 1H NMR (300 MHz, CDCl3), significative signals 
taken from the 1H NMR spectra of the diastereomer mixture, δ 7.86 (s, 1H), 7.14 (d, J = 
8.7 Hz, 2H), 6.67 (d, J = 8.4 Hz, 2H), 5.46 (d, J = 11.1 Hz, 1H), 3.98 (t, J = 10.5 Hz, 
1H), 3.75 (s, 3H), 3.69 (d, J = 10.5 Hz, 1H), 3.49 (s, 3H), 2.38 (s, 3H); 13C NMR (75 
MHz, CDCl3), significative signals taken from the 13C NMR spectra of the diastereomer 
mixture, δ 169.3 (C), 167.5 (C), 143.5 (C), 137.9 (C), 137.5 (C), 137.2 (C), 136.9 (C), 
131.8 (CH), 129.7 (CH), 129.3 (CH), 128.9 (CH), 128.1 (CH), 127.8 (CH), 127.3 (CH), 
122.4 (CH), 121.3 (CH), 57.4 (CH), 53.4 (CH3), 53.0 (CH3), 41.3 (CH), 21.7 (CH3); 
HRMS (ESI) m/z 594.0546 [M+Na]+, C27H26BrNNaO6S required 594.0556. 
 Dimethyl 2-[(S,E)-1-(4-nitrophenyl)-3-phenyl-3-(tosylamino)allyl]malonate (3ae) 
Chiral HPLC analysis: Chiralpak AD-H, hexane-iPrOH 80:20, 1 
mL/min, E-diastereomer: major enantiomer tr = 25.9 min, minor 
enantiomer tr = 30.3 min.; Z-diastereomer: unresolved tr = 58.9 
min. 
Major E-diastereomer: an oil; [α]D20 9.4 (c 1.1, CHCl3, ee = 
90%) for the mixture of diastereomers; 1H NMR (300 MHz, CDCl3) δ 8.06 (d, J = 8.7 
Hz, 2H), 7.61 (d, J = 8.4 Hz, 2H), 7.35-7.31 (m, 2H), 7.07 (d, J = 8.7 Hz, 2H), 6.89 (dd, 
J = 6.6, 1.2 Hz, 2H), 6.25 (bs, 1H), 5.88 (d, J = 10.5 Hz, 1H), 4.09 (t, J = 10.2 Hz, 1H), 
3.78 (d, J = 10.5 Hz, 1H), 3.69 (s, 3H), 3.45 (s, 3H), 2.42 (s, 3H); 13C NMR (75 MHz, 
CDCl3) δ 167.5 (C), 167.3 (C), 149.0 (C), 146.8 (C), 144.2 (C), 137.3 (C), 136.3 (C), 
134.8 (C), 129.7 (CH), 129.4 (CH), 128.8 (CH), 128.6 (CH), 128.5 (CH), 127.7 (CH), 
123.8 (CH), 113.8 (CH), 57.4 (CH), 52.9 (CH3), 52.7 (CH3), 43.6 (CH), 21.6 (CH3). 
Minor Z-diastereomer: an oil; 1H NMR (300 MHz, CDCl3), significative signals taken 
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from the 1H NMR spectra of the diastereomer mixture, δ 7.84 (s, 1H), 7.54 (d, J = 8.4 
Hz, 2H), 7.14 (d, J = 9.0 Hz, 2H), 5.48 (d, J =11.1 Hz, 1H), 4.29 (t, J = 10.5 Hz, 1H), 
3.75 (s, 3H), 3.51 (s, 3H), 2.38 (s, 3H); 13C NMR (75 MHz, CDCl3), significative 
signals taken from the 13C NMR spectra of the diastereomer mixture, δ 169.0 (C), 167.3 
(C), 147.1 (C), 146.4 (C), 143.6 (C), 137.7 (C), 137.1 (C), 129.5 (CH), 129.1 (CH), 
128.7 (CH), 128.1 (CH), 127.8 (CH), 127.4 (CH), 127.1 (CH), 123.5 (CH), 121.5 (CH), 
56.9 (CH), 53.5 (CH3), 53.1 (CH3), 43.2 (CH), 21.1 (CH3); HRMS (ESI) m/z 539.1498 
[M+H]+, C27H27N2O8S required 539.1483. 
Dimethyl 2-[(S,E)-1-(4-methoxyphenyl)-3-phenyl-3-(tosylamino)allyl]malonate 
(3af) 
Chiral HPLC analysis: Chiralpak AD-H, hexane-iPrOH 80:20, 1 
mL/min, E-diastereomer: major enantiomer tr = 18.0 min, minor 
enantiomer tr = 23.4 min.; Z-diastereomer: unresolved tr = 37.3 
min. 
Major E-diastereomer: an oil; [α]D20 -67.8 (c 1.0, CHCl3, ee = 
69%) for the mixture of diastereomers; 1H NMR (300 MHz, CDCl3) δ 7.59 (d, J = 8.4 
Hz, 2H), 7.32-7.29 (m, 3H), 7.18 (d, J = 7.8 Hz, 2H), 6.95-6.65 (m, 6H), 5.96 (s, 1H), 
5.92 (d, J = 10.8 Hz, 1H), 3.96 (t, J = 10.5 Hz, 1H), 3.80 (s, 3H), 3.72 (d, J = 10.5 Hz, 
1H), 3.66 (s, 3H), 3.43 (s, 3H), 2.42 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 168.1 (C), 
167.8 (C), 158.5 (C), 143.8 (C), 136.5 (C), 135.4 (C), 135.3 (C), 133.4 (C), 129.6 (CH), 
128.70 (CH), 128.67 (CH), 128.61 (CH), 127.7 (CH), 117.5 (CH), 114.1 (CH), 58.3 
(CH), 55.3 (CH3), 52.6 (CH3), 52.4 (CH3), 43.3 (CH), 21.7 (CH3). Minor Z-
diastereomer: an oil; 1H NMR (300 MHz, CDCl3), significative signals taken from the 
1H NMR spectra of the diastereomer mixture, δ 7.86 (s, 1H), 7.41 (dd, J = 8.1, 1.5 Hz, 
2H), 7.15 (d, J = 8.4 Hz, 2H), 5.51 (d, J = 10.8 Hz, 1H), 3.94 (t, J = 10.5 Hz, 1H), 3.79 
(s, 3H), 3.71 (s, 3H), 3.47 (s, 3H), 2.38 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 169.6 
(C), 167.7 (C), 158.7 (C), 143.3 (C), 137.8 (C), 137.4 (C), 136.1 (C), 130.8 (C), 129.7 
(CH), 129.1 (CH), 128.1 (CH), 127.8 (CH), 127.3 (CH), 123.4 (CH), 114.0 (CH), 57.9 
(CH), 55.3 (CH3), 53.2 (CH3), 52.8 (CH3), 53.1 (CH3), 42.7 (CH), 21.2 (CH3); HRMS 
(ESI) m/z 524.1742 [M+H]+, C28H30NO7S required 524.1737. 
Dimethyl 2-[(S,E)-1-(furan-2-yl)-3-phenyl-3-(tosylamino)allyl]malonate (3ag) 
Chiral HPLC analysis: Chiralpak AD-H, hexane-iPrOH 80:20, 1 
mL/min, E-diastereomer: major enantiomer tr = 17.9 min, minor 
enantiomer tr = 26.6 min.; Z-diastereomer: major enantiomer tr 
= 20.1 min, minor enantiomer tr = 23.5 min  
Major E-diastereomer: an oil; [α]D20 -78.8 (c 1.0, CHCl3, ee = 94%); 1H NMR (300 
MHz, CDCl3) δ 7.67 (d, J = 8.4 Hz, 2H), 7.32-7.25 (m, 6H), 7.09-7.04 (m, 2H), 6.23 
(dd, J = 3.3, 1.2 Hz, 1H), 6.16 (br s, 1H), 5.83 (dt, J = 3.3, 0.6 Hz, 1H), 5.76 (d, J = 10.8 
Hz, 1H), 4.12 (ddd, J = 10.8, 9.3, 0.6 Hz, 1H), 3.77 (d, J = 9.3 Hz, 1H), 3.61 (s, 3H), 
3.52 (s, 3H), 2.43 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 167.7 (C), 167.6 (C), 153.7 
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(C), 143.9 (C), 141.9 (CH), 137.1 (C), 136.5 (C), 134.9 (C), 129.7 (CH), 129.2 (CH), 
128.7 (CH), 128.6 (CH), 127.8 (CH), 113.4 (CH), 110.3 (CH), 106.3 (CH), 55.6 (CH), 
52.6 (CH3), 38.1 (CH), 21.7 (CH3). Minor Z-diastereomer: an oil; [α]D20 -30.2 (c 0.8, 
CHCl3, ee = 52%); 1H NMR (300 MHz, CDCl3) δ 7.87 (s, 1H), 7.57 (d, J = 8.4 Hz, 2H), 
7.50-7.47 (m, 2H), 7.33-7.25 (m, 5H), 7.11 (d, J = 8.1 Hz, 2H), 6.20 (dd, J = 5.1, 1.9 
Hz, 1H), 5.66 (d, J = 3.3 Hz, 1H), 5.58 (dd, J = 10.8, 0.6 Hz, 1H), 3.99 (dd, J =10.8 9.0 
Hz, 1H), 3.76 (d, J = 9.0 Hz, 1H), 3.67 (s, 3H), 3.62 (s, 3H), 2.34 (s, 3H); 13C NMR (75 
MHz, CDCl3) δ 168.9 (C), 168.1 (C), 151.5 (C), 143.4 (C), 142.1 (CH), 137.62 (C), 
137.60 (C), 136.9 (C), 129.6 (CH), 129.0 (CH), 128.1 (CH), 127.8 (CH), 127.2 (CH), 
119.5 (CH), 110.2 (CH), 106.7 (CH), 55.8 (CH), 53.2 (CH3), 53.1 (CH3), 37.2 (CH), 
21.6 (CH3); HRMS (ESI) m/z 506.1237 [M+Na]+, C25H25NNaO7S required 506.1244. 
Dimethyl 2-[(S,E)-1-(furan-3-yl)-3-phenyl-3-(tosylamino)allyl]malonate (3ah) 
Chiral HPLC analysis: Chiralpak AD-H, hexane-iPrOH 80:20, 1 
mL/min, E-diastereomer: major enantiomer tr = 15.3 min, minor 
enantiomer tr = 27.8 min; Z-diastereomer: major enantiomer tr = 
19.7 min, minor enantiomer tr = 33.8 min  
Major E-diastereomer: an oil; [α]D20 -49.1 (c 0.9, CHCl3, ee = 
85%); 1H NMR (300 MHz, CDCl3) δ 7.67 (d, J = 8.1 Hz, 2H), 7.32-7.25 (m, 6H), 7.01-
6.96 (m, 3H), 6.13 (dd, J = 1.8, 0.9 Hz, 1H), 6.06 (br s, 1H), 5.79 (d, J = 10.8 Hz, 1H), 
3.97 (dd, J = 10.8, 9.0 Hz, 1H), 3.63 (s, 3H), 3.57 (d, J = 9.0 Hz), 3.53 (s, 3H), 2.44 (s, 
3H); 13C NMR (75 MHz, CDCl3) δ 167.9 (C), 167.8 (C), 144.0 (C), 143.1 (CH), 139.5 
(CH), 136.6 (C), 136.1 (C), 135.1 (C), 129.7 (CH), 129.2 (CH), 128.7 (CH), 128.6 
(CH), 127.8 (CH), 125.1 (C), 115.9 (CH), 109.5 (CH), 57.5 (CH), 52.6 (CH3), 52.5 
(CH3), 35.2 (CH), 21.7 (CH3). Minor Z-diastereomer: an oil; [α]D20 -3.8 (c 0.6, CHCl3, 
ee = 60%); 1H NMR (300 MHz, CDCl3) δ 7.79 (s, 1H), 7.57 (d, J = 8.1 Hz, 2H), 7.44-
7.41 (m, 2H), 7.30-7.22 (m, 5H), 7.13 (dd, J = 8.1, 0.6 Hz, 2H), 6.84 (t, J = 0.6 Hz, 1H), 
6.04 (dd, J = 1.8, 0.6 Hz, 1H), 5.44 (d, J = 10.8 Hz, 1H), 3.94 (t, J = 10.8 Hz, 1H), 3.68 
(s, 3H), 3.62 (s, 3H), 3.58 (d, J = 10.5 Hz, 1H), 2.35 (s, 3H); 13C NMR (75 MHz, 
CDCl3) δ 169.1 (C), 168.2 (C), 143.6 (C), 143.0 (CH), 139.4 (CH), 137.6 (C), 137.2 
(C), 136.7 (C), 129.6 (CH), 128.9 (CH), 128.2 (CH), 127.8 (CH), 127.3 (CH), 123.2 
(C), 122.3 (CH), 109.3 (CH), 57.2 (CH), 53.2 (CH3), 53.0 (CH3), 34.4 (CH), 21.6 
(CH3); HRMS (ESI) m/z 506.1241 [M+Na]+, C25H25NNaO7S required 506.1244. 
Dimethyl 2-[(S,E)-1-methyl-3-phenyl-3-(tosylamino)allyl]malonate (3ai) 
Chiral HPLC analysis: Chiralpak AD-H, hexane-iPrOH 80:20, 1 
mL/min, E-diastereomer: major enantiomer tr = 12.1 min, minor 
enantiomer tr = 15.5 min.; Z-diastereomer: major enantiomer tr 
= 15.3 min, minor enantiomer tr = 19.8 min. 
Major E-diastereomer: an oil; [α]D20 10.4 (c 1.0, CHCl3, ee = 74%); 1H NMR (300 
MHz, CDCl3) δ 7.74 (d, J = 8.1 Hz, 2H), 7.33-7.29 (m, 5H), 7.07-7.04 (m, 2H), 5.87 (br 
s, 1H), 5.52 (d, J = 10.8 Hz, 1H), 3.66 (s, 3H), 3.62 (s, 3H), 3.24 (d, J = 8.7 Hz, 1H), 
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2.98-2.89 (m, 1H), 2.46 (s, 3H), 0.97 (d, J = 6.9 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 
168.6 (C), 168.5 (C), 144.0 (C), 136.8 (C), 135.5 (C), 135.0 (C), 129.7 (CH), 129.0 
(CH), 128.7 (CH), 128.6 (CH), 127.9 (CH), 119.4 (CH), 57.5 (CH), 52.50 (CH3), 52.48 
(CH3), 33.1 (CH), 21.7 (CH3), 19.6 (CH3). Minor Z-diastereomer: an oil; [α]D20 -33.6 
(c 0.45, CHCl3, ee = 44%); 1H NMR (300 MHz, CDCl3) δ 7.75 (br s, 1H), 7.63 (d, J = 
8.4 Hz, 2H), 7.46-7.43 (m, 2H), 7.30-7.27 (m, 3H), 7.25-7.23 (m, 2H), 5.13 (dd, J = 
10.5, 0.9 Hz, 1H), 3.74 (s, 3H), 3.67 (s, 3H), 3.19 (d, J = 9.0 Hz, 1H), 2.81-2.72 (m, 
1H), 2.40 (s, 3H), 0.57 (d, J = 6.6 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 169.6 (C), 
168.8 (C), 143.5 (C), 137.7 (C), 137.1 (C), 136.1 (C), 129.5 (CH), 128.7 (CH), 128.1 
(CH), 127.7 (CH), 127.6 (CH), 125.8 (CH), 57.4 (CH), 53.0 (CH3), 52.9 (CH), 32.4 
(CH), 21.6 (CH3), 18.2 (CH3). HRMS (ESI) m/z 454.1301 [M+Na]+, C22H25NNaO6S 
required 454.1295. 
Dimethyl 2-[(S,E)-3-(4-fluorophenyl)-1-phenyl-3-(tosylamino)allyl]malonate (3ak) 
Chiral HPLC analysis: Chiralpak AD-H, hexane-iPrOH 80:20, 1 
mL/min, E-diastereomer: major enantiomer tr = 14.0 min, minor 
enantiomer tr = 17.1 min.; Z-diastereomer: major enantiomer tr 
= 22.5 min, minor enantiomer tr = 47.4 min. 
Major E-diastereomer: an oil; [α]D20 -92.9 (c 1.0, CHCl3, ee = 
86%); 1H NMR (300 MHz, CDCl3) δ 7.53 (d, J = 8.4 Hz, 2H), 2.27-7.19 (m, 3H) , 7.15 
(d, J = 8.4 Hz, 2H), 6.98-6.87 (m , 6H), 6.02 (br s, 1H), 5.90 (d, J = 10.5 Hz, 1H), 3.95 
(t, J = 10.5 Hz, 1H), 3.75 (d, J = 10.5 Hz, 1H), 3.66 (s, 3H), 3.41 (s, 3H), 2.40 (s, 3H); 
13C NMR (75 MHz, CDCl3) δ 168.1 (C), 167.7 (C), 163 (d, JC-F = 247.6 Hz, C), 143.9 
(C), 141.0 (C) 136.4 (C), 135.0 (C), 131.20 (d, JC-F = 3.4 Hz, C), 130.8 (d, JC-F = 8.3 Hz, 
CH), 129.7 (CH), 128.8 (CH), 127.6 (CH), 127.2 (CH), 118.2 (CH), 115.7 (d, JC-F = 
21.5 Hz, CH), 58.0 (CH), 52.7 (CH3), 52.5 (CH3), 44.1 (CH), 21.7 (CH3); 19F NMR 
(282 MHz, CDCl3) δ -105.7 (s, 1F). Minor Z-diastereomer: an oil; [α]D20 -54.9 (c 0.4, 
CHCl3, ee = 55%); 1H NMR (300 MHz, CDCl3) δ 7.94 (s, 1H), 7.57 (d, J = 8.4 Hz, 2H), 
7.40-7.36 (m, 2H), 7.20-7.14 (m, 5H), 6.94 (t, J = 8.7 Hz, 2H), 6.76-6.73 (m, 2H), 5.46 
(d, J = 10.8 Hz, 1H), 3.94 (t, J = 10.2 Hz, 1H), 3.74 (d, J = 10.5 Hz, 1H), 3.71 (s, 3H), 
3.45 (s, 3H), 2.38 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 169.9 (C), 168.0 (C), 163.5 (d, 
JC-F = 246.2 Hz, C), 143.8 (C), 139.0 (C), 137.5 (C), 135.6 (C), 134.1 (d, JC-F = 3.1 Hz, 
C), 130.0 (CH), 129.9 (d, JC-F = 8.2 Hz, CH), 128.9 (CH), 127.9 (CH), 127.7 (CH), 
127.5 (CH), 122.9 (CH), 115.3 (d, JC-F = 21.6 Hz, CH), 57.9 (CH), 53.6 (CH3), 53.1 
(CH3), 43.7 (CH), 21.9 (CH3); 19F NMR (282 MHz, CDCl3) δ -113.5 (s, 1F); HRMS 
(ESI) m/z 534.1373 [M+Na]+, C27H26FNNaO6S required 534.1357.  
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Dimethyl 2-[(S,E)-3-(4-chlorophenyl)-1-phenyl-3-(tosylamino)allyl]malonate (3al) 
Chiral HPLC analysis: Chiralpak AD-H, hexane-iPrOH 90:10, 1 
mL/min, E-diastereomer: major enantiomer tr = 39.6 min, minor 
enantiomer tr = 42.0 min. 
Chiral HPLC analysis: Chiralpak AD-H, hexane-iPrOH 80:20, 1 
mL/min, Z-diastereomer: major enantiomer tr = 20.8 min, minor 
enantiomer tr = 43.6 min. 
Major E-diastereomer: an oil; [α]D20 -111.6 (c 1.0, CHCl3, ee = 80%); 1H NMR (300 
MHz, CDCl3) δ 7.56 (d, J = 8.4 Hz, 2H), 7.30-7.24 (m, 5H), 7.19 (d, J = 8.4 Hz, 2H), 
6.99-6.96 (m, 2H), 6.90 (d, J = 8.4 Hz, 2H), 6.15 (s, 1H), 5.95 (d, J = 10.8 Hz, 1H), 3.99 
(t, J = 10.8 Hz, 1H), 3.78 (d, J = 10.2 Hz, 1H), 3.70 (s, 3H), 3.45 (s, 3H), 2.45 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 168.0 (C), 167.6 (C), 143.9 (C), 140.9 (C), 136.3 (C), 
135.1 (C), 134.9 (C), 133.6 (C), 130.2 (CH), 129.7 (CH), 128.8 (CH), 127.6 (CH), 
127.2 (CH), 118.8 (CH), 58.0 (CH), 52.7 (CH3), 52.5 (CH3), 44.1 (CH), 21.7 (CH3). 
Minor Z-diastereomer: an oil; [α]D20 -56.3 (c 0.6, CHCl3, ee = 46%); 1H NMR (300 
MHz, CDCl3) δ 7.94 (s, 1H), 7.57 (d, J = 8.1 Hz, 2H), 7.34 (d, J = 8.7 Hz, 2H), 7.24-
7.14 (m, 7H), 6.75-6.71 (m, 2H), 5.51 (dd, J = 10.8, 0.6 Hz, 1H), 3.94 (t, J = 10.8 Hz, 
1H), 3.74 (d, J = 10.8 Hz, 1H), 3.71 (s, 3H), 3.45 (s, 3H), 2.38 (s, 3H); 13C NMR (75 
MHz, CDCl3) δ 169.6 (C), 167.7 (C), 143.7 (C), 138.6 (C), 137.2 (C), 136.4 (C), 135.6 
(C), 134.7 (C), 129.8 (CH), 129.1 (CH), 128.7 (CH), 128.3 (CH), 127.6 (CH), 127.5 
(CH), 127.3 (CH), 123.3 (CH), 57.7 (CH), 53.4 (CH3), 52.8 (CH3), 43.5 (CH), 21.7 
(CH3). HRMS (ESI) m/z 550.1062 [M+Na]+, C27H26ClNNaO6S required 550.1062. 
Dimethyl 2-[(S,E)-3-(4-nitrophenyl)-1-phenyl-3-(tosylamino)allyl]malonate (3am) 
Chiral HPLC analysis: Chiralpak AD-H, hexane-iPrOH 80:20, 1 
mL/min, E-diastereomer: major enantiomer tr = 24.2 min, minor 
enantiomer tr = 32.0 min; Z-diastereomer: major enantiomer  tr 
= 44.6 min, minor enantiomer tr = 76.1 min. 
Major E-diastereomer: an oil; [α]D20 -87.9 (c 1.0, CHCl3, ee = 
82%); 1H NMR (300 MHz, CDCl3) δ 8.11 (d, J = 8.7 Hz, 2H), 7.50 (d, J = 8.4 Hz, 2H), 
7.28-7.21 (m, 3H), 7.16 (d, J = 9 Hz, 4H), 6.92-6.89 (m, 2H), 6.45 (br s, 1H), 5.96 (d, J 
= 11.1 Hz, 1H), 3.92 (t, J = 10.8 Hz, 1H), 3.73 (d, J = 9.9 Hz, 1H), 3.65 (s, 3H), 3.41 (s, 
3H), 2.41 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 167.9 (C), 167.4 (C), 147.9 (C), 144.2 
(C), 141.6 (C), 140.2 (C), 136.0 (C), 134.1 (C), 130.1 (CH), 129.8 (CH), 129.0 (CH), 
127.5 (CH), 127.4 (CH), 123.7 (CH), 121.7 (CH), 57.8 (CH), 52.8 (CH3), 52.6 (CH3), 
44.0 (CH), 21.7 (CH3). Minor Z-diastereomer: an oil; [α]D20 -37.8 (c 0.6, CHCl3, ee = 
49%); 1H NMR (300 MHz, CDCl3) δ 8.12 (d, J = 8.7 Hz, 2H), 8.08 (br s, 1H), 7.59 (d, J 
= 8.4 Hz, 4H), 7.22-7.15 (m, 5H), 6.74-6.70 (m, 2H), 5.70 (d, J = 10.8 Hz, 1H), 3.94 (t, 
J = 10.5 Hz, 1H), 3.76 (d, J = 9.9 Hz, 1H), 3.72 (s, 3H), 3.46 (s, 3H), 2.40 (s, 3H); 13C 
NMR (75 MHz, CDCl3) δ 169.6 (C), 167.7 (C), 148.0 (C), 144.5 (C), 144.0 (C), 138.1 
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(C), 137.0 (C), 134.9 (C), 130.0 (CH), 128.8 (CH), 128.5 (CH), 127.6 (CH), 127.3 
(CH), 126.5 (CH), 123.5 (CH), 121.7 (CH), 57.5 (CH), 53.4 (CH3), 53.0 (CH3), 43.5 
(CH), 21.7 (CH3); HRMS (ESI) m/z 539.1497 [M+H]+, C27H27N2O8S required 
539.1483. 
Dimethyl 2-[(S,E)-3-(4-methoxyphenyl)-1-phenyl-3-(tosylamino)allyl]malonate 
(3an). 
Chiral HPLC analysis: Chiralpak AD-H, hexane-iPrOH 80:20, 1 
mL/min, E-diastereomer: major enantiomer  tr = 20.3 min, 
minor enantiomer tr = 24.6 min.; Z-diastereomer: major 
enantiomer tr = 34.8 min, minor enantiomer tr = 82.7 min. 
Major E-diastereomer: an oil; [α]D20 -29.6 (c 0.9, CHCl3, ee = 
80%); 1H NMR (300 MHz, CDCl3) δ 7.54 (d, J = 8.5 Hz, 2H), 
7.26-7.19 (m, 3H), 7.14 (d, J = 8.5 Hz, 2H), 6.97-6.94 (m, 2H), 6.84 (d, J = 9.0 Hz, 2H), 
6.77 (dt, J = 9.0 Hz, 2H), 5.96 (s, 1H), 5.86 (d, J = 10.8 Hz, 1H), 4.01 (t, J = 10.5 Hz, 
1H), 3.80 (s, 3H), 3.75 (d, J = 10.2 Hz, 1H), 3.65 (s, 3H), 3.40 (s, 3H), 2.40 (s, 3H); 13C 
NMR (75 MHz, CDCl3) δ 168.1 (C), 167.8 (C), 160.0 (C), 143.7 (C), 141.3 (C), 136.5 
(C), 135.6 (C), 130.1 (CH), 129.6 (CH), 128.7 (CH), 127.7 (CH), 127.6 (CH), 127.5 
(C), 127.0 (CH), 116.8 (CH), 114.0 (CH), 58.1 (CH), 53.4 (CH3), 52.7 (CH3), 52.4 
(CH3), 44.2 (CH), 21.7 (CH3). Minor Z-diastereomer: [α]D20 -2.0 (c 0.74, CHCl3, ee = 
42%); 1H NMR (300 MHz, CDCl3) δ 7.89 (s, 1H), 7.57 (d, J = 8.1 Hz, 2H), 7.36 (d, J = 
9.0 Hz, 2H), 7.19-7.12 (m, 5H), 6.79 (d, J = 9.0 Hz, 2H), 6.73-6.70 (m, 2H), 5.40 (d, J = 
10.8 Hz, 1H), 3.91 (t, J = 10.2 Hz, 1H), 3.86 (d, J = 6.0 Hz, 1H), 3.80 (s, 3H), 3.71 (s, 
3H), 3.43 (s, 3H), 2.37 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 169.6 (C), 167.8 (C), 
160.3 (C), 143.4 (C), 139.0 (C), 137.3 (C), 136.1 (C), 130.3 (CH), 129.7 (CH), 129.2 
(CH), 128.6 (CH), 127.6 (CH), 127.3 (CH), 121.1 (CH), 116.8 (CH), 113.5 (CH), 57.9 
(CH), 55.4 (CH3), 53.3 (CH3), 52.8 (CH3), 43.5 (CH), 21.7 (CH3); HRMS (ESI) m/z 
524.1740 [M+H]+, C28H30NO7S required 524.1737. 
Dimethyl 2-[(S,E)-3-(2-fluorophenyl)-1-phenyl-3-(tosylamino)allyl]malonate (3ao) 
Chiral HPLC analysis: Chiralpak AD-H, hexane-iPrOH 80:20, 1 
mL/min, E-diastereomer: major enantiomer tr = 18.9 min, minor 
enantiomer tr = 34.1 min.; Z-diastereomer: major enantiomer tr 
= 39.7 min, minor enantiomer tr = 49.7 min. 
Major E-diastereomer: an oil; [α]D20 -75.4 (c 1.0, CHCl3, ee = 82%); 1H NMR (300 
MHz, CDCl3) δ 7.54 (d, J = 8.4 Hz, 2H), 7.34-7.27 (m, 1H), 7.25-7.19 (m, 3H), 7.11 (d, 
J = 8.1 Hz, 2H), 7.03 (td, J = 7.5, 1.2 Hz, 1H), 7.00-6.94 (m, 3H), 6.83 (td, J = 7.5, 1.8 
Hz, 1H), 6.15 (br s, 1H), 6.04 (d, J = 10.2 Hz, 1H), 3.82 (t, 10.5 Hz, 1H), 3.73 (d, J = 
10.2 Hz, 1H), 3.62 (s, 3H), 3.39 (s, 3H), 2.38 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 
167.8 (C), 167.6 (C), 159.8 (d, JC-F = 247.7 Hz, C), 143.7 (C), 140.6 (C), 136.1 (C), 
131.4 (d, JC-F = 3.0 Hz, CH), 131.2 (d, JC-F = 8.1 Hz, CH), 130.4 (CH), 129.5 (CH), 
128.7 (CH), 127.8 (CH), 127.7 (CH), 127.1 (CH), 124.1 (d, JC-F = 3.5 Hz, CH), 122.5 
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(d, JC-F = 15.2 Hz, C); 120.3 (CH), 115.9 (d, JC-F = 21.2 Hz, CH), 58.1 (CH), 25.7 
(CH3), 52.4 (CH3), 44.4 (CH), 21.6 (CH3); 19F NMR (282 MHz, CDCl3) δ -116.3 (s, 
1F). Minor Z-diastereomer: an oil; [α]D20 -33.3 (c 1.0, CHCl3, ee = 28%); 1H NMR 
(300 MHz, CDCl3) δ 7.67 (br s, 1H), 7.48 (d, J = 8.4 Hz, 2H), 7.32 (td, J = 7.5, 1.8 Hz, 
1H), 7.25-7.18 (m, 4H), 7.09 (d, J = 8.4 Hz, 2H), 7.04 (dt, J = 7.5, 1.8 Hz, 1H), 6.92-
6.83 (m, 3H), 5.60 (d, J = 10.8 Hz, 1H), 4.11 (t, J = 9.9 Hz, 1H), 3.75 (d, J = 9.9 Hz, 
1H), 3.73 (s, 3H), 3.49 (s, 3H), 2.34 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 169.3 (C), 
167.8 (C), 160.2 (d, JC-F = 248.3 Hz, C), 143.3 (C), 138.7 (C), 137.2 (C), 131.4 (d, JC-F 
= 2.6 Hz, CH), 130.4 (C), 130.2 (d, JC-F = 8.4 Hz, CH), 129.6 (CH), 128.7 (CH), 127.6 
(CH), 127.4 (CH), 127.2 (CH), 126.2 (d, JC-F = 3.2 Hz, CH), 123.8 (d, JC-F = 3.6 Hz, 
CH), 115.7 (d, JC-F = 21.9 Hz, CH), 57.6 (CH), 53.2 (CH3), 52.8 (CH3), 43.2 (CH), 21.6 
(CH3); 19F NMR (282 MHz, CDCl3) δ -113.9 (s, 1F); HRMS (ESI) m/z 534.1372 
[M+Na]+, C27H26FNNaO6S required 534.1357. 
Dimethyl 2-[(S,E)-3-(3-nitrophenyl)-1-phenyl-3-(tosylamino)allyl]malonate (3ap) 
Chiral HPLC analysis: Chiralpak AD-H, hexane-iPrOH 80:20, 
1 mL/min, E-diastereomer: major enantiomer tr = 23.1 min, 
minor enantiomer tr = 31.7 min.; Z-diastereomer: major 
enantiomer tr = 37.5 min, minor enantiomer tr = 54.8 min. 
Major E-diastereomer: an oil; [α]D20 -69.5 (c 1.0, CHCl3, ee 
= 84%); 1H NMR (300 MHz, CDCl3) δ 8.18-8.12 (m, 2H), 7.56-7.46 (m, 5H), 7.31-7.22 
(m, 3H), 7.14 (d, J = 8.4 Hz, 2H), 6.97-6.94 (m, 2H), 6.51 (br s, 1H), 6.00 (d, J = 10.8 
Hz, 1H), 3.91 (t, J = 10.8 Hz, 1H), 3.76 (d, J = 10.2 Hz, 1H), 3.67 (s, 3H), 3.41 (s, 3H), 
2.41 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 167.9 (C), 167.4 (C), 140.1 (C), 144.3 (C), 
140.1 (C), 136.6 (C), 135.9 (C), 135.3 (CH), 133.8 (C), 129.8 (CH), 129.6 (CH), 129.0 
(CH), 127.6 (CH), 127.5 (CH), 127.4 (CH), 123.9 (CH), 123.8 (CH), 121.9 (CH), 57.9 
(CH), 52.8 (CH3), 52.5 (CH3), 44.1 (CH), 21.6 (CH3). Minor Z-diastereomer: an oil; 
[α]D20 -21.8 (c 0.5, CHCl3, ee = 48%); 1H NMR (300 MHz, CDCl3) δ 8.13-8.07 (m, 
3H), 7.81 (dt, J = 8.4, 1.5 Hz, 1H), 7.57 (d, J = 8.4 Hz, 2H), 7.45 (dd, J = 8.7, 1.2 Hz, 
1H), 7.25-7.21 (m, 3H), 7.16 (d, J = 8.4 Hz, 2H), 6.83-6.77 (m, 2H), 5.67 (dd, J = 10.8 
Hz, 1H), 4.02 (t, J = 10.8, 0.6 Hz, 1H), 3.77 (d, J = 9.9 Hz, 1H), 3.73 (s, 3H), 3.47 (s, 
3H), 2.38 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 169.6 (C), 167.7 (C), 148.2 (C), 144.0 
(C), 139.8 (C), 138.2 (C), 137.0 (C), 134.6 (C), 134.0 (CH), 130.0 (CH), 129.1 (CH), 
128.9 (CH), 127.7 (CH), 127.6 (CH), 127.3 (CH), 125.4 (CH), 123.4 (CH), 122.4 (CH), 
57.5 (CH), 53.4 (CH3), 52.9 (CH3), 43.5 (CH), 21.6 (CH3); HRMS (ESI) m/z 539.1487 
[M+H]+, C27H27N2O8S required 539.1483. 
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5.1.3. Synthetic transformations from compound 3aa 
Dimethyl 2-[(S)-3-oxo-1,3-diphenylpropyl]malonate (4)157 
37% Hydrochloric acid (6 drops) was dropwise added to a solution 
of compound 3aa (26.2 mg, 0.053 mmol, ee = 82%) in THF 2mL 
under nitrogen. The reaction flask was introduced in a bath at 40 °C 
for 2 h. After this time, the reaction was left at room temperature and water (5 mL) was 
added. The mixture was extracted with dichloromethane (3 × 20 mL), dried over 
MgSO4, filtered and concentrated under reduced pressure to give 18.0 mg (100%) of 
ketone 4 with identical spectroscopic features as those described in the literature.157 
Chiral HPLC analysis: Chiralpak AS-H, hexane-iPrOH 90:10, 1 mL/min, major 
enantiomer tr = 14.3 min, minor enantiomer tr = 19.1 min. [α]D20 +13.1 (c 0.96, CHCl3, 
ee = 82%), Lit.157 [α]D20 +18 (CHCl3, ee = 90%) for the S-enantiomer. 
Dimethyl 2-[(1S,3R)-1,3-diphenyl-3-(tosylamino)allyl]malonate (5) and dimethyl 2-
[(1S,3S)-1,3-diphenyl-3-(tosylamino)allyl]malonate (6) 
A solution of (S,E)-3aa (140 mg, 0.29 
mmol, ee = 86%) in MeOH (12 mL) was 
stirred under hydrogen atmosphere 
(balloon) in the presence of 5% Pd/C (4 
mg) for 4 h. Then, the reaction mixture was filtered through a short pad of silica gel 
eluting with EtOAc. The solvent was removed under reduced pressure to give 134 mg 
(95%) of a ca. 25:75 mixture of compounds 5 and 6 which were separated after column 
chromatography on silica gel eluting with hexane/EtOAc (90:10 to 60:40). Order of 
elution: compound 6 (minor diastereomer) first, compound 5 (major diastereomer) 
second. 
Chiral HPLC analysis: Chiralpak IC, hexane-iPrOH 80:20, 1 mL/min, Major 
diastereomer 5: major enantiomer tr = 55.6 min, minor enantiomer tr = 63.6 min.; Minor 
diastereomer 6: major enantiomer tr = 39.7 min, minor enantiomer tr = 46.6 min. 
Major diastereomer (1S,3R)-5: an oil; [α]D20 -3.4 (c 1.0, CHCl3, ee = 86%); 1H NMR 
(300 MHz, CDCl3) δ 7.34 (d, J = 8.4 Hz, 2H), 7.30-7.27 (m, 3H), 7.24-7.17 (m, 3H), 
7.08 (d, J = 8.4 Hz, 2H), 7.00-6.97 (m, 2H), 6.84-6.81 (m, 2H), 4.61 (d, J = 6.0 Hz, 1H), 
3.77-3.70 (m, 1H), 3.72 (s, 3H), 3.59 (d, J = 10.5 Hz, 1H), 3.32 (s, 3H), 2.91 (td, J = 
11.2 Hz, 1H), 2.45-2.26 (m, 2 H), 2.37 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 168.5 (C), 
167.9 (C), 143.2 (C), 138.9 (C), 138.7 (C), 137.0 (C), 129.5 (CH), 129.0 (CH), 128.7 
(CH), 128.6 (CH), 128.4 (CH), 127.6 (CH), 127.3 (CH), 127.2 (CH), 58.4 (CH), 56.4 
(CH), 52.7 (CH3), 52.3 (CH3), 42.3 (CH), 39.7 (CH2), 21.6 (CH3). Minor diastereomer 
(1S,3S)-6: an oil; [α]D20 -2.0 (c 0.6, CHCl3, ee = 86%); 1H NMR (300 MHz, CDCl3) δ 
7.54 (d, J = 8.4 Hz, 2H), 7.25-7.21 (m, 3H), 7.15-7.08 (m, 5H), 6.94-6.87 (m, 4H), 5.45 
(d, J = 6.6 Hz, 1H), 4.08-4.01 (m, 1H), 3.77 (s, 3H), 3.59 (d, J = 10.2 Hz, 1H), 3.42 (td, 
J = 10.2, 3.0 Hz, 1H), 3.41 (s, 3H), 2.38 (s, 3H), 2.08-1.92 (m, 2H); 13C NMR (75 MHz, 
CDCl3) δ 169.3 (C), 168.0 (C), 143.0 (C), 142.0 (C), 139.5 (C), 137.8 (C), 129.5 (CH), 
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128.8 (CH), 128.5 (CH), 128.4 (CH), 127.7 (CH), 127.4 (CH), 127.3 (CH), 126.1 (CH), 
57.7 (CH), 56.1 (CH), 53.0 (CH3), 52.5 (CH3), 43.4 (CH2), 43.3 (CH), 21.6 (CH3); 
HRMS (ESI) m/z 518.1613 [M+Na]+, C27H29NNaO6S required 516.1608. 
(3S,5R)-Methyl 3,5-diphenyl-5-(tosylamino)pentanoate (7) A 25% solution of 
tetraethylammonium hydroxyde in MeOH (157 µL, 0.23 mmol) 
was added to a solution of compound 5 (95.4 mg, 0.19 mmol, ee = 
82%) in dimethylsulfoxide (5.2 mL) under nitrogen, and the 
reaction flask was introduced in a bath at 80 °C. Additional tetraethylammonium 
hydroxyde was added after 6 h (157 µL, 0.23 mmol) and 24 h (53 µL, 0.08 mmol). 
After a total reaction time of 24h, the reaction mixture was diluted with EtOAc (60 mL), 
washed with water (3 × 4 mL), brine (4 mL), and dried over MgSO4. Purification by 
column chromatography eluting with hexane/EtOAc gave 9 mg (10%) of lactam 9, 
followed by 58.0 mg (70%) of compound 7: Chiral HPLC analysis: Chiralpak IC 
hexane-iPrOH 80:20, 1 mL/min, major enantiomer tr = 26.5 min, minor enantiomer tr = 
29.1 min. Oil; [α]D20 -9.1 (c 1.0, CHCl3, ee = 82%); 1H NMR (300 MHz, CDCl3) δ 7.40 
(d, J = 8.4 Hz, 2H), 7.35-7.25 (m, 3H), 7.21-7.12 (m, 3H), 7.08 (d, J = 8.4 Hz, 2H), 
7.05-6.97 (m, 2H), 6.91-6.82 (m, 2H), 5.09 (d, J = 6.6 Hz, 1H), 3.88 (ddd, J = 10.5, 6.6, 
5.4 Hz, 1H), 3.52 (s, 3H), 2.73 (m. 1H), 2.52 (m, 2H), 2.37 (s, 3H), 2.35-2.12 (m, 2H); 
13C NMR (75 MHz, CDCl3) δ 172.2 (C), 143.0 (C), 142.2 (C), 139.6 (C), 137.2 (C), 
129.4 (CH), 128.76 (CH), 128.75 (CH), 128.0 (CH), 127.8 (CH), 127.2 (CH), 127.1 
(CH), 127.0 (CH), 56.4 (CH), 51.5 (CH3), 42.2 (CH2), 41.7 (CH2), 38.7 (CH), 21.6 
(CH3); HRMS (ESI) m/z 460.1560 [M+Na]+, C25H27NNaO4S required 460.1553.  
(3S,5S)-Methyl 3,5-diphenyl-5-(tosylamino)pentanoate (8) 
Following the same procedure as for the synthesis of 7, starting 
from compound 6 (23.7 mg, 0.058 mmol, ee = 82%), it was 
obtained 15.9 mg of compound 8 (63%): Chiral HPLC analysis: 
Chiralpak IC, hexane-iPrOH 80:20, 1 mL/min, major enantiomer tr = 55.5 min, minor 
enantiomer tr = 34.6 min. Oil; [α]D20 -16.3 (c 1.0, CHCl3, er = 82%); 1H NMR (300 
MHz, CDCl3) δ 7.50 (d, J = 8.4 Hz, 2H), 7.30-7.19 (m, 1H), 7.24 (d, J = 8.4 Hz, 2H), 
7.13-7.04 (m, 5H), 7.05-6.82 (m, 4H), 5.34 (d, J = 7.2 Hz, 1H), 4.11 (ddd, J = 10.8, 7.2, 
3.9 Hz, 1H), 3.63 (s, 3H), 3.17 (m, 1H), 2.56 (m, 2H), 2.36 (s, 3H), 2.01 (ddd, J = 14.2, 
10.2, 3.9 Hz, 1H), 1.93 (ddd, J = 14.2, 9.9, 4.0 Hz, 1H); 13C NMR (75 MHz, CDCl3) δ 
173.0 (C), 143.0 (C), 142.8 (C), 141.7 (C), 137.8 (C), 129.4 (CH), 128.8 (CH), 128.5 
(CH), 127.6 (CH), 127.29 (CH), 127.28 (CH), 127.1 (CH), 126.2 (CH), 56.3 (CH), 51.9 
(CH3), 45.0 (CH2), 41.0 (CH2), 38.6 (CH), 21.6 (CH3); HRMS (ESI) m/z 460.1562 
[M+Na]+, C25H27NNaO4S required 460.1553.  
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(3R,4S,6R)-Methyl 2-oxo-4,6-diphenyl-1-tosylpiperidine-3-carboxylate (9) 
 A solution of compound 5 (27.7 mg, 0.056 mmol) in toluene (1.2 
mL) under nitrogen was treated with 1M LiHMDS in THF (112 µL, 
0.112 mmol). The mixture was stirred at 90 °C for 18 h. Then, the 
reaction was quenched with 1M HCl (1 mL), diluted with water (4 
mL), extracted with dichloromethane (3×30 mL), dried over MgSO4 and concentrated 
under reduced pressure to give 19 mg (73%) of compound 9: an oil; [α]D20 2.1 (c 0.8, 
CHCl3, ee = 82%); 1H NMR (300 MHz, CDCl3) δ 7.56 (d, J = 8.4 Hz, 2H), 7.40-7.20 
(m, 8H), 7.14 (d, J = 8.4 Hz, 2H), 7.10-6.98 (m, 2H), 5.90 (dd, J = 5.1, 2.4 Hz, 1H), 
3.72 (d, J = 12.0 Hz, 1H), 3.58 (s, 3H), 3.50 (td, J = 12.0, 3.0 Hz, 1H), 2.59 (td, J = 
13.5, 5.4 Hz, 1H), 2.40 (s, 3H), 2.21 (ddd, J = 13.5, 3.0, 2.5 Hz, 1H); 13C NMR (75 
MHz, CDCl3) δ 169.2 (C), 166.8 (C), 144.3 (C), 140.0 (C), 139.5 (C), 135.9 (C), 129.8 
(CH), 128.9 (CH), 128.7 (CH), 128.0 (CH), 127.7 (CH), 126.8 (CH), 59.9 (CH), 58.3 
(CH), 52.6 (CH3), 37.8 (CH2), 37.4 (CH), 21.6 (CH3); HRMS (ESI) m/z 464.1529 
[M+H]+, C26H26NO5S required 464.1526. 
(4S,6R)-4,6-Diphenyl-1-tosylpiperidin-2-one (10) 
 A solution of compound 7 (31.3 mg, 0.072 mmol) in toluene (1.4 mL) 
under nitrogen was treated with 1M LiHMDS in THF (143 µL, 0.143 
mmol). The mixture was stirred at 100 °C for 19h. Then, the reaction 
was quenched with 1M HCl (4 mL), diluted with water (4 mL), extracted 
with dichloromethane (3×30 mL), dried over MgSO4 and concentrated under reduced 
pressure to give 26.2 mg (90%) of compound 10: Oil; [α]D20 -5.6 (c 0.95, CHCl3, ee = 
82%); 1H NMR (300 MHz, CDCl3) δ 7.35 (d, J = 8.1 Hz, 2H), 7.32-7.25 (m, 3H), 7.19-
7.16 (m, 3H), 7.10-6.90 (m, 4H), 6.86 (m, 2H), 5.30 (dd, J = 6.6, 2.7 Hz, 1H), 3.87 (dd, 
J = 14.7, 7.8 Hz, 1H), 2.70 (m, 1H), 2.55 (t, J = 7.2 Hz, 1H), 2.60-2.27 (m, 2H 
overlapped), 2.34 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 176.3 (C), 143.2 (C), 142.0 
(C), 139.5 (C), 137.1 (C), 129.4 (CH), 128.9 (CH), 128.8 (CH), 128,0 (CH), 127.8 
(CH), 127.21 (CH), 127.20 (CH), 126.2 (CH), 56.4 (CH), 42.0 (CH), 41.3 (CH2), 38.5 
(CH), 21.6 (CH3); HRMS (ESI) m/z 406.1469 [M+H]+, C24H24NO3S required 406.1471.  
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5.2. Enantioselective Michael addition of malonate esters to β-
trifluoromethyl-α,β-unsaturated N-tosyl imines 
5.2.1. Synthesis and characterization of β-trifluoromethyl α,β-unsaturated N-tosyl 
imines 11   
The procedure by A. D. Smith was followed.103 A solution of the corresponding 
trifluoromethyl enone166a,199 (2.8 mmol) and TsNH2 (465 mg, 2.7 mmol) in dry CH2Cl2 
(15 mL) under nitrogen atmosphere was introduced in a bath at 0 °C (ice-water). After 
10 min, dry triethylamine (1.18 mL, 8.4 mmol) was added via syringe followed by 
TiCl4 (0.46 mL, 4.2 mmol). After 15 min, the bath was removed and the reaction 
mixture was stirred for 24 h at room temperature. Then, the solvent was removed under 
reduced pressure, water (100 mL) was added and the mixture was extracted with ethyl 
acetate (3×50 mL). ¡¡ interphases may form !!. The extract was dried over MgSO4, 
filtered and concentrated under reduced pressure. Imine 11 was obtained after quick 
column chromatography eluting with hexane-EtOAc mixtures. In most of the cases an 
additional purification by crystallization from hexane-EtOAc or Et2O-EtOAc mixtures 
was required. Nitro-containing imines 11e and 11i hydrolyzed almost completely when 
chromatographed. They could only be obtained in low yield after repeated 
crystallizations. 
4-Methyl-N-((1Z,2E)-4,4,4-trifluoro-1-phenylbut-2-en-1-ylidene)benzene-
sulfonamide (11a)103 
1H NMR (300 MHz, CDCl3) δ 8.00-7.65 (5H, m, Ar, =CH), 7.59 (1H, tt, 
J = 7.5, 1.8 Hz, Ar), 7.46 (2H, t, J = 7.5 Hz, Ar), 7.35 (2H, d, J = 8.1 
Hz, Ar), 6.12 (1H, dq, J = 16.5, 6.0 Hz, =CH), 2.45 (s, Me-Ar); 19F 
NMR (282 MHz, CDCl3) δ = -65.6 (s, CF3). 
4-Methyl-N-((1Z,2E)-4,4,4-trifluoro-1-(p-tolyl)but-2-en-1-ylidene)benzene-
sulfonamide (11b)103 
1H NMR (300 MHz, CDCl3) δ 7.89 (2H, d, J = 7.8 Hz, Ar), 7.77 
(1H, m, =CH), 7.63 (2H, d, J = 8.1 Hz, Ar), 7.35 (2H, d, J = 7.8 
Hz, Ar), 7.25 (2H, d, J = 8.1 Hz, Ar), 6.10 (1H, dq, J = 16.2, 6.3 
Hz, =CH), 2.45 (3H, s, Me-Ar), 2.42 (3H, s, Me-Ar); 19F NMR 
(282 MHz, CDCl3) δ = -65.5 (s, CF3). 
N-((1E,2E)-1-(4-Chlorophenyl)-4,4,4-trifluorobut-2-en-1-ylidene)-4-methyl-
benzenesulfonamide (11c) 
1H NMR (300 MHz, CDCl3) δ 7.88 (2H, d, J = 8.1 Hz, Ar), 7.80 
(1H, m, =CH), 7.65 (2H, unresolved d, Ar), 7.44 (2H, dd, J = 
6.9, 2.1 Hz, Ar), 7.37 (2H, d, J = 7.8 Hz, Ar), 6.11 (1H, dq, J = 
16.5, 6.0 Hz, =CH), 2.45 (3H, s, Me-Ar); 19F NMR (282 MHz, 
CDCl3) δ = -65.6 (s, CF3); HRMS (ESI) m/z 388.0378 [M+H]+, C17H13ClF3NO2S 
requires 388.0380. 
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N-((1E,2E)-1-(4-Bromophenyl)-4,4,4-trifluorobut-2-en-1-ylidene)-4-methyl-
benzenesulfonamide (11d)103 
1H NMR (300 MHz, CDCl3) δ 7.88 (2H, d, J = 7.5 Hz, Ar), 7.87-
7.84 (1H, m, =CH), 7.62-7.58 (4H, m, Ar), 7.36 (2H, d, J = 8.4 
Hz, Ar), 6.11 (1H, dq, J = 16.5, 6.3 Hz, =CH), 2.45 (3H, s, Me-
Ar); 19F NMR (282 MHz, CDCl3) δ = -65.6 (s, CF3). 
N-((1E,2E)-1-(4-Nitrophenyl)-4,4,4-trifluorobut-2-en-1-ylidene)-4-methyl-
benzenesulfonamide (11e)  
This compound could not be obtained pure and was used 
contaminated with enone and TsNH2. 1H NMR (300 MHz, 
CDCl3) δ 8.30 (2H, d, J = 7.5 Hz, Ar), 8.00-7.80 (5H, m, =CH, 
Ar), 7.37 (2H, d, J = 8.1 Hz, Ar), 6.11 (1H, m, =CH), 2.46 (3H, 
s, Me-Ar); 19F NMR (282 MHz, CDCl3) δ = -65.6 (s, CF3). 
4-Methyl-N-((1E,2E)-4,4,4-trifluoro-1-(4-methoxyphenyl)but-2-en-1-ylidene)-
benzenesulfonamide (11f) 
1H NMR (300 MHz, CDCl3) δ 7.89 (2H, d, J = 8.4 Hz, Ar), 
7.76 (2H, d, J = 9,0 Hz, Ar), 7.70-7.60 (1H, m, =CH), 7.34 (2H, 
d, J = 8.4 Hz, Ar), 6.93 (2H, d, J = 9.0 Hz, Ar), 6.09 (1H, dq, J 
= 16.5, 6.0 Hz, =CH), 3.87 (3H, s, MeO), 2.44 (3H, s, Me-Ar); 
19F NMR (282 MHz, CDCl3) δ = -65.5 (s, CF3); HRMS (ESI) m/z 384.0878 [M+H]+, 
C18H17F3NO3S requires 384.0876. 
4-Methyl-N-((1E,2E)-4,4,4-trifluoro-1-(m-tolyl)but-2-en-1-ylidene)benzene-
sulfonamide (11g) 
1H NMR (300 MHz, CDCl3) δ 7.89 (2H, d, J = 7.8 Hz, Ar), 
7.77 (1H, m, =CH), 7-55-7.25 (6H, m, Ar), 6.10 (1H, dq, J = 
16.2, 6.0 Hz, =CH), 2.45 (3H, s, Me-Ar), 2.39 (3H, s, Me-Ar); 
19F NMR (282 MHz, CDCl3) δ = -65.6 (s, CF3); HRMS (ESI) 
m/z 368.0935 [M+H]+, C18H17F3NO2S requires 368.0927. 
 N-((1E,2E)-1-(3-Chlorophenyl)-4,4,4-trifluorobut-2-en-1-ylidene)-4-methyl-
benzenesulfonamide (11h) 
1H NMR (300 MHz, CDCl3) δ 7.89 (2H, d, J = 8.7 Hz, Ar), 7.81 
(1H, m, =CH), 7.71 (1H, m, Ar), 7.55 (2H, m, Ar), 7.41 (1H, t, J 
= 7.8 Hz, Ar), 7.36 (2H, d, J = 8.7 Hz, Ar), 6.13 (1H, dq, J = 
16.2, 6.0 Hz, =CH), 2.46 (3H, s, Me-Ar); 19F NMR (282 MHz, 
CDCl3) δ = -65.6 (s, CF3); HRMS (ESI) m/z 388.0378 [M+H]+, C17H14ClF3NO2S 
requires 388.0380. 
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N-((1E,2E)-1-(3-Nitrophenyl)-4,4,4-trifluorobut-2-en-1-ylidene)-4-methyl-
benzenesulfonamide (11i) 
1H NMR (300 MHz, CDCl3) δ 8.52 (1H, s, Ar), 8.43 (1H, ddd, 
J = 8.1, 2.1, 1.0 Hz, Ar), 8.10-7.75 (4H, m, =CH, Ar), 7.69 (1H, 
t, J = 8.1 Hz, Ar), 7.37 (2H, d, J = 8.1 Hz, Ar), 6.15 (1H, dq, J = 
16.5, 6.0 Hz, =CH), 2.46 (3H, s, Me-Ar); 19F NMR (282 MHz, 
CDCl3) δ = -65.6 (s, CF3); HRMS (ESI) m/z 399.0628 [M+H]+, C17H14F3N2O4S requires 
399.0621 
4-Methyl-N-((1E,2E)-4,4,4-trifluoro-1-(3-methoxyphenyl)but-2-en-1-ylidene)-
benzenesulfonamide (11j) 
1H NMR (300 MHz, CDCl3) δ 7.88 (2H, d, J = 7.8 Hz, Ar), 
7.81 (1H, m, =CH), 7.48-7.20 (6H, m, Ar), 7.13 (1H, dd, J = 
8.1, 2.4 Hz, Ar), 6.13 (1H, dq, J = 16.2, 6.3 Hz, =CH), 3.82 
(3H, s, MeO), 2.45 (3H, s, Me-Ar); 19F NMR (282 MHz, 
CDCl3) δ = -65.6 (s, CF3); HRMS (ESI) m/z 384.0877 [M+H]+, C18H17F3NO3S requires 
384.0876. 
4-Methyl-N-((1E,2E)-4,4,4-trifluoro-1-(2-methoxyphenyl)but-2-en-1-ylidene) 
benzenesulfonamide (11k) 
1H NMR (300 MHz, CDCl3) δ 7.89-7.53 (2H, m, Ar, =CH), 7.47 
(1H, dt, J = 8.3, 1.5 Hz, Ar), 7.30-7.20 (3H, m), 7.04-6.89 (3H, m), 
6.04 (1H, m, =CH), 3.75 (3H, s, MeO), 2.42 (3H, s, Me-Ar); 19F 
NMR (282 MHz, CDCl3) δ = -65.4 (s, CF3); HRMS (ESI) m/z 
384.0877 [M+H]+, C18H17F3NO3S requires 384.0876. 
4-Methyl-N-((1E,2E)-4,4,4-trifluoro-1-(naphthalen-2-yl)but-2-en-1-ylidene) 
benzenesulfonamide (11l)103   
1H NMR(300 MHz, CDCl3) δ 8.19 (1H, s, Ar), 7.94-7.86 (7H, 
m, Ar, =CH), 7.64-7.55 (2H, m, Ar), 7.36 (2H, d, J = 8.1 Hz , 
Ar), 6.18 (1H, dq, J = 16.4 , 6.0 Hz, =CH), 2.45 (3H, s, Me-Ar). 
19F NMR (282 MHz, CDCl3) δ = -65.5 (s, CF3). 
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5.2.2. General procedure for the enantioselective conjugate addition of methyl 
malonate to β-trifluoromethyl α,β-unsaturated N-tosyl imines 11  
5.2.2.1. General procedure for the enantioselective conjugate addition 
Cu(OTf)2 (4.5 mg, 0.0125 mmol) was dried in a Schlenk tube under vacuum. BOX7 
(4.4 mg, 0.0125 mmol) was added and the tube was filled with nitrogen. CH2Cl2 (0.55 
mL) was added via syringe and the mixture was stirred for 30 min. A solution of imine 
11 (0.125 mmol) dissolved in dry CH2Cl2 (0.5 mL), was added via syringe, followed by 
4 Å MS (110 mg) and dimethyl malonate (34 µL, 0.3 mmol). The mixture was stirred at 
room temperature for the indicated time and chromatographed on silica gel eluting with 
hexane/EtOAc mixtures to give compounds 12.  
For the Mg(II)-catalyzed reaction, Mg(OTf)2 was used instead of Cu(OTf)2. The 
reaction tube was introduced in a bath at 0 °C before the addition of the imine. 
5.2.2.2. General procedure for the synthesis of the racemic products 
Racemic compounds for comparative purpose were prepared by following the same 
procedure, using La(OTf)3-pyBOX (rac) at 40 °C. 
5.2.2.3. Characterization of products 12 
See Table 6 (Page 73) and Table 8 (Page 75) for yield, dr and ee. The following data 
refers to products 12 obtained with the BOX7-Cu(OTf)2 catalyst.  
Dimethyl (S,E)-2-(1,1,1-trifluoro-4-((4-methylphenyl)sulfonamido)-4-phenylbut-3-
en-2-yl)malonate (12aa) 
Chiral HPLC analysis: Chiralpak AD-H, hexane-iPrOH 80:20, 1 
mL/min, E-diastereomer: major enantiomer (S) tr = 8.4 min, 
minor enantiomer (R) tr = 14.0 min; Z-diastereomer: major 
enantiomer tr = 12.4 min, minor enantiomer tr = 9.4 min. 
Major E-diastereomer: White solid, mp 159-161 °C (hexane-EtOAc); [α]D20 -54.0 (c 
1.0, CHCl3, ee = 95%) for the mixture of diastereomers; 1H NMR (300 MHz, CDCl3) δ 
7.76 (2H, d, J = 8.4 Hz, Ar), 7.40-7.27 (5H, m, Ar), 7.10 (2H, m, Ar), 6.21 (1H, s, NH), 
5.57 (1H, d, J = 10.8 Hz, =CH), 3.73 (3H, s, MeO), 3.68 (1H, d, J = 8.4 Hz, CH-
CO2Me), 3.64 (1H, m, CH-CF3), 3.63 (3H, s, MeO), 2.45 (3H, s, Me-Ar); 13C NMR (75 
MHz, CDCl3) δ 166.7 (C), 166.4 (C), 144.2 (C), 141.3 (C), 135.9 (C), 134.0 (C), 129.6 
(CH), 129.5 (CH), 128.7 (CH), 128.6 (CH), 127.7 (CH), 125.4 (C, q, JC-F = 264.8 Hz), 
102.9 (CH, q, JC-F = 2.4 Hz), 52.93 (CH3), 52.90 (CH3), 51.0 (CH), 42.7 (CH, q, JC-F = 
27.9 Hz), 21.5 (CH3); 19F NMR (282 MHz, CDCl3) δ = -70.1 (s, CF3); HRMS (ESI) m/z 
486.1197 [M+H]+, C22H23F3NO6S requires 486.1193. 
Minor Z-diastereomer: 1H NMR (300 MHz, CDCl3, ee = 75%) δ 7.95 (s, 1H), 7.59 
(2H, d, J = 8.4 Hz, Ar), 7.41 (2H, dd, J = 8.1, 1.5 Hz, Ar), 7.36-7.26 (3H, m, Ar), 7.22 
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(2H, d, J = 8.4 Hz, Ar), 5.22 (1H, d, J =11.1 Hz, =CH), 3.81 (3H, s, MeO), 3.76-3.48 
(2H, m, CH-CF3, CH-CO2Me), 3.68 (3H, s, MeO), 2.39 (s, 3H, Me-Ar); 19F NMR (282 
MHz, CDCl3) δ = -69.8 (s, CF3). 
Dimethyl (S,E)-2-(1,1,1-trifluoro-4-((4-methylphenyl)sulfonamido)-4-(p-tolyl)but-
3-en-2-yl)malonate (12ab) 
Chiral HPLC analysis: Lux Amylose-1, hexane-iPrOH 85:15, 1 
mL/min, E-diastereomer: major enantiomer (S) tr = 13.4 min, 
minor enantiomer (R) tr = 16.1 min; Z-diastereomer: major 
enantiomer tr = 14.5 min, minor enantiomer tr = 11.9 min. 
Major E-diastereomer: White solid, mp 138-146 °C (hexane-
EtOAc); [α]D20 -38.6 (c 0.95, CHCl3, ee = 94%) for the mixture of diastereomers; 1H 
NMR (300 MHz, CDCl3) δ 7.75 (2H, d, J = 8.4 Hz, Ar), 7.32 (2H, d, J = 8.4 Hz, Ar), 
7.13 (2H, d, J = 8.1 Hz, Ar), 6.97 (2H, d, J = 8.1 Hz, Ar), 6.18 (1H, s, NH), 5.52 (1H, d, 
J = 10.8 Hz, =CH), 3.72 (3H, s, MeO), 3.67 (1H, d, J = 8.1 Hz, CH-CO2Me), 3.64 (1H, 
m, CH-CF3), 3.63 (3H, s, MeO), 2.45 (3H, s, Me-Ar), 2.33 (3H, s, Me-Ar); 13C NMR 
(75 MHz, CDCl3) δ 166.8 (C), 166.5 (C), 144.2 (C), 141.3 (C), 139.5 (C), 135.9 (C), 
131.2 (C), 129.6 (CH), 129.5 (CH), 128.4 (CH), 127.7 (CH), 125.4 (C, q, JC-F = 249.7 
Hz), 102.6 (CH, q, JC-F = 2.0 Hz), 52.94 (CH3), 52.91 (CH3), 51.0 (CH), 42.7 (CH, q, JC-
F = 27.9 Hz), 21.5 (CH3), 21.3 (CH3); 19F NMR (282 MHz, CDCl3) δ = -70.2 (s, CF3) 
ppm; HRMS (ESI) m/z 500.1356 [M+H]+, C23H25F3NO6S requires 500.1349. 
Minor Z-diastereomer: 1H NMR (300 MHz, CDCl3, ee = 40%), representative signals 
taken from the 1H NMR of the diastereomer mixtures, δ 7.91 (1H, s, NH), 7.86 (2H, d, J 
= 8.1 Hz, Ar), 7.60 (2H, d, J = 8.1 Hz, Ar), 7.25 (2H, d, J = 8.1 Hz, Ar), 7.22 (2H, d, J = 
8.1 Hz, Ar), 5.16 (1H, d, J = 10.8 Hz, =CH), 3.82-3.60 (2H, m, CH-CF3, CH-CO2Me), 
3.76 (3H, s, MeO), 3.67 (3H, s, MeO), 2.43 (3H, s, Me-Ar), 2.39 (3H, s, Me-Ar); 19F 
NMR (282 MHz, CDCl3) δ = -69.9 (s, CF3). 
Dimethyl (S,E)-2-(4-(4-chlorophenyl)-1,1,1-trifluoro-4-((4-methylphenyl)-
sulfonamido)-but-3-en-2-yl)malonate (12ac) 
Chiral HPLC analysis: Lux Amylose-1, hexane-iPrOH 95:05, 1 
mL/min, E-diastereomer: major enantiomer (S) tr = 38.4 min, 
minor enantiomer (R) tr = 47.9 min; Z-diastereomer: major 
enantiomer tr = 48.4 min, minor enantiomer tr = 33.9 min.  
Major E-diastereomer: White solid, mp 142-150 °C (hexane-
EtOAc); [α]D20  -21.3 (c 0.95, CHCl3, ee = 97%) for the mixture of diastereomers; 1H 
NMR (300 MHz, CDCl3) δ 7.70 (2H, d, J = 8.4 Hz, Ar), 7.34-7.24 (4H, m, Ar), 7.04 
(2H, d, J = 8.7 Hz, Ar), 6.42 (1H, s, NH), 5.52 (1H, d, J = 10.8 Hz, =CH), 3.72 (3H, s, 
MeO), 3.67 (1H, d, J = 8.4 Hz, CH-CO2Me), 3.64 (3H, s, MeO), 3.55 (1H, m, CH-CF3), 
2.44 (3H, s, Me-Ar); 13C NMR (75 MHz, CDCl3) δ 166.6 (C), 166.5 (C), 144.3 (C), 
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140.4 (C), 135.9 (C), 135.6 (C), 132.3 (C), 130.2 (CH), 129.7 (CH), 129.0 (CH), 127.6 
(CH), 125.4 (C, q, JC-F = 278 Hz), 104.3 (CH, q, JC-F = 2.5 Hz), 53.04 (CH3), 52.99 
(CH3), 50.9 (CH), 42.6 (CH, q, JC-F = 28.0 Hz), 21.6 (CH3); 19F NMR (282 MHz, 
CDCl3) δ = -70.1 (s, CF3); HRMS (ESI) m/z 520.0795 [M+H]+, C22H22ClF3NO6S 
requires 520.0803. 
Minor Z-diastereomer: 1H NMR (300 MHz, CDCl3, ee = 32%), representative signals 
taken from the 1H NMR of the diastereomer mixtures, δ 8.01 (1H, s, NH), 7.57 (2H, d, J 
= 8.4 Hz, Ar), 7.40-7.19 (6H, m, Ar), 5.19 (1H, d, J = 11.4 Hz, =CH), 3.80 (3H, s, 
MeO), 3.76 (1H, d, J = 7.2 Hz, CH-CO2Me), 3.68 (3H, s, MeO), 3.51 (1H, m, CH-CF3), 
2.39 (3H, s, Me-Ar); 19F NMR (282 MHz, CDCl3) δ = -69.8 (s, CF3). 
Dimethyl (S,E)-2-(4-(4-bromophenyl)-1,1,1-trifluoro-4-((4-methylphenyl) 
sulfonamido)but-3-en-2-yl)malonate (12ad) 
Chiral HPLC analysis: Chiralpak IC, hexane-iPrOH 95:05, 1 
mL/min, E-diastereomer: major enantiomer (S) tr = 47.9 min, 
minor enantiomer (R) tr = 57.1 min; Z-diastereomer: major 
enantiomer tr = 31.9 min, minor enantiomer tr = 40.2 min. 
Major E-diastereomer: Yellow solid, mp 130-133 °C (hexane-
EtOAc); [α]D20 -12.8 (c 1.02 , CHCl3, ee = 95%) for the mixture of diastereomers; 1H 
NMR (300 MHz, CDCl3) δ 7.71 (2H, d, J = 8.4 Hz, Ar), 7.45 (2H, d, J = 8.4 Hz, Ar), 
7.31 (2H, d, J = 8.4 Hz, Ar), 7.04 (2H, d, J = 8.4 Hz, Ar), 6.29 (1H, s, NH), 5.53 (1H, d, 
J = 10.8 Hz, =CH), 3.73 (3H, s, MeO), 3.68 (1H, d, J = 8.4 Hz, CH-CO2Me), 3.65 (3H, 
s, MeO), 3.55 (1H, m, CH-CF3), 2.45 (3H, s, Me-Ar); 13C NMR (75 MHz, CDCl3) δ 
166.6 (C), 166.5 (C), 144.4 (C), 140.4 (C), 135.9 (C), 132.8 (C), 132.0 (CH), 130.4 
(CH), 129.7 (CH), 127.6 (CH), 125.4 (C, q, JC-F = 278 Hz), 124.0 (C), 104.3 (CH, q, JC-
F = 2.3 Hz), 53.07 (CH3), 53.01 (CH3), 50.9 (CH), 42.6 (CH, q, JC-F = 28.0 Hz), 21.6 
(CH3); 19F NMR (282 MHz, CDCl3) δ = -70.0 (s, CF3); HRMS (ESI) m/z 564.0295 
[M+H]+, C22H22BrF3NO6S requires 564.0298. 
Minor Z-diastereomer: 1H NMR (300 MHz, CDCl3, ee = 43%), representative signals 
taken from the 1H NMR of the diastereomer mixtures, δ 8.01 (1H, s, NH), 7.58 (2H, d, J 
= 8.4 Hz, Ar), 7.41 (2H, d, J = 8.4 Hz, Ar), 7.31 (2H, d, J = 8.4 Hz, Ar), 7.25 (2H, d, J = 
8.4 Hz, Ar), 5.21 (1H, d, J = 11.4 Hz, =CH), 3.80 (3H, s, MeO), 3.77 (1H, d, J = 7.2 Hz, 
CH-CO2Me), 3.68 (3H, s, MeO), 3.52 (1H, m, CH-CF3), 2.40 (3H, s, Me-Ar); 19F NMR 
(282 MHz, CDCl3) δ = -69.8 (s, CF3). 
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Dimethyl (S,E)-2-(1,1,1-trifluoro-4-((4-methylphenyl)sulfonamido)-4-(4-
nitrophenyl)but-3-en-2-yl)malonate (12ae) 
Chiral HPLC analysis: Chiralpak IC, hexane-iPrOH 90:10, 1 
mL/min, E-diastereomer: major enantiomer (S) tr = 60.4 min, 
minor enantiomer (R) tr = 69.2 min; Z-diastereomer: major 
enantiomer tr = 50.2 min, minor enantiomer tr = 94.8 min. 
Major E-diastereomer: Orange oil; [α]D20 1.1 (c 1.0, CHCl3, ee 
= 90%) for the mixture of diastereomers; 1H NMR (300 MHz, CDCl3) δ 8.14 (2H, d, J = 
9.0 Hz, Ar), 7.68 (2H, d, J = 8.1 Hz, Ar), 7.37.34-7,28 (4H, m, Ar), 6.80 (1H, s, NH), 
5.58 (1H, d, J = 11.1 Hz, =CH), 3.73 (3H, s, MeO), 3.68 (1H, d, J = 8.4 Hz, CH-
CO2Me), 3.65 (3H, s, MeO), 3.49 (1H, m, CH-CF3), 2.45 (3H, s, Me-Ar); 13C NMR (75 
MHz, CDCl3) δ 166.5 (C), 166.4 (C), 148.2 (C), 144.6 (C), 140.1 (C), 139.6 (C), 135.7 
(C), 130.2 (CH), 129.7 (CH), 127.6 (CH), 125.2 (C, q, JC-F = 279 Hz), 123.8 (C), 106.5 
(CH, q, JC-F = 2.1 Hz), 53.2 (CH3), 53.1 (CH3), 50.7 (CH), 42.6 (CH, q, JC-F = 28.2 Hz), 
21.6 (CH3); 19F NMR (282 MHz, CDCl3) δ = -69.9 (s, CF3); HRMS (ESI) m/z 531.1034 
[M+H]+, C22H22ClF3N2O8S requires 531.1043. 
Minor Z-diastereomer: 1H NMR (300 MHz, CDCl3, ee = 54%), representative signals 
taken from the 1H NMR of the diastereomer mixture, δ 8.19 (1H, s, NH), 8.14 (2H, d, J 
= 9.0 Hz, Ar), 7.60 (4H, m, Ar), 7.25 (2H, d, J = 8.0 Hz, Ar), 5.40 (1H, d, J = 10.8 Hz, 
=CH), 3.83 (3H, s, MeO), 3.80 (1H, d, J = 5.7 Hz, CH-CO2Me), 3.69 (3H, s, MeO), 
3.49 (1H, m, CH-CF3), 2.40 (3H, s, Me-Ar); 13C NMR (75 MHz, CDCl3) δ 168.2 (C), 
166.9 (C), 148.2 (C), 144.4 (C), 143.2 (C), 140.0 (C), 136.5 (C), 129.7 (CH), 128.7 
(CH), 126.9 (CH), 125.2 (C, q, JC-F = 279 Hz), 123.3 (C), 114.8 (CH, q, JC-F = 2.1 Hz), 
54.0 (CH3), 53.4 (CH3), 50.7 (CH), 41.8 (CH, q, JC-F = 29.0 Hz), 21.4 (CH3); 19F NMR 
(282 MHz, CDCl3) δ = -69.9 (s, CF3). 
Dimethyl (S,E)-2-(1,1,1-trifluoro-4-(4-methoxyphenyl)-4-((4-methylphenyl) 
sulfonamido)but-3-en-2-yl)malonate (12af) 
Chiral HPLC analysis: Chiralpak IC, hexane-iPrOH 90:10, 1 
mL/min, E-diastereomer: major enantiomer (S) tr = 44.2 min, 
minor enantiomer (R) tr = 63.8 min; Z-diastereomer: major 
enantiomer tr = 38.0 min, minor enantiomer tr = 50.9 min. 
Major E-diastereomer: Yellow oil; [α]D20 -16.3 (c 1.0, CHCl3) 
for the mixture of diastereomers; 1H NMR (300 MHz, CDCl3, ee = 94%) δ 7.75 (2H, d, 
J = 8.1 Hz, Ar), 7.32 (2H, d, J = 8.1 Hz, Ar), 7.03 (2H, d, J = 8.7 Hz, Ar), 6.84 (2H, d, J 
= 8.7 Hz, Ar), 6.16 (1H, s, NH), 5.48 (1H, d, J = 10.8 Hz, =CH), 3.79-3.66 (2H, m, CH-
CF3, CH-CO2Me), 3.80 (3H, s, MeO), 3.73 (3H, s, MeO), 3.64 (3H, s, MeO), 2.45 (3H, 
s, Me-Ar); 13C NMR (75 MHz, CDCl3) δ 166.8 (C), 166.5 (C), 160.3 (C), 144.1 (C), 
141.2 (C), 136.0 (C), 130.0 (CH), 129.6 (CH), 127.7 (CH), 125.6 (C, q, JC-F = 279 Hz), 
114.1 (CH), 102.7 (C, q, JC-F = 2.0 Hz), 55.2 (CH3), 52.96 (CH3), 52.91 (CH3), 51.1 
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(CH), 42.6 (CH, q, JC-F = 27.8 Hz), 21.6 (CH3); 19F NMR (282 MHz, CDCl3) δ = -70.2 
(s, CF3); HRMS (ESI) m/z 516.1294 [M+H]+, C23H25F3NO7S requires 516.1298. 
Minor Z-diastereomer: 1H NMR (300 MHz, CDCl3, ee = 56%), representative signals 
taken from the 1H NMR of the diastereomer mixture, δ 7.60 (2H, d, J = 8.1 Hz, Ar), 
7.23 (2H, d, J = 8.1 Hz, Ar), 6.93 (2H, d, J = 9.0 Hz, Ar), 6.79 (2H, d, J = 9.0 Hz, Ar), 
5.09 (1H, d, J = 11.4 Hz, =CH), 2.43 (3H, s, Me-Ar); 19F NMR (282 MHz, CDCl3) δ = -
69.9 (s, CF3). 
Dimethyl (S,E)-2-(1,1,1-trifluoro-4-((4-methylphenyl)sulfonamido)-4-(m-tolyl)but-
3-en-2-yl)malonate (12ag) 
Chiral HPLC analysis: Lux Amylose-1, hexane-iPrOH 80:20, 1 
mL/min, E-diastereomer: major enantiomer (S) tr = 7.0 min, 
minor enantiomer (R) tr = 10.7 min; Z-diastereomer: major 
enantiomer tr = 9.5 min, minor enantiomer tr = 7.8 min. 
Major E-diastereomer: White solid, mp 117-120 °C (hexane-EtOAc); [α]D20 -40.7 (c 
1.0, CHCl3, ee = 94%) for the mixture of diastereomers; 1H NMR (300 MHz, CDCl3) δ 
7.75 (2H, d, J = 8.1 Hz, Ar), 7.32 (2H, d, J = 8.1 Hz, Ar), 7.21-7.13 (2H, m, Ar), 6.89 
(1H, d, J = 7,5 Hz, Ar), 6.81 (1H, s, Ar), 6.18 (1H, s, NH), 5.55 (1H, d, J = 10.8 Hz, 
=CH), 3.76-3.67 (2H, m, CH-CF3, CH-CO2Me), 3.73 (3H, s, MeO), 3.63 (3H, s, MeO), 
2.45 (3H, s, Me-Ar), 2.28 (3H, s, Me-Ar); 13C NMR (75 MHz, CDCl3) δ 166.8 (C), 
166.5 (C), 144.2 (C), 141.4 (C), 138.5 (C), 136.0 (C), 134.0 (C), 130.2 (CH), 129.6 
(CH), 129.1 (CH), 128.7 (CH), 127.7 (CH), 125.6 (CH), 125.4 (C, q, JC-F = 255 Hz), 
102.9 (CH, q, JC-F = 2.0 Hz), 52.93 (CH3), 52.91 (CH3), 51.1 (CH), 42.6 (CH, q, JC-F = 
27.9 Hz), 21.5 (CH3), 21.3 (CH3); 19F NMR (282 MHz, CDCl3) δ = -70.2 (s, CF3); 
HRMS (ESI) m/z 500.1354 [M+H]+, C23H25F3NO6S requires 500.1349. 
Minor Z-diastereomer: 1H NMR (300 MHz, CDCl3, ee = 41%), representative signals 
taken from the 1H NMR of the diastereomer mixture, δ 7.90 (1H, s, NH), 7.58 (2H, d, J 
= 8.4 Hz, Ar), 7.35-6.75 (6H, m, Ar), 5.22 (1H, d, J = 11.4 Hz, =CH), 3.82-3.60 (2H, m, 
CH-CF3, CH-CO2Me), 3.80 (3H, s, MeO), 3.68 (3H, s, MeO), 2.43 (3H, s, Me-Ar), 2.26 
(3H, s, Me-Ar); 19F NMR (282 MHz, CDCl3) δ = -69.8 (s, CF3). 
Dimethyl (S,E)-2-(4-(3-chlorophenyl)-1,1,1-trifluoro-4-((4-methylphenyl) 
sulfonamido)but-3-en-2-yl)malonate (12ah) 
Chiral HPLC analysis: Lux Amylose-1, hexane-iPrOH 80:20, 1 
mL/min, E-diastereomer: major enantiomer (S) tr = 7.2 min, 
minor enantiomer (R) tr = 11.1 min; Z-diastereomer: major 
enantiomer tr = 9.5 min, minor enantiomer tr = 8.2 min. 
Major E-diastereomer: yellow solid, mp 100-107 °C (hexane-EtOAc); [α]D20 -20.8 (c 
0.96, CHCl3, ee = 91%) for the mixture of diastereomers; 1H NMR (300 MHz, CDCl3) δ 
7.71 (2H, d, J = 8.4 Hz, Ar), 7.32 (2H, d, J = 8.4 Hz, Ar), 7.31-7.17 (2H, m, Ar), 7.05 
(1H, dt, J = 7.2, 1.5 Hz, Ar), 6.93 (1H, t, J = 1.5 Hz, Ar), 6.34 (1H, s, NH), 5.58 (1H, d, 
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J = 10.8 Hz, =CH), 3.74 (3H, s, MeO), 3.68 (1H, d, J = 8.1 Hz, CH-CO2Me), 3.64 (3H, 
s, MeO), 3.56 (1H, m, CH-CF3), 2.45 (3H, s, Me-Ar); 13C NMR (75 MHz, CDCl3) δ 
166.6 (C), 166.4 (C), 144.4 (C), 140.1 (C), 135.8 (C), 135.5 (C), 134.5 (C), 130.0 (CH), 
129.7 (CH), 129.6 (CH), 128.8 (CH), 127.6 (CH), 127.0 (CH), 125.4 (C, q, JC-F = 280 
Hz), 104.9 (CH, q, JC-F = 2.0 Hz), 53.03 (CH3), 52.98 (CH3), 50.9 (CH), 42.6 (CH, q, JC-
F = 28.0 Hz), 21.5 (CH3); 19F NMR (282 MHz, CDCl3) δ = -70.0 (s, CF3); HRMS (ESI) 
m/z 520.0801 [M+H]+, C22H22ClF3NO6S requires 520.0803. 
Minor Z-diastereomer: 1H NMR (300 MHz, CDCl3, ee = 49%), representative signals 
taken from the 1H NMR of the diastereomer mixture, δ 8.00 (1H, s, NH), 7.57 (2H, d, J 
= 8.4 Hz, Ar), 7.33-7.20 (6H, m, Ar), 5.26 (1H, dd, J = 10.8, 0.6 Hz, =CH), 3.81 (3H, s, 
MeO), 3.78 (1H, d, J = 6.3 Hz, CH-CO2Me), 3.69 (3H, s, MeO), 3.56 (1H, m, CH-CF3), 
2.39 (3H, s, Me-Ar); 19F NMR (282 MHz, CDCl3) δ = -69.7 (s, CF3). 
Dimethyl (S,E)-2-(1,1,1-trifluoro-4-((4-methylphenyl)sulfonamido)-4-(3-
nitrophenyl)but-3-en-2-yl)malonate (12ai) 
Chiral HPLC analysis: Lux Amylose-1, hexane-iPrOH 95:05, 2 
mL/min, E-diastereomer: major enantiomer (S) tr = 42.9 min, 
minor enantiomer (R) tr = 78.2 min; Z-diastereomer: major 
enantiomer tr = 50.6 min, minor enantiomer tr = 30.9 min. 
Major E-diastereomer: Yellow oil; [α]D20 -9.5 (c 0.97, CHCl3, ee = 83%) for the 
mixture of diastereomers; 1H NMR (300 MHz, CDCl3) δ 8.18 (1H, m, Ar), 7.82 (1H, 
ddd, J = 7.8, 1.8, 1.2 Hz, Ar), 7.76 (1H, t, J = 1.8 Hz, Ar), 7.65 (2H, d, J = 8.0 Hz, Ar), 
7.54 (1H, t, J = 8.0 Hz, Ar), 7.30 (2H, d, J = 8.0 Hz, Ar), 6.62 (1H, s, NH), 5.63 (1H, d, 
J = 11.1 Hz, =CH), 3.76 (3H, s, MeO), 3.67 (1H, d, J = 7.4 Hz, CH-CO2Me), 3.65 (3H, 
s, MeO), 3.48 (1H, m, CH-CF3), 2.44 (3H, s, Me-Ar); 13C NMR (75 MHz, CDCl3) δ 
166.5 (C), 166.4 (C), 148.1 (C), 144.7 (C), 139.5 (C), 135.7 (C), 135.2 (CH), 135.1 (C), 
129.8 (CH, overlaped signals), 127.5 (CH), 125.3 (C, q, JC-F = 279 Hz), 124.2 (CH), 
124.1 (CH), 106.9 (CH, q, JC-F = 2.0 Hz), 53.17 (CH3), 53.12 (CH3), 50.7 (CH), 42.6 
(CH, q, JC-F = 28.2 Hz), 21.5 (CH3); 19F NMR (282 MHz, CDCl3) δ = -69.9 (s, CF3); 
HRMS (ESI) m/z 531.1036 [M+H]+, C22H22ClF3N2O8S requires 531.1043. 
Minor Z-diastereomer: 1H NMR (300 MHz, CDCl3, ee = 58%), representative signals 
taken from the 1H NMR of the diastereomer mixture, δ 8.19 (1H, s, NH), 8.16 (1H, m, 
Ar), 8.11 (1H, t, J = 1.9 Hz, Ar), 7.63-7.53 (3H, m, Ar), 7.50 (1H, t, J = 8.1 Hz, Ar), 
7.23 (2H, d, J = 8.0 Hz, Ar), 5.38 (1H, dd, J = 10.8, 0.6 Hz, =CH), 3.83 (3H, s, MeO), 
3.81 (1H, d, J = 6.3 Hz, CH-CO2Me), 3.71 (3H, s, MeO), 3.58 (1H, m, CH-CF3), 2.39 
(3H, s, Me-Ar); 13C NMR (75 MHz, CDCl3) δ 168.2 (C), 167.0 (C), 148.0 (C), 144.4 
(C), 139.8 (C), 138.5 (C), 136.6 (C), 134.1 (CH), 129.7 CH), 129.2 (CH), 126.9 (CH), 
125.3 (C, q, JC-F = 279 Hz), 123.9 (CH), 122.7 (CH), 113.8 (CH, q, JC-F = 2.4 Hz), 54.0 
(CH3), 53.4 (CH3), 50.7 (CH), 41.9 (CH, q, JC-F = 28.29 Hz), 21.4 (CH3); 19F NMR (282 
MHz, CDCl3) δ = -69.6 (s, CF3). 
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Dimethyl (S,E)-2-(1,1,1-trifluoro-4-(3-methoxyphenyl)-4-((4-methylphenyl) 
sulfonamido)but-3-en-2-yl)malonate (12aj) 
Chiral HPLC analysis: Lux Amylose-1, hexane-iPrOH 90:10, 
1 mL/min, E-diastereomer: major enantiomer (S) tr = 19.4 
min, minor enantiomer (R) tr = 30.7 min; Z-diastereomer: 
major enantiomer tr = 26.5 min, minor enantiomer tr = 21.8 
min. 
Major E-diastereomer: Yellow solid, mp 102-105 °C (hexane-EtOAc); [α]D20 -40.3 (c 
0.95, CHCl3, ee = 87%) for the mixture of diastereomers; 1H NMR (300 MHz, CDCl3) δ 
7.82 (2H, d, J = 8.4 Hz, Ar), 7.38 (2H, d, J = 8.4 Hz, Ar), 7.28-7.25 (1H, m, Ar), 6.93 
(1H, ddd, J = 8.4, 2.4, 1.2 Hz, Ar), 6.71-6.69 (2H, m, Ar), 6.31 (1H, s, NH), 5.65 (1H, 
d, J = 10.8 Hz, =CH), 3.88 (1H, d, J = 8.7 Hz, CH-CO2Me), 3.80 (3H, s, MeO), 3.79 
(3H, s, MeO), 3.76-3.75 (1H, m, CH-CF3), 3.70 (3H, s, MeO), 2.50 (3H, s, Me-Ar); 13C 
NMR (75 MHz, CDCl3) δ 166.8 (C), 166.6 (C), 159.6 (C), 144.2 (C), 141.1 (C), 135.9 
(C), 135.3 (C), 129.9 (CH), 129.6 (CH), 127.7 (CH), 125.4 (C, q, JC-F = 257.3 Hz), 
120.6 (CH), 115.7 (CH), 113.6 (CH), 102.9 (CH, q, JC-F = 2.0 Hz), 55.2 (CH3), 52.95 
(CH3), 52.94 (CH3), 51.0 (CH), 42.6 (CH, q, JC-F = 27.9 Hz), 21.5 (CH3); 19F NMR (282 
MHz, CDCl3) δ = -70.2 (s, CF3); HRMS (ESI) m/z 516.1294 [M+H]+, C23H25F3NO7S 
requires 516.1298. 
Minor Z-diastereomer: 1H NMR (300 MHz, CDCl3, ee = 82%), representative signals 
taken from the 1H NMR of the diastereomer mixture, δ 7.99 (1H, s, NH), 7.65 (2H, d, J 
= 8.4 Hz, Ar), 7.37-7.32 (1H, m, Ar), 7.06 (dt, J = 7,8, 1,2 Hz, Ar), 6.75-6.65 (2H, m, 
Ar), 5.31 (1H, d, J = 11.4 Hz, =CH), 3.89-3.67 (2H, m, CH-CF3, CH-CO2Me), 3.86 
(3H, s, MeO), 3.80 (3H, s, MeO), 3.75 (3H, s, MeO), 2.45 (3H, s, Me-Ar); 19F NMR 
(282 MHz, CDCl3) δ = -69.8 (s, CF3). 
Dimethyl (S,E)-2-(1,1,1-trifluoro-4-(2-methoxyphenyl)-4-((4-methylphenyl)-
sulfonamido)but-3-en-2-yl)malonate (12ak) 
Chiral HPLC analysis: Chiralpak AD-H, hexane-iPrOH 90:10, 
1 mL/min, E-diastereomer: major enantiomer (S) tr = 21.6 
min, minor enantiomer (R) tr = 47.2 min; Z-diastereomer: 
major enantiomer tr = 38.3 min, minor enantiomer tr = 32.7 
min. 
Major E-diastereomer: Yellow solid, mp 129-133 °C (hexane-EtOAc); [α]D20 -32.2 (c 
0.92, CHCl3) for the mixture of diastereomers; 1H NMR (300 MHz, CDCl3, ee = 89%) δ 
7.72 (2H, d, J = 8.4 Hz, Ar), 7.28-7.25 (2H, m, Ar), 7.03-7.00 (2H, m, Ar), 6.89 (1H, dt, 
J = 7.5, 1.2 Hz, Ar), 6.82 (1H, dd, J = 8.4, 1.2 Hz, Ar), 6.18 (1H, s, NH), 5.69 (1H, d, J 
= 10.8 Hz, =CH), 3.75 (3H, s, MeO), 3.69-3.55 (2H, m, CH-CF3, CH-CO2Me), 3.65 
(3H, s, MeO), 3.60 (3H, s, MeO), 2.42 (3H, s, Me-Ar); 13C NMR (75 MHz, CDCl3) δ 
166.8 (C), 166.6 (C), 156.7 (C), 143.8 (C), 138.8 (C), 136.1 (C), 131.2 (C), 131.0 (C), 
129.3 (CH), 128.9 (CH), 127.9 (CH), 127.1 (CH), 125.0 (C, q, JC-F = 258.8 Hz), 120.6 
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(CH), 111.0 (CH), 113.6 (CH), 105.6 (CH, q, JC-F = 2.0 Hz), 55.1 (CH3), 52.9 (CH3), 
51.1 (CH), 42.8 (CH, q, JC-F = 27.8 Hz), 21.5 (CH3); 19F NMR (282 MHz, CDCl3) δ = -
70.2 (s, CF3); HRMS (ESI) m/z 516.1302 [M+H]+, C23H25F3NO7S requires 516.1298. 
Minor Z-diastereomer: 1H NMR (300 MHz, CDCl3, ee = 17%), representative signals 
taken from the 1H NMR of the diastereomer mixture, δ 7.81 (2H, d, J = 8.1 Hz, Ar), 
7.38-6.49 (7H, m, Ar, NH), 5.44 (1H, d, J = 10.8 Hz, =CH), 3.82-3.60 (2H, m, CH-CF3, 
CH-CO2Me), 3.83 (3H, s, MeO), 3.73 (3H, s, MeO), 3.55 (3H, s, MeO), 2.31 (3H, s, 
Me-Ar); 19F NMR (282 MHz, CDCl3) δ = -69.5 (s, CF3). 
Dimethyl (S,E)-2-(1,1,1-trifluoro-4-((4-methylphenyl)sulfonamido)-4-(naphthalen-
2-yl)but-3-en-2-yl)malonate (12al) 
Chiral HPLC analysis: Lux Amylose-1, hexane-iPrOH 80:20, 1 
mL/min, E-diastereomer: major enantiomer (S) tr = 11.3 min, 
minor enantiomer (R) tr = 13.8 min; Z-diastereomer: major 
enantiomer tr = 12.3 min, minor enantiomer tr = 9.4 min 
Major E-diastereomer: Yellow solid, mp 98-103 °C (hexane-
EtOAc); [α]D20 1.0 (c 0.96, CHCl3, ee = 93%) for the mixture of diastereomers; 1H 
NMR (300 MHz, CDCl3) δ 7.80-7.74 (5H, m, Ar), 7.59-7.58 (1H, m, Ar), 7.53-7.49 
(2H, m, Ar), 7.30 (2H, d, J = 8.1 Hz Ar), 7.14 (1H, dd, J = 8.1, 1.8 Hz, Ar), 6.38 (1H, s, 
NH), 5.65 (1H, d, J = 10.8 Hz, =CH), 3.82-3.69 (2H, m, CH-CF3, CH-CO2Me), 3.76 
(3H, s, MeO), 3.60 (3H, s, MeO), 2.44 (3H, s, Me-Ar); 13C NMR (75 MHz, CDCl3) δ 
166.7 (C), 166.5 (C), 144.2 (C), 141.4 (C), 136.0 (C), 133.3 (C), 132.8 (C), 131.2 (C), 
129.6 (CH), 128.64 (CH), 128.57 (CH), 128.3 (CH), 127.7 (CH), 127.1 (CH), 126.6 
(CH), 125.5 (CH), 125.4 (C, q, JC-F = 264.8 Hz), 123.7 (CH), 104.0 (CH, q, JC-F = 2.0 
Hz), 53.0 (CH3), 52.9 (CH3), 51.1 (CH), 42.7 (CH, q, JC-F = 28.5 Hz), 21.5 (CH3); 19F 
NMR (282 MHz, CDCl3) δ = -70.0 (s, CF3); HRMS (ESI) m/z 536.1346 [M+H]+, 
C26H25F3NO6S requires 536.1349. 
Minor Z-diastereomer: 1H NMR (300 MHz, CDCl3, ee = 27%), representative signals 
taken from the 1H NMR of the diastereomer mixture, δ 8.05 (1H, s, NH), 7.87-6.94 
(11H, m, Ar), 5.37 (1H, d, J = 11,1 Hz, =CH), 3.82 (3H, s, MeO), 3.80-3.60 (2H, m, 
CH-CF3, CHCO2Me), 3.68 (3H, s, MeO), 2.34 (3H, s, Me-Ar); 19F NMR (282 MHz, 
CDCl3) δ =  -69.6 (s, CF3). 
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5.2.3. Synthetic transformations from compound 12aa 
Dimethyl 2-((2S,4R)-1,1,1-trifluoro-4-((4-methylphenyl)sulfonamido)-4-phenyl-
butan-2-yl)malonate (13) and 2-((2S,4S)-1,1,1-trifluoro-4-((4-
methylphenyl)sulfonamido)-4-phenyl-butan-2-yl)malonate (14) 
To a sample of compound (S,E)-12aa 
(52.0 mg, 0.11 mmol, E/Z 96:4, ee = 
89%/69%), dissolved in dry CH2Cl2 (3.3 
mL) under nitrogen atmosphere was 
added triethylsilane (50 µL, 0.428 mmol) followed by BF3·Et2O (67 µL, 0.471 mmol). 
After stirring for 48 h at room temperature, the mixture was chromatographed on silica 
gel eluting with hexane/EtOAc (80:20) to give 48.1 mg (92%) of a ca. 88:12 mixture of  
two diastereomeric compounds 13 and 14. Chiral HPLC analysis: Lux Amylose-1, 
hexane-iPrOH 90:10, 1 mL/min, (2S,4R)-13 (ee = 87%), major enantiomer tr = 16.4 
min, minor enantiomer tr = 15.0 min; (2S,4S)-14, unresolved tr = 8.3 min. Chiralpak IC, 
hexane-iPrOH 95:05, 2 mL/min, (2S,4R)-13, tr > 120 min; (2S,4S)-14 (ee = 89%), major 
enantiomer tr = 37.6 min, minor enantiomer tr = 35.8 min; 
(2S,4R)-13 (major): colorless oil; [α]D20 7.8 (c 0.97, CHCl3) for the diastereomer 
mixture; 1H NMR (300 MHz, CDCl3) δ 7.52 (2H, d, J = 8.1 Hz, Ar), 7.20-7.13 (3H, m, 
Ar), 7.10 (2H, d, J = 8.1 Hz, Ar), 7.02-6.90 (2H, m, Ar), 5.13 (1H, d, J = 8.1 Hz, NH), 
4.47 (1H, q, J = 7.8 Hz, CH-Ph), 3.73 (3H, s, MeO), 3.69 (1H, d, J = 5.4 Hz, CH-
CO2Me), 2.83 (1H, m, CH-CF3), 2.34 (3H, s, Me-Ar), 2.32-2.10 (2H, m, CH2); 13C 
NMR (75 MHz, CDCl3) δ 167.1 (C), 167.0 (C), 143.1 (C), 138.8 (C), 137.2 (C), 129.3 
(CH), 128.6 (CH), 128.5 (C), 127.9 (CH), 127.0 (CH), 126.8 (CH), 126.6 (C, q, JC-F = 
278 Hz), 56.4 (CH), 53.1 (CH3), 52.8 (CH3), 49.9 (CH), 40.0 (CH, q, JC-F = 26.8 Hz), 
33.4 (CH2), 21.4 (CH3); 19F NMR (282 MHz, CDCl3) δ = -68.5 (s, CF3); HRMS (ESI) 
m/z 488.1357 [M+H]+, C22H25F3NO6S requires 488.1349. 
(2S,4S)-14 (minor): 1H NMR (300 MHz, CDCl3), representative signals taken from the 
diastereomer mixture δ 7.58 (2H, d, J = 8.4 Hz, Ar), 7.40-6.90 (7H, m, Ar), 5.95 (1H, d, 
J = 6.9 Hz, NH), 4.45 (1H, m, CH-Ph), 3.81 (3H, s, MeO), 3.72 (3H, s, MeO), 2.83 (1H, 
m, CH-CF3), 2.34 (3H, s, Me-Ar), 2.32-2.10 (2H, m, CH2); 19F NMR (282 MHz, 
CDCl3) δ = -70.1 (s, CF3). 
Methyl (3R,4S,6R)-2-oxo-6-phenyl-1-tosyl-4-(trifluoromethyl)piperidine-3-
carboxylate (15) 
A 25% solution of tetraethylammonium hydroxyde in MeOH (24 µL, 
0.14 mmol) was added to a solution of compound 13 (28.0 mg, 0.037 
mmol, ee = 87%) in dimethylsulfoxide (1.6 mL) under nitrogen, and 
the reaction flask was introduced in a bath at 80 °C. After 14 h, the 
reaction mixture was diluted with EtOAc (75 mL), washed with water (5 × 5 mL), brine 
(5 mL), and dried over MgSO4. Purification by column chromatography eluting with 
hexane/EtOAc (80:20) gave 13.2 mg (78%) of compound 15. Chiral HPLC analysis: 
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Lux Amylose-1, hexane-iPrOH 90:10, 1 mL/min, major enantiomer tr = 24.0 min, 
minor enantiomer tr = 22.1 min. White solid, mp 177-179 °C (hexane-EtOAc); [α]D20    
-4.5 (c 1.0, CHCl3, ee = 87% ); 1H NMR (300 MHz, CDCl3) δ 7.56 (2H, d, J = 8.5 Hz, 
Ar), 7.40-7.32 (3H, m, Ar), 7.20-7.14 (4H, m, Ar), 5.93 (1H, t, J = 3.8 Hz, CH-Ph), 3.78 
(3H, s, OMe), 3.65 (1H, d, J = 11.4 Hz, CH-CO2Me), 3.11 (1H, m, CH-CF3), 2.40 (3H, 
s, Me-Ar), 2.35-2.28 (2H, m, CH2); 13C NMR (75 MHz, CDCl3) δ 168.3 (C), 164.3 (C), 
145.4 (C), 138.1 (C), 134.5 (C), 129.7 (CH), 129.0 (CH), 128.5 (C), 126.5 (CH), 125.6 
(C, q, JC-F = 278 Hz), 58.3 (CH), 53.4 (CH3), 52.8 (CH3), 50.2 (CH), 37.1 (CH, q, JC-F = 
28.5 Hz), 29.9 (CH2), 21.7 (CH3); 19F NMR (282 MHz, CDCl3) δ = -73.1 (s, CF3); 
HRMS (ESI) m/z 456.1087 [M+H]+, C21H21F3NO5S requires 456.1077. 
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5.3. Mukaiyama-Michael addition with N-tosyl imines derived from 
β,γ-unsaturated α-keto esters: E,Z-stereodivergent synthesis of α,β-
dehydroamino esters 
5.3.1. Synthesis and characterization of α,β-unsaturated N-tosyl imines 17   
The procedure reported by Carretero was followed:22 TiCl4 (0.45 mL, 5.6 mmol) was 
added dropwise to a solution of keto ester (5.6 mmol),200 p-toluensulfonamide (0.95g, 
5.6 mmol) and triethylamine (1.55 mL, 11.2 mmol) in dry dichloromethane (17 ml) at 0 
ºC under nitrogen. The mixture was heated at reflux temperature for 24 h and, after 
cooling to room temperature, treated with water (150 ml), extracted with 
dichloromethane (4 × 80 mL), dried over MgSO4 and concentrated under reduced 
pressure. Column chromatography on silica gel eluting with hexane/EtOAc mixtures 
afforded imines 17. 
Ethyl (2Z,3E)-4-phenyl-2-(tosylimino)but-3-enoate (17a) 
Yellow oil; 1H NMR (300 MHz, CDCl3) δ 7.90 (d, J = 8.5 Hz, 
2H), 7.60-7.28 (m, 6H), 7.36 (d, J = 8.5 Hz, 2H), 6.83 (d, J = 16.5 
Hz, 1H), 4.54 (q, J = 7.2 Hz, 2H), 2.44 (s, 3H), 1.49 (t, J = 7.2 Hz, 
3H); 13C NMR (75 MHz, CDCl3) δ 167.6 (C), 164.4 (C), 149.4 
(C), 144.7 (C), 135.8 (C), 133.9 (CH), 131.7 (CH), 129.7 (2CH), 129.6 (3CH), 129.1 
(CH), 128.7 (CH), 128.0 (CH), 123.5 (CH), 63.1 (CH2), 21.6 (CH3), 14.0 (CH3); HRMS 
(ESI) m/z 357.1037 [M]+, C19H19NO4S requires 357.1035.  
Ethyl (2Z,3E)-4-(p-tolyl)-2-(tosylimino)but-3-enoate (17b) 
Yellow solid, mp 112-116 ºC (hexane-EtOAc); 1H NMR (300 
MHz, CDCl3) δ 7.90 (d, J = 8.4 Hz, 2H),  7.39 (d, J = 8.4 Hz, 
2H), 7.36 (d, J = 16.4 Hz, 1H overlapped), 7.34 (d, J = 8.4 Hz, 
2H), 7.20 (d, J = 8.4 Hz, 2H), 6.78 (d, J = 16.4 Hz, 1H), 4.55 
(q, J = 7.2 Hz, 2H), 2.43 (s, 3H), 2.38 (s, 3H), 1.48 (t, J = 7.2 Hz, 3H); 13C NMR (75 
MHz, CDCl3) δ 168.0 (C), 164.8 (C), 149.7 (C), 144.7 (C), 142.9 (C), 131.5 (2CH), 
130.1 (4CH), 129.8 (2CH), 128.9 (CH), 128.1 (CH), 122.9 (C), 63.3 (CH2), 21.8 
(2CH3), 14.1 (CH3); HRMS (ESI) m/z 371.1195 [M]+, C20H21NO4S requires 371.1191. 
Ethyl (2Z,3E)-4-(4-chlorophenyl)-2-(tosylimino)but-3-enoate (17c) 
Yellow solid, mp 70-73 ºC (hexane-EtOAc); 1H NMR (300 
MHz, CDCl3) δ 7.89 (d, J = 8.4 Hz, 2H), 7.50-7.27 (m, 7H), 
6.78 (d, J = 16.5 Hz, 1H), 4.54 (q, J = 7.2 Hz, 2H), 2.44 (s, 
3H), 1.48 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 
167.2 (C), 164.4 (C), 147.5 (C), 144.8 (C), 137.8 (C), 135.7 (C), 132.4 (CH), 129.7 
(3CH), 129.5 (4CH), 128.0 (CH), 124.0 (CH), 63.3 (CH2), 21.6 (CH3), 14.0 (CH3); 
HRMS (ESI) m/z 391.0645 [M]+, C19H18ClNO4S requires 391.0645.  
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Ethyl (2Z,3E)-4-(4-nitrophenyl)-2-(tosylimino)but-3-enoate (117d) 
White solid,  mp 119-121 ºC (hexane-EtOAc); 1H NMR (300 
MHz, CDCl3) δ 8.26 (d, J = 8.4 Hz, 2H), 7.90 (d, J = 8.1, 
2H), 7.66 (d, J = 8.4 Hz, 2H), 7.40 (d, J = 16.5 Hz, 1H 
overlapped), 7.36 (d, J = 8.1 Hz, 2H), 6.91 (d, J = 16.5 Hz, 
1H), 4.56 (q, J = 7.0 Hz, 2H), 2.45 (s, 3H), 1.50 (t, J = 7.0 Hz, 3H); 13C NMR (75 MHz, 
CDCl3) δ 166.4 (C), 164.0 (C), 149.0 (C), 145.1 (C), 139.7 (C), 129.8 (4CH), 129.1 
(CH), 128.2 (CH), 127.4 (C), 124.3 (4CH), 63.5 (CH2), 21.69 (CH3), 14.0 (CH3); 
HRMS (ESI) m/z 425.0083 [M+Na]+, C19H18N2NaO6S requires 425.0078. 
Ethyl (2Z,3E)-4-(4-methoxyphenyl)-2-(tosylimino)but-3-enoate (17e)  
Yellow oil; 1H NMR (300 MHz, CDCl3) δ 7.89 (d, J = 8.3 
Hz, 2H), 7.46 (d, J = 8.4 Hz, 2H), 7.34 (d, J = 16.5 Hz, 1H 
overlapped), 7.32 (d, J = 8.3 Hz, 2H), 6.90 (d, J = 8.4 Hz, 
2H), 6.69 (d, J = 16.5 Hz, 1H), 4.53 (q, J = 7.2 Hz, 2H), 3.83 
(s, 3H), 2.42 (s, 3H), 1.47 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 167.9 (C), 
164.7 (C), 162.7 (C), 149.4 (C), 144.4 (C), 130.7 (CH), 129.6 (2CH), 127.8 (CH), 126.7 
(2CH), 120.9 (C), 114.7 (4CH), 63.0 (CH2), 55.4 (CH3), 21.6 (CH3), 13.9 (CH3); HRMS 
(ESI) m/z 388.1215 [M+H]+, C20H21NO5S requires 388.1213. 
Ethyl (2Z,3E)-4-(3-chlorophenyl)-2-(tosylimino)but-3-enoate (17f) 
Pale yellow solid, mp 84-86 ºC (hexane-EtOAc); 1H NMR (300 
MHz, CDCl3) δ 7.89 (d, J = 8.4 Hz, 2H), 7.47 (s, 1H), 7.41-7.26 
(m, 4H), 7.34 (d, J = 8.4 Hz, 2H), 6.80 (d, J = 16.4 Hz, 1H), 4.54 
(q, J = 7.1 Hz, 2H), 2.43 (s, 3H), 1.48 (t, J = 7.1 Hz, 3H); 13C 
NMR (75 MHz, CDCl3) δ 167.0 (C), 164.2 (C), 147.1 (C), 144.8 
(C), 135.6 (C), 135.2 (C), 131.4 (CH), 130.3 (3CH), 129.7 (2CH), 128.3 (CH), 128.0 
(CH), 126.6 (CH), 124.8 (CH), 63.3 (CH2), 21.6 (CH3), 13.9 (CH3); HRMS (ESI) m/z 
391.0646 [M]+, C19H18ClNO4S requires 391.0645. 
Ethyl (2Z,3E)-4-(3-nitrophenyl)-2-(tosylimino)but-3-enoate (17g) 
White solid, mp 124-125 ºC (hexane-EtOAc); 1H NMR (300 
MHz, CDCl3) δ 8.35 (s, 1H), 8.27 (d, J = 8.0 Hz, 1H), 7.90 (d, J = 
8.4 Hz, 2H), 7.82 (d, J = 8.0 Hz, 1H), 7.61 (t, J = 8.0 Hz, 1H), 
7.38 (d, J = 16.5 Hz, 1H overlapped), 7.36 (d, J = 8.4 Hz, 2H), 
6.91 (d, J = 16.5 Hz, 1H), 4.56 (q, J = 7.0 Hz, 2H), 2.45 (s, 3H), 
1.49 (t, J = 7.0 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 166.5 (C), 164.0 (C), 148.7 (C), 
145.3 (C), 145.1 (C), 135.6 (C), 133.7 (2CH), 130.2 (2CH), 129.8 (2CH), 128.1 (CH), 
126.3 (CH), 125.6 (CH), 123.0 (CH), 63.5 (CH2), 21.7 (CH3), 14.0 (CH3); HRMS (ESI) 
m/z 425.0080  [M+Na]+, C19H18N2NaO6S requires 425.0078. 
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Ethyl (2Z,3E)-4-(3-methoxyphenyl)-2-(tosylimino)but-3-enoate (17h) 
Yellow oil; 1H NMR (300 MHz, CDCl3) δ 7.90 (d, J = 8.4 Hz, 
2H), 7.34 (d, J = 8.4 Hz, 2H), 7.40-7.27 (m, 2H overlapped), 7.09 
(d, J = 7.2 Hz, 1H), 6.99 (s, 1H overlapped), 6.98 (d, J = 8.7 Hz, 
1H), 6.81 (d, J = 16.5 Hz, 1H), 4.55 (q, J = 7.1 Hz, 2H), 3.80 (s, 
3H), 2.43 (s, 3H), 1.48 (t, J = 7.1 Hz, 3H); 13C NMR (75 MHz, 
CDCl3) δ 167.6 (C), 164.4 (C), 160.0 (2C), 149.3 (C), 144.7 (C), 135.4 (CH), 130.1 
(2CH), 129.7 (2CH), 128.0 (CH), 123.7 (CH), 121.5 (CH), 117.9 (CH), 113.0 (CH), 
63.1 (CH2), 55.3 (CH3), 21.6 (CH3), 14.0 (CH3); HRMS (ESI) m/z 388.1215 [M+H]+, 
C20H21NO5S requires 388.1213. 
Ethyl (2Z,3E)-4-(2-chlorophenyl)-2-(tosylimino)but-3-enoate (17i) 
White solid, mp 117-120 ºC (hexane-EtOAc); 1H NMR (300 
MHz, CDCl3) δ 7.90 (d, J = 8.4 Hz, 2H), 7.82 (d, J = 16.6 Hz, 
1H), 7.61 (d, J = 6.9 Hz, 1H), 7.43 (d, J = 7.7 Hz, 1H), 7.38-7.28 
(m, 2H overlapped), 7.35 (d, J = 8.4 Hz, 2H),  6.81 (d, J = 16.6 
Hz, 1H), 4.57 (q, J = 7.2 Hz, 2H), 2.44 (s, 3H), 1.50 (t, J = 7.2 Hz, 3H); 13C NMR (75 
MHz, CDCl3) δ 167.6 (C), 164.2 (C), 144.9 (C), 144.8 (C), 135.6 (C), 135.5 (C), 132.3 
(CH), 132.0 (CH), 130.4 (2CH), 129.7 (2CH), 128.1 (CH), 127.5 (CH), 127.4 (CH), 
125.8 (CH), 63.2 (CH2), 21.7 (CH3), 14.1 (CH3); HRMS (ESI) m/z 391.0647 [M]+, 
C19H18ClNO4S requires 391.0645. 
Ethyl (2Z,3E)-4-(2-nitrophenyl)-2-(tosylimino)but-3-enoate (17j) 
Pale yellow solid, mp 161-162 ºC (hexane-EtOAc); 1H NMR (300 
MHz, CDCl3) δ 8.09 (d, J = 7.8 Hz, 1H), 7.92 (d, J = 8.4 Hz, 1H), 
7.89 (d, J = 8.1 Hz, 2H), 7.76-7.50 (m, 3H), 7.35 (d, J = 8.1 Hz, 
2H), 6.72 (d, J = 16.4 Hz, 1H), 4.56 (q, J = 7.2 Hz, 2H), 2.44 (s, 
3H), 1.50 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 167.1 (C), 163.9 (C), 147.9 
(C), 145.1 (C), 144.3 (CH), 135.2 (C), 133.9 (CH), 131.3 (CH), 130.0 (C), 129.8 (2CH), 
128.9 (CH), 128.2 (2CH), 128.1 (CH), 125.3 (CH), 63.4 (CH2), 21.7 (CH3), 14.0 (CH3); 
HRMS (ESI) 425.0076 m/z [M+Na]+, C19H18N2NaO6S requires 425.0078. 
Ethyl (2Z,3E)-4-(2-methoxyphenyl)-2-(tosylimino)but-3-enoate (17k) 
Yellow oil; 1H NMR (300 MHz, CDCl3) δ 7.90 (d, J = 8.4 Hz, 
2H), 7.73 (d, J = 16.5 Hz, 1H), 7.45-7.30 (m, 2H), 7.32 (d, J = 8.4 
Hz, 2H), 7.03-6.84 (m, 3H), 4.55 (q, J = 7.2 Hz, 2H), 3.86 (s, 3H), 
2.42 (s, 3H), 1.48 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) 
δ 168.6 (C), 164.7 (C), 158.7 (C), 145.2 (C), 144.5 (C), 133.3 (CH), 129.6 (2CH), 129.5 
(C), 129.1 (CH), 128.0 (CH), 123.8 (CH), 122.9 (CH), 120.9 (CH), 111.3 (2CH), 62.9 
(CH2), 55.6 (CH3), 21.6 (CH3), 14.0 (CH3); HRMS (ESI) 388.1215 m/z [M+H]+, 
C20H21NO5S requires 388.1213. 
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Ethyl (2Z,3E)-4-(furan-2-yl)-2-(tosylimino)but-3-enoate (17l) 
Brown oil; 1H NMR (300 MHz, CDCl3) δ 7.89 (d, J = 8.1 Hz, 2H), 
7.55 (s, 1H), 7.33 (d, J = 8.1 Hz, 2H), 7.15 (d, J = 16.1 Hz, 1H), 
6.75 (s, 1H overlapped), 6.69 (d, J = 16.1 Hz, 1H), 6.53 (s, 1H), 
4.51 (q, J = 7.0 Hz, 2H), 2.43 (s, 3H), 1.46 (t, J = 7.0 Hz, 3H); 13C 
NMR (75 MHz, CDCl3) δ 167.2 (C), 164.5 (C), 150.8 (2CH), 146.7 (CH), 144.8 (C), 
136.0 (C), 134.3 (CH), 129.6 (2CH), 127.9 (CH), 120.8 (C), 118.1 (CH), 113.3 (CH), 
63.1 (CH2), 21.6 (CH3), 14.0 (CH3); HRMS (ESI) m/z 348.0898 [M+H]+, C17H18NO5S 
requires 348.0900. 
Ethyl (2Z,3E)-4-(thiophen-2-yl)-2-(tosylimino)but-3-enoate (17m)  
Yellow oil; 1H NMR (300 MHz, CDCl3) δ 7.89 (d, J = 8.4 Hz, 
2H), 7.53-7.48 (m, 2H), 7.33 (d, J = 8.4 Hz, 2H), 7.09 (d, J = 4.8 
Hz, 1H), 6.60 (d, J = 16.2 Hz, 1H), 4.53 (q, J = 6.3 Hz, 2H), 2.43 
(s, 3H), 1.47 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 
167.2 (C), 144.6 (C), 144.5 (C), 141.38 (CH), 141.36 (C), 139.6 (C), 133.2 (CH), 131.5 
(CH), 129.7 (2CH), 128.7 (2CH), 127.9 (CH), 122.1 (CH), 63.2 (CH2), 21.6 (CH3), 13.9 
(CH3); HRMS (ESI) m/z 364.0674 [M+H]+, C17H18NO4S2 requires 364.0672. 
Methyl (2Z,3E)-4-phenyl-2-(tosylimino)but-3-enoate (17n) 
Brown oil; 1H NMR (300 MHz, CDCl3) δ 7.89 (d, J = 8.1 Hz, 
2H), 7.66-7.29 (m, 6H), 7.34 (d, J = 8.1 Hz, 2H), 6.83 (d, J = 16.4 
Hz, 1H), 4.07 (s, 3H), 2.44 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 
167.4 (C), 164.9 (C), 149.6 (C), 144.8 (C), 135.7 (C), 133.9 (CH), 
131.8 (CH), 129.7 (2CH), 129.1 (4CH), 128.7 (CH), 128.0 (CH), 123.4 (CH), 53.0 
(CH3), 21.7 (CH3); HRMS (ESI) m/z 343.0880  [M]+, C18H17NO4S requires 343.0878.  
Isopropyl (2Z,3E)-4-phenyl-2-(tosylimino)but-3-enoate (17o) 
Orange oil; 1H NMR (300 MHz, CDCl3) δ 7.90 (d, J = 8.4 Hz, 
2H), 7.64-7.29 (m, 6H), 7.34 (d, J = 8.4 Hz, 2H), 6.81 (d, J = 16.4 
Hz, 1H), 5.45 (hept, J = 6.3 Hz, 1H), 2.43 (s, 3H), 1.48 (d, J = 6.3 
Hz, 6H); 13C NMR (75 MHz, CDCl3) δ 167.8 (C), 164.0 (C), 
149.1 (C), 144.6 (C), 135.9 (C), 133.9 (2CH), 131.7 (CH), 129.7 (2CH), 129.1 (3CH), 
128.6 (CH), 128.0 (CH), 123.7 (CH), 71.58 (CH), 21.65 (CH3), 21.62 (CH3); HRMS 
(ESI) m/z 371.1196 [M]+, C20H21NO4S requires 371.1191. 
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5.3.2. General procedure for the non-catalyzed Mukaiyama-Michael reaction 
2-Methyl-1-methoxy-1-trimethylsilyoxyprop-1-ene (16, 122 µL, 0.6 mmol) was added 
to a solution of imine 17 (0.25 mmol) in CH2Cl2 (1.2 mL) at rt under nitrogen 
atmosphere and the mixture was stirred overnight until the reaction was complete (20-
24h). The reaction products 18 were isolated by column chromatography on silica gel 
eluting with hexane/EtOAc mixtures. 
5.3.2.1. Characterization of products (Z)-18 
See Table 9 (Page 81) for yield and dr. 
(Z)-1-Ethyl 6-methyl 5,5-dimethyl-2-(4-methylphenylsulfonamido)-4-phenylhex-2-
enedioate (Z)-18a 
Colourless oil; 1H NMR (300 MHz, CDCl3) δ 7.50 (d, J = 8.4 Hz, 
2H) 7.31 (d, J = 11.4 Hz, 1H overlapped), 7.30-7.27 (m, 3H), 
7.17-7.15 (m, 2H overlapped), 7.16 (d, J = 8.4 Hz, 2H), 6.20 (s, 
1H), 4.41 (d, J = 11.4 Hz, 1H), 3.96 (2 overlapped q, J = 7.2 Hz, 
2H), 3.65 (s, 3H), 2.36 (s, 3H), 1.18 (s, 3H), 1.17 (s, 3H), 1.09 (t, J 
= 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 176.9 (C), 164.2 (C), 143.7 (C), 140.5 (C), 
138.1 (C), 136.0 (C), 129.5 (CH), 129.3 (CH), 128.1 (CH), 127.6 (CH), 127.2 (CH), 
125.9 (C), 61.8 (CH2), 51.9 (CH3), 50.5 (C), 47.1 (CH), 23.9 (CH3), 22.4 (CH3), 21.5 
(CH3), 13.9 (CH3); HRMS (ESI) m/z 458.1641 [M-H]-, C24H28NO6S requires 458.1643.  
(Z)-1-Ethyl 6-methyl 5,5-dimethyl-2-(4-methylphenylsulfonamido)-4-(p-tolyl)hex-2-
enedioate (Z)-18b 
Pale yellow oil; 1H NMR (300 MHz, CDCl3) δ 7.51 (d, J = 8.1 
Hz, 2H), 7.29 (d, J = 11.1 Hz, 1H), 7.16 (d, J = 8.4 Hz, 2H), 
7.10 (d, J = 8.1 Hz, 2H), 7.03 (d, J = 8.1 Hz, 2H), 6.14 (s, 1H), 
4.35 (d, J = 11.4 Hz, 1H), 3.96 (2 overlapped q, J = 7.2 Hz, 2H), 
3.64 (s, 3H), 2.36 (s, 3H), 2.33 (s, 3H), 1.16 (s, 6H), 1.08 (t, J = 
7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 177.0 (C), 164.2 (C), 143.7 (C), 140.9 (C), 
136.8 (C), 136.1 (C), 135.0 (C), 129.3 (CH), 128.8 (CH), 127.6 (CH), 125.8 (CH), 61.7 
(CH2), 51.8 (CH3), 50.1 (C), 47.1 (CH), 23.8 (CH3), 22.4 (CH3), 21.5 (CH3), 21.1 
(CH3), 13.9 (CH3); HRMS (ESI) m/z 472.1782 [M-H]-, C25H30NO6S requires 472.1799. 
(Z)-1-Ethyl 6-methyl 4-(4-chlorophenyl)-5,5-dimethyl-2-(4-
methylphenylsulfonamido)hex-2-enedioate (Z)-18c 
Pale yellow oil; 1H NMR (300 MHz, CDCl3) δ 7.47 (d, J = 8.4 
Hz, 2H), 7.27 (d, J = 8.4 Hz, 2H), 7.26 (d, J = 11.4 Hz, 1H), 
7.15 (d, J = 8.4 Hz, 2H), 7.13 (d, J = 8.4 Hz, 2H), 6.28 (s, 1H), 
4.46 (d, J = 11.4 Hz, 1H), 3.84 (m, 2H), 3.63 (s, 3H), 2.35 (s, 
3H), 1.17 (s, 6H), 1.06 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz, 
CDCl3) δ 176.5 (C), 163.9 (C), 143.8 (C), 139.9 (C), 136.7 (C), 135.7 (CH), 132.9 (C), 
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130.7 (CH), 129.3 (CH), 128.1 (CH), 127.5 (CH), 126.1 (C), 61.8 (CH2), 51.8 (CH3), 
49.8 (CH), 47.0 (C), 23.5 (CH3), 22.5 (CH3), 21.4 (CH3), 13.8 (CH3); HRMS (ESI) m/z 
492.1255 [M-H]-, C24H27ClNO6S requires 492.1253.  
(Z)-1-Ethyl 6-methyl 5,5-dimethyl-2-(4-methylphenylsulfonamido)-4-(4-
nitrophenyl)hex-2-enedioate (Z)-18d 
Pale yellow oil; 1H NMR (300 MHz, CDCl3) δ 8.18 (d, J = 
9.0 Hz, 2H), 7.45-7.40 (m, 4H), 7.31 (d, J =11.4 Hz, 1H), 
7.17 (d, J = 8.4 Hz, 2H), 6.16 (s, 1H), 4.69 (d, J = 11.4 Hz, 
1H), 3.93 (m, 2H), 3.65 (s, 3H), 2.36 (s, 3H), 1.21 (s, 3H), 
1.20 (s, 3H), 1.05 (t, J = 6.9 Hz, 3H); 13C NMR (75 MHz, 
CDCl3) δ 176.0 (C), 163.4 (C), 147.0 (C), 146.1 (C), 144.1 (C), 139.1 (CH), 135.5 (C), 
130.4 (CH), 129.4 (CH), 127.5 (CH), 126.8 (C), 123.2 (CH), 62.1 (CH2), 52.0 (CH3), 
50.6 (CH), 47.3 (C), 23.5 (CH3), 23.0 (CH3), 21.5 (CH3), 13.8 (CH3); HRMS (ESI) m/z 
503.1489 [M-H]-, C24H27N2O8S requires 503.1494. 
(Z)-1-Ethyl 6-methyl 4-(4-methoxyphenyl)-5,5-dimethyl-2-(4-
methylphenylsulfonamido)hex-2-enedioate (Z)-18e 
Yellow oil; 1H NMR (300 MHz, CDCl3) δ 7.51 (d, J = 8.1 
Hz, 2H), 7.27 (d, J = 11.4 Hz, 1H), 7.17 (d, J = 8.1 Hz, 2H), 
7.09 (d, J = 8.7 Hz, 2H), 6.83 (d, J = 8.7 Hz, 2H), 6.18 (s, 
1H), 4.35 (d, J = 11.4 Hz, 1H), 3.96 (2 overlapped q, J = 7.2 
Hz, 2H), 3.80 (s, 3H), 3.64 (s, 3H), 2.37 (s, 3H), 1.16 (s, 6H), 
1.08 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 177.1 (C), 164.2 (C), 158.6 (C), 
143.7 (C), 140.8 (C), 136.0 (C), 130.4 (CH), 130.1(C), 129.3 (CH), 127.6 (CH), 125.6 
(CH), 113.5 (CH), 61.7 (CH2), 55.1 (CH3), 51.9 (CH3), 49.7 (C), 47.2 (CH), 23.7 (CH3), 
22.4 (CH3), 21.5 (CH3), 13.9 (CH3); HRMS (ESI) m/z 488.1747 [M-H]-, C25H30NO7S 
requires 488.1748.  
(Z)-1-Ethyl 6-methyl 4-(3-chlorophenyl)-5,5-dimethyl-2-(4-
methylphenylsulfonamido)hex-2-enedioate (Z)-18f 
White oil; 1H NMR (300 MHz, CDCl3) δ 7.47 (d, J = 8.1 Hz, 2H), 
7.23 (d, J = 11.4 Hz, 1H), 7.22-7.03 (m, 4H), 7.16 (d, J = 8.4 Hz, 
2H), 6.30 (s, 1H), 4.41 (d, J = 11.4 Hz, 1H), 3.95 (2 overlapped q, 
J = 7.2 Hz, 2H), 3.62 (s, 3H), 2.35 (s, 3H), 1.16 (s, 6H), 1.07 (t, J 
= 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 176.5 (C), 163.9 (C), 
143.8 (C), 140.2 (C), 139.4 (C), 135.8 (CH), 133.7 (C), 129.3 
(CH), 129.18 (CH), 129.15 (CH), 127.8 (CH), 127.5 (CH), 127.3 (CH), 126.4 (CH), 
125.2 (C), 61.9 (CH2), 51.9 (CH3), 50.1 (CH), 47.1 (C), 23.5 (CH3), 22.5 (CH3), 21.4 
(CH3), 13.8 (CH3); HRMS (ESI) m/z 492.1255 [M-H]-, C24H27ClNO6S requires 
492.1253.  
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(Z)-1-Ethyl 6-methyl 5,5-dimethyl-2-(4-methylphenylsulfonamido)-4-(3-
nitrophenyl)hex-2-enedioate (Z)-18g 
Yellow oil; 1H NMR (300 MHz, CDCl3) δ 8.13 (ddd, J = 8.1, 2.4, 
1.2 Hz, 1H), 8.03 (t, J = 2.1 Hz, 1H), 7.61 (dt, J = 7.8, 1.2 Hz, 
1H), 7.49 (t, J = 8.1 Hz, 1H), 7.43 (d, J = 8.4 Hz, 2H), 7.29 (d, J = 
11.4 Hz, 1H), 7.16 (d, J = 8.4 Hz, 2H), 6.21 (s, 1H), 4.65 (d, J = 
11.4 Hz, 1H), 4.10-3.93 (m, 2H), 3.65 (s, 3H), 2.35 (s, 3H), 1.21 
(s, 3H), 1.20 (s, 3H), 1.07 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz, 
CDCl3) δ 176.0 (C), 163.6 (C), 147.9 (C), 144.1 (C), 140.5 (C), 138.8 (CH), 136.3 
(CH), 135.6 (C), 129.4 (CH), 128.9 (CH), 127.4 (CH), 126.9 (C), 123.6 (CH), 122.2 
(CH), 62.1 (CH2), 52.0 (CH3), 50.3 (CH), 47.2 (C), 23.2 (CH3), 23.0 (CH3), 21.4 (CH3), 
13.8 (CH3); HRMS (ESI) m/z 503.1497 [M-H]-, C24H27N2O8S requires 503.1494.  
(Z)-1-Ethyl 6-methyl 4-(3-methoxyphenyl)-5,5-dimethyl-2-(4-
methylphenylsulfonamido)hex-2-enedioate (Z)-18h 
Yellow oil; 1H NMR (300 MHz, CDCl3) δ 7.52 (d, J = 8.4 Hz, 
2H), 7.27 (d, J = 11.1 Hz, 1H), 7.24-7.16 (m, 3H), 6.85-6.70 (m, 
3H), 6.18 (s, 1H), 4.37 (d, J = 11.1 Hz, 1H),  3.97 (2 overlapped q, 
J = 7.2 Hz, 2H), 3.80 (s, 3H), 3.65 (s, 3H), 2.36 (s, 3H), 1.18 (s, 
3H), 1.17 (s, 3H), 1.08 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz, 
CDCl3) δ 176.9 (C), 164.2 (C), 159.2 (C), 143.8 (C), 140.5 (CH), 
139.6 (C), 136.0 (C), 129.3 (CH), 128.9 (CH), 127.6 (CH), 126.0 (C), 121.8 (CH), 
115.8 (CH), 112.2 (CH), 61.8 (CH2), 55.1 (CH3), 51.9 (CH3), 50.5 (CH3), 47.1 (C), 23.9 
(CH3), 22.5 (CH3), 21.5 (CH3), 13.9 (CH3); HRMS (ESI) m/z 488.1746 [M-H]-, 
C25H30NO7S requires 488.1748. 
(Z)-1-Ethyl 6-methyl 4-(2-chlorophenyl)-5,5-dimethyl-2-(4-
methylphenylsulfonamido)hex-2-enedioate (Z)-18i 
Yellow oil; 1H NMR (300 MHz, CDCl3) δ 7.62 (d, J = 8.4 Hz, 
2H), 7.38-7.35 (m, 1H), 7.35 (d, J = 10.5 Hz, 1H), 7.19 (d, J = 8.4 
Hz, 2H), 7.17-7.09 (m, 3H), 6.11 (s, 1H), 5.03 (d, J = 10.5 Hz, 
1H), 3.95 (2 overlapped q, J = 7.2 Hz, 2H), 3.66 (s, 3H), 2.36 (s, 
3H), 1.26 (s, 3H), 1.22 (s, 3H), 1.01 (t, J = 7.2 Hz, 3H); 13C NMR 
(75 MHz, CDCl3) δ 176.7 (C), 164.1 (C), 143.6 (C), 140.0 (CH), 136.7 (C), 136.6 (C), 
135.2 (C), 130.1 (CH), 129.9 (CH), 129.3 (CH), 128.2 (CH), 127.4 (CH), 126.7 (C), 
126.4 (CH), 61.7 (CH2), 52.0 (CH3), 47.4 (CH), 45.4 (C), 24.5 (CH3), 22.0 (CH3), 21.4 
(CH3), 13.8 (CH3); HRMS (ESI) m/z 492.1255 [M-H]-, C24H27ClNO6S requires 
492.1253. 
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(Z)-1-Ethyl 6-methyl 5,5-dimethyl-2-(4-methylphenylsulfonamido)-4-(2-
nitrophenyl)hex-2-enedioate (Z)-18j 
Yellow oil; 1H NMR (300 MHz, CDCl3) δ 7.77 (dd, J = 8.1, 1.5 
Hz, 1H), 7.67 (d, J = 8.4 Hz, 2H), 7.51 (td, J = 7.8, 1.5 Hz, 1H), 
7.38 (td, J = 7.8, 1.5 Hz, 1H), 7.31 (dd, J = 7.8, 1.2 Hz, 1H), 7.21 
(d, J = 8.4 Hz, 2H), 7.03 (d, J = 10.2 Hz, 1H), 6.65 (s, 1H), 4.93 
(d, J = 10.2 Hz, 1H), 4.06 (q, J = 7.2 Hz, 2H), 3.59 (s, 3H), 2.36 
(s, 3H), 1.18 (s, 3H), 1.15 (t, J = 7.2 Hz, 3H), 1.08 (s, 3H); 13C NMR (75 MHz, CDCl3) 
δ 175.9 (C), 164.01 (C), 150.6 (C), 143.7 (C), 136.9 (C), 134.0 (CH), 133.0 (C), 132.1 
(CH), 130.6 (CH), 129.3 (CH), 129.1 (C), 128.1 (CH), 127.4 (CH), 124.9 (C), 61.8 
(CH2), 52.1 (CH3), 47.0 (CH), 42.8 (C), 23.3 (CH3), 23.2 (CH3), 21.5 (CH3), 13.8 
(CH3); HRMS (ESI) m/z 503.1496 [M-H]-, C24H27N2O8S requires 503.1494.   
(Z)-1-Ethyl 6-methyl 4-(2-methoxyphenyl)-5,5-dimethyl-2-(4-
methylphenylsulfonamido)hex-2-enedioate (Z)-18k 
Yellow oil; 1H NMR (300 MHz, CDCl3) δ 7.60 (d, J = 8.4 Hz, 
2H), 7.34 (d, J = 10.8 Hz, 1H), 7.22-7.17 (m, 3H), 7.04 (dd, J = 
7.8, 1.8 Hz, 1H), 6.86 (2 overlapped t, J = 8.1 Hz, 2H), 6.19 (s, 
1H), 4.69 (d, J = 10.8 Hz, 1H), 4.00 (q, J = 6.9 Hz, 2H), 3.82 (s, 
3H), 3.64 (s, 3H), 2.37 (s, 3H), 1.15 (s, 3H), 1.13 (s, 3H), 1.09 (t, J 
= 6.9 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 177.2 (C), 164.4 (C), 157.4 (C), 143.4 (C), 
140.2 (CH), 136.8 (CH), 130.0 (C), 129.2 (CH), 128.2 (C), 127.5 (CH), 127.0 (CH), 
126.1 (C), 120.3 (CH), 111.1 (CH), 61.5 (CH2), 55.6 (CH3), 51.8 (CH3), 46.7 (C), 43.5 
(CH), 24.6 (CH3), 22.3 (CH3), 21.5 (CH3), 13.9 (CH3); HRMS (ESI) m/z 488.1752 [M-
H]-, C25H30NO7S requires 488.1748.  
(Z)-1-Ethyl 6-methyl 4-(furan-2-yl)-5,5-dimethyl-2-(4-
methylphenylsulfonamido)hex-2-enedioate (Z)-18l 
Yellow oil; 1H NMR (300 MHz, CDCl3) δ 7.56 (d, J = 8.4 Hz, 
2H), 7.33 (dd, J = 1.8, 0.9 Hz, 1H), 7.18 (d, J = 8.7 Hz, 2H), 7.04 
(d, J = 11.4 Hz, 1H), 6.40 (s, 1H), 6.30 (dd, J = 3.3, 1.8 Hz, 1H), 
6.12 (dt, J = 3.3, 0.6 Hz, 1H), 4.56 (d, J = 11.4 Hz, 1H), 4.02-3.90 
(m, 2H), 3.66 (s, 3H), 2.36 (s, 3H), 1.19 (s, 3H), 1.15 (s, 3H), 1.08 
(t, J = 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 176.8 (C), 164.0 (C), 151.6 (C), 143.8 
(C), 141.7 (CH), 137.1 (CH), 136.0 (C), 129.3 (CH), 127.5 (CH), 126.4 (C), 110.1 
(CH), 108.3 (CH), 61.8 (CH2), 52.1 (CH3), 46.9 (CH), 44.5 (C), 23.5 (CH3), 22.3 (CH3), 
21.4 (CH3), 13.8 (CH3); HRMS (ESI) m/z 448.1437 [M-H]-, C22H26NO7S requires 
448.1435. 
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(Z)-Dimethyl 5,5-dimethyl-2-(4-methylphenylsulfonamido)-4-phenylhex-2-
enedioate (Z)-18n 
Yellow oil; 1H NMR (300 MHz, CDCl3) δ 7.50 (d, J = 8.4 Hz, 
2H), 7.30 (d, J = 11.1 Hz, 1H overlapped), 7.30-7.25 (m, 3H), 
7.17-7.11 (m, 4H), 6.23 (s, 1H), 4.35 (d, J = 11.1 Hz, 1H), 3.64 
(s, 3H), 3.52 (s, 3H), 2.37 (s, 3H), 1.17 (s, 3H), 1.15 (s, 3H); 13C 
NMR (75 MHz, CDCl3) δ  177.0 (C), 164.7 (C), 143.7 (C), 140.6 
(CH), 137.9 (C), 136.0 (C), 129.5 (CH), 129.3 (CH), 128.1 (CH), 127.5 (CH), 127.2 
(CH), 125.8 (C), 52.5 (CH3), 51.9 (CH3), 50.4 (C), 47.1 (CH), 24.0 (CH3), 22.2 (CH3), 
21.5 (CH3); HRMS (ESI) m/z 444.1492 [M-H]-, C23H26NO6S requires 444.1486.  
(Z)-1-Isopropyl 6-methyl 5,5-dimethyl-2-(4-methylphenylsulfonamido)-4-
phenylhex-2-enedioate (Z)-18o 
Yellow oil; 1H NMR (300 MHz, CDCl3) δ 7.49 (d, J = 8.4 Hz, 
2H), 7.31-7.26 (m, 3H), 7.29 (d, J = 11.4 Hz, 1H overlapped), 
7.19-7.14 (m, 4H), 6.24 (s, 1H), 4.79 (hept, J = 6.3 Hz, 1H), 4.45 
(d, J = 11.4 Hz, 1H), 3.65 (s, 3H), 2.36 (s, 3H), 1.19 (s, 6H), 
1.11(d, J = 6.3 Hz, 3H), 1.04 (d, J = 6.3 Hz, 3H); 13C NMR (75 
MHz, CDCl3) δ 176.8 (C), 163.7 (C), 143.7 (C), 140.1 (C), 138.2 (C), 135.9 (C), 129.4 
(CH), 129.3 (CH), 128.0 (CH), 127.6 (CH), 127.1 (CH), 126.1 (C), 69.7 (CH), 51.8 
(CH3), 50.4 (C), 47.1 (CH), 23.7 (CH3), 22.5 (CH3), 21.4 (CH3), 21.3 (CH3); HRMS 
(ESI) m/z 472.1784 [M-H]-, C25H30NO6S requires 472.1799.  
5.3.3. General procedure for the copper-catalyzed Mukaiyama-Michael reaction 
A solution of imine 17 (0.25 mmol) in dry CH2Cl2 (1 mL) was added to a suspension of 
anhydrous Cu(OTf)2 (9 mg, 0.025 mmol) in dry CH2Cl2 (0.9 mL) contained in a 
Schlenck tube under nitrogen at rt, followed by 2-methyl-1-methoxy-1-
trimethylsilyoxyprop-1-ene (16, 122 µL, 0.6 mmol). The mixture was stirred until the 
reaction was complete (30-90 min). The reaction products (E)-18 were isolated by 
column chromatography on silica gel eluting with hexane/EtOAc mixtures. 
5.3.3.1. Characterization of products (E)-18 
See Table 10 (Page 82) for yield and dr. 
(E)-1-Ethyl 6-methyl 5,5-dimethyl-2-(4-methylphenylsulfonamido)-4-phenylhex-2-
enedioate (E)-18a 
Colourless oil; 1H NMR (300 MHz, CDCl3) δ 7.52 (d, J = 8.1 Hz, 
2H), 7.29-7.22 (m, 3H), 7.14-7.09 (m, 4H), 7.01 (d, J = 11.4 Hz, 
1H), 6.61 (s, 1H), 4.81 (d, J = 11.4 Hz, 1H), 4.00 (q, J = 6.9 Hz, 
2H), 3.59 (s, 3H), 2.36 (s, 3H), 1.173 (s, 3H), 1.168 (s, 3H), 1.12 
(t, J = 6.9 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 176.2 (C), 
162.9 (C), 143.8 (C), 139.7 (C), 136.3 (C), 135.9 (C), 129.4 (CH), 129.3 (CH), 128.0 
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(CH), 127.5 (CH), 127.0 (CH), 124.8 (C), 61.8 (CH2), 51.7 (CH3), 50.4 (C), 46.8 (CH), 
23.1 (CH3), 22.3 (CH3), 21.4 (CH3), 13.9 (CH3); HRMS (ESI) m/z 458.1644 [M-H]-, 
C24H28NO6S requires 458.1643.  
(E)-1-Ethyl 6-methyl 5,5-dimethyl-2-(4-methylphenylsulfonamido)-4-(p-tolyl)hex-
2-enedioate (E)-18b 
Pale yellow oil; 1H NMR (300 MHz, CDCl3) δ 7.53 (d, J = 8.4 
Hz, 2H), 7.13 (d, J = 8.4 Hz, 2H), 7.06 (d, J = 8.1 Hz, 2H), 
6.974 (d, J = 11.4 Hz, 1H), 6.972 (d, J =  8.1 Hz, 2H), 6.58 (br 
s, 1H), 4.77 (d, J = 11.4 Hz, 1H), 4.00 (2 overlapped q, J = 7.2 
Hz, 2H), 3.59 (s, 3H), 2.36 (s, 3H), 2.31 (s, 3H), 1.15 (s, 6H), 
1.12 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 176.8 (C), 163.0 (C), 143.7 (C), 
136.54 (C), 136.51 (C), 129.4 (CH), 129.1 (CH), 128.7 (CH), 127.5 (CH), 124.6 (CH), 
124.5 (CH), 61.8 (CH2), 51.6 (CH3), 50.0 (C), 46.8 (CH), 23.2 (CH3), 22.3 (CH3), 21.5 
(CH3), 21.0 (CH3), 13.9 (CH3); HRMS (ESI) m/z 472.1782 [M-H]-, C25H30NO6S 
requires 472.1799. 
(E)-1-Ethyl 6-methyl 4-(4-chlorophenyl)-5,5-dimethyl-2-(4-
methylphenylsulfonamido)hex-2-enedioate (E)-18c 
Colourless oil; 1H NMR (300 MHz, CDCl3) δ 7.52 (d, J = 8.4 
Hz, 2H), 7.23 (d, J = 8.7 Hz, 2H), 7.15 (d, J = 8.7 Hz, 2H), 
7.02 (d, J = 8.4 Hz, 2H), 6.91 (d, J = 11.4 Hz, 1H), 6.62 (s, 
1H), 4.77 (d, J = 11.4 Hz, 1H), 4.00 (q, J = 7.2 Hz, 2H), 3.59 
(s, 3H), 2.37 (s, 3H), 1.14 (s, 6H), 1.11 (t, J = 7.2 Hz, 3H); 13C 
NMR (75 MHz, CDCl3) δ 176.5 (C), 162.6 (C), 144.0 (C), 138.4 (C), 135.9 (C), 135.3 
(CH), 132.8 (C), 130.6 (CH), 129.5 (CH), 128.2 (CH), 127.4 (CH), 125.2 (C), 61.9 
(CH2), 51.8 (CH3), 49.7 (CH), 46.7 (C), 23.2 (CH3), 22.1 (CH3), 21.5 (CH3), 13.9 
(CH3); HRMS (ESI) m/z 492.1257 [M-H]-, C24H27ClNO6S requires 492.1253. 
(E)-1-Ethyl 6-methyl 5,5-dimethyl-2-(4-methylphenylsulfonamido)-4-(4-
nitrophenyl)hex-2-enedioate (E)-18d 
Pale yellow oil; 1H NMR (300 MHz, CDCl3) δ 8.09 (d, J = 
8.4 Hz, 2H), 7.57 (d, J = 8.4 Hz, 2H), 7.24 (d, J = 8.4 Hz. 
2H), 7.18 (d, J = 8.4 Hz, 2H), 6.90 (d, J = 10.8 Hz, 1H), 6.71 
(s, 1H), 4.88 (d, J = 10.8 Hz, 1H), 4.00 (q, J = 7.2 Hz, 2H), 
3.60 (s, 3H), 2.37 (s, 3H), 1.16 (s, 3H), 1.15 (s, 3H), 1.10 (t, J 
= 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 176.1 (C), 162.2 (C), 147.7 (C), 146.7 (C), 
144.2 (C), 135.9 (C), 133.3 (CH), 130.1 (CH), 129.6 (CH), 127.4 (CH), 126.0 (C), 
123.0 (CH), 62.1 (CH2), 52.0 (CH3), 50.1 (CH), 46.8 (C), 23.4 (CH3), 22.1 (CH3), 21.5 
(CH3), 13.9 (CH3); HRMS (ESI) m/z 503.1491 [M-H]-, C24H27N2O8S requires 503.1494. 
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(E)-1-Ethyl 6-methyl 4-(4-methoxyphenyl)-5,5-dimethyl-2-(4-
methylphenylsulfonamido)hex-2-enedioate (E)-18e 
Yellow oil; 1H NMR (300 MHz, CDCl3) δ 7.52 (d, J = 8.4 
Hz, 2H), 7.13 (d, J = 8.4 Hz, 2H), 7.02 (d, J = 8.7 Hz, 2H), 
6.96 (d, J = 11.4 Hz, 1H), 6.80 (d, J = 8.7 Hz, 2H), 6.58 (s, 
1H), 4.76 (d, J = 11.4 Hz, 1H), 3.99 (q, J = 7.2 Hz, 2H), 3.78 
(s, 3H), 2.35 (s, 3H), 1.14 (s, 6H), 1.11 (t, J = 7.2 Hz, 3H); 
13C NMR (75 MHz, CDCl3) δ 176.8 (C), 162.9 (C), 158.5 (C), 143.8 (C), 136.8 (C), 
136.0 (C), 131.7 (C), 130.2 (CH), 129.4 (CH), 127.5 (CH), 124.5 (CH), 113.4 (CH), 
61.8 (CH2), 55.2 (CH3), 51.7 (CH3), 49.6 (C), 46.8 (CH), 23.1 (CH3), 22.2 (CH3), 21.5 
(CH3), 13.9 (CH3); HRMS (ESI) m/z 488.1741 [M-H]-, C25H30NO7S requires 488.1748. 
(E)-1-Ethyl 6-methyl 4-(3-chlorophenyl)-5,5-dimethyl-2-(4-
methylphenylsulfonamido)hex-2-enedioate (E)-18f 
White oil; 1H NMR (300 MHz, CDCl3) δ 7.56 (d, J = 8.4 Hz, 
2H), 7.20-7.19 (m, 2H), 7.17 (d, J = 8.4 Hz, 2H), 7.04 (t, J = 0.9 
Hz, 1H), 6.98 (m, 1H), 6.89 (d, J = 11.1 Hz, 1H), 6.67 (s, 1H), 
4.75 (d, J = 11.1 Hz, 1H), 4.02 (q, J = 7.2 Hz, 2H), 3.60 (s, 3H), 
2.36 (s, 3H), 1.16 (s, 3H), 1.15 (s, 3H), 1.12 (t, J = 7.2 Hz, 3H); 
13C NMR (75 MHz, CDCl3) δ 176.4 (C), 162.7 (C), 144.0 (C), 
141.9 (C), 135.9 (C), 134.4 (CH), 133.8 (C), 129.5 (CH), 129.4 (CH), 129.2 
(CH),127.44 (CH), 127.38 (CH), 127.1 (CH), 125.4 (C), 62.0 (CH2), 51.8 (CH3), 50.0 
(CH), 46.8 (C), 23.3 (CH3), 22.1 (CH3), 21.5 (CH3), 13.9 (CH3); HRMS (ESI) m/z 
492.1255 [M-H]-, C24H27ClNO6S requires 492.1253. 
(E)-1-Ethyl 6-methyl 5,5-dimethyl-2-(4-methylphenylsulfonamido)-4-(3-
nitrophenyl)hex-2-enedioate (E)-18g 
Pale yellow oil; 1H NMR (300 MHz, CDCl3)  δ 8.09-8.05 (m, 
1H), 7.91 (t, J = 1.4 Hz, 1H), 7.59 (d, J = 8.4 Hz, 2H) 7.44-7.42 
(m, 2H), 7.18 (d, J = 8.4 Hz, 2H), 6.89 (d, J = 10.8 Hz, 1H), 6.74 
(s, 1H), 4.88 (d, J = 10.8 Hz, 1H), 4.03 (q, J = 6.9 Hz, 2H), 3.62 
(s, 3H), 2.36 (s, 3H), 1.16 (s, 6H), 1.12 (t, J = 6.9 Hz, 3H); 13C 
NMR (75 MHz, CDCl3) δ 176.1 (C), 162.3 (C), 147.8 (C), 144.2 
(C), 142.2 (C), 135.9 (C), 135.3 (CH), 132.8 (CH), 129.6 (CH), 128.8 (CH), 127.3 
(CH), 126.1 (C), 124.0 (C), 122.0 (CH), 62.2 (CH2), 52.0 (CH3), 50.0 (CH), 46.8 (C), 
23.5 (CH3), 21.9 (CH3), 21.4 (CH3), 13.9 (CH3). HRMS (ESI) m/z 503.1495 [M-H]-, 
C24H27N2O8S requires 503.1494. 
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(E)-1-Ethyl 6-methyl 4-(3-methoxyphenyl)-5,5-dimethyl-2-(4-
methylphenylsulfonamido)hex-2-enedioate (E)-18h 
Yellow oil; 1H NMR (300 MHz, CDCl3) δ 7.52 (d, J = 8.4 Hz, 
2H), 7.17 (t, J = 8.1 Hz, 1H), 7.12 (d, J = 8.7 Hz, 2H), 6.97 (d, J 
= 11.4 Hz, 1H), 6.77 (ddd, J = 8.1, 2.7, 0.9 Hz, 1H),  6.67 (d, J = 
8.1 Hz, 1H), 6.66 (s, 1H overlapped),  6.59 (s, 1H), 4.79 (d, J = 
11.4 Hz, 1H), 4.00 (q, J = 7.2 Hz, 2H), 3.78 (s, 3H), 3.60 (s, 3H), 
2.35 (s, 3H), 1.167 (s, 3H), 1.165 (s, 3H), 1.12 (t, J = 7.2 Hz, 3H); 
13C NMR (75 MHz, CDCl3) δ 176.9 (C), 164.1 (C), 159.2 (C), 143.8 (C), 140.5 (C), 
139.6 (CH), 136.0 (C), 129.3 (CH), 128.9 (CH), 127.6 (CH), 126.0 (C), 121.8 (CH), 
115.8 (CH), 112.2 (CH), 61.8 (CH2), 55.1 (CH3), 51.9 (CH3), 50.5 (CH3), 47.1 (C), 23.9 
(CH3), 22.5 (CH3), 21.5 (CH3), 13.9 (CH3); HRMS (ESI) m/z 488.1749 [M-H]-, 
C25H30NO7S requires 488.1748. 
(E)-1-Ethyl 6-methyl 4-(2-chlorophenyl)-5,5-dimethyl-2-(4-
methylphenylsulfonamido)hex-2-enedioate (E)-18i 
Pale yellow oil; 1H NMR (300 MHz, CDCl3) δ 7.48 (d, J = 8.4 
Hz, 2H), 7.35 (dd, J = 8.5, 1.5 Hz, 1H), 7.23-7.14 (m, 3H), 7.11 
(d, J = 8.7 Hz, 2H), 6.93 (d, J = 11.4 Hz, 1H), 6.65 (s, 1H), 5.35 
(d, J = 11.4 Hz, 1H), 4.10 (q, J = 7.2 Hz, 2H), 3.62 (s, 3H), 2.35 
(s, 3H), 1.22 (s, 3H), 1.20 (s, 3H), 1.10 (t, J = 7.2 Hz, 3H); 13C 
NMR (75 MHz, CDCl3) δ 176.3 (C), 163.2 (C), 143.8 (C), 137.7 (C), 135.8 (C), 134.8 
(CH), 134.7 (C), 130.4 (CH), 129.8 (CH), 129.4 (CH), 128.1 (CH), 127.5 (CH), 126.5 
(CH), 125.2 (C), 62.2 (CH2), 51.9 (CH3), 47.4 (CH), 45.4 (C), 24.0 (CH3), 22.3 (CH3), 
21.5 (CH3), 13.9 (CH3); HRMS (ESI) m/z 492.1258 [M-H]-, C24H27ClNO6S requires 
492.1253. 
(E)-1-Ethyl 6-methyl 5,5-dimethyl-2-(4-methylphenylsulfonamido)-4-(2-
nitrophenyl)hex-2-enedioate (E)-18j 
Yellow oil; 1H NMR (300 MHz, CDCl3) δ 7.74 (dd, J = 7.8 Hz, 
1H), 7.56-7.53 (m, 1H), 7.46-7.31 (m, 3H), 7.44 (d, J = 8.4 Hz, 
2H),  7.10 (d, J = 8.4 Hz, 2H), 6.88 (d, J = 11.4 Hz, 1H), 6.69 (s, 
1H), 5.42 (d, J = 11.4 Hz, 1H), 4.11 (2 overlapped q, J = 7.2 Hz, 
2H), 3.60 (s, 3H), 2.34 (s, 3H), 1.24 (s, 3H), 1.18 (s, 3H), 1.13 (t, 
J = 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 175.9 (C), 163.0 (C), 150.5 (C), 144.0 
(C), 135.6 (C), 134.0 (C), 132.6 (CH), 132.0 (CH), 130.4 (CH), 129.5 (CH), 127.8 
(CH), 127.4 (CH), 126.0 (C), 124.5 (CH), 62.5 (CH2), 52.0 (CH3), 47.3 (CH), 42.9 (C), 
23.6 (CH3), 23.3 (CH3), 21.5 (CH3), 13.8 (CH3); HRMS (ESI) m/z 503.1496 [M-H]-, 
C24H27N2O8S requires 503.1494. 
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(E)-1-Ethyl 6-methyl 4-(2-methoxyphenyl)-5,5-dimethyl-2-(4-
methylphenylsulfonamido)hex-2-enedioate (E)-18k 
Yellow oil; 1H NMR (300 MHz, CDCl3) δ 7.54 (d, J = 8.4 Hz, 
2H), 7.19 (td, J = 7.8, 1.8 Hz, 1H), 7.12 (d, J = 8.7 Hz, 2H), 7.06 
(d, J = 11.1 Hz, 1H), 7.04 (dd, J = 7.8, 1.8 Hz, 1H), 6.87 (t, J = 
7.8 Hz, 1H), 6.83 (d, J = 7.8 Hz, 1H), 6.57 (s, 1H), 5.18 (d, J = 
11.1 Hz, 1H), 4.00 (q, J = 7.2 Hz, 2H), 3.76 (s, 3H), 3.60 (s, 3H), 
2.34 (s, 3H), 1.14 (s, 6H), 1.08 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 176.8 
(C), 163.4 (C), 157.2 (C), 143.6 (C), 137.0 (CH), 136.0 (C), 130.4 (CH), 129.3 (CH), 
128.2 (C), 127.9 (CH), 127.5 (CH), 124.3 (C), 120.1 (CH), 110.5 (CH), 61.7 (CH2), 
55.1 (CH3), 51.6 (CH3), 46.8 (C), 43.7 (CH), 23.9 (CH3), 22.4 (CH3), 21.4 (CH3), 13.8 
(CH3); HRMS (ESI) m/z 488.1752 [M-H]-, C25H30NO7S requires 488.1748. 
(E)-1-Ethyl 6-methyl 4-(furan-2-yl)-5,5-dimethyl-2-(4-
methylphenylsulfonamido)hex-2-enedioate (E)-18l 
Yellow oil; 1H NMR (300 MHz, CDCl3) δ 7.62 (d J = 8.4 Hz, 
2H), 7.29 (d, J = 1.8 Hz, 1H), 7.21 (d, J = 8.4 Hz, 2H), 6.71 (s, 
1H overlapped), 6.69 (d, J = 11.4 Hz, 1H), 6.26 (dd, J = 3.3, 1.8 
Hz, 1H), 5.98 (d, J = 3.3 Hz, 1H), 5.04 (d, J = 11.4 Hz, 1H), 4.07 
(2 overlapped q, J = 7.2 Hz, 2H), 3.62 (s, 3H), 2.37 (s, 3H), 1.17 (t, J = 7.2 Hz, 3H), 
1.13 (s, 3H), 1.12 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 176.6 (C), 163.0 (C), 153.1 
(C), 143.9 (C), 141.5 (CH), 135.9 (C), 131.5 (CH), 129.5 (CH), 127.5 (CH), 125.7 (C), 
111.0 (CH), 107.2 (CH), 62.1 (CH2), 51.9 (CH3), 46.7 (CH), 44.4 (C), 23.3 (CH3), 21.7 
(CH3), 21.5 (CH3), 13.8 (CH3); HRMS (ESI) m/z 448.1437 [M-H]-, C22H26NO7S 
requires 448.1435. 
(E)-Dimethyl 5,5-dimethyl-2-(4-methylphenylsulfonamido)-4-phenylhex-2-
enedioate (E)-18n 
Pale yellow solid, mp 126-129 ºC (hexane-CH2Cl2); 1H NMR 
(300 MHz, CDCl3) δ 7.52 (d, J = 8.4 Hz, 2H), 7.26-7.21 (m, 3H), 
7.13 (d, J = 8.4 Hz, 2H), 7.07 (dd, J = 7.6, 2.4 Hz, 2H), 7.00 (d, J 
= 11.1 Hz, 1H), 6.57 (s, 1H), 4.72 (d, J = 11.1 Hz, 1H), 3.59 (s, 
3H), 3.52 (s, 3H),  2.37 (s, 3H), 1.17 (s, 3H), 1.16 (s, 3H); 13C 
NMR (75 MHz, CDCl3) δ 176.7 (C), 163.4 (C), 144.0 (C), 140.0 (CH), 136.8 (C), 136.0 
(C), 129.6 (CH), 129.4 (CH), 128.1 (CH), 127.7 (CH), 127.1 (CH), 124.8 (C), 52.4 
(CH3), 51.9 (CH3), 50.7 (C), 46.9 (CH), 23.1 (CH3), 22.7 (CH3), 21.6 (CH3); HRMS 
(ESI) m/z 444.1491 [M-H]-, C23H26NO6S requires 444.1486.  
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(E)-1-Isopropyl 6-methyl 5,5-dimethyl-2-(4-methylphenylsulfonamido)-4-
phenylhex-2-enedioate (E)-18o 
Yellow oil; 1H NMR (300 MHz, CDCl3) δ 7.49 (d, J = 8.4 Hz, 
2H), 7.31-7.23 (m, 3H), 7.14-7.08 (m, 4H), 6.98 (d, J = 11.7 Hz, 
1H), 6.60 (s, 1H), 4.89-4.83 (m, 2H), 3.59 (s, 3H), 2.34 (s, 3H), 
1.17 (s, 6H), 1.15 (d, J = 6.3 Hz, 3H), 1.04 (d, J = 6.3 Hz, 3H); 
13C NMR (75 MHz, CDCl3) δ 176.7 (C), 162.6 (C), 143.7 (C), 
139.6 (C), 136.0 (C), 135.9 (C), 129.4 (CH), 129.3 (CH), 128.0 (CH), 127.5 (CH), 
127.0 (CH), 125.0 (C), 70.1 (CH), 51.7 (CH3), 50.2 (C), 46.8 (CH), 23.3 (CH3), 22.1 
(CH3), 21.6 (CH3), 21.43 (CH3), 21.41 (CH3); HRMS (ESI) m/z 472.1780 [M-H]-, 
C25H30NO6S requires 472.1799. 
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5.4. Enantioselective conjugate addition of malonate esters to N-tosyl 
imines derived from β,γ-unsaturated α-keto esters 
5.4.1. General procedure for the enantioselective conjugate addition of 
diethylmalonate to α,β-usaturated N-tosyl imino esters catalyzed by La(OTf)3. 
5.4.1.1. General procedure for the enantioselective conjugate addition 
La(OTf)3 (14.7 mg, 0.025 mmol) was dried in a Schlenk tube under vacuum. pyBOX1 
(9.24 mg, 0.025 mmol) was added and the tube was filled with nitrogen. CH2Cl2 (1.1 
mL) was added via syringe and the mixture was stirred for 30 min. A solution of imine 
17 (0.25 mmol) dissolved in dry CH2Cl2 (1.1 mL), was added via syringe, followed by 4 
Å MS (110 mg) and diethyl malonate (92 µL, 0.63 mmol). The mixture was stirred at 
room temperature for the indicated time and chromatographed on silica gel eluting with 
hexane/EtOAc mixtures to give compound 19. 
5.4.1.2. General procedure for the synthesis of the racemic products 
Racemic compounds for comparative purpose were prepared by following the same 
procedure, using La(OTf)3-pyBOX (rac) at 40 °C. 
5.4.1.3. Characterization of products 19 and 20 
See Table 14 (Page 90) and Table 15 (Page 91) for yield, dr and ee. 
(S,Z)-Triethyl 4-(4-methylphenylsulfonamido)-2-phenylbut-3-ene-1,1,4-
tricarboxylate (19ba) 
Chiral HPLC analysis: Lux Amylose-1, hexane-iPrOH 80:20, 1 
mL/min, E-isomer: major enantiomer tr = 25.8 min, minor 
enantiomer tr = 18.6 min. Z-isomer: major enantiomer tr = 46.8 
min, minor enantiomer tr = 23.8 min. 
Colorless oil; [α]D20 21.5 (c 1.0, CHCl3, ee = 91 % for the major diastereomer) 1H 
NMR (300 MHz, CDCl3) δ 7.69 (d, J = 8.4 Hz, 2H), 7.30-7.21 (m, 5H), 7.16-7.13 (m, 
2H), 6.90 (d, J = 11.1 Hz, 1H), 6.72 (s, 1H), 4.64 (dd, J = 11.1, 9.6 Hz, 1H), 4.17 (q, J = 
7.2 Hz , 2H), 4.01 (q, J = 7.2 Hz , 2H), 3.974 (q, J = 7.2 Hz, 1H), 3.968 (q, J = 6.9 Hz, 
1H), 3.81 (d, J = 9.6 Hz, 1H), 2.39 (s, 3H), 1.22 (t, J = 7.2 Hz, 3H), 1.12 (t, J = 6.9 Hz, 
3H), 1.02 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 168.1 (C), 166.9 (C), 164.2 
(C), 143.6 (C), 138.5 (CH), 137.8 (C), 136.9 (C), 129.4 (CH), 128.6 (CH), 128.4 (CH), 
127.53 (CH), 127.49 (CH), 126.4 (C), 62.0 (CH2), 61.8 (CH2), 61.6 (CH2), 57.2 (CH), 
43.0 (CH), 21.5 (CH3), 13.9 (CH3), 13.7 (CH3); HRMS (ESI) m/z 518.1836 [M+H]+, 
C26H31NO8S requires 518.1843. 
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(S,Z)-Triethyl 4-(4-methylphenylsulfonamido)-2-(p-tolyl)but-3-ene-1,1,4-
tricarboxylate (19bb) 
Chiral HPLC analysis: Chiralcel AD-H, hexane-iPrOH 80:20, 1 
mL/min, E-isomer: major enantiomer tr = 25.6 min, minor 
enantiomer tr = 19.4 min. Z-isomer: major enantiomer tr = 57.4 
min, minor enantiomer tr = 25.6 min. 
Colorless oil; [α]D20 8.9 (c 1.0, CHCl3, ee = 88% for the major 
diastereomer); 1H NMR (300 MHz, CDCl3) δ 7.70 (d, J = 8.4 Hz, 2H), 7.23 (d, J = 8.4 
Hz, 2H), 7.09-7.01 (m, 4H), 6.88 (d, J = 11.1 Hz, 1H), 6.74 (s, 1H), 4.60 (dd, J = 11.1, 
9.9 Hz, 1H), 4.17 (q, J = 7.2 Hz , 2H), 4.04-3.95 (m, 2H),  4.00 (q, J = 7.2 Hz, 2H), 3.79 
(d, J = 9.9 Hz, 1H), 2.39 (s, 3H), 2.30 (s, 3H), 1.22 (t, J = 7.2 Hz, 3H), 1.11 (t, J = 6.9 
Hz, 3H), 1.04 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 168.2 (C), 167.0 (C), 
164.3 (C), 143.6 (C), 138.8 (CH), 137.2 (C), 136.9 (C), 134.8 (C), 129.4 (CH), 129.3 
(CH), 128.1 (CH), 127.5 (CH), 126.1 (C), 62.0 (CH2), 61.7 (CH2), 61.6 (CH2), 57.3 
(CH), 42.7 (CH), 21.5 (CH3), 21.0 (CH3), 13.9 (CH3), 13.7 (CH3); HRMS (ESI) m/z 
532.1987 [M+H]+, C27H33NO8S   requires 532.2000.   
(S,Z)-Triethyl 2-(4-chlorophenyl)-4-(4-methylphenylsulfonamido)but-3-ene-1,1,4-
tricarboxylate (19bc) 
Chiral HPLC analysis: Lux Amylose-1, hexane-iPrOH 80:20, 1 
mL/min, E-isomer: major enantiomer tr = 21.5 min, minor 
enantiomer tr = 19.7 min. Z-isomer: major enantiomer tr = 67.8 
min, minor enantiomer tr = 23.5 min. 
Colorless oil; [α]D20 24.5 (c 1.0, CHCl3, ee = 88% for the major 
diastereomer); 1H NMR (300 MHz, CDCl3) δ 7.66 (d, J = 8.4 Hz, 2H), 7.27-7.21 (m, 
4H), 7.15 (d, J = 8.4 Hz, 2H), 6.89 (d, J = 10.8 Hz, 1H), 6.65 (s, 1H), 4.72 (dd, J = 11.1, 
9.6 Hz, 1H), 4.17 (q, J = 7.2 Hz , 2H), 4.04-3.95 (m, 4H), 3.78 (d, J = 9.6 Hz, 1H), 2.39 
(s, 3H), 1.22 (t, J = 7.2 Hz, 3H), 1.10 (t, J = 6.9 Hz, 3H), 1.07 (t, J = 7.2 Hz, 3H); 13C 
NMR (75 MHz, CDCl3) δ 167.8 (C), 166.8 (C), 164.0 (C), 143.8 (C), 138.3 (CH), 136.6 
(C), 136.5 (C), 133.4 (C), 129.7 (CH), 129.4 (CH), 128.8 (CH), 127.5 (CH), 126.5 (C), 
62.1 (CH2), 61.9 (CH2), 61.7 (CH2), 57.1 (CH), 42.4 (CH), 21.5 (CH3), 13.89 (CH3), 
13.86 (CH3), 13.76 (CH3); HRMS (ESI) m/z 552.1443  [M+H]+, C26H30ClNO8S requires 
552.1453. 
(S,Z)-Triethyl 4-(4-methylphenylsulfonamido)-2-(4-nitrophenyl)but-3-ene-1,1,4-
tricarboxylate (19bd) 
Chiral HPLC analysis: Chiralcel OD-H, hexane-iPrOH 90:10, 1 
mL/min, E-isomer: major enantiomer tr = 38.3 min, minor 
enantiomer tr = 41.3 min. Z-isomer: major enantiomer tr = 80.5 
min, minor enantiomer tr = 33.7 min. 
Yellow oil; [α]D20 27,0 (c 1.0, CHCl3, ee = 69% for the major 
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diastereomer); 1H NMR (300 MHz, CDCl3) δ 8.17 (d, J = 9.0 Hz, 2H), 7.62 (d, J = 8.4 
Hz, 2H), 7.48 (d, J = 9.0 Hz, 2H), 7.23 (d, J = 8.4 Hz, 2H), 6.98 (d, J = 10.8 Hz, 1H), 
6.52 (s, 1H), 5.00 (dd, J = 10.8, 9.3 Hz, 1H), 4.18 (q, J = 7.2 Hz, 1H), 4.17 (q, J = 7.2 
Hz, 1H), 4.04 (q, J = 6.9 Hz, 1H), 4.03 (q, J = 7.2 Hz, 1H), 3.96 (q, J = 7.2 Hz, 1H), 
3.95 (q, J = 7.2 Hz, 1H), 3.86 (d, J = 9.3 Hz, 1H), 2.39 (s, 3H), 1.22 (t, J = 7.2 Hz, 3H), 
1.10 (t, J = 7.2 Hz, 3H), 1.07 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 167.3 
(C), 166.6 (C), 163.6 (C), 147.2 (C), 145.7 (C), 144.0 (C), 137.6 (CH), 136.2 (C), 129.5 
(2CH), 127.5 (CH), 123.8 (CH), 62.2 (CH2), 62.1 (CH2), 61.9 (CH2), 56.8 (CH), 42.7 
(CH), 21.5 (CH3), 13.9 (CH3), 13.8 (2CH3); HRMS (ESI) m/z 563.1681 [M+H]+, 
C26H30N2O10S requires 563.1694. 
(S,Z)-Triethyl 2-(4-methoxyphenyl)-4-(4-methylphenylsulfonamido)but-3-ene-
1,1,4-tricarboxylate (19be) 
Chiral HPLC analysis: Lux Amylose-1, hexane-iPrOH 90:10 
(70 min), 85:15 (5 min), 80:20, 1 mL/min, E-isomer: major 
enantiomer tr = 29.9 min, minor enantiomer tr = 35.2 min. Z-
isomer: major enantiomer tr = 97.1 min, minor enantiomer tr = 
33.0 min. 
Yellow oil; [α]D20 11.6 (c 1.0, CHCl3, ee = 86% for the major diastereomer); 1H NMR 
(300 MHz, CDCl3) δ 7.69 (d, J = 8.4 Hz, 2H), 7.23 (d, J = 8.7 Hz, 2H), 7.08 (d, J = 8.7 
Hz, 2H), 6.87 (d, J = 11.1 Hz, 1H), 6.80 (d, J = 8.7 Hz, 2H), 6.74 (s, 1H), 4.60 (dd, J = 
11.1, 9.6 Hz, 1H), 4.17 (q, J = 7.2 Hz , 2H), 4.04-3.95 (m, 4H), 3.77 (s, 3H), 3.76 (d, J = 
9.6 Hz, 1H), 2.39 (s, 3H), 1.22 (t, J = 7.2 Hz, 3H), 1.11 (t, J = 6.9 Hz, 3H), 1.05 (t, J = 
6.9 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 168.1 (C), 167.0 (C), 164.3 (C), 158.9 (C), 
143.6 (C), 138.9 (CH), 136.9 (C), 129.8 (C), 129.4 (CH), 129.3 (CH), 127.5 (CH), 
126.0 (C), 114.0 (CH), 62.0 (CH2), 61.7 (CH2), 61.6 (CH2), 57.4 (CH), 55.2 (CH3), 42.3 
(CH), 21.5 (CH3), 13.9 (CH3), 13.8 (CH3); HRMS (ESI) m/z  548.1930 [M+H]+, 
C27H33NO9S  requires 548.1949. 
(S,Z)-Triethyl 2-(3-chlorophenyl)-4-(4-methylphenylsulfonamido)but-3-ene-1,1,4-
tricarboxylate (19bf) 
Chiral HPLC analysis: Chiralcel AD-H, hexane-iPrOH 80:20, 1 
mL/min, E-isomer: major enantiomer tr = 22.7 min, minor 
enantiomer tr = 17.3 min. Z-isomer: major enantiomer tr = 35.7 
min, minor enantiomer tr = 28.6 min. 
Yellow oil; [α]D20 20.7 (c 1.0, CHCl3, ee = 90% for the major diastereomer); 1H NMR 
(300 MHz, CDCl3) δ 7.67 (d, J = 8.4 Hz, 2H), 7.26-7.20 (m, 4H), 7.12-7.09 (m, 2H), 
6.87 (d, J = 11.1 Hz, 1H), 6.73 (s, 1H), 4.65 (dd, J = 11.1, 9.3 Hz, 1H), 4.17 (q, J = 6.9 
Hz, 2H), 4.05-3.98 (m, 4H), 3.77 (d, J = 9.3 Hz, 1H), 2.40 (s, 3H), 1.22 (t, J = 7.2 Hz, 
3H), 1.12 (t, J = 7.2 Hz, 3H), 1.06 (t, J = 6.9 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 
167.8 (C), 166.7 (C), 164.1 (C), 143.8 (C), 140.0 (CH), 137.6 (CH), 136.7 (C), 134.3 
(C), 129.9 (CH), 129.5 (CH), 128.3 (CH), 127.8 (CH), 127.5 (CH), 126.9 (C), 126.6 
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(CH), 62.1 (CH2), 61.9 (CH2), 61.8 (CH2), 57.1 (CH), 42.6 (CH), 21.5 (CH3), 13.9 
(CH3), 13.7 (CH3); HRMS (ESI) m/z 552.1445 [M+H]+, C26H30ClNO8S  requires 
552,1453. 
(S,Z)-Triethyl 4-(4-methylphenylsulfonamido)-2-(3-nitrophenyl)but-3-ene-1,1,4-
tricarboxylate (19bg) 
Chiral HPLC analysis: Lux Amylose-1, hexane-iPrOH 80:20, 1 
mL/min, E-isomer: major enantiomer tr = 28.4 min, minor 
enantiomer tr = 25.1 min. Z-isomer: major enantiomer tr = 58.2 
min, minor enantiomer tr = 39.1 min. 
Yellow oil; [α]D20 20.3 (c 0.97, CHCl3, ee = 52% for the major diastereomer); 1H NMR 
(300 MHz, CDCl3) δ 8.14-8.11 (m, 2H), 7.68 (dt, J = 7.8, 1.5 Hz, 1H), 7.62 (d, J = 8.4 
Hz, 2H), 7.52-7.47 (m, 1H), 7.23 (d, J = 8.4 Hz, 2H), 7.00 (d, J = 10.8 Hz, 1H), 6.56 (s, 
1H), 4.98 (dd, J = 10.8, 9.0 Hz, 1H), 4.18 (q, J = 7.2 Hz, 2H), 4.043 (q, J = 6.9 Hz, 1H), 
4.036 (q, J = 7.2 Hz, 1H), 3.982 (q, J = 7.2 Hz, 1H), 3.978 (q, J = 7.2 Hz, 1H), 3.87 (d, 
J = 9 Hz, 1H), 2.38 (s, 3H), 1.22 (t, J = 7.2 Hz, 3H), 1.094 (t, J = 7.2 Hz, 3H), 1.087 (t, 
J = 6.9 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 167.3 (C), 166.6 (C), 163.7 (C), 148.3 
(C), 144.1 (C), 140.5 (C), 137.4 (CH), 136.3 (C), 135.4 (CH), 129.54 (CH), 129.49 
(CH), 127.5 (CH), 127.2 (C), 122.9 (CH), 122.6 (CH), 62.15 (CH2), 62.09 (CH2), 61.9 
(CH2), 57.0 (CH), 42.5 (CH), 21.5 (CH3), 13.9 (CH3), 13.85 (CH3), 13.80 (CH3); HRMS 
(ESI) m/z 563,1680 [M+H]+,C26H30N2O10S  requires 563.1694. 
(S,Z)-Triethyl 2-(3-methoxyphenyl)-4-(4-methylphenylsulfonamido)but-3-ene-
1,1,4-tricarboxylate (19bh) 
Chiral HPLC analysis: Chiralcel AD-H, hexane-iPrOH 80:20, 1 
mL/min, E-isomer: major enantiomer tr = 30.2 min, minor 
enantiomer tr = 21.2 min. Z-isomer: major enantiomer tr = 45.4 
min, minor enantiomer tr = 33.0 min. 
Colorless oil; [α]D20 15.1 (c 0.96, CHCl3, ee = 88% for the major diastereomer); 1H 
NMR (300 MHz, CDCl3) δ 7.70 (d, J = 8.4 Hz, 2H), 7.22 (d, J = 8.1 Hz, 2H), 7.17 (d, J 
= 7.8 Hz, 1H), 6.88 (d, J = 10.8 Hz, 1H), 6.75-6.73 (m, 3H), 4.63 (dd, J = 10.8, 9.9 Hz, 
1H), 4.17 (q, J = 6.9 Hz, 2H), 4.04-3.96 (m, 4H), 3.81 (d, J = 9.9 Hz, 1H), 3.79 (s, 3H), 
2.39 (s, 3H), 1.22 (t, J = 7.2 Hz, 3H), 1.11 (t, J = 7.2 Hz, 3H), 1.05 (t, J = 7.2 Hz, 3H); 
13C NMR (75 MHz, CDCl3) δ 168.1 (C), 166.9 (C), 164.2 (C), 159.7 (C), 143.7 (C), 
139.3 (C), 138.5 (CH), 136.8 (C), 129.6 (CH), 129.4 (CH), 127.5 (CH), 126.4 (C), 
120.2 (CH), 114.3 (CH), 112.8 (CH), 62.0 (CH2), 61.7 (CH2), 61.6 (CH2), 57.1 (CH), 
55.2 (CH3), 43.0 (CH), 21.5 (CH3), 13.9 (CH3), 13.7 (CH3); HRMS (ESI) m/z 548.1941 
[M+H] +,  C27H33NO9S requires 548,1949. 
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(S,Z)-Triethyl 2-(2-chlorophenyl)-4-(4-methylphenylsulfonamido)but-3-ene-1,1,4-
tricarboxylate (19bi) 
Chiral HPLC analysis: Chiralcel AD-H, hexane-iPrOH 80:20, 1 
mL/min, E-isomer: major enantiomer tr = 23.4 min, minor 
enantiomer tr = 26.9 min. Z-isomer: major enantiomer tr = 58.8 
min, minor enantiomer tr = 25.2 min. 
Colorless oil;  [α]D20 44.4 (c 1.0, CHCl3, ee = 95% for the major diastereomer); 1H 
NMR (300 MHz, CDCl3) δ 7.65 (d, J = 8.4 Hz, 2H), 7.35-7.31 (m, 1H), 7.26-7.16 (m, 
6H), 6.70 (s, 1H), 5.02 (dd, J = 10.5, 8.1 Hz, 1H), 4.19-4.00 (m, 7H), 2.35 (s, 3H), 1.17 
(t, J = 7.2 Hz, 3H), 1.13 (t, J = 6.9 Hz, 3H),  1.11 (d, J = 7.2 Hz, 3H); 13C NMR (75 
MHz, CDCl3) δ 167.8 (C), 167.3 (C), 164.2 (C), 143.5 (C), 136.8 (C), 136.0 (CH), 
135.7 (C), 133.7 (C), 130.5 (CH), 130.2 (CH), 129.3 (CH), 128.7 (CH), 127.5 (C), 
127.3 (CH), 126.9 (CH), 61.8 (CH2), 54.8 (CH), 40.4 (CH), 21.5 (CH3), 13.90 (CH3), 
13.87 (CH3), 13.78 (CH3); HRMS (ESI) m/z 552.1441 [M+H]+, C26H30ClNO8S requires 
552.1453. 
(S,Z)-Triethyl 4-(4-methylphenylsulfonamido)-2-(2-nitrophenyl)but-3-ene-1,1,4-
tricarboxylate (19bj) 
Major Z-diastereomer: Chiral HPLC analysis: Chiralcel OD-
H, hexane-iPrOH 80:20, 1 mL/min, major enantiomer tr = 37.6 
min, minor enantiomer tr = 16.1 min. 
Orange oil; [α]D20 33.4 (c 1.0, CHCl3, ee = 20%); 1H NMR (300 
MHz, CDCl3) δ 7.94 (dd, J = 8.1, 1.2 Hz, 1H), 7.59-7.49 (m, 4H), 7.45-7.40 (m, 1H), 
7.22 (d, J = 9.6 Hz, 1H), 7.32 (d, J = 8.4 Hz, 2H), 6.63 (s, 1H), 5.32 (dd, J = 9.6, 7.2 Hz, 
1H), 4.21-4.05 (m, 5H), 4.00 (q, J = 7.2 Hz, 2H), 2.34 (s, 3H), 1.18 (t, J = 7.2 Hz, 3H), 
1.14 (t, J = 7.2 Hz, 3H), 1.09 (d, J = 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 167.6 
(C), 167.3 (C), 163.8 (C), 149.3 (C), 143.7 (C), 136.2 (C), 135.4 (CH), 133.8 (C), 133.0 
(CH), 131.2 (CH), 129.2 (CH), 128.4 (CH), 127.7 (C), 127.4 (CH), 125.3 (CH), 61.93 
(CH2), 61.91 (CH2), 61.8 (CH2), 56.1 (CH), 38.6 (CH), 21.4 (CH3), 13.9 (CH3), 13.82 
(CH3), 13.80 (CH3); HRMS (ESI) m/z 563.1674 [M+H]+, C26H30N2O10S requires 
563.1694. 
Minor E-diastereomer: Chiral HPLC analysis: Lux Amylose-1, hexane-iPrOH 80:20, 
1 mL/min, major enantiomer tr = 28.2 min, minor enantiomer tr = 55.7 min. 
Orange oil; [α]D20 35.5 (c 1.0, CHCl3, ee = 60%); 1H NMR (300 MHz, CDCl3) δ 7.82 
(dd, J = 8.1, 1.5 Hz, 1H), 7.56 (td, J = 7.5, 1.5 Hz, 1H), 7.50-7.46 (m, 3H), 7.43-7.38 
(m, 1H), 7.10 (d, J = 8.7 Hz, 2H), 6.93 (d, J = 9.9 Hz, 1H), 6.68 (s, 1H), 5.59 (dd, J = 
10.2, 7.8 Hz, 1H), 4.15 (q, J = 7.2 Hz, 1H), 4.14 (q, J = 6.9 Hz, 1H), 4.08-3.99 (m, 5H), 
2.34 (s, 3H), 1.20 (t, J = 7.2 Hz, 3H), 1.10 (t, J = 7.2 Hz, 3H), 1.05 (d, J = 7.2 Hz, 3H); 
13C NMR (75 MHz, CDCl3) δ 167.3 (C), 167.0 (C), 162.6 (C), 149.4 (C), 143.8 (C), 
135.6 (C), 135.2 (C), 132.8 (C), 131.5 (CH), 130.4 (CH), 129.4 (CH), 128.0 (CH), 
Experimental Section 
161 
127.4 (CH), 126.2 (C), 124.5 (CH), 62.4 (CH2), 61.7 (CH2), 61.6 (CH2), 56.2 (CH), 37.9 
(CH), 21.4 (CH3), 13.9 (CH3), 13.74 (CH3), 13.70 (CH3); HRMS (ESI) m/z 563.1685 
[M+H]+, C26H30N2O10S  requires 563,1694 . 
(S,Z)-Triethyl 4-(4-methylphenylsulfonamido)-2-(thiophen-2-yl)but-3-ene-1,1,4-
tricarboxylate (19bl) 
Chiral HPLC analysis: Chiralcel AD-H, hexane-iPrOH 80:20, 1 
mL/min, E-isomer: major enantiomer tr = 17.0 min, minor 
enantiomer tr = 28.0 min. Z-isomer: major enantiomer tr = 23.5 
min, minor enantiomer tr = 20.5 min. 
Orange oil;  [α]D20 11.9 (c 1.01, CHCl3, ee = 84% for the major diastereomer); 1H 
NMR (300 MHz, CDCl3) δ 7.68 (dt, J = 8.1 Hz, 2H), 7.32 (dd, J = 2.1, 0.9 Hz, 1H), 
7.22 (d, J = 8.1 Hz, 2H), 6.90 (d, J = 10.8 Hz, 1H), 6.72 (s, 1H), 6.28 (dd, J = 3.3, 1.8 
Hz, 1H), 6.11 (dt, J = 3.3, 0.6 Hz, 1H), 4.76 (d, J = 10.8, 8.4 Hz, 1H), 4.16 (q, J = 7.2 
Hz, 2H), 4.14-4.07 (m, 2H), 4.02 (q, J = 7.2 Hz, 2H), 3.89 (d, J = 8.4 Hz, 1H), 2.38 (s, 
3H), 1.21 (t, J = 6.9 Hz, 3H), 1.17 (t, J = 6.9 Hz, 3H), 1.13 (t, J = 7.2 Hz, 3H); 13C 
NMR (75 MHz, CDCl3) δ 167.5 (C), 167.1 (C), 164.1 (C), 150.5 (C), 143.7 (C), 142.0 
(CH), 136.5 (C), 135.4 (CH), 129.4 (CH), 127.5 (CH), 127.1 (C), 110.4 (CH), 107.8 
(CH), 61.88 (CH2), 61.85 (CH2), 55.2 (CH), 37.1 (CH), 21.5 (CH3), 13.89 (CH3), 13.86 
(CH3); HRMS (ESI) m/z  508.1629 [M+H]+, C24H29NO9S requires 508.1636. 
(S,Z)-1,1-Diethyl 4-methyl 4-(4-methylphenylsulfonamido)-2-phenylbut-3-ene-
1,1,4-tricarboxylate (19bn) 
Chiral HPLC analysis: Chiralcel AD-H, hexane-iPrOH 80:20, 1 
mL/min, E-isomer: major enantiomer tr = 28.1 min, minor 
enantiomer tr = 26.0 min. Z-isomer: major enantiomer tr = 76.5 
min, minor enantiomer tr = 32.8 min. 
White solid, mp 94-95 °C (hexane-EtOAc); [α]D20 20.2 (c 0.98, CHCl3, ee = 87% for 
the major diastereomer); 1H NMR (300 MHz, CDCl3) δ 7.71 (d, J = 8.4Hz, 2H), 7.32-
7.23 (m, 5H), 7.12-7.09 (m, 2H), 6.90 (s, 1H), 6.88 (d, J = 11.1Hz, 1H), 4.56 (dd, J = 
10.8, 9.9 Hz, 1H), 4.179 (q, J = 7.2 Hz , 1H), 4.177 (q, J = 7.2 Hz , 1H), 3.972 (q, J = 
7.2 Hz, 1H), 3.966 (q, J = 6.9 Hz, 1H), 3.80 (d, J = 9.9 Hz, 1H), 3.58 (s, 3H), 2.41 (s, 
3H), 1.22 (t, J = 7.2 Hz, 3H), 1.01 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 
168.2 (C), 166.9 (C), 164.8 (C), 143.6 (C), 138.4 (CH), 137.6 (C), 136.8 (C), 129.5 
(CH), 128.6 (CH), 128.2 (CH), 127.6 (CH), 127.4 (CH), 126.3 (C), 62.1 (CH2), 61.7 
(CH2), 57.1 (CH), 52.5 (CH3), 43.0 (CH), 21.5 (CH3), 13.9 (CH3), 13.7 (CH3); HRMS 
(ESI) m/z 504.1673
 
[M+H]+, C25H29NO8S requires 504.1687. 
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(S,Z)-1,1-Diethyl 4-isopropyl 4-(4-methylphenylsulfonamido)-2-phenylbut-3-ene-
1,1,4-tricarboxylate (19bo) 
Chiral HPLC analysis: Chiralcel AD-H, hexane-iPrOH 80:20, 1 
mL/min, E-isomer: major enantiomer tr = 20.8 min, minor 
enantiomer tr = 15.0 min. Z-isomer: major enantiomer tr = 35.1 
min, minor enantiomer tr = 22.4 min. 
Colorless oil; [α]D20 18.4 (c 1.0, CHCl3, ee = 89% for the major diastereomer); 1H 
NMR (300 MHz, CDCl3) δ 7.68 (dt, J = 8.1 Hz, 2H), 7.32-7.16 (m, 7H), 6.89 (d, J = 
10.8 Hz, 1H), 6.71 (s, 1H), 4.83 (hept, J = 6.3 Hz, 1H), 4.69 (dd, J = 10.8, 9.6 Hz, 1H), 
4.18 (q, J = 6.9 Hz, 2H), 3.983 (q, J = 7.2 Hz, 1H), 3.977 (q, J = 7.2 Hz, 1H), 3.82 (d, J 
= 9.6 Hz, 1H), 2.39 (s, 3H), 1.23 (t, J = 7.2 Hz, 3H), 1.11 (d, J = 6.3 Hz, 3H), 1.08 (d, J 
= 6 Hz, 3H), 1.03 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 168.0 (C), 166.9 
(C), 163.7 (C), 143.6 (C), 138.3 (CH), 137.9 (C), 136.7 (C), 129.4 (CH), 128.6 (CH), 
128.3 (CH), 127.49 (CH), 127.46 (CH), 126.5 (C), 69.7 (CH), 62.0 (CH2), 61.6 (CH2), 
57.3 (CH), 43.0 (CH), 21.47 (CH3), 21.43 (CH3), 21.36 (CH3), 13.9 (CH3), 13.7 (CH3); 
HRMS (ESI) m/z 532.1982 [M+H]+, C27H33NO8S requires 532.2000. 
(S,Z)-4-Ethyl 1,1-dimethyl 4-(4-methylphenylsulfonamido)-2-phenylbut-3-ene-
1,1,4-tricarboxylate (19aa) 
Chiral HPLC analysis: Chiralcel AD-H, hexane-iPrOH 80:20, 1 
mL/min, E-isomer: major enantiomer tr = 34.5 min, minor 
enantiomer tr = 22.9 min. Z-isomer: major enantiomer tr = 34.5 
min, minor enantiomer tr = 26.8 min. 
Colorless oil;  [α]D20 5.5 (c 1.0, CHCl3, ee = 86%  for the major diastereomer); 1H 
NMR (300 MHz, CDCl3) δ 7.68 (d, J = 8.4 Hz, 2H), 7.32-7.16 (m, 7H), 6.97 (d, J = 
11.1 Hz, 1H), 6.60 (s, 1H), 4.75 (dd, J = 10.8, 9.6 Hz, 1H), 3.99 (q, J = 7.2 Hz, 2H), 
3.87 (d, J = 9.6 Hz, 1H), 3.72 (s, 3H), 3.54 (s, 3H), 2.39 (s, 3H), 1.11 (t, J = 7.2 Hz, 
3H); 13C NMR (75 MHz, CDCl3) δ 168.4 (C), 167.4 (C), 164.1 (C), 143.7 (C), 138.8 
(CH), 137.9 (C), 136.7 (C), 129.5 (CH), 128.7 (CH), 128.1 (CH), 127.6 (CH), 127.5 
(CH), 126.3 (C), 61.8 (CH2), 57.0 (CH), 52.9 (CH3), 52.6 (CH3), 43.1 (CH), 21.5 (CH3), 
13.9 (CH3); HRMS (ESI) m/z 490.1524 [M+H]+, C24H27NO8S requires 490.1530. 
(S,Z)-4-Ethyl 1,1-diisopropyl 4-(4-methylphenylsulfonamido)-2-phenylbut-3-ene-
1,1,4-tricarboxylate (19ca) 
Chiral HPLC analysis: Chiralcel AD-H, hexane-iPrOH 80:20, 1 
mL/min, E-isomer: major enantiomer tr = 17.2 min, minor 
enantiomer tr = 14.6 min. Z-isomer: major enantiomer tr = 28.9 
min, minor enantiomer tr = 18.7 min. 
Colorless oil; [α]D20 25.1 (c 1.0, CHCl3, ee = 73% for the major diastereomer); 1H 
NMR (300 MHz, CDCl3) δ 7.70 (d, J = 8.4 Hz, 2H), 7.28-7.20 (m, 5H), 7.11-7.08 (m, 
2H), 6.94 (s, 1H), 6.82 (d, J = 10.8 Hz, 1H), 5.02 (hept, J = 6 Hz, 1H), 4.79 (hept, J = 
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6.3 Hz, 1H), 4.52 (dd, J = 10.8, 9.9 Hz, 1H), 4.04 (q, J = 6.9 Hz, 2H), 3.73 (d, J = 9.9 
Hz, 1H), 2.39 (s, 3H), 1.21 (d, J = 6.6 Hz, 3H), 1.18 (d, J = 6.3 Hz, 3H), 1.13 (t, J = 7.2 
Hz, 3H), 1.03 (d, J = 6.3 Hz, 3H), 0.99 (d, J = 6.0 Hz, 3H); 13C NMR (75 MHz, CDCl3) 
δ 167.8 (C), 166.4 (C), 164.3 (C), 143.5 (C), 138.2 (CH), 137.8 (C), 137.0 (C), 129.4 
(CH), 128.5 (CH), 128.3 (CH), 127.4 (CH), 126.5 (C), 69.8 (CH), 69.3 (CH), 61.7 
(CH2), 57.5 (CH), 42.9 (CH), 21.52 (CH3), 21.48 (CH3), 21.4 (CH3), 21.2 (CH3), 13.9 
(CH3); HRMS (ESI) m/z 546.2144 [M+H]+, C28H35NO8S requires 546.2156. 
(R,Z)-Dimethyl 2-(3,3-bis(4-methylphenylsulfonamido)-1-phenylallyl)-2-
methylmalonate (20da) 
Chiral HPLC analysis: Lux Amylose-1, hexane-iPrOH 80:20, 1 
mL/min, E-isomer: major enantiomer tr = 14.2 min, minor 
enantiomer tr = 23.4 min. Z-isomer: major enantiomer tr = 14.9 
min, minor enantiomer tr = 12.7 min. 
Colorless oil; [α]D20 71.3 (c 1.0, CHCl3, ee = 83% for the major diastereomer); 1H 
NMR (300 MHz, CDCl3) δ 7.62 (d, J = 8.4 Hz, 2H), 7.26-7.23 (m, 3H), 7.18-7.14 (m, 
3H), 7.06-7.03 (m, 2H), 6.94 (s, 1H), 4.52 (d, J = 11.1 Hz, 1H), 4.06 (q, J = 7.2 Hz, 
2H), 3.71 (s, 3H), 3.60 (s, 3H), 2.37 (s, 3H), 1.40 (s, 3H), 1.15 (t, J = 7.2 Hz, 3H); 13C 
NMR (75 MHz, CDCl3) δ 171.4 (C), 171.2 (C), 164.5 (C), 143.5 (C), 137.3 (CH), 136.9 
(C), 136.5 (C), 129.34 (CH), 129.26 (CH), 128.3 (CH), 127.6 (CH), 127.3 (CH), 126.6 
(C), 61.7 (CH2), 58.6 (C), 52.8 (CH3), 52.7 (CH3), 47.6 (CH), 21.5 (CH3), 18.7 (CH3), 
13.9 (CH3); HRMS (ESI) m/z  504.1684 [M+H]+, C25H29NO8S requires 504.1687. 
(R,Z)-1-Ethyl 4,4-dimethyl 3-(4-chlorophenyl)-1-(4-
methylphenylsulfonamido)pent-1-ene-1,4,4-tricarboxylate (20dc) 
Chiral HPLC analysis: Lux Amylose-1, hexane-iPrOH 80:20, 1 
mL/min, E-isomer: major enantiomer tr = 22.4 min, minor 
enantiomer tr = 48.9 min. Z-isomer: major enantiomer tr = 13.1 
min, minor enantiomer tr = 13.8 min 
Colorless oil; [α]D20 17.8 (c 1.0, CHCl3, ee = 40% for the major 
diastereomer); 1H NMR (300 MHz, CDCl3) δ 7.60 (d, J = 8.4 Hz, 2H), 7.27-7.07 (m, 
7H), 6.77 (s, 1H), 4.64 (d, J = 10.8 Hz, 1H), 4.02 (q, J = 6.9 Hz, 2H), 3.72 (s, 3H), 3.64 
(s, 3H), 2.38 (s, 3H), 1.42 (s, 3H), 1.12 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) 
δ 171.2 (C), 171.1 (C), 164.2 (C), 143.7 (C), 137.4 (CH), 136.6 (C), 135.3 (C), 133.6 
(C), 130.8 (CH), 129.4 (CH), 128.4 (CH), 127.4 (CH), 126.7 (C), 61.8 (CH2), 58.5 (C), 
52.82 (CH3), 52.76 (CH3), 47.1 (CH), 21.5 (CH3), 18.8 (CH3), 13.9 (CH3); HRMS (ESI) 
m/z 538.1298 [M+H] +, C25H28ClNO8S requires 538.1297. 
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(R,Z)-1-Ethyl 4,4-dimethyl 1-(4-methylphenylsulfonamido)-3-(4-nitrophenyl)pent-
1-ene-1,4,4-tricarboxylate (20dd) 
Chiral HPLC analysis: Lux Amylose-1, hexane-iPrOH 90:10, 1 
mL/min, E-isomer: major enantiomer tr = 52.8 min, minor 
enantiomer tr = 96.5 min. Z-isomer: major enantiomer tr = 81.8 
min, minor enantiomer tr = 69.5 min. 
Pale yellow oil; [α]D20 77.1 (c 1.0, CHCl3, ee = 81% for the 
major diastereomer); 1H NMR (300 MHz, CDCl3) δ 8.14 (d, J = 9 Hz, 2H), 7.53 (d, J = 
8.4 Hz, 2H), 7.42 (d, J = 8.7 Hz, 2H), 7.28 (d, J = 10.5 Hz, 1H), 7.18 (d, J = 8.1 Hz, 
2H), 6.56 (s, 1H), 4.93 (d, J = 10.8 Hz, 1H), 3.97 (q, J = 7.2 Hz, 1H), 3.96 (q, J = 7.2 
Hz, 2H), 3.70 (s, 3H), 3.66 (s, 3H), 2.36 (s, 3H), 1.45 (s, 3H), 1.07 (t, J = 7.2 Hz, 3H); 
13C NMR (75 MHz, CDCl3) δ 170.8 (C), 170.7 (C), 163.7 (C), 147.2 (C), 144.6 (C), 
143.9 (C), 137.2 (CH), 136.1 (C), 130.7 (CH), 129.4 (CH), 127.4 (CH), 127.2 (C), 
123.2 (CH), 62.0 (CH2), 58.4 (C), 52.9 (CH3), 52.8 (CH3), 47.6 (CH), 21.4 (CH3), 19.1 
(CH3), 13.8 (CH3); HRMS (ESI) m/z  549.1542 [M+H]+,  C25H28N2O10S requires 
549,1537. 
(R,Z)-1-Ethyl 4,4-dimethyl 3-(4-methoxyphenyl)-1-(4-
methylphenylsulfonamido)pent-1-ene-1,4,4-tricarboxylate (20de) 
Chiral HPLC analysis: Lux Amylose-1, hexane-iPrOH 90:10, 1 
mL/min, E-isomer: major enantiomer tr = 22.4 min, minor 
enantiomer tr = 39.9 min. Z-isomer: major enantiomer tr = 25.6 
min, minor enantiomer tr = 34.9 min 
Yellow oil; [α]D20 57.8 (c 0.83, CHCl3, ee = 97%  for the major 
diastereomer); 1H NMR (300 MHz, CDCl3) δ 7.64 (d, J = 8.1 Hz, 2H), 7.18 (d, J = 8.1 
Hz, 2H), 7.13 (d, J = 11.1 Hz, 1H), 6.99 (d, J = 8.7 Hz, 2H), 6.90 (s, 1H), 6.78 (d, J = 
8.7 Hz, 2H), 4.49 (d, J = 11.1 Hz, 1H), 4.05 (q, J = 6.9 Hz, 2H), 3.78 (s, 3H), 3.71 (s, 
3H), 3.62 (s, 3H), 2.38 (s, 3H), 1.40 (s, 3H), 1.14 (t, J = 7.2 Hz, 3H); 13C NMR (75 
MHz, CDCl3) δ 171.6 (C), 171.3 (C), 164.5 (C), 159.0 (C), 143.5 (C), 137.7 (CH), 
137.0 (C), 130.4 (CH), 129.4 (CH), 128.5 (C), 127.4 (CH), 126.2 (C), 113.7 (CH), 61.7 
(CH2), 58.7 (C), 55.1 (CH3), 52.8 (CH3), 52.7 (CH3), 46.9 (CH), 21.5 (CH3), 18.7 
(CH3), 13.9 (CH3); HRMS (ESI) m/z 534.1785 [M+H]+, C26H31NO9S requires 
534.1792. 
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5.4.2. Synthetic transformations from compound 19bn 
(S)-1,1-Diethyl 4-methyl 4-oxo-2-phenylbutane-1,1,4-tricarboxylate (21bn) 
A solution of (S,Z)-19bn (14.0 mg, 0.04 mmol, ee = 86%) 
dissolved in dry CH2Cl2 (0.8 mL), was added via syringe to 
La(OTf)3 (14.6 mg, 0.025 mmol), previously dried in a Schlenk 
tube, under nitrogen atmosphere, followed by 4 Å MS (8 mg) 
and benzylamine (9 µL, 0.08 mmol). The mixture was stirred at 
rt for 18 hours and chromatographed on silica gel eluting with hexane/EtOAc (85:15) 
mixture to give compound 21bn (11.8 mg, 84%). Chiral HPLC analysis: Chiralcel AD-
H, hexane-iPrOH 80:20, 1 mL/min, major enantiomer tr = 16.5 min, minor enantiomer 
tr = 13.3 min. Colorless oil; [α]D20 14.9 (c 0.70, CHCl3, ee = 86%); 1H NMR (300 MHz, 
CDCl3) δ 7.31 - 7.17 (m, 5H), 4.20 (q, J = 7.2 Hz, 2H), 4.08-4.00 (m 1H), 3.95 (q, J = 
7.2 Hz, 2H), 3.81 (s, 3H), 3.74 (d, J = 10.2 Hz, 1H), 3.43 (dd, J = 18.0, 8.7 Hz, 1H), 
3.33 (q, J = 18.0, 5.1 Hz, 1H),  1.26 (t, J = 6.9 Hz, 3H), 1.01 (t, J = 7.2 Hz, 3H); 13C 
NMR (75 MHz, CDCl3) δ 191.3 (C), 168.1 (C), 167.4 (C), 160.9 (C), 139.8 (C), 128.5 
(CH), 128.2 (CH), 127.4 (CH), 61.8 (CH2), 61.4 (CH2), 57.2 (CH), 53.0 (CH3), 43.4 
(CH), 39.9 (CH), 14.0 (CH3), 13.7 (CH3); HRMS (ESI) m/z 351.1430 [M+H]+, 
C18H22O7 requires 351.1438.  
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5.5. Diastereodivergent enantioselective conjugate addition of 2-
chloromalonate esters to N-tosyl imines derived from β,γ-unsaturated 
α-keto esters 
5.5.1. Enantioselective conjugate addition of diethyl 2-chloromalonate to α,β-
unsaturated N-tosyl imino esters catalyzed by La(OTf)3 
5.5.1.1. General procedure for the enantioselective conjugate addition 
La(OTf)3 (7.3 mg, 0.0125 mmol) was dried in a Schlenk tube under vacuum. pyBOX9 
(6.5 mg, 0.0125 mmol) was added and the tube was filled with nitrogen. CH2Cl2 (0.55 
mL) was added via syringe and the mixture was stirred for 30 min. A solution of imine 
17 (0.125 mmol) in dry CH2Cl2 (0.5 mL) was added via syringe, followed by 4 Å MS 
(110 mg), and the mixture was introduced in a -10ºC bath. After 10 minutes, diethyl 2-
chloromalonate (1e, 32 µL, 0.187 mmol) was added to the reaction. The mixture was 
stirred at -10 ºC for the indicated time and chromatographed on silica gel eluting with 
hexane/EtOAc mixtures to give compound (Z)-22. 
5.5.1.2. General procedure for the synthesis of the racemic products 
Racemic compounds for comparative purpose were prepared by following the same 
procedure, using La(OTf)3 in absence of chiral ligand and performing the reaction at 
room temperature. 
5.5.1.3. Characterization of products (S,Z)-22 
See Table 17 (Page 95) for yield, dr and ee.  
(S,Z)-Triethyl 1-chloro-4-(4-methylphenylsulfonamido)-2-phenylbut-3-ene-1,1,4-
tricarboxylate, (S,Z)-22ea 
Chiral HPLC analysis: Chiralcel AD-H, hexane-iPrOH 90:10, 1 
mL/min, E-isomer: major enantiomer tr = 54.5 min, minor 
enantiomer tr = 36.4 min. Z-isomer: major enantiomer tr = 29.3 
min, minor enantiomer tr = 69.7 min. 
White oil; [α]D20 -30.3 (c 0.98, CHCl3, ee = 86% for the major diastereomer); 1H NMR 
(300 MHz, CDCl3) δ 7.64 (dt, J = 8.4, 1.8 Hz, 2H), 7.27-7.26 (m, 5H), 7.21 (d, J = 10.2 
Hz, 1H), 7.20 (dd, J = 8.4, 0.9 Hz, 2H), 6.65 (s, 1H), 5.07 (d, J = 9.9 Hz, 1H), 4.34-4.22 
(m, 2H), 4.12-4.04 (m, 2H), 4.01 (q, J = 7.2 Hz, 1H), 2.38 (s, 3H), 1.28 (t, J = 7.2 Hz, 
3H), 1.13 (t, J = 7.2 Hz, 3H), 1.11 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 
166.4 (C), 164.8 (C), 164.1 (C), 143.6 (C), 136.9 (CH), 136.6 (C), 135.2 (C), 129.7 
(CH), 129.4 (CH), 128.2 (CH), 127.5 (CH), 126.5 (CH), 74.3 (C), 63.4 (CH2), 63.3 
(CH2), 61.8 (CH2), 48.1 (CH), 21.5 (CH3), 13.9 (CH3), 13.7 (CH3), 13.6 (CH3); HRMS 
(ESI) m/z 552.1459
 
[M+H]+, C26H30ClNO8S requires 552.1453. 
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(S,Z)-Triethyl (Z)-1-chloro-4-((4-methylphenyl)sulfonamido)-2-(p-tolyl)but-3-ene-
1,1,4-tricarboxylate, (S,Z)-22eb 
Chiral HPLC analysis: Lux Amylose-1, hexane-iPrOH 90:10, 1 
mL/min, E-isomer: major enantiomer tr = 38.8 min, minor 
enantiomer tr = 26.4 min. Z-isomer: major enantiomer tr = 22.7 
min, minor enantiomer tr = 44.5 min. 
White oil; [α]D20 -31.8 (c 0.87, CHCl3, ee = 86% for the major 
diastereomer), 1H NMR (300 MHz, CDCl3) δ 7.65 (dt, J = 8.1, 2.1 Hz, 2H), 7.20 (d, J = 
9.9 Hz, 3H), 7.15 (d, J = 8.4 Hz, 2H), 7. 07 (d, J = 8.1 Hz, 2H), 6.64 (s, 1H), 5.02 (d, J 
= 9.9 Hz, 1H), 4.29 (q, J = 7.2 Hz, 1H), 4.26 (q, J = 7.2 Hz, 1H), 4.09 (q, J = 6.9 Hz, 
1H), 4.06 (q, J = 7.2 Hz, 1H), 4.00 (q, J = 7.2 Hz, 2H), 2.38 (s, 3H), 2.30 (s, 3H), 1.27 
(t, J = 7.2 Hz, 3H), 1.15 (t, J = 7.2 Hz, 3H), 1.11 (d, J = 7.2 Hz, 3H); 13C NMR (75 
MHz, CDCl3) δ 166.4 (C), 164.8 (C), 164.1 (C), 143.6 (C), 137.9 (C), 137.2 (CH), 
136.6 (C), 132.1 (C), 129.5 (CH), 129.3 (CH), 128.9 (CH), 127.4 (CH), 126.3 (C), 74.4 
(C), 63.4 (CH2), 63.3(CH2), 61.8 (CH2), 47.7 (CH), 21.5 (CH3), 21.1(CH3), 13.9 (CH3), 
13.71 (CH3), 13.67 (CH3); HRMS (ESI) m/z 566.1606 [M+H]+, C27H32ClNO8S requires 
566.1610. 
(S,Z)-Triethyl 1-chloro-2-(4-chlorophenyl)-4-(4-methylphenylsulfonamido)but-3-
ene-1,1,4-tricarboxylate, (S,Z)-22ec 
Chiral HPLC analysis: Lux Amylose-1, hexane-iPrOH 95:05, 1.6 
mL/min, E-isomer: major enantiomer tr = 93.8 min, minor 
enantiomer tr = 58.0 min. Z-isomer: major enantiomer tr = 47.6 
min, minor enantiomer tr = 68.8 min. 
White oil; [α]D20 -37.9 (c 1.0, CHCl3, ee = 86% for the major 
diastereomer); 1H NMR (300 MHz, CDCl3) δ 7.62 (dt, J = 8.4, 1.8 Hz, 2H), 7.28-7.25 
(m, 4H), 7.21 (dd, J = 8.4, 0.9 Hz, 2H), 7.20 (d, J = 9.9 Hz, 1H), 6.52 (s, 1H), 5.18 (d, J 
= 9.6 Hz, 1H), 4.29 (q, J = 6.9 Hz, 1H), 4.27 (q, J = 7.2 Hz, 1H), 4.12 (q, J = 7.2 Hz, 
1H), 4.09 (q, J = 7.2 Hz, 1H), 3.98 (q, J = 7.2 Hz, 2H), 2.38 (s, 3H), 1.28 (t, J = 7.2 Hz, 
3H), 1.17 (t, J = 7.2 Hz, 3H), 1.09 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 
166.1 (C), 164.7 (C), 163.9 (C), 143.8 (C), 136.8 (CH), 136.3 (C), 134.2 (C), 133.9 (C), 
131.2 (CH), 129.4 (CH), 128.4 (CH), 127.5 (CH), 126.7 (C), 74.1 (C), 63.5 (CH2), 63.4 
(CH2), 61.9 (CH2), 47.5 (CH3), 21.5 (CH3), 13.8 (CH3), 13.7(CH3); HRMS (ESI) m/z 
586.1074 [M+H]+, C26H29Cl2NO8S requires 586.1064. 
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(S,Z)-Triethyl 1-chloro-4-(4-methylphenylsulfonamido)-2-(4-nitrophenyl)but-3-
ene-1,1,4-tricarboxylate, (S,Z)-22ed 
Chiral HPLC analysis: Lux Amylose-1, hexane-iPrOH 80:20, 1 
mL/min, E-isomer: major enantiomer tr = 36.7 min, minor 
enantiomer tr = 21.8 min. Z-isomer: major enantiomer tr = 24.6 
min, minor enantiomer tr = 43.7 min. 
Pale yellow oil; [α]D20 -52.3 (c 1.0, CHCl3, ee = 87% for the 
major diastereomer); 1H NMR (300 MHz, CDCl3) δ 8.15 (dt, J = 8.7, 2.4 Hz, 2H), 7.59 
(dt, J = 9.0, 2.1 Hz, 2H), 7.56 (dt, J = 8.4, 2.1 Hz, 2H), 7.26 (d, J = 9.6 Hz, 1H), 7.21 
(dd, J = 8.7, 0.6 Hz, 2H), 6.41 (s, 1H), 5.46 (d, J = 10.2 Hz, 1H), 4.30 (q, J = 7.2 Hz, 
1H), 4.28 (q, J = 7.2 Hz, 1H), 4.14 (q, J = 7.2 Hz, 1H), 4.12 (q, J = 6.9 Hz, 1H), 3.95 (q, 
J = 7.2 Hz, 1H), 3.94 (q, J = 7.2 Hz, 1H), 2.37 (s, 3H), 1.28 (t, J = 7.2 Hz, 3H), 1.19 (t, 
J = 7.2 Hz, 3H), 1.05 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 165.6 (C), 164.5 
(C), 163.4 (C), 147.5 (C), 144.1 (C), 142.9 (C), 136.4 (CH), 135.8 (C), 131.1 (CH), 
129.4 (CH), 127.5 (CH), 127.3 (C), 123.1 (CH), 73.6 (C), 63.64 (CH2), 63.59 (CH2), 
62.1 (CH2), 47.8 (CH3), 21.4 (CH3), 13.8 (CH3), 13.7 (CH3); HRMS (ESI) m/z 597.1310 
[M+H]+, C26H29ClN2O10S requires 597.1304. 
(S,Z)-Triethyl 1-chloro-2-(4-methoxyphenyl)-4-(4-methylphenylsulfonamido)but-3-
ene-1,1,4-tricarboxylate, (S,Z)-22ee 
Chiral HPLC analysis: Chiralcel AD-H, hexane-iPrOH 80:20, 1 
mL/min, E-isomer: major enantiomer tr = 28.8 min, minor 
enantiomer tr = 22.9 min. Z-isomer: major enantiomer tr = 17.4 
min, minor enantiomer tr = 33.5 min. 
Yellow oil; [α]D20 -29.3 (c 1.0, CHCl3, ee = 86% for the major 
diastereomer); 1H NMR (300 MHz, CDCl3) δ 7.64 (dt, J = 8.4, 1.8 Hz, 2H), 7.20 (d, J = 
8.7 Hz, 4H), 7.12 (d, J = 9.9 Hz, 1H), 6.79 (dt, J = 8.7, 1.8 Hz, 2H), 6.65 (s, 1H), 5.03 
(d, J = 9.9 Hz, 1H), 4.28 (q, J = 7.2 Hz, 2H), 4.25 (q, J = 7.2 Hz, 1H), 4.09 (q, J = 6.9 
Hz, 1H), 4.06 (q, J = 7.2 Hz, 1H), 4.00 (q, J = 7.2 Hz, 2H), 3.77 (s, 3H), 2.38 (s, 3H), 
1.27 (t, J = 6.9 Hz, 3H), 1.15 (t, J = 6.9 Hz, 3H), 1.10 (t, J = 7.2 Hz, 3H); 13C NMR (75 
MHz, CDCl3) δ 166.4 (C), 164.8 (C), 164.1 (C), 159.3 (C), 143.6 (C), 137.2 (CH), 
136.6 (C), 130.8 (CH), 129.3 (CH), 127.4 (CH), 127.1 (C), 126.1 (C), 113.6 (CH), 74.5 
(C), 63.4 (CH2), 63.2 (CH2), 61.8 (CH2), 55.1 (CH3), 47.4 (CH), 21.4 (CH3), 13.8 
(CH3), 13.7 (CH3); HRMS (ESI) m/z 582.1565 [M+H]+, C27H32ClNO9S requires 
582.1559. 
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(S,Z)-Triethyl 1-chloro-2-(3-chlorophenyl)-4-(4-methylphenylsulfonamido)but-3-
ene-1,1,4-tricarboxylate, (S,Z)-22ef 
Chiral HPLC analysis: Chiralcel AD-H, hexane-iPrOH 85:15, 0.7 
mL/min, E-isomer: major enantiomer tr = 33.3 min, minor 
enantiomer tr = 25.4 min. Z-isomer: major enantiomer tr = 27.6 
min, minor enantiomer tr = 39.7 min. 
White oil; [α]D20 -31.6 (c 1.0, CHCl3, ee = 82% for the major diastereomer); 1H NMR 
(300 MHz, CDCl3) δ 7.62 (dt, J = 8.1, 1.8 Hz, 2H), 7.25-7.20 (m, 6H), 7.17 (d, J = 9.6 
Hz, 1H), 6.59 (s, 1H), 5.11 (d, J = 9.9 Hz, 1H), 4.29 (q, J = 6.9 Hz, 2H), 4.27 (q, J = 7.2 
Hz, 1H), 4.12 (q, J = 7.2 Hz, 1H), 4.10 (q, J = 7.2 Hz, 1H), 4.01 (q, J = 6.9 Hz, 2H), 
2.38 (s, 3H), 1.28 (t, J = 7.2 Hz, 3H), 1.17 (t, J = 7.2 Hz, 3H), 1.11 (t, J = 6.9 Hz, 3H); 
13C NMR (75 MHz, CDCl3) δ 166.0 (C), 164.6 (C), 163.9 (C), 143.8 (C), 137.3 (C), 
136.4 (C), 136.2 (CH), 133.8 (C), 129.8 (CH), 129.4 (CH), 129.3 (C), 128.4 (CH), 
128.2 (CH), 127.4 (CH), 127.0 (CH), 74.0 (C), 63.54 (CH2), 63.46 (CH2), 62.0 (CH2), 
47.7 (CH3), 21.5 (CH3), 13.8 (CH3), 13.70 (CH3), 13.68 (CH3); HRMS (ESI) m/z 
586.1067 [M+H]+, C26H29Cl2NO8S requires 586.1064. 
(S,Z)-Triethyl 1-chloro-4-(4-methylphenylsulfonamido)-2-(3-nitrophenyl)but-3-
ene-1,1,4-tricarboxylate, (S,Z)-22eg 
Chiral HPLC analysis: Lux Amylose-1, hexane-iPrOH 80:20, 1 
mL/min, E-isomer: major enantiomer tr = 28.0 min, minor 
enantiomer tr = 20.2 min. Z-isomer: major enantiomer tr = 17.3 
min, minor enantiomer tr = 24.2 min. 
Yellow oil; [α]D20 -59.0 (c 1.0, CHCl3, ee = 87% for the major diastereomer); 1H NMR 
(300 MHz, CDCl3) δ 8.21 (t, J = 2.1 Hz, 1H), 8.15 (dq, J = 8.1, 2.4, 1.2 Hz, 1H), 7.75 
(dt, J = 7.8, 1.2 Hz, 1H), 7.55 (dt, J = 8.4, 1.8 Hz, 2H), 7.49 (t, J = 7.8 Hz, 1H), 7.28 (d, 
J = 9.3 Hz, 1H), 7.20 (dd, J = 8.4, 0.9 Hz, 1H), 6.42 (s, 1H), 5.43 (d, J = 9.6 Hz, 1H), 
4.31 (q, J = 7.2 Hz, 1H), 4.28 (q, J = 7.2 Hz, 1H), 4.16 (q, J = 7.2 Hz, 1H), 4.14 (q, J = 
7.2 Hz, 1H), 3.98 (q, J = 7.2 Hz, 1H), 3.97 (q, J = 6.9 Hz, 1H), 2.36 (s, 3H), 1.29 (t, J = 
7.2 Hz, 3H), 1.21 (t, J = 7.2 Hz, 3H), 1.08 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz, 
CDCl3) δ 165.5 (C), 164.5 (C), 163.5 (C), 147.8 (C), 144.1 (C), 137.6 (C), 136.7 (CH), 
136.1 (CH), 135.9 (C), 129.4 (CH), 128.9 (CH), 127.4 (CH), 127.3 (C), 124.6 (CH), 
123.1 (CH), 73.8 (C), 63.6 (CH2), 62.2 (CH2), 47.7 (CH3), 21.4 (CH3), 13.8 (CH3), 13.7 
(CH3); HRMS (ESI) m/z 597.1308 [M+H]+, C26H29ClN2O10S requires 597.1304. 
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(S,Z)-Triethyl 1-chloro-2-(3-methoxyphenyl)-4-(4-methylphenylsulfonamido)but-3-
ene-1,1,4-tricarboxylate, (S,Z)-22eh 
Chiral HPLC analysis: Lux Amylose-1, hexane-iPrOH 90:10, 1 
mL/min, E-isomer: major enantiomer tr = 53.5 min, minor 
enantiomer tr = 39.6 min. Z-isomer: major enantiomer tr = 31.9 
min, minor enantiomer tr = 50.0 min. 
Yellow oil; [α]D20 -8.7 (c 0.98, CHCl3, ee = 85% for the major diastereomer); 1H NMR 
(300 MHz, CDCl3) δ 7.65 (dt, J = 8.1, 1.8 Hz, 2H), 7.20 (dd, J = 8.1, 0.9 Hz, 2H), 7.18 
(td, J = 7.2, 0.9 Hz, 1H), 7.17 (d, J = 9.9 Hz, 1H), 6.88-6.84 (m, 3H), 6.65 (s, 1H), 5.03 
(d, J = 9.9 Hz, 1H), 4.29 (q, J = 7.2 Hz, 2H), 4.26 (q, J = 7.2 Hz, 1H), 4.10 (q, J = 6.9 
Hz, 1H), 4.07 (q, J = 7.2 Hz, 1H), 4.01 (q, J = 7.2 Hz, 1H), 3.78 (s, 3H), 2.38 (s, 3H), 
1.27 (t, J = 6.9 Hz, 3H), 1.14 (t, J = 7.2 Hz, 3H), 1.11 (t, J = 7.2 Hz, 3H); 13C NMR (75 
MHz, CDCl3) δ 166.3 (C), 164.8 (C), 164.1 (C), 159.2 (C), 143.7 (C), 136.8 (CH), 
136.64 (C), 136.58 (C), 129.3 (CH), 129.1 (CH), 127.4 (CH), 126.6 (C), 122.0 (CH), 
115.9 (CH), 113.3 (CH), 74.2 (C), 63.4 (CH2), 63.3 (CH2), 61.8 (CH2), 55.2 (CH3), 48.0 
(CH), 21.4 (CH3), 13.9 (CH3), 13.7 (CH3), 13.6 (CH3); HRMS (ESI) m/z 582.1566 
[M+H]+, C27H32ClNO9S requires 582.1559. 
 
(S,Z)-Triethyl 1-chloro-2-(2-chlorophenyl)-4-(4-methylphenylsulfonamido)but-3-
ene-1,1,4-tricarboxylate, (S,Z)-22ei 
Chiral HPLC analysis: Chiralcel AD-H, hexane-iPrOH 90:10, 1 
mL/min, E-isomer: major enantiomer tr = 46.1 min, minor 
enantiomer tr = 54.4 min. Z-isomer: major enantiomer tr = 50.3 
min, minor enantiomer tr = 71.5 min. 
Colorless oil; [α]D20 -37.1 (c 0.97, CHCl3, ee = 88% for the major diastereomer); 1H 
NMR (300 MHz, CDCl3) δ 7.74 (dt, J = 8.4, 1.8 Hz, 2H), 7.65-7.62 (m, 1H), 7.35-7.32 
(m, 1H), 7.23-7.20 (m, 4H), 6.99 (s, 1H), 6.94 (d, J = 9.9 Hz, 1H), 5.74 (d, J = 9.6 Hz, 
1H), 4.34 (q, J = 7.2 Hz, 1H), 4.30 (q, J = 7.2 Hz, H), 4.12 (q, J = 7.2 Hz, 1H), 4.06-
3.96 (m, 3H), 2.38 (s, 3H), 1.29 (t, J = 7.2 Hz, 3H), 1.11 (t, J = 6.9Hz, 3H), 1.09 (d, J = 
6.9 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 166.6 (C), 164.6 (C), 163.9 (C), 143.3 (C), 
137.7 (C), 134.8 (C), 133.7 (C), 133.4 (CH), 130.1 (CH), 129.9 (CH), 129.2 (CH), 
127.8 (C), 127.2 (CH), 126.8 (CH), 73.9 (C), 63.7 (CH2), 63.5 (CH2), 61.7 (CH2), 43.0 
(CH), 21.5 (CH3), 13.8 (CH3), 13.7 (CH3), 13.5 (CH3); HRMS (ESI) m/z 586.1060 
[M+H]+, C26H29Cl2NO8S requires 586.1064. 
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(S,Z)-Triethyl 1-chloro-4-(4-methylphenylsulfonamido)-2-(2-nitrophenyl)but-3-
ene-1,1,4-tricarboxylate, (S,Z)-22ej 
Chiral HPLC analysis: Lux Amylose-1, hexane-iPrOH 80:20, 1 
mL/min, E-isomer: major enantiomer tr = 21.5 min, minor 
enantiomer tr = 18.8 min. Z-isomer: major enantiomer tr = 41.1 
min, minor enantiomer tr = 53.0 min. 
Orange oil; [α]D20 - 37.1 (c 0.96, CHCl3, ee = 88% for the major diastereomer); 1H 
NMR (300 MHz, CDCl3) δ 7.88 (dd, J = 8.1, 1.2 Hz, 1H), 7.75 (dd, J = 7.8, 1.2 Hz, 
1H), 7.61-7.55 (m, 3H), 7.46 (ddd, J = 8.1, 7.2, 1.5 Hz, 1H), 7.17 (dd, J = 8.1, 0.9 Hz, 
2H), 6.97 (d, J = 8.7 Hz, 1H), 6.92 (s, 1H), 5.98 (d, J = 8.7 Hz, 1H), 4.31 (q, J = 7.2 Hz, 
1H), 4.30 (q, J = 7.2 Hz, 1H),  4.18-3.96 (m, 4H), 2.35 (s, 3H), 1.29 (t, J = 7.2 Hz, 3H), 
1.14 (t, J = 7.2 Hz, 3H), 1.12 (d, J = 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 165.5 
(C), 164.8 (C), 163.6 (C), 150.1 (C), 143.5 (C), 137.1 (C), 132.5 (CH), 131.5 (CH), 
130.7 (C), 130.3 (CH), 129.3 (C), 129.1 (CH), 128.9 (CH), 127.2 (CH), 125.0 (CH), 
73.9 (C), 63.8 (CH2), 63.7 (CH2), 61.9 (CH2), 40.7 (CH), 21.4 (CH3), 13.8 (CH3), 13.7 
(CH3), 13.5 (CH3); HRMS (ESI) m/z 597.1316 [M+H]+, C26H29ClN2O10S requires 
597.1304. 
(S,Z)-Triethyl 1-chloro-2-(2-methoxyphenyl)-4-(4-methylphenylsulfonamido)but-3-
ene-1,1,4-tricarboxylate, (S,Z)-22ek 
Chiral HPLC analysis: Lux Amylose-1, hexane-iPrOH 80:20, 1 
mL/min, E-isomer: major enantiomer tr = 27.4 min, minor 
enantiomer tr = 22.1 min. Z-isomer: major enantiomer tr = 12.4 
min, minor enantiomer tr = 31.4 min. 
Yellow oil; [α]D20 -25.2 (c 0.98, CHCl3, ee = 87% for the major diastereomer); 1H 
NMR (300 MHz, CDCl3) δ 7.72 (dt, J = 8.4, 1.8 Hz, 2H), 7.43 (dd, J = 8.4, 1.8 Hz, 1H), 
7.24-7.20 (m, 3H), 7.03 (s, 1H), 7.02 (d, J = 10.2 Hz, 1H), 6.89 (td, J = 7.2, 1.2 Hz 1H), 
5.55 (d, J = 9.9 Hz, 1H), 4.31 (q, J = 7.2 Hz, 1H), 4.28 (q, J = 6.9 Hz, 1H), 4.07 (q, J = 
7.2 Hz, 1H), 4.030 (q, J = 7.2 Hz, 1H), 4.027 (q, J = 7.2 Hz, 2H), 3.83 (s, 3H), 2.38 (s, 
3H), 1.28 (t, J = 6.9 Hz, 3H), 1.11 (t, J = 7.2 Hz, 3H), 1.08 (d, J = 7.2 Hz, 3H); 13C 
NMR (75 MHz, CDCl3) δ 166.5 (C), 165.2 (C), 164.1 (C), 156.9 (C), 143.1 (C), 138.0 
(C), 134.3 (CH), 129.8 (CH), 129.2 (CH), 129.1 (CH), 127.2(CH), 127.0 (C), 124.1 (C), 
120.5 (CH), 110.8 (CH), 73.7 (C), 63.3 (CH2), 63.1 (CH2), 61.5 (CH2), 55.6 (CH3), 40.6 
(CH), 21.5 (CH3), 13.8 (CH3), 13.7 (CH3), 13.5 (CH3); HRMS (ESI) m/z 582.1560 
[M+H]+, C27H32ClNO9S requires 582.1559. 
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(S,Z)-Triethyl 1-chloro-4-(4-methylphenylsulfonamido)-2-(thiophen-2-yl)but-3-
ene-1,1,4-tricarboxylate, (S,Z)-22em 
Chiral HPLC analysis: Lux Amylose-1, hexane-iPrOH 90:10, 1 
mL/min, E-isomer: major enantiomer tr = 70.0 min, minor 
enantiomer tr = 41.7 min. Z-isomer: major enantiomer tr = 32.9 
min, minor enantiomer tr = 58.9 min. 
Yellow oil; [α]D20 -30.4 (c 0.98, CHCl3, ee = 84% for the major diastereomer); 1H 
NMR (300 MHz, CDCl3) δ 7.63 (dt, J = 8.4, 1.8 Hz, 2H), 7.24 (dd, J = 5.1, 1.2 Hz, 1H), 
7.20 (dd, J = 8.7, 0.9 Hz, 2H), 7.12 (d, J = 9.9 Hz, 1H), 7.01 (dq, J = 3.6, 0.6 Hz, 1H), 
6.93 (dd, J = 5.1, 3.6 Hz, 1H), 6.52 (s, 1H), 5.54 (d, J = 9.9 Hz, 1H), 4.28 (q, J = 7.2 Hz, 
1H), 4.27 (q, J = 7.2 Hz, 1H), 4.18 (q, J = 6.9 Hz, 1H), 4.16 (q, J = 7.2 Hz, 1H), 3.99 (q, 
J = 7.2 Hz, 2H), 2.37 (s, 3H), 1.28 (t, J = 6.9 Hz, 3H), 1.21 (t, J = 6.9 Hz, 3H), 1.09 (t, J 
= 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 165.8 (C), 164.6 (C), 163.9 (C), 143.8 (C), 
136.4 (C), 136.24 (C), 136.21 (CH), 129.3 (CH), 128.4 (CH), 127.5 (CH), 126.4 (C), 
126.2 (CH), 125.9 (CH), 74.3 (C), 63.5 (CH2), 63.4 (CH2), 61.9 (CH2), 44.4 (CH3), 21.4 
(CH3), 13.8 (CH3), 13.7 (CH3); HRMS (ESI) m/z 558.1019 [M+H]+, C24H28ClNO8S2 
requires 558.1018.  
(S,Z)-1,1-Diethyl 4-methyl 1-chloro-4-(4-methylphenylsulfonamido)-2-phenylbut-3-
ene-1,1,4-tricarboxylate, (S,Z)-22en 
Chiral HPLC analysis: Chiralcel AD-H, hexane-iPrOH 80:20, 1 
mL/min, E-isomer: major enantiomer tr = 26.5 min, minor 
enantiomer tr = 16.1 min. Z-isomer: major enantiomer tr = 14.1 
min, minor enantiomer tr = 19.3 min. 
Pale yellow oil; [α]D20 -31.9 (c 0.98, CHCl3, ee = 83% for the major diastereomer); 1H 
NMR (300 MHz, CDCl3) δ 7.65 (dt, J = 8.4, 2.1 Hz, 2H), 7.25 (s,5H), 7.20 (dd, J = 8.4, 
0.6 Hz, 2H), 7.19 (d, J = 9.9 Hz, 1H), 6.75 (s, 1H), 5.00 (d, J = 9.9 Hz, 1H), 4.34-4.21 
(m, 2H), 4.11-3.99 (m, 2H), 3.57 (s, 3H), 2.39 (s, 3H), 1.27 (t, J = 7.2 Hz, 3H), 1.12 (t, J 
= 6.9 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 166.4 (C), 164.7 (C), 164.6 (C), 143.6 (C), 
136.9 (CH), 136.6 (C), 135.1 (C), 129.6 (CH), 129.4 (CH), 128.2 (CH), 127.4 (CH), 
126.4 (C), 74.2 (C), 63.5 (CH2), 63.3 (CH2), 52.5 (CH3), 48.1 (CH), 21.5 (CH3), 13.7 
(CH3), 13.6 (CH3); HRMS (ESI) m/z 538.1298 [M+H]+, C25H28ClNO8S requires 
538.1297. 
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(S,Z)-1,1-Diethyl 4-isopropyl (Z)-1-chloro-4-((4-methylphenyl)sulfonamido)-2-
phenylbut-3-ene-1,1,4-tricarboxylate, (S,Z)-22eo 
Chiral HPLC analysis: Lux Amylose-1, hexane-iPrOH 80:20, 1 
mL/min, E-isomer: major enantiomer tr = 16.0 min, minor 
enantiomer tr = 11.9 min. Z-isomer: major enantiomer tr = 10.4 
min, minor enantiomer tr = 28.7 min. 
Yellow oil; [α]D20 -30.8 (c 0.96, CHCl3, ee = 92% for the major diastereomer); 1H 
NMR (300 MHz, CDCl3) δ 7.63 (dt, J = 8.4, 1.8 Hz, 2H), 7.28-7.26 (m, 5H), 7.21 (d, J 
= 9.9 Hz, 1H), 7.19 (dd, J = 8.7, 0.9 Hz, 2H), 6.59 (s, 1H), 5.13 (d, J = 9.9 Hz, 1H), 
4.82 (quint, J = 6.3 Hz, 1H), 4.30 (q, J = 7.2 Hz, 1H), 4.27 (q, J = 7.2 Hz, 1H), 4.08 (q, 
J = 7.2 Hz, 1H), 4.06 (q, J = 6.9 Hz, 1H), 2.37 (s, 3H), 1.28 (t, J = 6.9 Hz, 3H), 1.14 (t, 
J = 7.2 Hz, 3H), 1.10 (d, J = 6.6 Hz, 3H), 1.08 (d, J = 6.3 Hz, 3H); 13C NMR (75 MHz, 
CDCl3) δ 166.3 (C), 164.8 (C), 163.6 (C), 143.6 (C), 136.7 (CH), 136.5 (C), 135.4 (C), 
129.8 (CH), 129.4 (CH), 128.1 (CH), 127.5 (CH), 126.7 (C), 74.4 (C), 69.8 (CH), 63.4 
(CH2), 63.3 (CH2), 48.1 (CH), 21.44 (CH3), 21.40 (CH3), 21.3 (CH3), 13.72 (CH3), 
13.66 (CH3); HRMS (ESI) m/z 566.1612 [M+H]+, C27H32ClNO8S requires 566.1610. 
(S,Z)-4-Ethyl 1,1-dimethyl 1-chloro-4-(4-methylphenylsulfonamido)-2-phenylbut-
3-ene-1,1,4-tricarboxylate, (S,Z)-22fa 
Chiral HPLC analysis: Lux Amylose-1, hexane-iPrOH 80:20, 1 
mL/min, E-isomer: major enantiomer tr = 24.9 min, minor 
enantiomer tr = 16.0 min. Z-isomer: major enantiomer tr = 17.0 
min, minor enantiomer tr = 21.4 min. 
Colorless oil; [α]D20 -35.4 (c 0.98, CHCl3, ee = 84% for the major diastereomer); 1H 
NMR (300 MHz, CDCl3) δ 7.61 (dt, J = 8.1, 1.8 Hz, 2H), 7.27-7.25 (m, 5H), 7.24 (d, J 
= 9.9 Hz, 1H), 7.18 (dd, J = 8.7, 0.9 Hz, 2H), 6.65 (s, 1H), 5.15 (d, J = 9.9 Hz, 1H), 
3.98 (q, J = 7.2 Hz, 2H), 3.81 (s, 3H), 3.61 (s, 3H), 2.36 (s, 3H), 1.09 (t, J = 7.2 Hz, 
3H); 13C NMR (75 MHz, CDCl3) δ 166.7 (C), 165.3 (C), 164.0 (C), 143.7 (C), 137.1 
(CH), 136.4 (C), 135.2 (C), 129.7 (CH), 129.4 (CH), 128.3 (CH), 128.2 (CH), 127.5 
(CH), 126.6 (C), 74.2 (C), 61.9 (CH2), 54.1 (CH3), 53.8 (CH3), 48.2 (CH), 21.5 (CH3), 
13.9 (CH3); HRMS (ESI) m/z 524.1143 [M+H]+, C24H26ClNO8S requires 524.1140. 
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5.5.2. Enantioselective conjugate addition of diethyl 2-chloromalonate to α,β-
unsaturated N-tosyl imino esters catalyzed by Ca(OTf)2. 
5.5.2.1. General procedure for the enantioselective conjugate addition 
Ca(OTf)2 (2.1 mg, 0.00625 mmol) was dried in a Schlenk tube under vacuum. pyBOX1 
(2.3 mg, 0.00625 mmol) was added and the tube was filled with nitrogen. CH2Cl2 (0.55 
mL) was added via syringe and the mixture was stirred for 30 min. A solution of imine 
17 (0.25 mmol) dissolved in dry CH2Cl2 (0.5 mL) was added via syringe followed by 4 
Å MS (110 mg), and the mixture was introduced in an ice bath. After 10 minutes, 
diethyl 2-chloromalonate (32 µL, 0.187 mmol) was added to the reaction. The mixture 
was stirred at 0º C for the indicated time and chromatographed on silica gel eluting with 
hexane/EtOAc mixtures to give compound (E)-22. 
5.5.2.2. General procedure for the synthesis of the racemic products 
Racemic compounds for comparative purpose were prepared by following the same 
procedure, using La(OTf)3 in absence of chiral ligand and performing the reaction at 
room temperature. 
5.5.2.3. Characterization of products (S,E)-22 
See Table 19 (Page 97) for yield, dr and ee. 
(S,E)-Triethyl 1-chloro-4-(4-methylphenylsulfonamido)-2-phenylbut-3-ene-1,1,4-
tricarboxylate, (S,E)-22ea 
Chiral HPLC analysis: Chiralcel AD-H, hexane-iPrOH 80:20, 1 
mL/min, E-isomer: major enantiomer tr = 22.2 min, minor 
enantiomer tr = 15.4 min. Z-isomer: major enantiomer tr = 14.1 
min, minor enantiomer tr = 28.4 min. 
White solid; mp 75-77 ºC; [α]D20 60.7 (c 1.00, CHCl3, ee = 97% for the major 
diastereomer); 1H NMR (300 MHz, CDCl3) δ 7.50 (dt, J = 8.4, 1.8 Hz, 2H), 7.31-7.25 
(m, 5H), 7.12 (d, J = 10.2 Hz, 1H), 7.09 (dd, J = 7.8, 0.9 Hz, 2H), 6.63 (s, 1H), 5.62 (d, 
J = 10.5 Hz, 1H), 4.19 (q, J = 7.2 Hz, 2H), 4.07 (q, J = 7.2 Hz, 1H), 4.06 (q, J = 6.9 Hz, 
1H), 4.03 (q, J = 7.2 Hz, 2H), 2.34 (s, 3H), 1.23 (t, J = 7.2 Hz, 3H), 1.12 (t, J = 6.9 Hz, 
3H), 1.11 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 165.7 (C), 165.1 (C), 162.6 
(C), 143.7 (C), 136.8 (C), 135.7(C), 132.8 (CH), 129.8 (CH), 129.4 (CH), 128.1 (CH), 
127.9 (CH), 127.6 (CH), 124.9 (C), 74.4 (C), 63.1 (CH2), 63.0 (CH2), 62.0 (CH2), 48.2 
(CH), 21.4 (CH3), 13.9 (CH3), 13.7 (CH3), 13.6 (CH3); HRMS (ESI) m/z 552.1456 
[M+H]+, C26H30ClNO8S requires 552.1453. 
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(S,E)-Triethyl 1-chloro-4-(4-methylphenylsulfonamido)-2-(p-tolyl)but-3-ene-1,1,4-
tricarboxylate, (S,E)-22eb 
Chiral HPLC analysis: Lux Amylose-1, hexane-iPrOH 90:10, 1 
mL/min, E-isomer: major enantiomer tr = 46.5 min, minor 
enantiomer tr = 27.9 min. Z-isomer: major enantiomer tr = 24.4 
min, minor enantiomer tr = 41.3 min. 
Pale yellow oil; [α]D20 70.6 (c 0.98, CHCl3, ee = 98% for the 
major diastereomer); 1H NMR (300 MHz, CDCl3) δ 7.52 (dt, J = 8.4, 1.8 Hz, 2H), 7.16 
(dt, J = 8.1, 1.8 Hz, 2H), 7.12-7.05 (m, 4H), 7.10 (d, J = 10.2 Hz, 1H), 6.64 (s, 1H), 5.59 
(d, J = 10.2 Hz, 1H), 4.19 (q, J = 7.2 Hz, 2H), 4.09 (q, J = 7.2 Hz, 1H), 4.07 (q, J = 7.2 
Hz, 1H), 4.023 (q, J = 7.2 Hz, 1H), 4.022 (q, J = 7.2 Hz, 1H), 2.35 (s, 3H), 2.30 (s, 3H), 
1.23 (t, J = 6.9 Hz, 3H), 1.14 (t, J = 7.2 Hz, 3H), 1.12 (d, J = 7.2 Hz, 3H); 13C NMR (75 
MHz, CDCl3) δ 165.7 (C), 165.1 (C), 162.6 (C), 143.6 (C), 137.6 (C), 135.7 (C), 133.7 
(C), 132.9 (CH), 129.5 (CH), 129.3 (CH), 128.8 (CH), 127.6 (CH), 124.6 (C), 74.5 (C), 
63.1 (CH2), 62.9 (CH2), 61.9 (CH2), 47.7 (CH), 21.4 (CH3), 21.0 (CH3), 13.8 (CH3), 
13.69 (CH3), 13.67 (CH3); HRMS (ESI) m/z 566.1616 [M+H]+, C27H32ClNO8S requires 
566.1610. 
(S,E)-Triethyl 1-chloro-2-(4-chlorophenyl)-4-(4-methylphenylsulfonamido)but-3-
ene-1,1,4-tricarboxylate, (S,E)-22ec  
Chiral HPLC analysis: Lux Amylose-1, hexane-iPrOH 95:05, 1.6 
mL/min, E-isomer: major enantiomer tr = 95.9 min, minor 
enantiomer tr = 61.2 min. Z-isomer: major enantiomer tr = 52.3 
min, minor enantiomer tr = 73.5 min. 
White; mp 87-88 ºC; [α]D20 77.8 (c 1.0, CHCl3, ee = 98% for the 
major diastereomer); 1H NMR (300 MHz, CDCl3) δ 7.52 (dt, J = 
8.4, 1.8 Hz, 2H), 7.23 (s, 4H), 7.13 (dd, J = 8.4, 0.9 Hz, 2H), 7.03 (d, J = 10.2 Hz, 1H), 
6.65 (s, 1H), 5.60 (d, J = 10.2 Hz, 1H), 4.19 (q, J = 7.2 Hz, 2H), 4.10 (q, J = 7.2 Hz, 
1H), 4.09 (q, J = 7.2 Hz, 1H), 4.03 (q, J = 7.2 Hz, 2H), 2.36 (s, 3H), 1.23 (t, J = 6.9 Hz, 
3H), 1.14 (t, J = 7.2 Hz, 3H), 1.12 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 
165.5 (C), 165.0 (C), 162.3 (C), 143.9 (C), 135.8 (C), 135.4 (C), 133.9 (C), 131.9 (CH), 
131.2 (CH), 129.4 (CH), 128.2 (CH), 127.5 (CH), 125.2 (C), 74.1 (C), 63.3 (CH2), 63.2 
(CH2), 62.1 (CH2), 47.5 (CH3), 21.5 (CH3), 13.9 (CH3), 13.7(CH3); HRMS (ESI) m/z  
586.1056 [M+H]+, C26H29Cl2NO8S requires 586.1064. 
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(S,E)-Triethyl 1-chloro-4-(4-methylphenylsulfonamido)-2-(4-nitrophenyl)but-3-
ene-1,1,4-tricarboxylate, (S,E)-22ed 
Chiral HPLC analysis: Lux Amylose-1, hexane-iPrOH 80:20, 1 
mL/min, E-isomer: major enantiomer tr = 34.2 min, minor 
enantiomer tr = 21.1 min. Z-isomer: major enantiomer tr = 27.6 
min, minor enantiomer tr = 43.5 min. 
Yellow solid; Mp 128-129 ºC; [α]D20 44.8 (c 1.0, CHCl3, ee = 
97% for the major diastereomer); 1H NMR (300 MHz, CDCl3) δ 8.09 (dt, J = 9.0, 2.1 
Hz, 2H), 7.57 (dt, J = 8.4, 2.1 Hz, 2H), 7.44 (dt, J = 8.7, 1.8 Hz, 2H), 7.17 (dt, J = 8.7, 
0.9 Hz, 2H), 6.98 (d, J = 9.9 Hz, 1H), 6.76 (s, 1H), 5.70 (d, J = 9.9 Hz, 1H), 4.20 (q, J = 
7.2 Hz, 2H), 4.11 (q, J = 7.2 Hz, 1H), 4.10 (q, J = 7.2 Hz, 1H), 4.04 (q, J = 7.2 Hz, 2H), 
2.37 (s, 3H), 1.23 (t, J = 7.2 Hz, 3H), 1.15 (t, J = 7.2 Hz, 3H), 1.12 (t, J = 7.2 Hz, 3H); 
13C NMR (75 MHz, CDCl3) δ 165.1 (C), 164.8 (C), 161.9 (C), 147.2 (C), 144.4 (C), 
144.1 (C), 135.8 (C), 130.9 (CH), 129.8 (CH), 129.5 (CH), 127.5 (CH), 126.1 (C), 
123.0 (CH), 73.7 (C), 63.5 (CH2), 63.4 (CH2), 62.2 (CH2), 47.8 (CH3), 21.4 (CH3), 13.8 
(CH3), 13.7 (CH3); HRMS (ESI) m/z 597.1281 [M+H]+, C26H29ClN2O10S requires 
597.1304. 
(S,E)-Triethyl 1-chloro-2-(4-methoxyphenyl)-4-(4-methylphenylsulfonamido)but-3-
ene-1,1,4-tricarboxylate, (S,E)-22ee  
Chiral HPLC analysis: Chiralcel AD-H, hexane-iPrOH 80:20, 1 
mL/min, E-isomer: major enantiomer tr = 28.7 min, minor 
enantiomer tr = 23.1 min. Z-isomer: major enantiomer tr = 18.1 
min, minor enantiomer tr = 34.7 min. 
Yellow oil; [α]D20 84.2 (c 0.95, CHCl3, ee = 98% for the major 
diastereomer); 1H NMR (300 MHz, CDCl3) δ 7.51 (dt, J = 8.4, 1.8 Hz, 2H), 7.22 (dt, J 
= 9.0, 3.0 Hz, 2H), 7.12 (dd, J = 8.4, 0.9 Hz, 2H), 7.09 (d, J = 10.5 Hz, 1H), 6.80 (dt, J 
= 8.7, 3.3 Hz, 2H), 6.60 (s, 1H), 5.59 (d, J = 10.5 Hz, 1H), 4.19 (q, J = 6.9 Hz, 2H), 4. 
09 (q, J = 7.2 Hz, 1H), 4.08 (q, J = 7.2 Hz, 1H), 4.03 (q, J = 7.2 Hz, 2H), 3.78 (s, 3H), 
2.35 (s, 3H), 1.23 (t, J = 6.9 Hz, 3H), 1.14 (t, J = 6.9 Hz, 3H), 1.13 (t, J = 7.2 Hz, 3H); 
13C NMR (75 MHz, CDCl3) δ 165.7 (C), 165.2 (C), 162.6 (C), 159.2 (C), 143.7 (C), 
135.8 (C), 133.3 (CH), 130.9 (CH), 129.4 (CH), 128.8 (CH), 127.6 (CH), 124.6 (C), 
113.5 (CH), 74.6 (C), 63.1 (CH2), 63.0 (CH2), 61.9(CH2), 55.2 (CH3), 47.3 (CH), 21.5 
(CH3), 13.9 (CH3), 13.7 (CH3); HRMS (ESI) m/z  582.1547 [M+H]+, C27H32ClNO9S 
requires 582.1559. 
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(S,E)-Triethyl 1-chloro-2-(3-chlorophenyl)-4-(4-methylphenylsulfonamido)but-3-
ene-1,1,4-tricarboxylate, (S,E)-22ef 
Chiral HPLC analysis: Chiralcel AD-H, hexane-iPrOH 85:15, 0.7 
mL/min, E-isomer: major enantiomer tr = 39.2 min, minor 
enantiomer tr = 29.8 min. Z-isomer: major enantiomer tr = 27.9 
min, minor enantiomer tr = 33.6 min. 
Colorless oil; [α]D20 44.5 (c 1.0, CHCl3, ee = 96% for the major diastereomer); 1H 
NMR (300 MHz, CDCl3) δ 7.55 (dt, J = 8.4, 1.8 Hz, 2H), 7.25-7.18 (m, 4H), 7.15 (dd, J 
= 8.4, 0.6 Hz, 2H), 7.01 (d, J = 10.2 Hz, 1H), 6.71 (s, 1H), 5.57 (d, J = 10.2 Hz, 1H), 
4.20 (q, J = 7.2 Hz, 2H), 4.11 (q, J = 7.2 Hz, 1H), 4.10 (q, J = 6.9 Hz, 1H), 4.05 (q, J = 
6.9 Hz, 2H), 2.36 (s, 3H), 1.23 (t, J = 7.2 Hz, 3H), 1.15 (t, J = 6.9 Hz, 3H), 1.13 (t, J = 
7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 165.4 (C), 164.9 (C), 162.3 (C), 143.9 (C), 
138.9 (C), 135.7 (C), 133.7 (C), 131.1 (C), 130.0 (CH), 129.4 (CH), 129.3 (CH), 128.0 
(CH), 127.9 (CH), 127.5 (CH), 125.4 (C), 74.1 (C), 63.3 (CH2), 63.2 (CH2), 62.1 (CH2), 
47.8 (CH3), 21.4 (CH3), 13.8 (CH3), 13.69 (CH3), 13.68 (CH3); HRMS (ESI) m/z  
586.1057 [M+H]+, C26H29Cl2NO8S requires 586.1064. 
(S,E)-Triethyl 1-chloro-4-(4-methylphenylsulfonamido)-2-(3-nitrophenyl)but-3-
ene-1,1,4-tricarboxylate, (S,E)-22eg  
Chiral HPLC analysis: Lux Amylose-1, hexane-iPrOH 80:20, 1 
mL/min, E-isomer: major enantiomer tr = 27.6 min, minor 
enantiomer tr = 20.0 min. Z-isomer: major enantiomer tr = 17.9 
min, minor enantiomer tr = 24.5 min. 
Yellow solid; Mp 94-96 ºC; [α]D20 2.6 (c 1.0, CHCl3, ee = 93% for the major 
diastereomer); 1H NMR (300 MHz, CDCl3) δ 8.13 -8.08 (m, 2H), 7.67 (dt, J = 7.8, 1.2 
Hz, 1H), 7.60 (dt, J = 8.4, 1.8 Hz, 2H), 7.45 (t, J = 7.8 Hz, 1H), 7.17 (dd, J = 8.7, 0.6 
Hz, 2H), 6.99 (d, J = 9.9 Hz, 1H), 6.78 (s, 1H), 5.70 (d, J = 9.9 Hz, 1H), 4.212 (q, J = 
7.2 Hz, 2H), 4.21 (q, J = 7.2 Hz, 1H), 4.13 (q, J = 7.2 Hz, 1H), 4.06 (q, J = 7.2 Hz, 2H), 
2.36 (s, 3H), 1.24 (t, J = 7.2 Hz, 3H), 1.17 (t, J = 7.2 Hz, 3H), 1.15 (t, J = 7.2 Hz, 3H); 
13C NMR (75 MHz, CDCl3) δ 165.2 (C), 165.1 (C), 162.2 (C), 149.4 (C), 144.0 (C), 
135.6 (C), 132.4 (CH), 132.3 (C), 131.8 (CH), 129.5 (CH), 128.6 (CH), 128.4 (CH), 
127.4 (CH), 126.5 (C), 124.5 (CH), 74.1 (C), 63.3 (CH2), 63.2 (CH2), 62.5 (CH2), 40.9 
(CH3), 21.4 (CH3), 13.8 (CH3), 13.7 (CH3), 13.4 (CH3); HRMS (ESI) m/z  597.1302 
[M+H]+, C26H29ClN2O10S requires 597.1304. 
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(S,E)-Triethyl 1-chloro-2-(3-methoxyphenyl)-4-(4-methylphenylsulfonamido)but-3-
ene-1,1,4-tricarboxylate, (S,E)-22eh  
Chiral HPLC analysis: Lux Amylose-1, hexane-iPrOH 90:10, 1 
mL/min, E-isomer: major enantiomer tr = 53.3 min, minor 
enantiomer tr = 40.5 min. Z-isomer: major enantiomer tr = 34.1 
min, minor enantiomer tr = 51.3 min. 
Yellow solid; Mp 66-67 ºC; [α]D20 76.9 (c 1.0, CHCl3, ee = 96% for the major 
diastereomer); 1H NMR (300 MHz, CDCl3) δ 7.50 (dt, J = 8.4, 1.8 Hz, 2H), 7.18 (t, J = 
7.5 Hz, 1H), 7.10 (dd, J = 8.4, 0.9 Hz, 2H), 7.09 (d, J = 10.2 Hz, 1H), 6.88-6.80 (m, 
3H), 6.63 (s, 1H), 5.61(d, J = 10.5 Hz, 1H), 4.19 (q, J = 7.2 Hz, 2H), 4.10 (q, J = 7.2 
Hz, 1H), 4.08 (q, J = 7.2 Hz, 1H), 4.029 (q, J = 7.2 Hz, 1H), 4.027 (q, J = 7.2 Hz, 1H), 
3.78 (s, 3H), 2.34 (s, 3H), 1.23 (t, J = 6.9 Hz, 3H), 1.13 (t, J = 7.2 Hz, 3H), 1.12 (t, J = 
6.9 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 165.7 (C), 165.1 (C), 162.6 (C), 159.8 (C), 
143.7 (C), 138.1 (C), 135.8 (C), 132.8 (CH), 129.4 (CH), 129.0 (CH), 127.5 (CH), 
124.9 (C), 122.1 (CH), 115.5 (CH), 113.0 (CH), 74.4 (C), 63.1 (CH2), 63.0 (CH2), 62.0 
(CH2), 55.1 (CH3), 48.0 (CH), 21.4 (CH3), 13.9 (CH3), 13.70 (CH3), 13.67 (CH3); 
HRMS (ESI) m/z  582.1545 [M+H]+, C27H32ClNO9S requires 582.1559. 
(S,E)-Triethyl 1-chloro-2-(2-chlorophenyl)-4-(4-methylphenylsulfonamido)but-3-
ene-1,1,4-tricarboxylate, (S,E)-22ei  
Chiral HPLC analysis: Chiralcel AD-H, hexane-iPrOH 90:10, 1 
mL/min, E-isomer: major enantiomer tr = 52.9 min, minor 
enantiomer tr = 47.9 min. Z-isomer: major enantiomer tr = 73.5 
min, minor enantiomer tr = 51.6 min. 
White solid; Mp 73-75 ºC; [α]D20 2.7 (c 0.97, CHCl3, ee = 98% for the major 
diastereomer); 1H NMR (300 MHz, CDCl3) δ 7.55 (dd, J = 6.3, 1.5 Hz, 1H), 7.52 (dt, J 
= 8.4, 1.8 Hz, 2H), 7.33-7.30 (m, 1H), 7.24-7.20 (m, 2H), 7.12 (dd, J = 8.4, 0.9 Hz, 2H), 
6.74 (s, 1H), 6.13 (d, J = 10.2 Hz, 1H), 4.24- 3.99 (m, 6H), 2.35 (s, 3H), 1.23 (t, J = 7.2 
Hz, 3H), 1.11 (t, J = 7.2 Hz, 3H), 1.09 (d, J = 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) 
δ 165.5 (C), 165.0 (C), 162.7 (C), 143.8 (C), 135.7 (C), 135.1 (C), 134.3 (C), 131.3 
(CH), 130.0 (CH), 129.40 (CH), 129.38 (CH), 128.9 (CH), 127.5 (CH), 126.7 (CH), 
125.8 (C), 74.1 (C), 63.3 (CH2), 63.1 (CH2), 62.4 (CH2), 55.2 (CH3), 43.2 (CH), 21.4 
(CH3), 13.9 (CH3), 13.7 (CH3), 13.5 (CH3); HRMS (ESI) m/z  586.1056 [M+H]+, 
C26H29Cl2NO8S requires 586.1064. 
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(S,E)-Triethyl 1-chloro-4-(4-methylphenylsulfonamido)-2-(2-nitrophenyl)but-3-
ene-1,1,4-tricarboxylate, (S,E)-22ej  
Chiral HPLC analysis: Lux Amylose-1, hexane-iPrOH 80:20, 1 
mL/min, E-isomer: major enantiomer tr = 23.4 min, minor 
enantiomer tr = 20.4 min. Z-isomer: major enantiomer tr = 45.5 
min, minor enantiomer tr = 60.1 min. 
Orange oil; [α]D20 -117.4 (c 1.0, CHCl3, ee = 99% for the major diastereomer); 1H 
NMR (300 MHz, CDCl3) δ 7.85 (dd, J = 8.1, 1.5 Hz, 1H), 7.79 (dd, J = 8.1, 1.5 Hz, 
1H), 7.59 (td, J = 7.5, 1.5 Hz, 1H), 7.49 (dt, J = 8.4, 1.8 Hz, 2H), 7.44 (ddd, J = 8.1, 7.2, 
1.2 Hz, 1H), 7.14 (dd, J = 8.7, 0.9 Hz, 2H), 6.92 (d, J = 9.9 Hz, 1H), 6.74 (s, 1H), 6.29 
(d, J = 9.9 Hz, 1H), 4.17 (q, J = 7.2 Hz, 2H), 4.12- 3.98 (m, 4H), 2.36 (s, 3H), 1.21 (t, J 
= 7.2 Hz, 3H), 1.12 (t, J = 7.2 Hz, 3H), 1.05(d, J = 7.2 Hz, 3H); 13C NMR (75 MHz, 
CDCl3) δ 165.2 (C), 165.1 (C), 162.2 (C), 149.4 (C), 144.0 (C), 135.6 (C), 132.4 (CH), 
132.3 (C), 131.8 (CH), 129.5 (CH), 128.6 (CH), 128.4 (CH), 127.4 (CH), 126.5 (C), 
124.5 (CH), 74.1 (C), 63.3 (CH2), 63.2 (CH2), 62.5 (CH2), 40.9 (CH), 21.4 (CH3), 13.8 
(CH3), 13.7 (CH3), 13.4 (CH3); HRMS (ESI) m/z  597.1307 [M+H]+, C26H29ClN2O10S 
requires 597.1304. 
(S,E)-Triethyl 1-chloro-2-(2-methoxyphenyl)-4-(4-methylphenylsulfonamido)but-3-
ene-1,1,4-tricarboxylate, (S,E)-22ek  
Chiral HPLC analysis: Lux Amylose-1, hexane-iPrOH 80:20, 1 
mL/min, E-isomer: major enantiomer tr = 26.3 min, minor 
enantiomer tr = 21.9 min. Z-isomer: major enantiomer tr = 12.7 
min, minor enantiomer tr = 32.0 min. 
Yellow oil; [α]D20 15.9 (c 0.97, CHCl3, ee = 95% for the major diastereomer); 1H NMR 
(300 MHz, CDCl3) δ 7.56 (dt, J = 8.4, 1.8 Hz, 2H), 7.32 (dd, J =7.5, 1.5 Hz, 1H), 7.23 
(ddd, J = 8.1, 7.5, 1.8 Hz, 1H), 7.12 (dd, J = 8.1, 0.9 Hz, 2H), 7.09 (d, J = 10.2 Hz, 1H), 
6.89 (td, J = 7.5, 1.2 Hz 1H), 6.79 (dd, J = 8.1, 1.2 Hz, 1H), 6.67 (s, 1H), 5.90 (d, J = 
9.9 Hz, 1H), 4.17-3.97 (m, 4H), 3.76 (s, 3H), 2.34 (s, 3H), 1.24 (t, J = 7.2 Hz, 3H), 1.13 
(t, J = 6.9 Hz, 3H), 1.06 (d, J = 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 165.8 (C), 
165.4 (C), 162.9 (C), 156.8 (C), 143.5 (C), 135.8 (C), 132.4 (CH), 131.2 (CH), 129.3 
(CH), 128.8 (CH), 127.6 (CH), 125.6 (C), 124.8 (C), 120.2 (CH), 110.0 (CH), 73.9 (C), 
62.8 (CH2), 62.7 (CH2), 61.9 (CH2), 55.2 (CH3), 41.7 (CH), 21.4 (CH3), 13.7 (CH3), 
13.69 (CH3), 13.57 (CH3); HRMS (ESI) m/z  582.1552 [M+H]+, C27H32ClNO9S requires 
582.1559. 
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(S,E)-Triethyl 1-chloro-4-(4-methylphenylsulfonamido)-2-(thiophen-2-yl)but-3-
ene-1,1,4-tricarboxylate, (S,E)-22em  
Chiral HPLC analysis: Lux Amylose-1, hexane-iPrOH 90:10, 1 
mL/min, E-isomer: major enantiomer tr = 68.7 min, minor 
enantiomer tr = 42.0 min. Z-isomer: major enantiomer tr = 37.5 
min, minor enantiomer tr = 63.1 min. 
Yellow oil; [α]D20 64.3 (c 1.0, CHCl3, ee = 97% for the major diastereomer); 1H NMR 
(300 MHz, CDCl3) δ 7.53 (dt, J = 8.4, 2.1 Hz, 2H), 7.21 (dd, J = 5.1, 1.2 Hz, 1H), 7.15 
(dd, J = 8.7, 0.9 Hz, 2H), 7.02 (dq, J = 3.9, 0.6 Hz, 1H), 6.94 (d, J = 10.5 Hz, 1H), 6.93 
(dd, J = 5.1, 3.6 Hz, 1H), 6.67 (s, 1H), 6.04 (d, J = 10.5 Hz, 1H), 4.17 (q, J = 7.2 Hz, 
2H), 4.12 (q, J = 7.5 Hz, 2H), 4.11 (q, J = 6.9 Hz, 2H), 2.36 (s, 3H), 1.22 (t, J = 7.2 Hz, 
3H), 1.19 (t, J = 7.5 Hz, 3H), 1.17 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 
165.3 (C), 164.8 (C), 162.7 (C), 143.7 (C), 137.7 (C), 135.7 (C), 130.2 (CH), 129.4 
(CH), 127.5 (CH), 126.4 (CH), 125.3 (CH), 125.2 (C), 74.3 (C), 63.3 (CH2), 63.1 (CH2), 
62.2 (CH2), 43.9 (CH3), 21.4 (CH3), 13.8 (CH3), 13.7(CH3); HRMS (ESI) m/z  558.1009 
[M+H]+, C24H28ClNO8S2 requires 558.1018. 
(S,E)-1,1-Diethyl 4-methyl 1-chloro-4-(4-methylphenylsulfonamido)-2-phenylbut-
3-ene-1,1,4-tricarboxylate, (S,E)-22en 
Chiral HPLC analysis: Chiralcel AD-H, hexane-iPrOH 80:20, 1 
mL/min, E-isomer: major enantiomer tr = 25.9 min, minor 
enantiomer tr = 16.0 min. Z-isomer: major enantiomer tr = 14.7 
min, minor enantiomer tr = 19.5 min. 
Pale yellow oil; [α]D20 56.9 (c 1.0, CHCl3, ee = 98% for the major diastereomer); 1H 
NMR (300 MHz, CDCl3) δ 7.52 (dt, J = 8.1, 2.1 Hz, 2H), 7.26 (s, 5H), 7.13 (d, J = 9.9 
Hz, 1H), 7.12 (d, J = 7.8 Hz, 2H), 6.65 (s, 1H), 5.56 (d, J = 9.9 Hz, 1H), 4.20 (q, J = 7.2 
Hz, 2H), 4.07 (q, J = 7.2 Hz, 1H), 4.06 (q, J = 7.2 Hz, 1H), 3.55 (s, 3H), 2.35 (s, 3H), 
1.24 (t, J = 7.2 Hz, 3H), 1.11 (t, J = 6.9 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 165.7 
(C), 165.1 (C), 162.8 (C), 143.7 (C), 136.8 (C), 135.6 (C), 133.2 (CH), 129.7 (CH), 
129.4 (CH), 128.0 (CH), 127.9 (CH), 127.5 (CH), 124.7 (C), 74.3 (C), 63.1 (CH2), 63.0 
(CH2), 52.4 (CH3), 48.2 (CH), 21.4 (CH3), 13.7 (CH3), 13.6 (CH3); HRMS (ESI) m/z  
538.1288 [M+H]+, C25H28ClNO8S requires 538.1297. 
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(S,E)-1,1-Diethyl 4-isopropyl 1-chloro-4-(4-methylphenylsulfonamido)-2-
phenylbut-3-ene-1,1,4-tricarboxylate, (S,E)-22eo 
Chiral HPLC analysis: Lux Amylose-1, hexane-iPrOH 80:20, 1 
mL/min, E-isomer: major enantiomer tr = 15.1 min, minor 
enantiomer tr = 11.4 min. Z-isomer: major enantiomer tr = 10.2 
min, minor enantiomer tr = 26.7 min. 
Colorless oil; [α]D20 66.4 (c 0.96, CHCl3, ee = 98% for the major diastereomer); 1H 
NMR (300 MHz, CDCl3) δ 7.45 (dt, J = 8.1, 2.1 Hz, 2H), 7.31-7.26 (m,5H), 7.10 (d, J = 
10.5 Hz, 1H), 7.07 (d, J = 8.1 Hz, 2H), 6.65 (s, 1H), 5.67 (d, J = 10.5 Hz, 1H), 4.90 
(quint, J = 6.3 Hz, 1H), 4.19 (q, J = 7.2 Hz, 2H), 4.07 (q, J = 7.2 Hz, 1H), 4.06 (q, J = 
6.9 Hz, 1H), 2.33 (s, 3H), 1.23 (t, J = 7.2 Hz, 3H), 1.13 (d, J = 6.0 Hz, 3H), 1.12 (t, J = 
6.3 Hz, 3H), 1.04 (d, J = 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 165.6 (C), 165.1 
(C), 162.2 (C), 143.6 (C), 136.7 (C), 135.7(C), 132.6 (CH), 129.8 (CH), 129.3 (CH), 
128.1 (CH), 127.9 (CH), 127.5 (CH), 125.1 (C), 74.4 (C), 70.2 (CH), 63.1 (CH2), 63.0 
(CH2), 47.9 (CH), 21.5 (CH3), 21.46 (CH3), 21.42 (CH3), 21.39 (CH3), 13.71 (CH3), 
13.67 (CH3); HRMS (ESI) m/z  566.1598 [M+H]+, C27H32ClNO8S requires 566.1610. 
(S,E)-4-ethyl 1,1-dimethyl 1-chloro-4-(4-methylphenylsulfonamido)-2-phenylbut-3-
ene-1,1,4-tricarboxylate, (S,E)-22fa 
Chiral HPLC analysis: Lux Amylose-1, hexane-iPrOH 80:20, 1 
mL/min, E-isomer: major enantiomer tr = 25.9 min, minor 
enantiomer tr = 16.3 min. Z-isomer: major enantiomer tr = 17.5 
min, minor enantiomer tr = 22.8 min. 
White oil; [α]D20 50.1 (c 1.0, CHCl3, ee = 98% for the major diastereomer); 1H NMR 
(300 MHz, CDCl3) δ 7.52 (dt, J = 8.1, 1.8 Hz, 2H), 7.27-7.25 (m, 6H), 7.11 (dd, J = 8.1, 
0.9 Hz, 2H) 7.08 (d, J = 10.2 Hz, 1H), 6.66 (s, 1H), 5.16 (d, J = 9.9 Hz, 1H), 4.02 (q, J 
= 7.2 Hz, 2H), 3.73 (s, 3H), 3.61 (s, 3H), 2.34 (s, 3H), 1.10 (t, J = 7.2 Hz, 3H); 13C 
NMR (75 MHz, CDCl3) δ 166.1 (C), 165.6 (C), 162.5 (C), 143.7 (C), 136.7 (C), 135.7 
(C), 132.3 (CH), 129.6 (CH), 129.4 (CH), 128.1 (CH), 128.0 (CH), 127.6 (CH), 125.2 
(C), 74.3 (C), 62.0 (CH2), 53.8 (CH3), 53.7 (CH3), 48.2 (CH), 21.4 (CH3), 13.8 (CH3); 
HRMS (ESI) m/z  524.1133 [M+H]+, C24H26ClNO8S requires 524.1140. 
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5.5.3. Determination of the absolute stereochemistry of compounds 22  
(R,E)-Triethyl 4-(4-methylphenylsulfonamido)-2-phenylbut-3-ene-1,1,4-
tricarboxylate, (R,E)-19ba 
A solution of Rh(COD)BF4 (0.88 mg, 0.0022 mmol) and dppp 
(0.98 mg, 0.0024 mmol) in MeOH (1.5 mL) was stirred for 30 
minutes under nitrogen atmosphere. Then, (S,E)-22ea (30 mg, 
0.054 mmol, E/Z = 96:4, ee = 97%/70%, obtained from the 
pyBOX1-Ca catalyzed reaction) was added and the solution was 
stirred under H2 atmosphere (5 atm) for 25 hours. Purification by column 
chromatography on silica gel eluting with hexane/EtOAc (70:30) mixture gave 27.1 mg 
(97%) of compound (R,E)-19ba (Z/E : 5:95 ee = 48/97%). Chiral HPLC analysis: Lux 
Amylose-1, hexane-iPrOH 80:20, 1 mL/min, E-diastereomer: major enantiomer tr = 
22.8 min, minor enantiomer tr = 16.7 min; Z-diastereomer: major enantiomer tr = 40.4 
min, minor enantiomer tr = 21.7 min. Colorless oil; [α]D20 1.44 (c 1.0, CHCl3, E/Z = 
95:5, ee = 97%/48%); 1H NMR (300 MHz, CDCl3) δ 7.37 (dt, J = 8.4, 1.8 Hz, 2H), 
7.35-7.23 (m,5H), 7.05 (d, J = 8.1 Hz, 2H), 6.72 (d, J = 10.8 Hz, 1H), 6.52 (s, 1H), 5.23 
(t, J = 10.8, 1H), 4.15 (q, J = 7.2 Hz, 2H), 4.06 (q, J = 7.2 Hz, 2H), 3.95 (q, J = 7.2, 
1H), 3.94 (q, J = 7.2 Hz, 1H), 3.81 (d, J = 10.5 Hz, 1H), 2.33 (s, 3H), 1.22 (t, J = 7.2 
Hz, 3H), 1.14 (t, J = 7.2 Hz, 3H), 0.99 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 
167.4 (C), 167.1 (C), 162.9 (C), 143.6 (C), 139.6 (C), 136.1(CH), 135.6 (C), 129.4 
(CH), 128.6 (CH), 128.3 (CH), 127.4 (CH), 127.3 (CH), 124.5 (C), 62.0 (CH2), 61.7 
(CH2), 61.4 (CH2), 57.9 (CH), 43.3 (CH), 21.4 (CH3), 14.0 (CH3), 13.9 (CH3), 13.7 
(CH3); HRMS (ESI) m/z 518.1850 [M+H] +, C26H31NO8S requires 518.1843. 
(R,Z)-Triethyl 4-(4-methylphenylsulfonamido)-2-phenylbut-3-ene-1,1,4-
tricarboxylate, (R,Z)-19ba 
Following the above procedure (S,Z)-22ea (30 mg, E/Z = 8:92, 
ee = 83%/86%, obtained from the pyBOX9-La catalyzed 
reaction) was transformed into (R,Z)-19ba (E/Z = 8:92, ee = 
80%/86%), which showed the same spectroscopic features but 
inverted retention times for the major and minor enantiomer as 
compound (S,Z)-19ba (Section 5.4.1.3). 
(R)-Triethyl 4-oxo-2-phenylbutane-1,1,4-tricarboxylate (21ba)  
A solution of (R,E)-19ba (17.6 mg, 0.034 mmol) dissolved in 
dry CH2Cl2 (0.8 mL), was added via syringe to La(OTf)3 (2 mg, 
0.0034 mmol) previously dried in a Schlenk tube, under nitrogen 
atmosphere, followed by 4 Å MS (7 mg) and benzylamine 
(0.068 mmol). The mixture was stirred at rt for 18 hours and 
chromatographed on silica gel eluting with hexane/EtOAc (85:15) mixture to give 10.7 
mg (86%) of compound (R)-21ba. Chiral HPLC analysis: Chiralcel AD-H, hexane-
iPrOH 80:20, 1 mL/min, major enantiomer tr = 21.4 min, minor enantiomer tr = 14.0 
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min. Colorless oil; [α]D20 -18.0 (c 0.910, CHCl3, ee = 92%); 1H NMR (300 MHz, 
CDCl3) δ 7.26-7.17 (m, 5H), 4.232 (q, J = 7.2 Hz, 1H), 4.230 (q, J = 7.2 Hz, 1H), 4.19 
(q, J = 7.2 Hz, 1H), 4.188 (q, J = 6.9 Hz, 1H), 4.06 - 3.98 (m, 1H), 3.93 (q, J = 7.2 Hz, 
2H), 3.73 (d, J = 10.2 Hz, 1H), 3.41 (dd, J = 17.7, 8.7 Hz, 1H), 3.30 (q, J = 17.7, 5.1 
Hz, 1H), 1.30 (t, J = 7.2 Hz, 3H), 1.25 (t, J = 6.9 Hz, 3H), 0.99 (t, J = 7.2 Hz, 3H); 13C 
NMR (75 MHz, CDCl3) δ 191.6 (C), 168.0 (C), 167.4 (C), 160.4 (C), 139.8 (C), 128.5 
(CH), 128.2 (CH), 127.3 (CH), 62.4 (CH2), 61.7 (CH2), 61.3 (CH2), 57.2 (CH), 43.3 
(CH), 40.0 (CH), 13.9 (CH3), 13.8 (CH3), 13.7 (CH3); HRMS (ESI) m/z 365.1594 
[M+H] +, C19H24O7 requires 365.1595. 
Hydrolysis of (R,Z)-19ba following a similar procedure gave a product with identical 
spectroscopic features and retention times in HPLC. 
5.5.4. Synthetic transformations  
(2S,3S)-Diethyl 2-(2-ethoxy-1-(hydroxyimino)-2-oxoethyl)-3-phenylcyclopropane-
1,1-dicarboxylate (23ea) 
A solution of (S,E)-22ea (60 mg, 0.11 mmol, E/Z = 94:6, ee = 
96%/59%), NH2OH·HCl (18.1 mg, 0.26 mmol) and Et3N (37 µL, 
0.26 mmol) in DMSO (1.6 mL) was stirred at rt for 4 hours under 
nitrogen atmosphere. Column chromatography on silica gel eluting 
with hexane/EtOAc (60:40) mixture gave 37.4 mg (90%) of 
compound 23ea. Chiral HPLC analysis: Chiralpak IC, hexane-iPrOH 80:20, 1 mL/min, 
major enantiomer tr = 7.9 min, minor enantiomer tr = 17.2 min. Colorless oil; [α]D20 -
11.8 (c 1.0, CHCl3, ee = 92%); 1H NMR (300 MHz, CDCl3) δ 9.68 (br s, 1H), 7.31 - 
7.22 (m, 5H), 4.26 (dq, J = 7.2, 3.3 Hz, 2H), 4.17 (dq, J = 7.2, 4.5 Hz, 2H), 3.90 (dq, J = 
6.9, 4.8 Hz, 2H), 3.67 (d, J = 8.7 Hz, 1H), 3.27 (d, J = 9.0 Hz, 1H), 1.28 (t, J = 6.9 Hz, 
3H), 1.24 (t, J = 7.2 Hz, 3H), 0.89 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 
167.6 (C), 165.8 (C), 162.4 (C), 146.9 (C), 133.8 (C), 128.7 (CH), 128.2 (CH), 127.6 
(CH), 61.94 (CH2), 61.89 (CH2), 61.5 (CH2), 42.9 (C), 36.7 (CH), 25.8 (CH), 13.9 
(2CH3), 13.7 (CH3); HRMS (ESI) m/z 378.1547 [M+H]+, C19H25NO7 requires 378.1547. 
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5.6. Catalytic asymmetric formal [3+2] cycloaddition of 2-
isocyanatomalonate esters and unsaturated imines: synthesis of highly 
substituted chiral γ-lactams 
5.6.1. Synthesis of dialkyl 2-isocyanatomalonates 24 
 
a) Diisopropyl 2-aminomalonate hydrochloride.201 A 250 mL round bottom flask 
containing diisopropyl malonate (30.0 g, 159.4 mmol) was introduced in an ice bath. 
After 10 min, water (43 ml) was added followed by AcOH (32.8 mL, 569 mmol). 
NaNO2 (39.6 g, 569 mmol) was added in portions over 1 hour. The mixture was stirred 
for 24 h at room temperature and extracted with diethyl ether (3×70 mL), washed with 
aqueous saturated NaHCO3 until basic pH (6×50 mL), dried over MgSO4 and 
concentrated under reduced pressure. The resulting crude oxime was dissolved in EtOH 
(130 mL), and hydrogenated over 10% Pd/C (0.25 g) for 24 hours until no remaining 
oxime was observed in the reaction mixture (TLC). The mixture was filtered through 
Celite to remove the catalyst. The filtrate was concentrated under reduced pressure and 
dissolved in diethyl ether (250 mL). Dry HCl was bubbled through the solution for 1 
hour. The resulting white precipitate was filtered, washed with diethyl ether and dried 
under vacuum to give 23.4 g (62%) of diisopropyl 2-aminomalonate hydrochloride.  
b) Diisopropyl 2-isocyanatomalonate (24c).195 Diisopropyl 2-aminomalonate 
hydrochloride (3.53 g, 14.7 mmol), was dissolved in dioxane (11 mL) and cooled to 0 
°C under nitrogen atmosphere. Active charcoal (10.8 g) was added followed by 
triphosgene (4.36 g, 14.7 mmol). The reaction mixture was introduced in a bath at 80 °C 
for one hour and then heated at reflux temperature overnight. After this time, the 
reaction mixture was filtered to remove the charcoal and concentrated under reduced 
pressure. The concentrated was distilled under vacuum (oil pump) in a kugelrohr (T = 
160-170 °C) to give 3.17 g (93%) of diisopropyl 2-isocyanatomalonate (24c). 1H NMR 
(300 MHz, CDCl3) δ 5.13 (2H, hept, J = 6.3 Hz, CHO), 4.44 (1H, s, CH-CO), 1.30 (6H, 
t, J = 6.3 Hz, Me). 
c) Diethyl 2-isocyanatomalonate (24b). Starting from commercially available diethyl 2-
aminomalonate hydrochloride, it was prepared in 93% yield. (T = 150 °C, oil pump). 1H 
NMR (300 MHz, CDCl3) δ 4.52 (1H, s, CH-CO), 4.32 (2H, q, J = 7.2 Hz, CH2O), 4.31 
(2H, q, J = 7.2 Hz, CH2O), 1.32 (6H, t, J = 7.2 Hz, Me). 
c) Dimethyl 2-isocyanatomalonate (24a). Starting from commercially available 
dimethyl 2-aminomalonate hydrochloride, it was prepared in 82% yield. (T = 145 °C, 
oil pump). 1H NMR (300 MHz, CDCl3) δ 4.58 (1H, s, CH-CO), 3.87 (6H, s, MeO). 
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5.6.2. Synthesis of α,β-unsaturated N-(o-methoxyphenyl)imines 25 
Et3N (2.96 mL, 2.14 g, 21.3 mmol) followed by TiCl4 (1.16 mL, 2.0 g, 10.6 mmol) were 
added via syringe to a solution of the required E-enone (9.6 mmol) and o-anisidine 
(1.18 g, 9.6 mmol) in dry dichloromethane (120 mL) at 0 ºC under nitrogen atmosphere. 
The reaction was heated at reflux temperature for 16 h. Then it was cooled to room 
temperature and quenched with water (500 mL). The two layers were separated and the 
aqueous layer was extracted with ethyl acetate (6×150 mL). The combined organic 
layers were dried over MgSO4, filtered and concentrated under reduced pressure. 
Purification by flash column chromatography on silica gel eluting with hexane/EtOAc 
mixtures afforded the corresponding imines 25 as mixtures of C=N geometric isomers.  
N-((E)-1,3-Diphenylallylidene)-2-methoxyaniline (25a) 
Obtained as a 63:37 diastereomer mixture. Yellow oil; 1H NMR 
(300 MHz, CDCl3) δ (significant signals) 3.83 (s, 3H major 
diastereomer), 3.77 (s, 3H minor diastereomer); HRMS (ESI) m/z 
314.1532 [M+H]+, C22H19NO requires 314.1539. 
N-((E)-3-(4-Chlorophenyl)-1-phenylallylidene)-2-methoxyaniline (25b) 
Obtained as a 61:39 diastereomer mixture. Yellow oil; 1H 
NMR (300 MHz, CDCl3) δ (significant signals) 3.80 (s, 3H 
major diastereomer), 3.74 (s, 3H minor diastereomer); HRMS 
(ESI) m/z 348.1145 [M+H]+, C22H18ClNO requires 348.1150. 
 
2-Methoxy-N-((E)-3-(4-nitrophenyl)-1-phenylallylidene)aniline (25c) 
Obtained as a 56:44 diastereomer mixture. Red oil; 1H NMR 
(300 MHz, CDCl3) δ (significant signals) 8.21 (dt, J = 8.7, 
1.8 Hz, 2H minor diastereomer), 8.15 (dt, J = 9.0, 2.1 Hz, 2H 
major diastereomer), 3.80 (s, 3H major diastereomer), 3.75 
(s, 3H minor diastereomer); HRMS (ESI) m/z 359.1388 
[M+H]+, C22H18N2O3 requires 359.1390. 
2-Methoxy-N-((E)-3-(4-methoxyphenyl)-1-phenylallylidene)aniline (25d) 
Obtained as a 61:39 diastereomer mixture. Yellow oil; 1H 
NMR (300 MHz, CDCl3) δ (significant signals) 3.83 (s, 3H 
minor diastereomer), 3.80 (s, 3H major diastereomer), 3.79 
(s, 3H major diastereomer), 3.74 (s, 3H minor diastereomer); 
HRMS (ESI) m/z 344.1635 [M+H]+, C23H21NO2 requires 
344.1645. 
 
N
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N-((E)-3-(Furan-2-yl)-1-phenylallylidene)-2-methoxyaniline (24e) 
Obtained as a 66:34 diastereomer mixture. Brown oil; 1H NMR 
(300 MHz, CDCl3) δ (significant signals) 3.80 (s, 3H major 
diastereomer), 3.73 (s, 3H minor diastereomer); HRMS (ESI) m/z 
304.1325 [M+H]+, C20H17NO2 requires 304.1332. 
N-((E)-4,4-Dimethyl-1-phenylpent-2-en-1-ylidene)-2-methoxyaniline (25f) 
Obtained as a 64:36 diastereomer mixture. Yellow oil; 1H NMR (300 
MHz, CDCl3) δ 3.79 (s, 3H major diastereomer), 3.72 (s, 3H minor 
diastereomer), 1.08 (s, 9H minor diastereomer), 0.96 (s, 9H major 
diastereomer); HRMS (ESI) m/z 294.1845 [M+H] +, C26H21NO 
requires 294.1852. 
N-((E)-1-(4-Chlorophenyl)-3-phenylallylidene)-2-methoxyaniline (25g) 
Obtained as a 64:36 diastereomer mixture. Yellow oil; 1H 
NMR (300 MHz, CDCl3) δ (significant signals) 7.72 (dt, J = 
8.4, 2.4 Hz, 2H major diastereomer), 3.80 (s, 3H major 
diastereomer), 3.74 (s, 3H minor diastereomer); HRMS (ESI) 
m/z 348.1137 [M+H]+, C22H18ClNO requires 348.1150. 
2-Methoxy-N-((E)-1-(4-nitrophenyl)-3-phenylallylidene)aniline (25h) 
Obtained as a 66:34 diastereomer mixture. Orange oil; 1H 
NMR (300 MHz, CDCl3) δ (significant signals) 8.33 (dt, J = 
9.0, 2.1 Hz, 2H major diastereomer), 8.13 (dt, J = 8.7, 2.1 Hz, 
1H major diastereomer), 7.94 (dt, J = 8.7, 2.4 Hz, 2H major 
diastereomer), 3.82 (s, 3H major diastereomer), 3.74 (s, 3H 
minor diastereomer); HRMS (ESI) m/z 359.1385 [M+H]+, C22H18N2O3 requires 
359.1390. 
2-Methoxy-N-((E)-1-(4-methoxyphenyl)-3-phenylallylidene)aniline (25i) 
Obtained as a 68:32 diastereomer mixture. Yellow oil; 1H 
NMR (300 MHz, CDCl3) δ (significant signals) 7.77 (dt, J = 
6.9, 2.1 Hz, 2H major diastereomer), 7.49 (dd, J = 8.1, 1.8 
Hz, 1H major diastereomer), 3.88 (s, 3H major 
diastereomer), 3.80 (s, 3H major diastereomer), 3.77 (s, 3H 
minor diastereomer), 3.75 (s, 3H minor diastereomer); 
HRMS (ESI) m/z 344.1640 [M+H]+, C23H21NO2 requires 344.1645. 
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2-Methoxy-N-((E)-1-(3-nitrophenyl)-3-phenylallylidene)aniline (25j) 
Obtained as a 68:32 diastereomer mixture. Yellow oil; 1H 
NMR (300 MHz, CDCl3) δ (significant signals) 8.63 (t, J = 
1.8 Hz, 1H major diastereomer), 8.35 (dq, J = 8.4, 1.2 Hz, 1H 
major diastereomer), 8.15-8.08 (m, 2H major and minor 
diastereomers), 7.67 (d, J = 8.1 Hz, 1H major diastereomer), 
7.65 (d, J = 7.8 Hz, 1H minor diastereomer), 3.82 (s, 3H major diastereomer), 3.75 (s, 
3H minor diastereomer); HRMS (ESI) m/z 359.1384 [M+H]+, C22H18N2O3 requires 
359.1390. 
N-((E)-1-(2-Chlorophenyl)-3-phenylallylidene)-2-methoxyaniline (25k) 
Obtained as a 71:29 diastereomer mixture. Orange oil; 1H NMR 
(300 MHz, CDCl3) δ (significant signals) 3.84 (s, 3H minor 
diastereomer), 3.80 (s, 3H mayor diastereomer); HRMS (ESI) m/z 
348.1143 [M+H]+, C22H18ClNO requires 348.1150. 
2-Methoxy-N-((E)-1-(2-nitrophenyl)-3-phenylallylidene)aniline (25l) 
Obtained as a 60:30 diastereomer mixture. Orange solid; mp 48-49 
ºC; 1H NMR (300 MHz, CDCl3) δ (significant signals) 8.16 (dd, J 
= 8.4, 1.2 Hz, 1H minor diastereomer), 8.07 (dd, J = 8.1, 1.5 Hz, 
1H major diastereomer), 3.85 (s, 3H minor diastereomer), 3.77 (s, 
3H major diastereomer); HRMS (ESI) m/z 359.1378 [M+H]+, 
C22H18N2O3 requires 359.1390. 
N-((E)-1-(Furan-2-yl)-3-phenylallylidene)-2-methoxyaniline (25m) 
Obtained as a 78:22 diastereomer mixture: Brown oil; 1H NMR 
(300 MHz, CDCl3) δ (significant signals) 7.64 (q, J = 0.9 Hz, 1H 
major diastereomer), 7.46 (d, J = 15.9 Hz, 1H minor 
diastereomer), 7.12 (dd, J = 7.2, 1.8 Hz, 1H minor diastereomer), 
7.09 (dd, J = 7.2, 2.1 Hz, 1H minor diastereomer), 7.00 (dd, J = 
3.3, 0.6 Hz, 1H major diastereomer), 6.72 (d, J = 16.5 Hz, 1H major diastereomer), 6.56 
(q, J = 1.8 Hz, 1H major diastereomer), 6.30 (q, J = 1.8 Hz, 1H minor diastereomer), 
6.04 (dd, J = 3.6, 0.6 Hz, 1H minor diastereomer), 3.80 (s, 3H major diastereomer), 3.74 
(s, 3H minor diastereomer); HRMS (ESI) m/z 304.1320 [M+H]+, C20H17NO2 requires 
304.1332. 
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2-Methoxy-N-((E)-1-(naphthalen-2-yl)-3-phenylallylidene)aniline (25n) 
Obtained as a 66:34 diastereomer mixture: Orange solid; mp 
53-55 ºC;  1H NMR (300 MHz, CDCl3) δ (significant signals) 
6.99 (dt, J = 8.4, 1.5 Hz, 2H major and minor diastereomer), 
6.95 (d, J = 3.3 Hz, 2H major diastereomer), 6.91 (d, J = 1.8 
Hz, 2H minor diastereomer), 6.71 (dd, J = 8.1, 1.2 Hz, 1H 
minor diastereomer), 6.64 (dt, J = 7.5, 1.2 Hz, 1H minor diastereomer), 6.56 (dd, J = 
7.8, 1.5 Hz, 1H minor diastereomer), 3.83 (s, 3H major diastereomer), 3.76 (s, 3H minor 
diastereomer); HRMS (ESI) m/z 364.1678 [M+H],+ C26H21NO requires 364.1696. 
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5.6.3. Enantioselective [3+2] cycloaddition of 2-isocyanatomalonate esters 24 and 
unsaturated imines 25  
5.6.3.1. General procedure for the enantioselective reaction 
Mg(OTf)2 (4.0 mg, 0.0125 mmol) was dried in a Schlenk tube under vacuum. BOX10 
(6.1 mg, 0.0125 mmol) was introduced and the Schlenk tube was filled with nitrogen. 
Et2O (0.55 mL) was added via syringe and the mixture was stirred for 30 min. The tube 
was introduced in a bath at 0 °C, 4Å MS (110 mg) was then added followed by the 
imine 25 (0.125 mmol) dissolved in dry Et2O (0.5 mL), and by diisopropyl 2-
isocyanatomalonate (24c, 37 µL, 0.19 mmol). The mixture was stirred at 0 ºC for the 
indicated time and chromatographed on silica gel eluting with hexane/EtOAc mixtures 
to give compounds 26.  
5.6.3.2. General procedure for the synthesis of the racemic products 
Racemic compounds for comparative purposes were prepared by following the same 
procedure, in absence of chiral ligand and performing the reaction at room temperature.  
5.6.3.3. Characterization of products 26 
See Table 21 (Page 104) for yield, dr and ee. 
(R,Z)-Dimethyl 4-(((2-methoxyphenyl)amino)(phenyl)methylene)-5-oxo-3-
phenylpyrrolidine-2,2-dicarboxylate (26aa) 
Chiral HPLC analysis: Chiralcel AD-H, hexane-iPrOH 80:20, 1 
mL/min. major enantiomer tr = 11.0 min, minor enantiomer tr = 
18.9 min.  
Yellow solid, mp 72-74 ºC (hexane-EtOAc); [α]D20 -129.5 (c 
1.0, CHCl3, ee = 76%); 1H NMR (300 MHz, CDCl3) δ 10.60 
(1H, s, NH), 7.22 (1H, t, J = 7.5 Hz, Ar), 7.14 (2H, t, J = 7.5 Hz, Ar), 7.03-6.99 (m, 5H, 
Ar), 6.84-6.81 (2H, m, Ar), 6.75-6.73 (2H, m, Ar), 6.38 (1H, m, Ar), 6.14 (1H, s, NH), 
6.03 (dd, J = 8.1, 1.2 Hz, 1H, Ar), 4.85 (1H, s, CH-Ph), 3.88 (3H, s, MeO), 3.81 (3H, s, 
MeO), 3.13 (3H, s, MeO); 13C NMR (75 MHz, CDCl3) δ 172.5 (C), 169.0 (C), 167.5 
(C), 152.6 (C), 150.0 (C), 140.3 (C), 134.2 (C), 129.7 (C), 128.7 (CH), 128.31 (CH), 
128.27 (CH), 127.5 (CH), 126.8 (CH), 121.9 (CH), 119.9 (CH), 119.7 (CH), 110.4 
(CH), 101.4 (C), 71.8 (C), 55.7 (CH3), 53.4 (CH3), 52.3 (CH3), 49.2 (CH); HRMS (ESI) 
m/z 487.1880 [M+H]+, C28H26N2O6 requires 487.1864. 
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(R,Z)-Diethyl 4-(((2-methoxyphenyl)amino)(phenyl)methylene)-5-oxo-3-
phenylpyrrolidine-2,2-dicarboxylate (26ba) 
Chiral HPLC analysis: Chiralcel AD-H, hexane-iPrOH 80:20, 1 
mL/min. major enantiomer tr = 13.1 min, minor enantiomer tr = 
22.9 min. 
Yellow oil; [α]D20 -148.1 (c 1.0, CHCl3, ee = 77%); 1H NMR 
(300 MHz, CDCl3) δ 10.58 (1H, s, NH), 7.23 (1H, dt, J = 7.5, 1.2 
Hz, Ar), 7.15 (2H, t, J = 7.5 Hz, Ar), 7.01-6.96 (5H, m, Ar), 6.82-6.79 (2H, m, Ar), 
6.74-6.72 (2H, m, Ar), 6.40-6.35 (1H, m, Ar), 6.12 (1H, s, NH), 6.02 (1H, d, J = 8.1 Hz, 
Ar), 4.85 (s, CH-Ph), 4.36-4.20 (2H, m, CH3-CH2O), 3.88 (3H, s, MeO), 3.68-3.45 (2H, 
m, CH3-CH2O), 1.28 (3H, t, J = 7.2 Hz, CH3-CH2O), 0.74 (3H, t, J = 7.2 Hz, CH3-
CH2O); 13C NMR (75 MHz, CDCl3) δ 172.5 (C), 168.5 (C), 167.1 (C), 152.4 (C), 149.9 
(C), 140.4 (C), 134.3 (C), 129.8 (C), 128.7 (CH), 128.3 (CH), 127.5 (CH), 126.7 (CH), 
121.9 (CH), 119.9 (CH), 119.5 (CH), 110.3 (CH), 102.0 (C), 71.6 (C), 62.5 (CH2), 61.8 
(CH2), 55.7 (CH3), 48.9 (CH), 13.9 (CH3), 13.3 (CH3); HRMS (ESI) m/z 515.2177 
[M+H]+, C30H30N2O6 requires 515.2177. 
(R,Z)-Diisopropyl 4-(((2-methoxyphenyl)amino)(phenyl)methylene)-5-oxo-3-
phenylpyrrolidine-2,2-dicarboxylate (26ca) 
Chiral HPLC analysis: Chiralcel AD-H, hexane-iPrOH 80:20, 1 
mL/min. major enantiomer tr = 10.1 min, minor enantiomer tr = 
22.8 min. 
Yellow solid, mp 70-72 ºC (hexane-EtOAc); [α]D20 -197.4 (c 1.0, 
CHCl3, ee = 97%); 1H NMR (300 MHz, CDCl3) δ 10.60 (1H, s, 
NH), 7.23 (1H, t, J = 7.2 Hz, Ar), 7.16 (2H, t, J = 7.5 Hz, Ar), 6.99-6.95 (5H, m, Ar), 
6.78-6.71 (4H, m, Ar), 6.39-6.34 (1H, m, Ar), 6.16 (1H, s, NH), 6.14 (1H, dd, J = 8.1, 
1.2 Hz, Ar), 5.09 (1H, hept, J = 6.3 Hz, CHO), 4.85 (1H, s, CH-Ph), 4.50 (1H, hept, J = 
6.3 Hz, CHO), 3.88 (3H, s, MeO), 1.29 (3H, d, J = 6.3 Hz, iPr), 1.23 (3H, d, J = 6.3 Hz, 
iPr), 0.95 (3H, d, J = 6.3 Hz, iPr), 0.52 (3H, d, J = 6.3 Hz, iPr); 13C NMR (75 MHz, 
CDCl3) δ 172.4 (C), 168.0 (C), 166.5 (C), 152.1 (C), 149.8 (C), 140.4 (C), 134.4 (C), 
129.9 (C), 128.6 (CH), 128.4 (CH), 128.35 (CH), 128.3 (CH), 127.5 (CH), 126.6 (CH), 
121.7 (CH), 119.8 (CH), 119.3 (CH), 110.3 (CH), 102.7 (C), 71.4 (C), 70.3 (CH), 69.7 
(CH), 55.7 (CH3), 48.6 (CH), 21.5 (CH3), 21.3 (CH3), 21.2 (CH3), 20.5 (CH3); HRMS 
(ESI) m/z 543.2491 [M+H]+, C32H34N2O6 requires 543.2495. 
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(R,Z)-Diisopropyl 3-(4-chlorophenyl)-4-(((2-methoxyphenyl)amino)(phenyl) 
methylene)-5-oxopyrrolidine-2,2-dicarboxylate (26cb) 
Chiral HPLC analysis: Chiralcel AD-H, hexane-iPrOH 80:20, 
1 mL/min. major enantiomer tr = 7.6 min, minor enantiomer tr 
= 11.2 min. 
White solid, mp 179-181 ºC (hexane-EtOAc); [α]D20 -183.2 (c 
1.0, CHCl3, ee = 96%); 1H NMR (300 MHz, CDCl3) δ 10.56 
(1H, s, NH), 7.25 (1H, t, J = 7.2 Hz, Ar), 7.19 (2H, t, J = 7.2 Hz, Ar), 7.04-6.97 (2H, m, 
Ar), 6.94 (2H, dd, J = 8.7, 1.2 Hz, Ar), 6.75-6.70 (4H, m, Ar), 6.41-6.40 (1H, m, Ar), 
6.18 (1H, s, NH), 6.03 (1H, dd, J = 8.1, 1.2 Hz, Ar), 5.09 (1H, hept, J = 6.3 Hz, CHO), 
4.84 (1H, s, CH-Ar), 4.54 (1H, hept, J = 6.3 Hz, CHO), 3.87 (3H, s, MeO), 1.28 (3H, d, 
J = 6.3 Hz, iPr), 1.23 (3H, d, J = 6.3 Hz, iPr), 0.97 (3H, d, J = 6.3 Hz, iPr), 0.59 (d, J = 
6.3 Hz, iPr); 13C NMR (75 MHz, CDCl3) δ 172.2 (C), 167.9 (C), 166.4 (C), 152.5 (C), 
150.0 (C), 139.1 (C), 132.4 (C), 129.7 (CH), 129.6 (C), 128.8 (CH), 128.5 (CH), 128.3 
(CH), 127.6 (CH), 122.0 (CH), 119.8 (CH), 119.6 (CH), 110.4 (CH), 102.0 (C), 71.3 
(C), 70.4 (CH), 69.9 (CH), 55.7 (CH3), 47.9 (CH), 21.5 (CH3), 21.3 (CH3), 21.2 (CH3), 
20.6 (CH3); HRMS (ESI) m/z 577.2108 [M+H]+, C32H33ClN2O6 requires 577.2100. 
(R,Z)-Diisopropyl 4-(((2-methoxyphenyl)amino)(phenyl)methylene)-3-(4-
nitrophenyl)-5-oxopyrrolidine-2,2-dicarboxylate (26cc) 
Chiral HPLC analysis: Chiralcel AD-H, hexane-iPrOH 80:20, 
1 mL/min. major enantiomer tr = 10.2 min, minor enantiomer 
tr = 14.5 min. 
Orange solid, mp 225-227 ºC (hexane-EtOAc); [α]D20 -204.0 (c 
1.0, CHCl3, ee = 98%); 1H NMR (300 MHz, CDCl3) δ 10.58 
(1H, s, NH), 7.83 (2H, d, J = 9.0 Hz, Ar), 7.26 (1H, t, J = 6.9 Hz, Ar), 7.18 (1H, br s, 
Ar), 6.93 (2H, d, J = 8.1 Hz, Ar), 6.74 (2H, dd, J = 5.1, 1.2 Hz, Ar), 6.44 (1H, s, NH), 
6.41-6.35 (1H, m, Ar), 6.05 (1H, d, J = 7.8 Hz, Ar), 5.10 (1H, hept, J = 6.3 Hz, CHO), 
5.00 (1H, s, CH-Ar), 4.52 (1H, hept, J = 6.3 Hz, CHO), 3.86 (3H, s, MeO), 1.29 (3H, d, 
J = 6 Hz, iPr), 1.23 (3H, d, J = 6 Hz, iPr), 0.96 (3H, d, J = 6.3 Hz, iPr), 0.53 (3H, d, J = 
6.3 Hz, iPr); 13C NMR (75 MHz, CDCl3) δ 172.0 (C), 167.6 (C), 166.2 (C), 153.0 (C), 
150.1 (C), 148.2 (C), 146.5 (C), 134.1 (C), 129.2 (C), 129.1 (CH), 129.0 (CH), 128.6 
(CH), 128.2 (CH), 122.7 (CH), 122.5 (CH), 120.0 (CH), 119.8 (CH), 110.4 (CH), 101.2 
(C), 71.0 (C), 70.7 (CH), 70.1 (CH), 55.7 (CH3), 48.1 (CH), 21.4 (CH3), 21.3 (CH3), 
21.1 (CH3), 20.6 (CH3); HRMS (ESI) m/z 588.2332 [M+H]+, C32H33N3O8 requires 
588.2340. 
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(R,Z)-Diisopropyl 3-(4-methoxyphenyl)-4-(((2-methoxyphenyl)amino) 
(phenyl)methylene)-5-oxopyrrolidine-2,2-dicarboxylate (26cd) 
Chiral HPLC analysis: Chiralcel AD-H, hexane-iPrOH 80:20, 
1 mL/min. major enantiomer tr = 9.1 min, minor enantiomer tr 
= 16.2 min 
Yellow oil; [α]D20 -133.3 (c 1.0, CHCl3, ee = 96%); 1H NMR 
(300 MHz, CDCl3) δ 10.55 (1H, s, NH), 7.23 (2H, dt, J = 6.9, 
1.2 Hz, Ar), 7.26 (1H, t, J = 6.9 Hz, Ar), 7.18 (1H, br s, Ar), 6.93 (1H, d, J = 8.1 Hz, 
Ar), 7.17 (2H, t, J = 6.9 Hz, Ar), 7.02 (2H, d, J = 6.9 Hz, Ar), 6.76-6.68 (4H, m, Ar), 
6.51 (2H, d, J = 9.0 Hz, Ar), 6.39-6.34 (1H, m, Ar), 6.11 (1H, s, NH), 6.01 (1H, dd, J = 
7.8, 1.2 Hz, Ar), 5.08 (1H, hept, J = 6.3 Hz, CHO), 4.78 (1H, s, CH-Ar), 4.53 (1H, hept, 
J = 6.3Hz, CHO), 3.88 (3H, s, MeO), 3.67 (3H, s, MeO), 1.27 (3H, d, J = 6.3 Hz, iPr), 
1.22 (3H, d, J = 6.3 Hz, iPr), 0.97 (3H, d, J = 6.3 Hz, iPr), 0.61 (3H, d, J = 6 Hz, iPr); 
13C NMR (75 MHz, CDCl3) δ 172.4 (C), 168.1 (C), 166.6 (C), 158.3 (C), 152.0 (C), 
149.8 (C), 134.4 (C), 132.7 (C), 129.9 (C), 129.4 (CH), 128.6 (CH), 128.34 (CH), 
128.32 (CH), 121.6 (CH), 119.8 (CH), 119.2 (CH), 112.8 (CH), 110.3 (CH), 102.8 (C), 
71.6 (C), 70.2 (CH), 69.7 (CH), 55.7 (CH3), 55.1(CH3), 47.8 (CH), 21.5 (CH3), 21.3 
(CH3), 21.2 (CH3), 20.7 (CH3); HRMS (ESI) m/z 573.2598 [M+H]+, C33H36N2O7 
requires 573.2595. 
(R,Z)-Diisopropyl 3-(furan-2-yl)-4-(((2-methoxyphenyl)amino)(phenyl)methylene)-
5-oxopyrrolidine-2,2-dicarboxylate (26ce) 
Chiral HPLC analysis: Chiralcel AD-H, hexane-iPrOH 80:20, 1 
mL/min. major enantiomer tr = 25.8 min, minor enantiomer tr = 
49.4 min 
Yellow oil; [α]D20 -108.0 (c 1.0, CHCl3, ee = 88%); 1H NMR 
(300 MHz, CDCl3) δ 10.55 (1H, s, NH), 7.28-7.21 (3H, m, Ar), 
7.11 (2H, br s, Ar), 7.04 (1H, q, J = 0.9 Hz, Ar), 6.75-6.73 (2H, m, Ar), 6.39 (1H, m, 
Ar), 6.06-6.02 (3H, m, Ar+ NH), 5.69 (1H, dd, J = 3.3, 0.6 Hz, Ar), 5.08 (1H, hept, J = 
6.3 Hz, CHO), 5.02 (1H, s, CH-fur), 4.72 (1H, hept, J = 6.3Hz, CHO), 3.87 (3H, s, 
MeO), 1.27 (3H, d, J = 6.3 Hz, iPr), 1.23 (3H, d, J = 6 Hz, iPr), 1.06 (3H, d, J = 6.3 Hz, 
iPr), 0.86 (3H, d, J = 6.3 Hz, iPr); 13C NMR (75 MHz, CDCl3) δ 171.8 (C), 167.7 (C), 
166.5 (C), 152.9 (C), 152.2 (C), 150.0 (C), 140.8 (CH), 134.2 (C), 129.8 (C), 128.8 
(CH), 128.4 (CH), 128.1 (CH), 122.0 (CH), 119.8 (CH), 119.7 (CH), 110.3 (CH), 110.0 
(CH), 107.6 (CH), 99.0 (C), 70.4 (CH), 70.3 (C), 70.0 (CH), 55.7 (CH3), 42.6 (CH), 
21.4 (CH3), 21.31 (CH3), 21.28 (CH3), 21.1 (CH3); HRMS (ESI) m/z 533.2275 [M+H] +, 
C30H32N2O7 requires 533.2282. 
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(R,Z)-Diisopropyl 3-(tert-butyl)-4-(((2-methoxyphenyl)amino)(phenyl)methylene)-
5-oxopyrrolidine-2,2-dicarboxylate (26cf) 
Chiral HPLC analysis: Chiralcel AD-H, hexane-iPrOH 80:20, 1 
mL/min. major enantiomer tr = 18.5 min, minor enantiomer tr = 
13.5 min 
White solid, mp 60-62 ºC; [α]D20 52.6 (c 0.71, CHCl3, ee = 
23%); 1H NMR (300 MHz, CDCl3) δ 10.29 (1H, s, NH), 7.50-
7.30 (5H, m, Ar), 6.77 (1H, dd, J = 8.1, 2.1 Hz, Ar), 6.73 (1H, td, J = 8.1, 1.2 Hz, Ar), 
6.42 (1H, td, J = 8.1, 1.8 Hz, Ar), 6.02 (1H, d, J = 7.8 Hz, Ar), 5.92 (1H, s, NH), 5.08 
(1H, hept, J = 6.3 Hz, CHO), 5.07 (1H, hept, J = 6.3 Hz, CHO), 3.98 (1H, J = 1.2 Hz, d, 
CH-tBu), 3.90 (3H, s, MeO), 1.28 (6H, J = 6.3Hz, d, iPr), 1.26 (6H, J = 6.3 Hz, d, iPr), 
0.67 (9H, s, tBu); 13C NMR (75 MHz, CDCl3) δ 172.6 (C), 167.6 (C), 168.9 (C), 168.1 
(C), 150.33 (C), 1450.30 (C), 135.8 (C), 131.0 (C), 129.9 (CH), 129.0 (CH), 128.5 
(CH), 121.3 (CH), 120.2 (CH), 119.8 (CH), 110.3 (CH), 102.9 (C), 71.3 (C), 70.5 (CH), 
70.2 (CH), 55.7 (CH3), 53.8 (CH), 36.7 (C), 28.2 (CH3), 21.7 (CH3), 21.5 (CH3), 21.4 
(CH3), 21.2 (CH3); HRMS (ESI) m/z 523.2800 [M+H] +, C30H38N2O6 requires 523.2803. 
(R,Z)-Diisopropyl 4-((4-chlorophenyl)((2-methoxyphenyl)amino)methylene)-5-oxo-
3-phenylpyrrolidine-2,2-dicarboxylate (26cg) 
Chiral HPLC analysis: Chiralcel AD-H, hexane-iPrOH 
80:20, 1 mL/min. major enantiomer tr = 8.0 min, minor 
enantiomer tr = 18.7 min. 
Yellow solid, mp 77-79 ºC (hexane-EtOAc); [α]D20 -167.7 (c 
1.0, CHCl3, ee = 99%); 1H NMR (300 MHz, CDCl3) δ 10.46 
(1H, s, NH), 7.13 (2H, d, J = 8.4 Hz, Ar), 7.01-6.98 (5H, m, 
Ar), 6.82-6.80 (2H, m, Ar), 6.76-6.73 (2H, m, Ar), 6.45-6.39 (1H, m, Ar), 6.21 (1H, s, 
NH), 6.07 (1H, dd, J = 7.8, 1.2 Hz, Ar), 5.09 (1H, hept, J = 6.3Hz, CHO), 4.81 (1H, s, 
CH-Ph), 4.50 (1H, hept, J = 6.3Hz, CHO), 3.86 (3H, s, MeO), 1.28 (3H, d, J = 6.3 Hz, 
iPr), 1.22 (3H, d, J = 6.3 Hz, iPr), 0.95 (3H, d, J = 6.3 Hz, iPr), 0.53 (3H, d, J = 6.3 Hz, 
iPr); 13C NMR (75 MHz, CDCl3) δ 172.2 (C), 167.9 (C), 166.4 (C), 150.9 (C), 150.1 
(C), 140.2 (C), 134.6 (C), 132.9 (C), 129.8 (CH), 129.6 (C), 128.6 (CH), 128.4 (CH), 
127.6 (CH), 126.8 (CH), 122.2 (CH), 119.9 (CH), 119.8 (CH), 110.4(CH), 103.0 (C), 
71.4 (C), 70.3 (CH), 69.8 (CH), 55.7 (CH3), 48.7 (CH), 21.5 (CH3), 21.3 (CH3), 21.2 
(CH3), 20.5 (CH3); HRMS (ESI) m/z 577.2109 [M+H]+, C32H33ClN2O6 requires 
577.2100. 
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(R,Z)-Diisopropyl 4-(((2-methoxyphenyl)amino)(4-nitrophenyl)methylene)-5-oxo-3-
phenylpyrrolidine-2,2-dicarboxylate (26ch) 
Chiral HPLC analysis: Chiralcel AD-H, hexane-iPrOH 
80:20, 1 mL/min. major enantiomer tr = 11.4 min, minor 
enantiomer tr = 32.9 min. 
Orange solid, mp 80-82 ºC (hexane-EtOAc); [α]D20 -189.8 (c 
1.0, CHCl3, ee = 95%); 1H NMR (300 MHz, CDCl3) δ 10.40 
(1H, s, NH), 7.98 (2H, d, J = 8.7 Hz, Ar), 7.19 (1H, br s, Ar), 
7.01-6.93 (3H, m, Ar), 6.81-6.71 (4H, m, Ar), 6.44-6.39 (1H, m, Ar), 6.37 (1H, s, NH), 
6.07 (1H, dd, J = 8.1, 1.2 Hz, Ar), 5.09 (1H, hept, J = 6.3Hz, 1H), 4.81 (s, 1H), 4.48 
(1H, hept, J = 6.3Hz, 1H), 3.84 (3H, s, MeO), 1.28 (3H, d, J = 6.3 Hz, iPr), 1.23 (3H, d, 
J = 6.0 Hz, iPr), 0.94 (3H, d, J = 6.3 Hz, iPr), 0.51 (3H, d, J = 6.3 Hz, iPr); 13C NMR 
(75 MHz, CDCl3) δ 172.0 (C), 167.8 (C), 166.3 (C), 150.6 (C), 149.8 (C), 147.5 (C), 
141.1 (C), 139.9 (C), 129.7 (CH), 129.0 (C), 128.4 (CH), 127.8 (CH), 127.1 (CH), 
123.4 (CH), 123.1 (CH), 120.7 (CH), 119.9 (CH), 110.6 (CH), 103.6 (C), 71.3 (C), 70.5 
(CH), 70.0 (CH), 55.6 (CH3), 48.3 (CH), 21.4 (CH3), 21.3 (CH3), 21.2 (CH3), 20.5 
(CH3); HRMS (ESI) m/z 588.2333 [M+H]+, C32H33N3O8 requires 588.2340. 
(R,Z)-Diisopropyl 4-((4-methoxyphenyl)((2-methoxyphenyl)amino)methylene)-5-
oxo-3-phenylpyrrolidine-2,2-dicarboxylate (26ci) 
Chiral HPLC analysis: Chiralcel AD-H, hexane-iPrOH 
80:20, 1 mL/min. major enantiomer tr = 15.3 min, minor 
enantiomer tr = 27.5 min. 
Yellow oil; [α]D20 -165.1 (c 1.0, CHCl3, ee = 98%); 1H 
NMR (300 MHz, CDCl3) δ 10.50 (1H, s, NH), 7.00-6.96 
(5H, m, Ar), 6.83-6.80 (2H, m, Ar), 6.75-6.68 (4H, m, Ar), 
6.42-6.37 (1H, m, Ar), 6.13 (1H, s, NH), 6.05 (1H, dd, J = 7.8, 1.2 Hz, Ar), 5.09 (1H, 
hept, J = 6.3 Hz, CHO), 4.86 (1H, s, CHPh), 4.50 (1H, hept, J = 6.3Hz, CHO), 3.87 
(3H, s, MeO), 3.76 (3H, s, MeO), 1.28 (3H, d, J = 6.3 Hz, iPr), 1.22 (3H, d, J = 6.3 Hz, 
iPr), 0.95 (3H, d, J = 6.3 Hz, iPr), 0.53 (3H, d, J = 6.3 Hz, iPr); 13C NMR (75 MHz, 
CDCl3) δ 172.4 (C), 168.1 (C), 166.6 (C), 159.8 (C), 151.9 (C), 149.8 (C), 140.5 (C), 
130.1 (C), 129.7 (CH), 129.1 (C), 128.4 (CH), 127.5 (CH), 126.8 (C), 126.6 (CH), 
121.5 (CH), 119.9 (CH), 119.3 (CH), 113.7 (CH), 110.3 (CH), 102.74 (C), 71.4 (C), 
70.2 (CH), 69.7 (CH), 55.7 (CH3), 55.1 (CH3), 48.6 (CH), 21.5 (CH3), 21.3 (CH3), 21.2 
(CH3), 20.5 (CH3); HRMS (ESI) m/z 573.2592 [M+H]+, C33H36N2O7 requires 573.2595. 
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(R,Z)-Diisopropyl 4-(((2-methoxyphenyl)amino)(3-nitrophenyl)methylene)-5-oxo-3-
phenylpyrrolidine-2,2-dicarboxylate (26cj) 
Chiral HPLC analysis: Chiralcel AD-H, hexane-iPrOH 
80:20, 1 mL/min. major enantiomer tr = 14.2 min, minor 
enantiomer tr = 48.2 min. 
Orange oil; [α]D20 -132.2 (c 0.98, CHCl3, ee = 97%); 1H 
NMR (300 MHz, CDCl3) δ 10.40 (1H, s, NH), 8.03 (2H, dt, 
J = 7.2, 1.8 Hz, Ar), 7.74 (1H, br s, Ar), 7.36-7.29 (2H, m, 
Ar), 6.98-6.93 (3H, m, Ar), 6.81-6.71 (4H, m, Ar), 6.42 (1H, dt, J = 7.8, 1.8 Hz, Ar), 
6.24 (1H, s, NH), 6.13 (1H, dd, J = 8.1, 1.2 Hz, Ar), 5.11 (1H, hept, J = 6.3 Hz, CHO), 
4.78 (1H, s, CH-Ph), 4.48 (1H, hept, J = 6.3 Hz, CHO), 3.84 (3H, s, MeO), 1.29 (3H, d, 
J = 6.3 Hz, iPr), 1.24 (3H, d, J = 6.3 Hz, iPr), 0.95 (3H, d, J = 6.3 Hz, iPr), 0.49 (3H, d, 
J = 6.3 Hz, iPr); 13C NMR (75 MHz, CDCl3) δ 172.1 (C), 167.8 (C), 166.4 (C), 150.9 
(C), 149.9 (C), 147.8 (C), 140.0 (C), 136.2 (C), 134.6 (CH), 129.3 (CH), 129.0 (C), 
128.4 (CH), 127.8 (CH), 127.1 (CH), 123.7 (CH), 123.4 (CH), 123.3 (CH), 121.2 (CH), 
120.0 (CH), 110.7 (CH), 103.3 (C), 71.3 (C), 70.5 (CH), 70.0 (CH), 55.6 (CH3), 48.4 
(CH), 21.5 (CH3), 21.3 (CH3), 21.1 (CH3), 20.5 (CH3); HRMS (ESI) m/z 588.2338 
[M+H]+, C32H33N3O8 requires 588.2340. 
(R,Z)-Diisopropyl 4-((2-chlorophenyl)((2-methoxyphenyl)amino)methylene)-5-oxo-
3-phenylpyrrolidine-2,2-dicarboxylate (26ck) 
Obtained as a ca.1:1 mixture of diastereomers. Yellow oil; 
[α]D20 -168.8 (c 1.0, CHCl3, for the diastereomer mixture); 
1H NMR (300 MHz, CDCl3) δ 10.75 (1H, s, NH), 10.70 (1H, 
s, NH), 7.62 (1H, dd, J = 7.5, 1.5 Hz, Ar), 7.40 (2H, m, Ar), 
7.22 (1H, td, J = 7.5, 1.2 Hz, Ar), 7.11 (1H, td, J = 7.5, 1.2 
Hz, Ar), 7.04-6.94 (7H, m, Ar), 6.76-6.70 (m, 6H), 6.63 (1H, 
td, J = 7.5, 1.2 Hz, Ar), 6.43-6.34 (2H, m, Ar), 6.24-6.20 (3H, m, Ar,2NH), 6.07 (1H, d, 
J = 7.5 Hz, Ar), 6.04 (1H, dd, J = 7.5, 1.2 Hz, Ar), 5.08 (2H, hept, J = 6.3 Hz, 2CHO), 
4.71 (1H, s, CH-Ph), 4.69 (1H, s, CH-Ph), 4.47 (2H, hept, J = 6.3 Hz, 2CHO), 3.88 (3H, 
s, MeO), 3.87 (3H, s, MeO), 1.28 (3H, d, J = 6.3 Hz, iPr), 1.27 (3H, d, J = 6.3 Hz, iPr), 
1.22 (3H, d, J = 6.3 Hz, iPr), 1.21 (3H, d, J = 6.3 Hz, iPr), 0.94 (3H, d, J = 6.3 Hz, iPr), 
0.93 (3H, d, J = 6 Hz, iPr), 0.47 (3H, d, J = 6.3 Hz, iPr), 0.45 (3H, d, J = 6.3 Hz, iPr); 
13C NMR (75 MHz, CDCl3) δ 172.3 (C), 172.2 (C), 168.0 (C), 167.8 (C), 166.7 (C), 
166.5 (C), 149.8 (C), 149.7 (C), 149.5 (C), 145.0 (C), 140.9 (C), 139.5 (C), 133.6 (C), 
133.2 (C), 132.9 (C), 132.5 (C), 130.6 (CH), 130.4 (CH), 130.1 (CH), 129.7 (CH), 
129.55 (C), 129.52 (CH), 129.4 (CH), 128.3 (CH), 127.5 (CH), 127.0 (CH), 126.8 (CH), 
126.6 (CH), 126.2 (CH), 122.1 (CH), 122.0 (CH), 120.1 (CH), 119.9 (CH), 118.3 (CH), 
117.7 (CH), 110.5 (CH), 110.3 (CH), 102.9 (C), 101.9 (C), 71.7 (C), 71.4 (C), 70.28 
(CH), 70.27 (CH), 69.7 (CH), 69.6 (CH), 55.8 (CH3), 55.7 (CH3), 48.8 (CH), 48.6 (CH), 
21.5 (CH3), 21.3 (CH3), 21.2 (CH3), 20.4 (CH3), 20.3 (CH3); HRMS (ESI) m/z 577.2111 
[M+H]+, C32H33ClN2O6 requires 577.2100. 
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Determination of the ee: Compound 7k dissolved in THF was treated with 37% 
hydrochloric acid at 40 °C. The resulting ketone was obtained as a ca. 78:22 
diastereomer mixture. Chiral HPLC analysis: Chiralcel AD-H, hexane-iPrOH 80:20, 1 
mL/min. major enantiomer (both diastereomers) tr = 12.9 min, minor enantiomer (both 
diastereomers) tr = 19.5 min. Major isomer (trans): [α]D20 32.4 (c 1.0, CHCl3, for the 
diastereomer mixture); 1H NMR (300 MHz, CDCl3) δ 7.41-7.21 (2H, m, Ar), 7.18 (1H, 
dd, J = 8.1, 1.2 Hz, Ar), 7.12, (td, J = 6.9, 1.8 Hz, Ar), 7.08-6.80 (5H, m, Ar), 6.63 (1H, 
s, NH), 5.11 (2H, hept, J = 6.3 Hz, 2CHO), 4.89 (1H, d, J = 7.5 Hz , CH-Ph), 4.81 (1H, 
d, J = 7.5 Hz, CH-CO), 4.48 (2H, hept, J = 6.3 Hz, 2CHO), 1.30 (3H, d, J = 6.3 Hz, 
iPr), 1.25 (3H, d, J = 6.3 Hz, iPr), 0.96 (3H, d, J = 6.3 Hz, iPr), 0.42 (3H, d, J = 6.3 Hz, 
iPr); Minor isomer (cis): 1H NMR (300 MHz, CDCl3) δ 7.58 (1H, ddd, J = 7.5, 1.8, 0.9 
Hz, Ar), 7.41-6.80 (8H, m, Ar), 6.60 (1H, s, NH), 5.16 (2H, hept, J = 6.3 Hz, 2CHO), 
4.94 (2H, s, CH-Ph+CH-CO), 4.61 (2H, hept, J = 6.3 Hz, 2CHO), 1.31 (3H, d, J = 6.3 
Hz, iPr), 1.25 (3H, d, J = 6.3 Hz, iPr), 1.03 (3H, d, J = 6.3 Hz, iPr), 0.56 (3H, d, J = 6.3 
Hz, iPr). 
(R,Z)-Diisopropyl 4-(((2-methoxyphenyl)amino)(2-nitrophenyl)methylene)-5-oxo-3-
phenylpyrrolidine-2,2-dicarboxylate (26cl) 
Obtained as a ca.1:1 mixture of diastereomers. Chiral HPLC 
analysis: Chiralcel AD-H, hexane-iPrOH 80:20, 1 mL/min. 
major enantiomer (both diastereomers) tr = 19.7 min, minor 
enantiomer (both diastereomers) tr = 26.4 min.  
Orange solid, mp 98-100 ºC (hexane-EtOAc); [α]D20 -15.1 (c 
0.97, CHCl3, for the diastereomer mixture); 1H NMR (300 
MHz, CDCl3) δ 10.81 (1H, s, NH), 10.70 (1H, s, NH), 8.02 (1H, dd, J = 8.1, 1.2 Hz, 
Ar), 7.74-7.63 (3H, m, Ar), 7.44 (1H, td, J = 7.5, 1.5 Hz, Ar), 7.29 (1H, td, J = 7.5, 1.5 
Hz, Ar), 6.97-6.84 (7H, m, Ar), 6.71-6.60 (6H, m, Ar), 6.35-6.11 (6H, m, Ar+NH), 5.82 
(1H, dd, J = 8.1, 2.4 Hz, Ar), 5.08 (2H, hept, J = 6.3 Hz, 2CHO), 4.51 (1H, s, CHO), 
4.40 (2H, hept, J = 6.3 Hz, 2CHO), 4.32 (1H, s, CH-Ph), 3.84 (3H, s, MeO), 3.79 (3H, 
s, MeO), 1.22 (3H, d, J = 6 Hz, iPr), 1.20 (3H, d, J = 6.3 Hz, iPr), 1.16 (3H, d, J = 6.3 
Hz, iPr), 1.15 (3H, d, J = 6.3 Hz, iPr), 0.86 (3H, d, J = 6.3 Hz, iPr), 0.85 (3H, d, J = 6.3 
Hz, iPr), 0.40 (d, J = 6.3 Hz, iPr); 13C NMR (75 MHz, CDCl3) δ 172.1 (C), 171.8 (C), 
168.0 (C), 167.4 (C), 166.4 (C), 150.2 (C), 150.1 (C), 149.9 (C), 148.2 (C), 147.7(C), 
146.1 (C), 140.3 (C), 138.7 (C), 134.2 (CH), 132.7 (CH), 131.6 (CH), 130.8 (CH), 
130.0 (CH), 129.6 (C), 129.5 (CH), 129.4 (C), 129.3 (CH), 128.5 (CH), 127.7 (CH), 
127.1 (CH), 126.9 (CH), 124.5 (CH), 124.4 (CH), 122.8 (CH), 122.3 (CH), 120.0 (CH), 
119.8 (CH), 118.4 (CH), 110.8 (CH), 110.5 (CH), 101.5 (C), 99.7 (C), 71.5 (C), 71.4 
(C), 70.5 (CH), 70.4 (CH), 69.8 (CH), 55.8 (CH3), 55.7 (CH3), 48.9 (CH), 48.3 (CH), 
21.43 (CH3), 21.39 (CH3), 21.3 (CH3), 21.1 (CH3), 20.4 (CH3); HRMS (ESI) m/z 
588.2331 [M+H] +, C32H33N3O8 requires 588.2340. 
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(R,Z)-Diisopropyl 4-(furan-2-yl((2-methoxyphenyl)amino)methylene)-5-oxo-3-
phenylpyrrolidine-2,2-dicarboxylate (26cm) 
Chiral HPLC analysis: Chiralcel AD-H, hexane-iPrOH 
80:20, 1 mL/min. major enantiomer tr = 14.3 min, minor 
enantiomer tr = 26.6 min 
Orange oil; [α]D20 -144.8 (c 0.97, CHCl3, ee = 83%); 1H 
NMR (300 MHz, CDCl3) δ 9.99 (1H, s, NH), 7.28 (1H, q, J 
= 0.9 Hz, Ar), 7.10-7.07 (5H, m, Ar), 6.84-6.77 (2H, m, Ar), 6.56 (1H, m, Ar), 6.25 
(1H, s, NH), 6.20 (1H, dd, J = 3.6, 1.5 Hz, Ar), 6.16 (1H, dd, J = 3.6, 0.9 Hz, Ar), 6.11 
(1H, dd, J = 8.1, 1.2 Hz, Ar), 5.30 (1H, s, CH-Ph), 5.10 (1H, hept, J = 6.3 Hz, CHO), 
4.51 (1H, hept, J = 6.3Hz, CHO), 3.86 (3H, s, MeO), 1.28 (3H, d, J = 6.3 Hz, iPr), 1.24 
(3H, d, J = 6.4 Hz, iPr), 0.98 (3H, d, J = 6.3 Hz, iPr), 0.62 (3H, d, J = 6.3 Hz, iPr); 13C 
NMR (75 MHz, CDCl3) δ 172.3 (C), 167.9 (C), 166.6 (C), 150.1 (C), 146.4 (C), 142.7 
(CH), 140.5 (C), 140.3 (C), 130.8 (C), 128.5 (CH), 127.7 (CH), 127.0 (CH), 122.0 
(CH), 120.2 (CH), 118.8 (CH), 113.3 (CH), 110.0 (CH), 110.4 (CH), 104.9 (C), 71.5 
(C), 70.4 (CH), 70.0 (CH), 55.7 (CH3), 48.6 (CH), 21.5 (CH3), 21.3 (CH3), 21.2 (CH3), 
20.6 (CH3); HRMS (ESI) m/z 533.2278 [M+H]+, C30H32N2O7 requires 533.2282. 
(R,Z)-Diisopropyl 4-(((2-methoxyphenyl)amino)(naphthalen-2-yl)methylene)-5-
oxo-3-phenylpyrrolidine-2,2-dicarboxylate (26cn) 
Chiral HPLC analysis: Chiralcel AD-H, hexane-iPrOH 
80:20, 1 mL/min. major enantiomer tr = 9.1 min, minor 
enantiomer tr = 17.5 min 
Yellow oil; [α]D20 -99.0 (c 0.97, CHCl3, ee = 98%); 1H 
NMR (300 MHz, CDCl3) δ 10.67 (1H, s, NH), 7.77 (1H, dd, 
J = 7.8, 1.5 Hz, Ar), 7.62 (2H, d, J = 8.4 Hz, Ar), 7.52-7.42 
(3H, m, Ar), 7.04 (1H, br s, Ar), 6.97 (1H, dt, J = 7.2, 1.2 Hz, Ar), 6.87 (2H, t, J = 7.8 
Hz, Ar), 6.76-6.67 (4H, m, Ar), 6.26 (1H, td, J = 8.1, 1.5 Hz, Ar), 6.21 (1H, s, NH), 
6.05 (1H, dd, J = 8.1, 1.5 Hz, Ar), 5.11 (1H, hept, J = 6.3 Hz, CHO), 4.83 (s, CH-Ph), 
4.49 (1H, hept, J = 6.3 Hz, CHO), 3.90 (3H, s, MeO), 1.30 (3H, d, J = 6.3 Hz, iPr), 1.24 
(3H, d, J = 6.3 Hz, iPr), 0.93 (3H, d, J = 6.3 Hz, iPr), 0.49 (3H, d, J = 6 Hz, iPr); 13C 
NMR (75 MHz, CDCl3) δ 172.4 (C), 168.0 (C), 166.5 (C), 151.9 (C), 149.8 (C), 140.6 
(C), 133.0 (C), 132.7 (C), 132.0 (C), 129.9 (C), 128.5 (CH), 128.3 (CH), 128.1 (CH), 
127.6 (CH), 127.5 (CH), 126.7 (CH), 126.5 (CH), 126.0 (CH), 125.5 (CH), 121.7 (CH), 
119.9 (CH), 119.2 (CH), 110.3 (CH), 103.2 (C), 71.5 (C), 70.3 (CH), 69.7 (CH), 55.7 
(CH3), 48.6 (CH), 21.5 (CH3), 21.3 (CH3), 21.2 (CH3), 20.5 (CH3); HRMS (ESI) m/z 
593.2650 [M+H]+,C36H36N2O6 requires 593.2646. 
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5.6.4. Synthetic transformations  
Diisopropyl (3S,4S)-4-benzoyl-5-oxo-3-phenylpyrrolidine-2,2-dicarboxylate (27ca). 
 37% Hydrochloric acid (0.3 mL) was added to a solution of 
compound 26ca (59.0 mg, 0.11 mmol, ee = 94%) in THF (4.3 mL). 
The reaction mixture was stirred for 30 min, quenched with water (60 
mL), extracted with dichloromethane (4×45 mL) and dried over 
MgSO4. After evaporation of the solvent under reduced pressure, column 
chromatography eluting with hexane/EtOAc (80:20) gave 43.0 mg (90%) of compound 
27ca. Chiral HPLC analysis: Chiralcel AD-H, hexane-iPrOH 85:15, 1 mL/min. major 
enantiomer tr = 22.1 min, minor enantiomer tr = 39.9 min. White solid, mp 58-60 ºC; 
[α]D20 63.2 (c 1.0, CHCl3, ee = 92%); 1H NMR (300 MHz, CDCl3) δ 7.99 (2H, dd, J = 
6.9, 1.2 Hz, Ar), 7.56 (1H, tt, J = 7.5, 1.2 Hz, Ar), 7.46 (1H, d, J = 7.8 Hz, Ar), 7.41-
7.38 (3H, m, Ar), 7.32-7.19 (3H, m, Ar), 6.81 (1H, s, NH), 5.13 (1H, hept, J = 6.3 Hz, 
CHO), 4.93 (1H, d, J = 7.2 Hz, CH-Ph), 4.81 (1H, d, J = 7.2 Hz, CH-CO), 4.63 (1H, 
hept, J = 6.3Hz, CHO), 1.26 (3H, d, J = 6.3 Hz, iPr), 1.25 (3H, d, J = 6.3 Hz, iPr), 1.04 
(3H, d, J = 6.3 Hz, iPr), 0.55 (3H, d, J = 6.3 Hz, iPr); 13C NMR (75 MHz, CDCl3) δ 
193.4 (C), 171.3 (C), 167.2 (C), 166.7 (C), 136.7 (C), 135.9 (C), 133.7 (CH), 129.4 
(CH), 128.7 (CH), 128.6 (CH), 128.5 (CH), 128.2 (CH), 71.8 (C), 70.7 (CH), 70.6 
(CH), 56.5 (CH), 48.1 (CH), 21.4 (CH3), 21.37 (CH3), 21.31 (CH3), 20.5 (CH3); HRMS 
(ESI) m/z 438.1913 [M+H]+, C25H27NO6 requires 438.1911.  
Diisopropyl (3S,4S)-4-((R)-((2-methoxyphenyl)amino)(phenyl)methyl)-5-oxo-3-
phenylpyrrolidine-2,2-dicarboxylate (28ca) 
NaBH3CN (41.8 mg, 0.67 mg) and AcOH (14 µL, 0.25 
mmol) were successively added to a solution of compound 
26ca (60 mg, 0.11 mmol, ee = 94%) in absolute EtOH (1.2 
mL) at 0 ºC under nitrogen atmosphere. The solution was 
stirred at room temperature for 25 hours and 
chromatographed on silica gel eluting with hexane/EtOAc (80:20) mixture to give 45.3 
mg (75%) of compound 28ca and 6.6 mg (11%) of its isomer 29ca. 
Chiral HPLC analysis: Chiralpak IC, hexane-iPrOH 80:20, 1 mL/min. Major 
diastereomer: major enantiomer tr = 11.2 min, minor enantiomer tr = 14.2 min. Minor 
diastereomer: major enantiomer tr = 27.4 min, minor enantiomer tr = 19.9 min. 
Major diastereomer 28ca: White solid; mp 93-95 °C (hexane-EtOAc); [α]D20 -1.6 (c 
1.0, CHCl3, ee = 95%); 1H NMR (300 MHz, CDCl3) δ 7.38 (2H, dd, J = 6.4, 1.5 Hz, 
Ar), 7.34-7.17 (8 H, m, Ar), 6.66-6.53 (3H, m, Ar), 6.29 (1H, dd, J = 7.8, 1.8 Hz, Ar), 
6.25 (1H, s, NH), 5.09 (1H, d, J = 6.6 Hz, NH), 4.99 (1H, hept, J = 6.3 Hz, CHO), 4.94 
(1H, dd, J = 6.6, 5.1 Hz, CH-NH), 4.59 (1H, hept, J = 6.3 Hz, CHO), 4.17 (1H, d, J = 
9.0 Hz, CH-Ph), 3.67 (3H, s, MeO), 3.50 (1H, dd, J = 9.0, 5.1 Hz, CH-CO), 1.20 (3H, d, 
J = 6.3 Hz, iPr), 1.18 (3H, d, J = 6.3 Hz, iPr), 1.03 (3H, d, J = 6 Hz, iPr), 0.49 (3H, d, J 
= 6.3 Hz, iPr); 13C NMR (75 MHz, CDCl3) δ 174.8 (C), 167.5 (C), 167.0 (C), 146.9 (C), 
H
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139.8 (C), 137.1 (C), 136.6 (C), 129.0 (CH), 128.6 (CH), 128.5 (CH), 127.9 (CH), 
127.52 (CH), 127.46 (CH), 121.0 (CH), 116.7 (CH), 111.1 (CH), 109.4 (CH), 71.1 (C), 
70.5 (CH), 70.4 (CH), 57.2 (CH), 55.4 (CH3), 53.2 (CH), 47.3 (CH), 21.41 (CH3), 21.36 
(CH3), 21.3 (CH3), 20.5 (CH3); HRMS (ESI) m/z 545.2657 [M+H]+, C32H36N2O6 
requires 545.2646. 
Minor diastereomer 29ca: White solid, mp 83-85 °C (hexane-EtOAc); [α]D20 -12.8 (c 
0.47, CHCl3, ee = 89%) 1H NMR (300 MHz, CDCl3) δ 7.39-7.15 (11H, m, Ar), 6.61-
6.57 (1H, m, Ar), 6.48-6.44 (2H, m, Ar), 6.40 (1H, s, NH), 5.84-5.81 (1H, m, CH-Ph), 
5.10 (1H, hept, J = 6.3 Hz, CHO), 4.63 (1H, hept, J = 6.3 Hz, CHO), 4.56 (1H, d, J = 
7.5 Hz, CH-Ph), 4.32 (1H, d, J = 9.3 Hz, NH), 3.76 (3H, s, MeO), 3.71 (1H, dd, J = 8.7, 
8.1 Hz, CH-CO), 1.27 (3H, d, J = 6.3 Hz, iPr), 1.24 (3H, d, J = 6.3 Hz, iPr), 1.02 (3H, d, 
J = 6.3 Hz, iPr), 0.55 (3H, d, J = 6.3 Hz, iPr); 13C NMR (75 MHz, CDCl3) δ 174.0 (C), 
167.3 (C), 166.0 (C), 146.7 (C), 141.4 (C), 136.2 (C), 135.0 (C), 128.1 (CH), 128.0 
(CH), 127.8 (CH), 127.5 (CH), 127.0 (CH), 120.8 (CH), 116.4 (CH), 111.1 (CH), 109.3 
(CH), 70.8 (CH), 70.5 (C), 70.2 (CH), 55.4 (CH3), 55.0 (CH), 51.3 (CH), 49.8 (CH), 
21.5 (CH3), 21.4 (CH3), 21.3 (CH3), 20.5 (CH3); HRMS (ESI) m/z 545.2650 [M+H]+, 
C32H36N2O6 requires 545.2646 . 
2-Isopropyl 2-methyl (2R,3R,Z)-4-(((2-methoxyphenyl)amino)(phenyl)methylene)-
5-oxo-3-phenylpyrrolidine-2,2-dicarboxylate (30ca). 
A 1 M solution of NaOMe in MeOH (55 µL, 0.055 mmol) 
was added to compound 26ca (30 mg, 0.055 mmol, ee = 
94%) dissolved in MeOH (1 mL) under nitrogen 
atmosphere. The solution was heated at 65 °C for 1 h, 
diluted with EtOAc (70 mL), washed with water (5×5 mL) 
and brine (5 mL), dried under MgSO4 and concentrated 
under reduced pressure to give 25.2 mg (89%) of compound 30ca: Chiral HPLC 
analysis: Lux Amylose-1, hexane-iPrOH 80:20, 1 mL/min. major enantiomer tr = 10.3 
min, minor enantiomer tr = 26.0 min. Colorless oil; [α]D20 -184.3 (c 1.0, CHCl3, ee = 
94%); 1H NMR (300 MHz, CDCl3) δ 10.55 (1H, s, NH), 7.28-7.20 (1H, m, Ar), 7.17 
(2H, t, J = 7.5 Hz, Ar), 7.10-6.89 (5H, m, Ar), 6.85-6.63 (4H, m, Ar), 6.38 (1H, ddd, J = 
8.4, 6.6, 2.7 Hz, Ar), 6.07 (1H, s, NH), 6.03 (1H, dd, J = 8.1, 1.2 Hz, Ar), 4.83 (1H, s, 
CH-Ph), 4.52 (1H, hept, J = 6.3Hz, CHO), 3.89 (3H, s, MeO), 3.81 (3H, s, MeO), 0.92 
(3H, d, J = 6.3 Hz, iPr), 0.57 (3H, d, J = 6.3 Hz, iPr); 13C NMR (75 MHz, CDCl3) δ 
172.4 (C), 169.2 (C), 166.4 (C), 152.4 (C), 149.9 (C), 140.4 (C), 129.8 (C), 128.7 (CH), 
128.4 (CH), 127.6 (CH), 126.8 (CH), 121.9 (CH), 119.9 (CH), 119.6 (CH), 110.4 (CH), 
102.3 (C), 71.5 (C), 70.0 (CH), 55.8 (CH3), 53.3 (CH3), 48.9 (CH), 21.2 (CH3), 20.6 
(CH3); HRMS (ESI) m/z 515.2179 [M+H]+, C30H31N2O6 requires 515.2177.  
 
 
Experimental Section 
200
(2R,3R,Z)-4-(((2-methoxyphenyl)amino)(phenyl)methylene)-5-oxo-3-
phenylpyrrolidine-2-carboxylic acid (31ca). 
A 25% solution of tetraethylammonium hydroxide in MeOH 
(38 µL, 0.22 mmol) was added to a solution of compound 
26ca (30.0 mg, 0.055 mmol, ee = 94%) in dimethylsulfoxide 
(1.5 mL) under nitrogen, and the reaction flask was introduced 
in a bath at 80 °C. After 36 h, water was added (10 mL). The 
mixture was acidified with 2M HCl until pH 2 and extracted 
with dichloromethane (3×30 mL), the organic layer was washed with water (3×5 mL), 
brine (5 mL), dried over MgSO4 and concentrated under reduced pressure to give 19.0 
mg (87%) of acid 31ca. Yellow oil; [α]D20 -88.9 (c 1.0, CHCl3, ee = 94%); 1H NMR 
(300 MHz, DMSO-d6) δ 10.53 (1H, s, OH), 8.01 (1H, s, NH), 7.26-7.20 (3H, m, Ar), 
7.18-7.13 (1H, m, Ar), 7.11-7.07 (3H, m, Ar), 6.98 (2H, d, J = 6.6 Hz, Ar), 6.89 (1H, 
dd, J = 8.1, 1.2 Hz, Ar ), 6.80 (2H, dd, J = 8.1, 1.8 Hz, Ar), 6.71 (1H, dt, J = 7.5, 1.5 
Hz, Ar), 6.38 (1H, dd, J = 7.8, 1.8 Hz, Ar), 5.96 (1H, dd, J = 7.8, 0.9 Hz, Ar), 4.10 (1H, 
s, CH-Ph), 3.83 (3H, s, MeO), 3.74 (1H, s, CH-CO); 13C NMR (75 MHz, DMSO-d6) δ 
173.3 (C), 149.6 (C), 149.3 (C), 145.2 (C), 134.5 (C), 129.4 (C), 128.7 (CH), 128.4 
(CH), 128.21 (CH), 128.17 (CH), 126.3 (CH), 126.2 (CH), 121.5 (CH), 119.8 (CH), 
119.1 (CH), 110.9 (CH), 104.4 (C), 61.9 (CH), 55.6 (CH3), 46.8 (CH); 1H NMR (300 
MHz, CDCl3) δ 10.56 (1H, s, NH), 7.25-6.80 (11H, m, Ar), 6.74 (1H, s, NH), 6.72 (1H, 
m, Ar), 6.37 (1H, ddd, J = 8.4, 6.6, 3.0 Hz, Ar), 6.01 (1H, d, J = 7.8 Hz, Ar), 4.27 (1H, 
d, J = 2.0 Hz, CH-Ph), 4.04 (1H, d, J = 2.0 Hz, CH-CO), 3.87 (3H, s, MeO); 13C NMR 
(75 MHz, CDCl3) δ 174.9 (C), 152.4 (C), 150.0 (C), 145.3 (C), 134.5 (C), 129.9 (C), 
128.5 (CH), 128.4 (CH), 128.2 (CH), 128.1 (CH), 126.7 (CH), 126.2 (CH), 121.8 (CH), 
119.8 (CH), 119.7 (CH), 110.4 (CH), 101.9 (C), 62.4 (CH), 55.7 (CH3), 47.1 (CH); 
HRMS (ESI) m/z 415.1655 [M+H]+, C25H22N2O4 requires 415.1655  
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6. CONCLUSIONS 
1. Several new asymmetric conjugate addition reactions of malonate ester 
derivatives and α,β-unsaturated imines have been developed using different chiral metal 
complexes as catalysts. In these reactions, the use of molecular sieves as an additive was 
crucial to obtain the desired products with high yields and stereoselectivity. 
2. The enantioselective conjugate addition of dimethyl malonate to α,β-unsaturated 
N-tosyl imines derived from chalcones was carried out in the presence of a catalytic 
amount of the pyBOX1-La(OTf)3 complex, achieving the corresponding chiral E-
enamines with excellent yields, good diastereomeric ratios and enantiomeric excesses 
up to 93%. The reaction could be applied to unsaturated imines bearing aromatic and 
heteroaromatic substituents in both, the β-carbon of the alkene and the azomethinic 
carbon. Also, the reaction tolerated aliphatic groups yielding the corresponding 1,4-
adducts with slightly lower enantiomeric excess. This reaction is the first example of 
enantioselective conjugate addition of 1,3-dicarbonyl compounds to α,β-unsaturated 
imines reported in literature. The (S,E) stereochemistry of the resulting products was 
established by NOESY experiments and chemical correlation with a compound of 
known stereochemistry.  
3. A similar reaction involving the addition of dimethyl malonate to β-
trifluoromethyl α,β-unsaturated N-tosyl imines has also been developed. In this case, the 
reaction performed better in the presence of the BOX7-Cu(OTf)2 or BOX7-Mg(OTf)2 
complexes than with pyBOX1-La(OTf)3. Better enantioselectivity was obtained with 
the copper catalyst while the magnesium complex provided the reaction products with 
better diastereoselectiviy. In both cases, the trifluoromethylated (S,E)-enamines were 
obtained, as it could be determined by X-ray analysis of one of the products. 
4. We have developed a diastereodivergent Mukaiyama-Michael reaction of 
silylketene acetals to conjugated N-tosyl ketimines derived from β,γ-unsaturated α-keto 
esters. Although the reaction could not be carried out in an enantioselective fashion, the 
E- or Z-dehydroamino esters were obtained in a stereocontrolled manner starting from a 
same set of reactants. The non-catalytic reaction favored the Z-diastereomer while in the 
presence of a catalytic amount of copper triflate the E-diastereomer was obtained. The 
stereochemistry of the resulting products was determined by both NOESY experiments 
and X-ray analysis. Based on these results, we also established a correlation between the 
1H NMR chemical shifts and the stereochemistry of the double bond in these 
compounds.  
 5. The pyBOX1-La(OTf)3 complex catalyzed the enantioselective conjugate 
addition of dialkyl malonates to conjugated N-tosyl imines derived from β,γ-unsaturated 
α-keto esters to give the corresponding chiral α,β-dehydroamino esters with excellent 
yields, diastereomeric ratios and high enantiomeric excesses. The reaction could be also 
performed with dimethyl 2-methylmalonate. In all the cases, the reaction delivered the 
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products with the Z configuration at the enamine double bond as it could be determined 
by NOESY experiments and X-ray analysis.  
6. An extension of the above reaction involved the enantioselective conjugate 
addition of diethyl 2-chloromalonate to α,β-unsaturated N-tosyl imines derived from 
β,γ-unsaturated α-keto esters. As with diethyl malonate, the addition of diethyl 2-
chloromalonate catalyzed by pyBOX-La(OTf)3 complexes led to the corresponding 
dehydroamino esters with the Z-configuration at the double bond. Excellent yields, 
diasteromeric ratios and good enantiomeric excesses were obtained for a number of 
imines. On the other hand, the reaction catalyzed by the pyBOX1-Ca(OTf)2 complex 
provided the dehydroamino esters with the E-configuration at the double bond, again 
with excellent yields, high diastereomeric ratios and almost full enantioselectivity. Thus 
both the E- and Z- chiral dehydroamino esters were available from the same set of 
reactants with high enantioselectivity by simply changing the catalyst. 
The resulting chloro-derivatives could be subjected to hydrogenolysis in the 
presence of a Rh-dppp complex without isomerization or erosion of the optical purity. 
This reaction gave access to compounds (E)-19 which were not directly available from 
diethyl malonate. 
7. The catalytic asymmetric formal [3+2] cycloaddition of diisopropyl 2-
isocyanatomalonate and α,β-unsaturated N-(o-methoxyphenyl)imines to give highly 
substituted chiral γ-lactams has been developed. The reaction was catalyzed by the 
BOX10-Mg(OTf)2 complex, and the chiral pyrrolidinones featuring a conjugated 
exocyclic double bond were obtained with excellent yields, full diastereoselectivity and 
high to excellent enantioselectivities, for a significative number of unsaturated imines. 
The use of the N-(o-methoxyphenyl) group was essential for the success of the reaction 
as neither the unsaturated ketone nor the unsaturated N-tosyl imine were reactive with 
this catalyst. Furthermore, the reaction did not require diastereomerically pure imines as 
starting materials. Also, the bulky diisopropyl ester was important to achieve high 
enantioselectivity. The reaction is thought to proceed by a tandem Michael 
addition/intramolecular addition to isocyanate process. The configuration of the chiral 
center as well as the geometry of the alkene in the resulting lactams was determined by 
X-ray analysis. 
8. The potential applicability of the products resulting from the above reactions has 
been proved by performing several synthetic transformations to obtain nitrogen-
containing compounds such as δ-amino esters, piperidones, pyrrolidones or 
cyclopropanic compounds. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
7. REFERENCES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
References 
203 
7. REFERENCES 
1. Chiral Drugs: Chemistry and Biological Action; Lin, G.-Q., You, Q.-D., Cheng, 
J.-F., Eds.; John Wiley and sons: Hoboken, New Jersey, 2011. 
2. Green, M. M.; Nolte, R. J. M.; Meijer, E. W. Materials Chirality. Topics in 
Stereochemistry Denmark, S. E., Siegel, J., Eds.; John Wiley and sons: Hoboken, 
New Jersey, 2003; Vol. 24. 
3. a) Comprehensive Asymmetric Catalysis: Suppl. 2; Jacobsen, E. N.; Pfaltz, A.; 
Yamamoto, H., Eds.; Springer-Verlag: Berlin, 2004.  b)  Asymmetric Catalysis on 
Industrial Scale: Challenges, Approaches and Solutions; Blaser, H.-U., Schmidt, 
E., Eds.; Wiley-VCH: Weinheim, 2004.                                            
4. Green Chemistry. Frontiers in Benign Chemical Synthesis and Processes, 
Anastas, P.T., Williamson, T. C., Eds.; Oxford University Press: Oxford, 1998. 
5. a) Perlmutter, P. Conjugate Addition Reactions in Organic Synthesis, Pergamon: 
Oxford, 1992. b) Alexakis, A. The conjugate Addition Reaction In Transition 
Metals for Organic Synthesis; Beller, M., Bolm, C., Eds.; Wiley-VCH: Weinheim, 
2004; Vol.1, pp. 553-562. d) Yamaguchi, M. Catalytic Conjugate Addition of 
Stabilized Carbanions In Comprehensive Asymmetric Catalysis; Jacobsen E. N., 
Pfaltz, A., Yamamoto, H., Eds.; Springer-Verlag: 1999; Vol. 3, pp. 1121-1139. e) 
Csaky, A. G.; de la Herran, G.; Murcia, M. C. Chem. Soc. Rev. 2010, 39, 4080-
4102.  
6. a) Nguyen, B. N.; Hii, K. K.; Szymanski, W.; Janssen, D. B. Conjugate Addition 
Reactions In Science of Synthesis, Stereoselective Synthesis; De Vries, J.G., 
Molander, G.A., Evans, D.A., Eds.; Georg ThiemeVerlag: Sttutgart, 2011; Vol. 1, 
pp. 571-688. b) Reyes, E.; Vicario, J. L.; Badia, D.; Carrillo, L. Org. Lett. 2006, 8, 
6135-6138. c) Jha, S. C.; Joshi, N. N. ARKIVOC 2002, 167-196. 
7. For a review on conjugate imines and iminium salts as acceptors of nucleophiles 
see: Shimizu, M.; Hachiya, I.; Mizota, I. Chem. Commun. 2009, 874-889. 
8. Mahgoub, S. A. Arch. Pharm. Res. 1990, 13, 319-324. 
9. Fernández De Trocóniz, G.; Ochoa De Retana, A. M.; Pascual, S.; Ezpeleta, J. M.; 
Palacios, F. Eur. J. Org. Chem. 2013, 5614-5620. 
10. Qiu, L.; Gao, L.; Tang, J.; Wang, D.; Guo, X.; Liu, S.; Yang, L.; Li, J.; Hu, W. J. 
Org. Chem. 2014, 79, 4142-4147. 
11. Shimizu, M.; Kamiya, M.; Hachiya, I. Chem. Lett. 2003, 32, 606-607. 
12. Shimizu, M.; Kurokawa, H.; Takahashi, A. Lett. Org. Chem. 2004, 1, 353-356. 
13. Shimizu, M.; Takahashi, A.; Kawai, S. Org. Lett. 2006, 8, 3585-3587. 
14. Takahashi, A.; Kawai, S.; Hachiya, I.; Shimizu, M. Eur. J. Org. Chem. 2010, 191-
200. 
15. Mizota, I.; Matsuda, Y.; Hachiya, I.; Shimizu, M. Org. Lett. 2008, 10, 3977-3980. 
16. Shimizu, M.; Kamiya, M.; Hachiya, I. Chem. Lett. 2005, 34, 1456-1457. 
17. Bonini, B. F.; Fochi, M.; Franchini, M. C.; Mazzanti, G.; Ricci, A.; Picard, J.-P.; 
Dunoguès, J.; Aizpurua, J.-M.; Palomo, C. Synlett 1997, 1321-1323. 
References 
204 
18. Tomioka, K.; Shioya, Y.; Nagaoka, Y.; Yamada, K. I. J. Org. Chem. 2001, 66, 
7051-7054. 
19. McMahon, J. P.; Ellman, J. A. Org. Lett. 2005, 7, 5393-5396. 
20. Soeta, T.; Kuriyama, M.; Tomioka, K. Tetrahedron 2005, 61, 297-300. 
21. Soeta, T.; Ishizaka, T.; Ukaji, Y. J. Org. Chem. 2016, 81, 2817-2826. 
22. Esquivias, J.; Gómez Arrayás, R.; Carretero J. C. J. Org. Chem. 2005, 70, 7451-
7454. 
23. Palacios, F.; Vicario, J. Org. Lett. 2006, 8, 5405-5408. 
24. Palacios, F.; Vicario, J. Synthesis 2007, 3923-3925. 
25. Westmeier, J.; von Zezschwitz, P. Chem. Commun. 2014, 50, 15897-15900. 
26. Gebhardt, S.; Müller, C. H.; Westmeier, J.; Harms, K.; Von Zezschwitz, P. Adv. 
Synth. Catal. 2015, 357, 507-514. 
27. Hirner, S.; Kolb, A.; Westmeier, J.; Gebhardt, S.; Middel, S.; Harms, K.; Von 
Zezschwitz, P. Org. Lett. 2014, 16, 3162-3165. 
28. Lee, A.; Kim, H. J. Am. Chem. Soc. 2015, 137, 11250-11253. 
29. Lee, A.; Kim, H. J. Org. Chem. 2016, 81, 3520-3527. 
30. Bi, B.; Lou, Q. X.; Ding, Y. Y.; Chen, S. W.; Zhang, S. S.; Hu, W. H.; Zhao, J. L. 
Org. Lett. 2015, 17, 540-543. 
31. Zhang, F.; Liu, Z.-J.; Liu, J.-T. Org. Biomol. Chem. 2011, 9, 3625-3628. 
32. Li, W.; Liu, H.; Jiang, X.; Wang, J. ACS Catal. 2012, 2, 1535-1538. 
33. Yamada, K.; Umeki, H.; Maekawa, M.; Yamamoto, Y.; Akindele, T.; Nakano, 
M.; Tomioka, K. Tetrahedron 2008, 64, 7258-7265. 
34. Shimizu, M.; Nishi, T. Synlett 2004, 889-891. 
35. Vicario, J.; Aparicio, D.; Palacios, F.; Uni, V. J. Org. Chem. 2009, 74, 452-455. 
36. Hashimoto, T.; Gálvez, A. O.; Maruoka, K. J. Am. Chem. Soc. 2015, 137, 16016-
16019. 
37. Afarinkia, K.; Cadogan, J. I. G.; Rees, C. W. Synlett 1992, 123. 
38. Moonen, K.; Van Meenen, E.; Verwée, A.; Stevens, C. V. Angew. Chem. - Int. 
Ed. 2005, 44, 7407-7411. 
39. Van Meenen, E.; Moonen, K.; Verwée, A.; Stevens, C. V. J. Org. Chem. 2006, 
71, 7903-7906. 
40. Huang, Y.; Chew, R. J.; Pullarkat, S. A.; Li, Y.; Leung, P. H. J. Org. Chem. 2012, 
77, 6849-6854. 
41. Shimizu, M.; Nishi, T. Chem. Lett. 2002, 31, 46-47. 
42. Ueda, M.; Miyabe, H.; Shimizu, H.; Sugino, H.; Miyata, O.; Naito, T. Angew. 
Chem. - Int. Ed. 2008, 47, 5600-5604. 
43. Sole, C.; Fernández, E. Chem. - An Asian J. 2009, 4, 1790-1793. 
44. Bonet, A.; Solé, C.; Gulyás, H.; Fernández, E. Curr. Org. Chem. 2010, 14, 2531-
2548. 
45. Bonet, A.; Solé, C.; Gulyás, H.; Fernández, E. Chem. - An Asian J. 2011, 6, 1011-
1014. 
46. Solé, C.; Tatla, A.; Mata, J. A.; Whiting, A.; Gulyás, H.; Fernández, E. Chem. - A 
Eur. J. 2011, 17, 14248-14257. 
References 
205 
47. Solé, C.; Whiting, A.; Gulyás, H.; Fernández, E. Adv. Synth. Catal. 2011, 353, 
376-384. 
48. Kitanosono, T.; Xu, P.; Isshiki, S.; Zhu, L.; Kobayashi, S. Chem. Commun. 2014, 
50, 9336-9339. 
49. Baydar, A. E.; Boyd, G, V. J.C.S. Chem. Comm. 1979, 178-179. 
50. Ito, Y.; Miyata, S.; Nakatsuka, M.; Saegusa, T. J. Am. Chem. Soc. 1981, 103, 
5250-5251. 
51. Serckx-Poncin, B.; Hesbain-Frisque, A.-M.; Ghosez, L. Tetrahedron Lett. 1982, 
23, 3261-3264. 
52. Ihara, M.; Kirihara, T.; Kawaguchi, A.; Fukumoto, K.; Kametani, T. Tetrahedron 
Lett. 1984, 25, 4541-4544. 
53. Komatsu, M.; Takamatsu, S.; Uesaka, M.; Yamamoto, S.; Ohshiro, Y.; Agawa, T. 
J. Org. Chem. 1984, 49, 2691-2699. 
54. Whitesell, M. A.; Kyba, E. P. Tetrahedron Lett. 1984, 25, 2119-2120. 
55. Hwang, Y. C.; Fowler, F. W. J. Org. Chem. 1985, 50, 2719-2726. 
56. Laguna, M. A.; Pulido, F. J.; González, B.; González, A. M.; Alberola, A. 
Tetrahedron Lett. 1986, 27, 2027-2030. 
57. Boger, D. L.; Kasper, A. M. J. Am. Chem. Soc. 1989, 111, 1517-1519. 
58. Boger, D. L.; Corbett, J. W. L.; Wiggins, J. M. J. Org. Chem. 1990, 55, 2999-
3000. 
59. Boger, D. L.; Corbett, W. L. J. Org. Chem. 1993, 58, 2068-2074. 
60. Boger, D. L.; Corbett, W. L.; Curran, T. T.; Kasper, A. M. J. Am. Chem. Soc. 
1991, 113, 1713-1729. 
61. Hong, B.-C.; Wu, J.-L.; Gupta, A. K.; Hallur, M. S.; Liao, J.-H. Org. Lett. 2004, 
6, 3453-3456. 
62. Boger, D. L.; Zhang, M. J. Org. Chem. 1992, 57, 3974-3977. 
63. Boger, D. L.; Hong, J. J. Am. Chem. Soc. 1998, 120, 1218-1222. 
64. Blagg, B. S. J.; Boger, D. L. Tetrahedron 2002, 58, 6343-6349. 
65. Schnermann, M. J.; Boger, D. L. J. Am. Chem. Soc. 2005, 127, 15704-15705. 
66. Teng, M.; Fowler, F. W. J. Org. Chem. 1990, 55, 5646-5653. 
67. Liu, K.; Chang, X.; Wang, C.-J. Org. Lett. 2016, 18, 6288-6291. 
68. Stokes, S.; Bekkam, M.; Rupp, M.; Mead, K. T. Synlett 2012, 389-392. 
69. Stokes, S.; Mead, K. T. Synth. Commun. 2013, 43, 2627-2633. 
70. Tiezte, L. F.; Schuffenhauer, A. Eur. J. Org. Chem. 1998, 1629-1637. 
71. Barluenga, J.; de la Rua, R. B.; de Saa, D.; Ballesteros, A.; Tomás, M. Angew. 
Chem. - Int. Ed. 2005, 44, 4981-4983. 
72. Clark, R. C.; Pfeiffer, S. S.; Boger, D. L. J. Am. Chem. Soc. 2006, 128, 2587-
2593. 
73. Vicario, J.; Aparicio, D.; Palacios, F. Tetrahedron Lett. 2011, 52, 4109-4111. 
74. Motorina I. A.; Grierson, D. S. Tetrahedron Letters, 1999, 40, 7211-7214. 
75. Motorina I. A.; Grierson, D. S. Tetrahedron Letters, 1999, 40, 7215-7218. 
76. Esquivias, J.; Gómez Arrayás, R.; Carretero, J. C. J. Am. Chem. Soc. 2007, 129, 
1480-1481. 
References 
206 
77. Esquivias, J.; Alonso, I.; Gómez Arrayás, R.; Carretero, J. Synthesis 2009, 113-
126. 
78. Chu, J. C. K.; Dalton, D. M.; Rovis, T. J. Am. Chem. Soc. 2015, 137, 4445-4452. 
79. Jiang, X.; Shi, X.; Wang, S.; Sun, T.; Cao, Y.; Wang, R. Angew. Chem. - Int. Ed. 
2012, 51, 2084-2087. 
80. He, L.; Laurent, G.; Retailleau, P.; Folleas, B.; Brayer, J.-L.; Masson, G.  Angew. 
Chem. - Int. Ed. 2013, 52, 11088-11091. 
81. Jones, R. C. F.; Anderson, M.W.; Smallridge, M. J. Tetrahedron Lett. 1988, 29, 
5001-5004. 
82. Palacios, F.; Ochoa de Retana, A. M.; Pascual, S.; Fernández de Trocóniz, G.; 
Ezpeleta, J. M. Eur. J. Org. Chem. 2010, 6618-6626. 
83. Fernández de Trocóniz, G.; Ochoa de Retana, A. M.; Pascual, S.; Ezpeleta, J. M.; 
Palacios, F. Eur. J. Org. Chem. 2013, 5614-5620. 
84. Chen, W.; Zhang, R. Z.; Lu, X. Y.; Xie, J. W. J. Braz. Chem. Soc. 2015, 26, 405-
410. 
85. Geirsson, J.K.F.; Gudmundsdottir, A. D. Acta Chem. Scand. 1989, 43, 618-619. 
86. Geirsson, J.K.F.; Johannesdottir, J. F. J. Org. Chem. 1996, 61, 7320-7325. 
87. Jiang, J.; Yu, J.; Sun, X. X.; Rao, Q. Q.; Gong, L. Z. Angew. Chem. - Int. Ed. 
2008, 47, 2458-2462. 
88. An, D.; Zhu, Z.; Zhang, G.; Gao, Y.; Gao, J.; Han, X.; Zheng, L.; Zhang, S. 
Tetrahedron: Asymmetry. 2015, 26, 897-906. 
89. Maeda, K.; Terada, T.; Iwamoto, T.; Kurahashi, T.; Matsubara, S. Org. Lett. 2015, 
17, 5284-5287. 
90. Han, B.; Li, J. L.; Ma, C.; Zhang, S. J.; Chen, Y. C. Angew. Chem. - Int. Ed. 2008, 
47, 9971-9974. 
91. Han, B.; He, Z. Q.; Li, J. L.; Li, R.; Jiang, K.; Liu, T. Y.; Chen, Y. C. Angew. 
Chem. - Int. Ed. 2009, 48, 5474-5477. 
92. He, Z.-Q.; Han, B.; Li, R.; Wu, L.; Chen, Y.-C. Org. Biomol. Chem. 2010, 8, 755-
757. 
93. Zhou, S. L.; Li, J. L.; Dong, L.; Chen, Y. C. Org. Lett. 2011, 13, 5874-5877. 
94. Li, Q. Z.; Ma, L.; Dong, L.; Chen, Y. C. ChemCatChem 2012, 4, 1139-1142. 
95. Feng, X.; Zhou, Z.; Ma, C.; Yin, X.; Li, R.; Dong, L.; Chen, Y. C. Angew. Chem. 
- Int. Ed. 2013, 52, 14173-14176. 
96. Yin, X.; Zhou, Q.; Dong, L.; Chen, Y. Chinese J. Chem. 2012, 30, 2669-2675. 
97. Li, J.-Y.; Li, Z.-L.; Zhao, W.-W.; Liu, Y.-K.; Tong, Z.-P.; Tan, R. Org. Biomol. 
Chem. 2016, 14, 2444-2453. 
98. Ma, C.; Gu, J.; Teng, B.; Zhou, Q.-Q.; Li, R.; Chen, Y.-C. Org. Lett. 2013, 15, 
6206-6209. 
99. Simal, C.; Lebl, T.; Slawin, A. M. Z.; Smith, A. D. Angew. Chem. - Int. Ed. 2012, 
51, 3653-3657. 
100. Yeh, P.-P.; Daniels, D. S. B.; Fallan, C.; Gould, E.; Simal, C.; Taylor, J. E.; 
Slawin, A. M. Z.; Smith, A. D. Org. Biomol. Chem. 2015, 13, 2177-2191. 
101. Young, C. M.; Stark, D. G.; West, T. H.; Taylor, J. E.; Smith, A. D. Angew. 
Chem. - Int. Ed. 2016, 55, 14394-14399. 
References 
207 
102. Izquierdo, J.; Pericàs, M. A. ACS Catal. 2016, 6, 348-356. 
103. Stark, D. G.; Morrill, L. C.; Yeh, P.-P.; Slawin, A. M. Z.; O’Riordan, T. J. C.; 
Smith, A. D. Angew. Chem. - Int. Ed. 2013, 52, 11642-11646. 
104. Hao, L.; Chen, X.; Chen, S.; Jiang, K.; Torres, J.; Chi, Y. R. Org. Chem. Front. 
2014, 1, 148-150. 
105. Wang, L.; Zhu, G.; Tang, W.; Lu, T.; Du, D. Tetrahedron 2016, 72, 6510-6517. 
106. He, M.; Struble, J. R.; Bode, J. W. J. Am. Chem. Soc. 2006, 128, 8418-8420. 
107. Shao, P. L.; Chen, X. Y.; Sun, L. H.; Ye, S. Chem. Commun. 2011, 47, 2381-
2383. 
108. Jian, T.-Y.; Sun, L.-H.; Ye, S. Chem. Commun. 2012, 48, 10907-10909. 
109. Wang, D. L.; Liang, Z. Q.; Chen, K. Q.; Sun, D. Q.; Ye, S. J. Org. Chem. 2015, 
80, 5900-5905. 
110. Zhao, X.; Ruhl, K. E.; Rovis, T. Angew. Chem. - Int. Ed. 2012, 51, 12330-12333. 
111. Hao, L.; Du, Y.; Lv, H.; Chen, X.; Jiang, H.; Shao, Y.; Chi, Y. R. Org. Lett. 2012, 
14, 2154-2157. 
112. Hao, L.; Chen, S.; Xu, J.; Tiwari, B.; Fu, Z.; Li, T.; Lim, J.; Chi, Y. R. Org. Lett. 
2013, 15, 4956-4959. 
113. Chen, S.; Hao, L.; Zhang, Y.; Tiwari, B.; Chi, Y. R. Org. Lett. 2013, 15, 5822-
5825. 
114. Han, R.; He, L.; Liu, L.; Xie, X.; She, X. Chem. - An Asian J. 2016, 11, 193-197. 
115. Jin, Z.; Yang, R.; Du, Y.; Tiwari, B.; Ganguly, R.; Chi, Y. R. Org. Lett. 2012, 14, 
3226-3229. 
116. Shi, Z.; Tong, Q.; Leong, W. W. Y.; Zhong, G. Chem. - A Eur. J. 2012, 18, 9802-
9806. 
117. Shi, Z.; Yu, P.; Loh, T. P.; Zhong, G. Angew. Chem. - Int. Ed. 2012, 51, 7825-
7829. 
118. Zhang, X.-N.; Chen, G.-Q.; Dong, X.; Wei, Y.; Shi, M. Adv. Synth. Catal. 2013, 
355, 3351-3357. 
119. Wang, G.; Rexiti, R.; Sha, F.; Wu, X.-Y. Tetrahedron 2015, 71, 4255-4262. 
120. Zhu, Y.-J.; Guo, X.-F.; Fan, Z.-J.; Chen, L.; Ma, L.-Y.; Wang, H.-X.; Wei, Y.; 
Xu, X.-M.; Lin, J.-P.; Bakulev, V. A. RSC Adv. 2016, 6, 112704-112711. 
121. Shi, Z.; Loh, T. P. Angew. Chem. - Int. Ed. 2013, 52, 8584-8587. 
122. Saito, T.; Kimura, H.; Chonan, T.; Soda, T.; Karakasa, T. Chem. Commun. 1997, 
1013-1014. 
123. Saito, T.; Kobayashi, S.; Ohgaki, M.; Wada, M.; Nagahiro, C. Tetrahedron Lett. 
2002, 43, 2627-2631. 
124. Kobayashi, S.; Furuya, T.; Otani, T.; Saito, T. Tetrahedron Lett. 2008, 49, 4513-
4515. 
125. Kobayashi, S.; Furuya, T.; Otani, T.; Saito, T. Tetrahedron 2008, 64, 9705-9716. 
126. Vugts, D. J.; Koningstein, M. M.; Schmitz, R. F.; de Kanter, F. J. J.; Groen, M. 
B.; Orru, R. V. A. Chem. - A Eur. J. 2006, 12, 7178-7189. 
127. Fernández de Trocóniz, G.; Ochoa de Retana, A. M.; Rubiales, G.; Palacios, F. J. 
Org. Chem. 2014, 79, 5173-5181. 
128. Morimoto, T.; Chatani, N.; Murai, S.  J. Am. Chem. Soc. 1999, 121, 1758-1759. 
References 
208 
129. Fontaine, P.; Masson, G.; Zhu, J. Org. Lett. 2009, 11, 1555-1558 
130. Yu, S.; Xiong, M.; Xie, X.; Liu, Y. Angew. Chem. - Int. Ed. 2014, 53, 11596-
11599. 
131. Xiong, M.; Yu, S.; Xie, X.; Li, S.; Liu, Y. Organometallics 2015, 34, 5597-5601. 
132. Mizuno, A.; Kusama, H.; Iwasawa, N. Angew. Chem. - Int. Ed. 2009, 48, 8318-
8320. 
133. Tang, D. D.; Wang, Y.; Wang, J. R.; Xu, P. F. Tetrahedron Lett. 2014, 55, 4133-
4135. 
134. Lu, L. Q.; Zhang, J. J.; Li, F.; Cheng, Y.; An, J.; Chen, J. R.; Xiao, W. J. Angew. 
Chem. - Int. Ed. 2010, 49, 4495-4498. 
135. Liu, C.-R.; Zhu, B.-H.; Zheng, J.-C.; Sun, X.-L.; Xie, Z.; Tang, Y. Chem. 
Commun. 2011, 47, 1342-1344. 
136. Tian, J.; Zhou, R.; Sun, H.; Song, H.; He, Z. J. Org. Chem. 2011, 76, 2374-2378. 
137. Zheng, P. F.; Ouyang, Q.; Niu, S. L.; Shuai, L.; Yuan, Y.; Jiang, K.; Liu, T. Y.; 
Chen, Y. C. J. Am. Chem. Soc. 2015, 137, 9390-9399. 
138. Schomaker, J. M.; Toste, F. D.; Bergman, R. G. Org. Lett. 2009, 11, 3698-3700. 
139. He, M.; Bode, J. W. J. Am. Chem. Soc. 2008, 130, 418-419. 
140. Chiang, P. C.; Rommel, M.; Bode, J. W. J. Am. Chem. Soc. 2009, 131, 8714-
8718. 
141. Chen, X.; X. Fang; Chi, Y. R. Chem. Sci. 2013, 4, 2177-2184. 
142. Tian, J.; He, Z. Chem. Commun. 2013, 49, 2058-2060. 
143. Li, E.; Jia, P.; Liang, L.; Huang, Y. ACS Catal. 2014, 4, 600-603. 
144. Du, D.; Xu, Q.; Li, X.-G.; Shi, M. Chem. - A Eur. J. 2016, 22, 4733-4737. 
145. Chen, X.; Zhang, J. Q.; Yin, S. J.; Li, H. Y.; Zhou, W. Q.; Wang, X. W. Org. Lett. 
2015, 17, 4188-4191. 
146. He, X. L.; Xiao, Y. C.; Du, W.; Chen, Y. C. Chem. - A Eur. J. 2015, 21, 3443-
3448. 
147. Zheng, J. C.; Liao, W. W.; Tang, Y.; Sun, X. L.; Dai, L. X. J. Am. Chem. Soc. 
2005, 127, 12222-12223. 
148. Zhang, R.-Z.; Meng, C.-Y.; Xie, J.-W.; Xu, M.-L.; Zhu, W.-D. Eur. J. Org. Chem. 
2014, 3104-3107. 
149. Tang, M.; Zhao, Y.; Cheng, Y. Synthesis 2014, 46, 87-95. 
150. Wang, Z. T.; Zhao, Y.; Wang, Z. Y.; Cheng, Y. J. Org. Chem. 2015, 80, 1727-
1734. 
151. Colby, D. A.; Bergman, R. G.; Ellman, J. A. J. Am. Chem. Soc. 2006, 128, 5604-
5606. 
152. Colby, D. A.; Bergman, R. G.; Ellman, J. A. J. Am. Chem. Soc. 2008, 130, 3645-
3651. 
153. Yamakawa, T.; Yoshikai, N. Org. Lett. 2013, 15, 196-199. 
154. Li, M.; González-Esguevillas, M.; Berritt, S.; Yang, X.; Bellomo, A.; Walsh, P. J. 
Angew. Chem. - Int. Ed. 2016, 55, 2825-2829. 
155. Blay, G.; Incerti, C.; Muñoz, M. C.; Pedro, J. R. Eur. J. Org. Chem. 2013, 1696-
1705. 
References 
209 
156. a) Hasegawa, M.; Ono, F.; Kanemasa, S. Tetrahedron Lett. 2008, 49, 5220-5223. 
b) Kubota, Y.; Ikeya, H.; Sugi, Y.; Yamada, T.; Tatsumi, T. J. Mol. Cat. A: 
Chemical 2006, 249, 181-190. c) Chen, D.; Chen, Z.; Xiao, X.; Yang, Z.; Lin, L.; 
Liu, X.; Feng, X. Chem. - A. Eur. J. 2011, 15, 6807-6810. e) Jiang, J.-J.; Huang, 
J.; Wang, D.; Yuan, Z.-L.; Zhao, M.-X.; Wang, F.-J.; Shi, M. Chirality 2011, 23, 
272-276. f) Palomo, C.; Pazos, R.; Oiarbide, M.; García, J. M. Adv. Synth. Catal. 
2006, 348, 1161-1164. 
157. Wang, J.; Li, H.; Zu, L.; Jiang, W.; Xie, H.; Duan, W.; Wang, W. J. Am. Chem. 
Soc. 2006, 128, 12652-12653. 
158. a) Desimoni, G.; Faita, G.; Guala, M.; Laurenti, A.; Mella, M. Chem. - A. Eur. J. 
2005, 11, 3816-3824. b) Desimoni, G.; Faita, G.; Piccinini, F.;  Toscanini, M. Eur. 
J. Org. Chem. 2006, 5228-5230. 
159. Christoffers, J. Eur. J. Org. Chem. 1998, 1259-1266. b) Sasai, H.; Arai, T.; 
Shibasaki, M. J. Am. Chem. Soc. 1994, 116, 1571-1572. 
160. Wang, J.; Zhou, Y.; Zhang, L.; Li, Z.; Chen, X.; Liu, H. Org. Lett. 2013, 15, 
1508-1511. 
161. Vicario, J. L.; Badia, D.; Carrillo, L. J. Org. Chem. 2001, 66, 5801-5807. 
162. a) Ojima, I.; Fluorine in Medicinal Chemistry and Chemical Biology; Wiley-
Blackwey: Chichester, 2009. b) Theodiridis, G. In Agrochemical, Archaelogical, 
Green Chemistry and Water; Tressaud, A., Ed.; Elsevier: Amsterdam, 2006; Vol. 
2, pp 121.  d) Purser, S.; Moore, P. R.; Swallow, S.; Gouverneur, V. Chem. Soc. 
Rev. 2008, 37, 320-330. c) Zhou, Y.; Wang, J.; Gu, Z.; Wang, S.; Zhu, W.; Aceña, 
J. L.; Soloshonok, V. A.; Izawa, K.; Liu, H. Chem. Rev. 2016, 116, 422-518. d) 
Wang, J.; Sánchez-Roselló, M.; Aceña, J. L.; del Pozo, C.; Sorochinsky, A. E.; 
Fustero, S.; Soloshonok, V. A.; Liu, H. Chem. Rev. 2014, 114, 2432-2506. 
163. a) Chapurlat, R. D. Ther. Adv. Musculoskel. Dis. 2015, 7, 103-109. b) Gaida, R.; 
Truter, I.; Grobler, C.; Kotze, T.; Godman, B. Expert Rev. Anti Infect. Ther. 2016, 
14, 377-388. c) Hosten, B.; Boisgard, R.; Jacob, A.; Goutal, S.; Saubamea, B.; 
Dolle, F.; Scherrmann, J.-M.; Cisternino, S.; Tournier, N. Eur. J. Pharm. Sci. 
2013, 50, 520-525. 
164. Dale, J. A.; Dull, D. L.; Mosher H. S. J. Org. Chem. 1969, 34, 2543-2549. 
165. a) Nie, J.; Guo, H.-C.; Cahard, D.; Ma, J.-A. Chem. Rev. 2011, 111, 455-529. b) 
Cahard, D.; Xu, X.; Couve-Bonnaire, S.; Pannecoucke, X. Chem. Soc. Rev. 2010, 
39, 558-568. 
166. a) Blay, G.; Fernandez, I.; Muñoz, M. C.; Pedro, J. R.; Vila, C. Chem. - A. Eur. J. 
2010, 16, 9117-9122. b) Kawai, H.; Yuan, Z.; Kitayama, T.; Tokunaga, E.; 
Shibata, N. Angew. Chem. - Int. Ed. 2013, 52, 5575-5579. c) Sanz-Marco, A.; 
Blay, G.; Muñoz, M. C.; Pedro, J. R. Chem. Commun. 2015, 51, 8958-8961. d) 
Zhao, M.-X.; Zhu, H.-K.; Dai, T.-L.; Shi, M. J. Org. Chem. 2015, 80, 11330-
11338.  
167. a) Hou, X.; Ma, H.; Zhang, Z.; Xie, L.; Qin, Z.; Fu, B. Chem. Commun. 2016, 52, 
1470-1473. b) Ma, C.-H.; Kang, T.-R.; He, L.; Liu, Q.-Z.  Eur. J. Org. Chem. 
2014, 3981-3985. c) Lalonde, M. P.; Chen, Y.; Jacobsen, E. N. Angew. Chem. - 
Int. Ed. 2006, 45, 6366-6370.   
References 
210 
168. Uneyama, K. Recent Advances in the Syntheses of Fluorinated Amino Acids. In 
Fluorine in Medicinal Chemistry and Chemical Biology; Ojima, I., Ed.; Wiley-
Blackwell: Chichester, 2009; pp. 213. 
169. Desimoni, G.; Faita, G.; Jørgensen, K. A. Chem. Rev. 2006, 106, 3561-3651. 
170. a) Kazmaier, U. Synthesis and Chemistry of α,β-Didehydroamino acids In Amino 
Acids, Peptides and Proteins in Organic Chemistry; Andrew, A. E., Ed.; Wiley-
VCH: Weinheim, Germany, 2009; Vol 2, pp 3. b) Jiang, J; Ma, Z.; Castle, S. L. 
Tetrahedron, 2015, 71, 5431-5451. 
171. a) Wang, S.; Zhou, S.; Liu, W. Curr. Opin. Chem. Biol. 2013, 17, 626-634. b) Li, 
B.; Cooper, L.E.; van der Donk, W. A. Methods Enzymol. 2009, 458, 533-558. 
172. a) Gupta, M.; Chauhan, V. S. Biopolymers 2011, 95, 161-173. b) Siodlak, D.; 
Bujak, M.; Stas, M. J. Mol. Struct. 2013, 1047, 229-236. 
173. a) Mathur, P.; Ramakumar, S.; Chauhan, V. S. Biopolymers 2004, 76, 150. b) 
Jimenez, J. C.: Bayo, N.; Chavarria, B.; Lopez-Macia, A.; Royo, M.;  Nicolas, E.; 
Giralt, E.; Albericio, F. Lett. Pept. Sci. 2002, 9, 135-141. 
174. Dugave, C.; Demange, L. Chem. Rev. 2003, 103, 2475-2532. 
175. Blaskovich, M. A. In Handbook on Syntheses of Amino Acids. General Route to 
Amino Acids, American Chemical Society and Oxford University Press: New 
York, 2010; pp. 225. 
176. Mazurkiewicz, R.; Kuznik, A.; Grymel M.; Kuznik, N. Magn. Reson. Chem. 
2005, 43, 36-40. 
177. Zhou, L.; Lin, L.; Wang, W.; Ji, J.; Liu, X.; Feng, X. Chem. Commun. 2010, 46, 
3601-3603. 
178. Sun, Y.; Yang, G.; Shen, Y.; Hua, Z.; Chai, Z. Tetrahedron, 2013, 69, 2733-2739. 
179. Kingsbury, C. A.; Durham, D. L.; Hutton, R. J. Org. Chem., 1978, 25, 4696-4700. 
180. Chelli, S.; Troshin, K.; Mayer, P.; Lakhdar, S.; Ofial A. R.; Mayr, H.  J. Am. 
Chem. Soc., 2016, 138, 10304-10313. 
181. Ohtsuru, M.; Tori, K. Tetrahedron Letters, 1970, 33, 2877-2879. 
182. Adams, J.; Hoffman, L, Jr.; Trost, B. M.  J. Org. Chem., 1970, 35, 1600-1604. 
183. a) Hanessian, S.; Auzzas, L. Acc. Chem. Res. 2008, 41, 1241-1251. b) Najera, C.; 
Yus, M. Tetrahedron: Asymmetry 1999, 10, 2245. c) Stefanucci, A.; Novellino, 
E.; Costante, R.; Mollica, A. Heterocycles 2014, 89, 1801-1825. 
184. Geoghegan, P.; O'Leary, P. Tetrahedron: Asymmetry 2010, 21, 867. 
185. a) Gulder, T. A. M.; Moore, B. S. Angew. Chem. - Int. Ed. 2010, 49, 9346-9367. 
b) Moloney, M. G.; Trippier, P. C.; Yaqoob, M.; Wang. Z. Curr. Drug Discovery 
Technol. 2004, 1, 181-199. c) Sakai, R.; Suzuki, K.; Shimamoto, K.; Kamiya, H. 
J. Org. Chem. 2004, 69, 1180-1185. d) Rombouts, Y.; Elass, E.; Biot, C.; Maes, 
E.; Coddeville, B.; Burguière, A.; Tokarski, C.; Buisine, E.; Trivelli, X.; Kremer, 
L.; Guérardel, Y. J. Am. Chem. Soc. 2010, 132, 16073-16084. 
186. a) Yuan, Q.; Liu, D.; Zhang, W. Org. Lett. 2017, 19, 1144-1147. b) Pace, V.; Rae, 
J. P.; Procter, D. J. Org. Lett. 2014, 16, 476-479. c) Bai, J.-F.; Wang, L.-L.; Peng, 
L.; Guo, Y.-L.; Jia, L.-N.; Tian, F.; He, G.-Y.; Xu, X.-Y.; Wang, L.-X. J. Org. 
Chem. 2012, 77, 2947-2953. 
References 
211 
187. a) Vellalath, S.; Van, K. N.; Romo, D. Angew. Chem. - Int. Ed.  2013, 52, 13688-
13693. b) Chen, L.; Wu, Z.-J.; Zhang, M.-L.; Yue, D.-F.; Zhang, X.-M.; Xu, X.-
Y.; Yuan, W.-C. J. Org. Chem. 2015, 80, 12668-12675. 
188. a) Raup, D. E. A.; Cardinal-David, B.; Holte, D.; Scheidt, K. A. Nat. Chem. 2010, 
2, 766-771. b) Zhao, X.; DiRocco, D. A.; Rovis, T. J. Am. Chem. Soc. 2011, 133, 
12466-12469. 
189. Companyo, X.; Geant, P.-Y.; Mazzanti, A.; Moyano, A.; Rios, R. Tetrahedron 
2014, 70, 75-82. 
190. Selected examples with aldehydes and ketones: a) Sladojevich, F.; Trabocchi, A.; 
Guarna, A.; Dixon, D. J. J. Am. Chem. Soc. 2011, 133, 1710-1713. b) de la 
Campa, R.; Ortin, I.; Dixon, D. J. Angew. Chem. - Int. Ed. 2015, 54, 4895-4898. 
Selected examples with imines: c) Shao, P.-L.; Liao, J.-Y.; Ho, Y. A.; Zhao, Y. 
Angew. Chem. - Int. Ed.  2014, 53, 5435-5439. d) Hayashi, M.; Iwanaga, M.; 
Shiomi, N.; Nakane, D.; Masuda, H.; Nakamura, S. Angew. Chem. - Int. Ed. 2014, 
53, 8411-8415. 
191. Selected examples with aldehydes and ketones: a) Willis, M. C.; Cutting, G. A. 
Piccio, V. J.-D.; Durbin, M. J.; John, M. P. Angew. Chem. - Int. Ed. 2005, 44, 
1543-1545; b) Li, L.; Klauber, E. G.; Seidel, D. J. Am. Chem. Soc. 2008, 130, 
12248-12249; c) Cao, Y.-M.; Shen, F.-F.; Zhang, F,-T.; Zhang, J.-L.; Wang, R. 
Angew. Chem. - Int. Ed. 2014, 53, 1862-1866; Selected examples with imines: d) 
Chen, X.; Dong, S.; Qiao, Z.; Zhu, Y.; Xie, M.; Lin, L.; Liu, X.; Feng, X. Chem. 
Eur. J. 2011, 17, 2583-2586; e) Kato, S.; Yoshino, T.; Shibasaki, M.; Kanai, M.; 
Matsunaga, S. Angew. Chem. - Int. Ed.  2012, 51, 7007-7010. 
192. Selected examples: a) Wang, L.-L.; Bai, J.-F.; Peng, L.; Qi, L.-W.; Jia, L.-N.; 
Guo, Y.-L.; Luo, X.-Y.; Xu, X.-Y.; Wang, L.-X. Chem. Commun. 2012, 48, 5175-
5177. b) Liao, J.-Y.; Shao, P.-L. Zhao, Y. J. Am. Chem. Soc. 2015, 137, 628-631. 
193. Selected examples: a) Cao, Y.; Jiang, X.; Liu, L.; Shen, F.; Zhang, F.; Wang, R. 
Angew. Chem. - Int. Ed. 2011, 50, 9124-9127. b) Cao, Y.-M.; Shen, F.-F.; Zhang, 
F.-T.; Zhang, J. L.; Wang, R. Angew. Chem. - Int. Ed. 2014, 53, 1862-1866. c) 
Zhao, H.-W.; Tian, T.; Pang, H.-L.; Li, B.; Chen, X.-Q.; Yang, Z.; Meng, W.; 
Song, X.-Q.; Zhao, Y.-D.; Liu, Y.-Y. Adv. Synth. Catal. 2016, 358, 2619-2630. 
194. Senica, L.; Stopar, K.; Friedrich, M.; Groselj, U.; Plavec, J.; Pockaj, M.; 
Podlipnik, C.; Stefane, B.; Svete, J. J. Org. Chem. 2016, 81, 146-161. 
195. Sakamoto, S.; Kazumi, N.; Kobayashi, Y.; Tsukano, C.; Takemoto, Y. Org. Lett. 
2014, 16, 4758-4761. 
196. Hayashi, Y.; Kumamoto, T.; Kawahata, M.; Yamaguchi, K.; Ishikawa, T. 
Tetrahedron 2010, 66, 3836-3841. 
197. Desimoni, G.; Faita, G.; Mella, M. Tetrahedron 1996, 52, 13649-13654. 
198. Wong, A.; Welch, C. J.; Kuether, J. T.; Vazquez, E.; Shaimi, M.; Henderson, D.; 
Davies, I. W.; Hughes, D. L. Org. Biomol. Chem. 2004, 2, 168-174. 
199. Yamazaki, T.; Kawasaki-Takasuka, T.; Furuta, A.; Sakamoto, S. Tetrahedron 
2009, 65, 5945-5948. 
200. Mei, L.-Y.; Wei, Y.; Xu, Q.; Shi, M. Organometallics 2012, 31, 7591-7599. 
201. May, Jr., D. A.; Lash, T. D. J. Org. Chem. 1992, 57, 4820-4828. 

  
 
 
 
 
 
 
 
 
 
 
 
 
8. RESUMEN EN CASTELLANO 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Resumen en Castellano 
213
8. RESUMEN EN CASTELLANO
8.1. Objetivos 
Las iminas α,β-insaturadas (1-azabutenos) han sido frecuentemente utilizadas como 
moléculas de partida para la síntesis de diferentes compuestos nitrogenados. La adición 
conjugada de nucleófilos carbonados a este tipo de compuestos es una manera eficiente 
de formar nuevos enlaces C-C dando lugar a la síntesis de enaminas con formación 
concomitante de un nuevo centro estereogénico. No obstante, al contrario de lo que 
sucede  con los compuestos carbonílicos insaturados y los nitroalquenos, la adición 
conjugada enantioselectiva de nucleófilos carbonados a iminas α,β-insaturadas ha sido 
mucho menos estudiada y en particular, no existían ejemplos de adición asimétrica de 
compuestos 1,3-dicarbonílicos antes de del inicio de esta investigación. 
El desarrollo de reacciones de adición conjugada enantioselectivas a iminas α,β-
insaturadas plantea diferentes retos: 
a. Menor reactividad del sustrato debido a la baja electronegatividad del átomo de N.
b. Control de la regioselectividad: los 1-azabutenos a menudo prefieren dar lugar a
productos de  adición 1,2 o productos de doble adición. 
c. Control de la diastereoselectividad: la geometría del doble enlace de las enaminas
formadas puede ser tanto E como Z. 
d. Control de la enantioselectividad: el nuevo centro estereogénico debe ser sintetizado
preferentemente en  una única configuración. 
Teniendo en cuenta estos desafíos, esta tesis se centra en el desarrollo de nuevas 
adiciones conjugadas diastereo- y enantioselectivas de nucleófilos carbonados a iminas 
α,β-insaturadas mediante catálisis metálica. Las siguientes reacciones han sido 
estudiadas: 
1. Adición conjugada asimétrica de ésteres malónicos a N-tosil iminas α,β-insaturadas
catalizada por complejos de La(III). 
2. Adición conjugada asimétrica de ésteres malónicos a β-trifluorometil N-tosil iminas
α,β-insaturadas catalizada por complejos de Cu(II) y complejos de Mg(II). 
3. Reacción de Mukaiyama-Michael diastereoselectiva de silil acetales de cetena y N-
tosil iminas derivadas de α-cetoésteres β,γ-insaturados. 
4. Adición conjugada asimétrica de ésteres malónicos a N-tosil iminas derivadas de α-
cetoésteres β,γ-insaturados catalizada por complejos de La(III). 
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5. Adición conjugada asimétrica diastereodivergente de 2-cloromalonatos a iminas
derivadas de α-cetoésteres β,γ-insaturados catalizada por complejos de La(III) o 
complejos de Ca(II). 
6. Cicloadición [3+2] asimétrica entre ésteres 2-isocianatomalónicos e iminas α,β-
insaturadas mediante un proceso tándem adición de Michael/adición intramolecular 
a isocianato. 
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8.2. Resumen y conclusiones 
1. Se han llevado a cabo diferentes reacciones de adición conjugada enantioselectiva de
ésteres malónicos a iminas α,β-insaturadas utilizando diferentes complejos metálicos 
quirales como catalizadores. En estas reacciones el uso de tamiz molecular como aditivo 
es crucial para obtener los productos deseados con altos rendimientos y 
estereoselectividades. 
2. La adición conjugada enantioselectiva de malonato de dimetilo a N-tosil iminas α,β-
insaturadas derivadas de chalconas se llevó a cabo en presencia de cantidades catalíticas 
del complejo pyBOX1-La(OTf)3, obteniendo las correspondientes enaminas quirales 
con excelentes rendimientos, buenas relaciones diastereoisoméricas y excesos 
enantioméricos de hasta 93% (Tabla 3, página 64). La reacción se puede llevar a cabo 
con iminas que poseen sustituyentes aromáticos o heteroaromáticos unidos tanto al 
carbono β como al carbono azometínico. La reacción también tolera sustituyentes 
alifáticos dando lugar a los correspondientes aductos 1,4 con un ligero descenso en el 
exceso enantiomérico. Esta reacción representa el primer ejemplo descrito en la 
literatura de adición conjugada enantioselectiva de compuestos 1,3-dicarbonílicos a 
iminas α,β-insaturadas. La estereoquímica (S,E) de los productos resultantes se 
estableció por experimentos de tipo NOESY y correlación química con un compuestos 
de estereoquímica conocida. 
3. También se ha estudiado una reacción similar consistente en la adición conjugada de
malonato de dimetilo a β-trifluorometil N-tosil iminas α,β-insaturadas. En este caso, la 
reacción funciona mejor en presencia de BOX7-Cu(OTf)2 o BOX7-Mg(OTf)2 que de 
pyBOX1-La(OTf)3. En presencia del complejo de cobre se obtuvieron mejores 
enantioselectividades (Tabla 6, página 73) mientras que en presencia del complejo de 
magnesio los productos fueron obtenidos con mejor diastereoselectividad (Tabla 8, 
página 75). En ambos casos, se obtuvieron las (S,E)-enaminas trifluorometiladas, tal y 
como se puedo determinar mediante análisis de rayos X. 
4. Hemos desarrollado la reacción de Mukaiyama-Michael diastereodivergente entre
silil acetales de cetena y N-tosyl cetiminas derivadas de α-cetoésteres β,γ-insaturados. 
Aunque la reacción no se pudo realizar de manera enantioselectiva, los E- o Z-
dehidroamino ésteres se obtuvieron de manera estereocontrolada, partiendo de los 
mismos sustratos. La reacción en ausencia de catalizador favoreció la obtención del 
diastereoisómero Z (Tabla 9, página 81) mientras que la presencia de una cantidad 
catalítica de triflato de cobre favoreció el diastereoisómero E (Tabla 10, página 82). La 
estereoquímica de los productos resultantes se determinó mediante experimentos tipo 
NOESY. También pudimos establecer una correlación entre los desplazamientos 
químicos de RMN de 1H y la estereoquímica del doble enlace en estos compuestos. 
5. El complejo pyBOX1-La(OTf)3 catalizó la adición conjugada enantioselectiva de
dialquil malonatos a N-tosil cetiminas derivadas de α-cetoésteres β,γ-insaturados dando 
lugar a los correspondientes α,β-dehidroamino ésteres con excelentes rendimientos y 
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relaciones diastereoisoméricas, y excesos enantioméricos elevados (Tabla 14, página 
90). La reacción también se pudo llevar a  cabo utilizando 2-metilmalonato de dimetilo 
(Tabla 15, página 91). En todos los casos, la reacción proporcionó los productos con la 
configuración Z en el doble enlace de la enamina como se pudo determinar mediante 
experimentos tipo NOESY y rayos X. 
6. Una prolongación de la reacción anterior consistió en la adición conjugada
enantioselectiva de 2-cloromalonato de dietilo a N-tosil iminas derivadas de α-
cetoésteres β,γ-insaturados. Al igual que con malonato de dietilo, la adición conjugada 
de 2-cloromalonato de dietilo catalizada por complejos de pyBOX-La(OTf)3 dio lugar a 
los correspondientes dehidroamino ésteres con la configuración Z en el doble enlace, 
obteniéndose excelentes rendimientos y relaciones diastereoisoméricas y buenos 
excesos enantioméricos para un conjunto de iminas (Tabla 17, página 95). Por otro lado, 
la reacción catalizada por el complejo pyBOX1-Ca(OTf)2 dio lugar a los dehidroamino 
esteres con la configuración E en el doble enlace, con excelentes rendimientos, altas 
relaciones diastereoisoméricas y excelente enantioselectividad (Tabla 19, página 97). 
De esta forma fue posible obtener los E o Z dehidroamino esteres quirales partiendo de 
los mismos reactivos simplemente cambiando el catalizador. 
Los cloro-derivados obtenidos se pudieron someter a hidrogenolisis en presencia del 
complejo de Rh-dppp sin isomerización en el doble enlace o erosión de la pureza óptica. 
Esta reacción permitió la obtención de los compuestos (E)-19, lo cuales no pudieron ser 
obtenidos directamente a partir de malonato de dietilo. 
7. Se ha desarrollado una cicloadición formal [3+2] catalítica enantioselectiva entre 2-
isocianatomalonato de diisopropilo y N-(o-metoxifenil)iminas α,β-insaturadas para dar 
γ-lactamas quirales altamente sustituidas. La reacción fue catalizada por el complejo 
BOX10-Mg(OTf)2, y las pirrolidinonas con un doble enlace exocíclico resultantes se 
obtuvieron con excelentes rendimientos, total diastereoselectividad y excelentes excesos 
enantioméricos (Tabla 21, página 104). El uso del grupo N-(o-metoxifenilo) fue esencial 
para el éxito de la reacción, ya que ni las correspondientes enonas ni las N-tosil iminas 
insaturadas reaccionaron en presencia de este catalizador. Además, la reacción no 
requiere el uso de iminas diastereoisoméricamente puras como sustratos de partida. 
Igualmente, el uso del éster diisopropílico fue crucial para la obtención de elevada 
enantioselectividad. La reacción posiblemente transcurre mediante un proceso tándem 
que implica una adición de Michael seguida de un proceso de adición intramolecular a 
isocianato. La configuración del centro quiral así como la geometría del doble enlace en 
las lactamas resultantes se determinó mediante difracción de rayos X. 
8. La potencial aplicabilidad de los productos obtenidos en las reacciones anteriores ha
sido demostrada mediante varias transformaciones sintéticas obteniendo diferentes 
compuestos nitrogenados como δ-amino esteres, piperidonas, pirrolidonas o 
ciclopropanos. 
ANNEX 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Annex 
217 
ANNEX. Publications resulting from this thesis at the moment of the lecture  
 
Annex 
218 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Annex 
219 
 
 
 
